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2  Chapter 1 
 
1.1  The Neuropeptide Y (NPY) Family 
Neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) belong to a peptide 
family of neuroendocrine hormones, referred to as the neuropeptide Y family (Figure 1). All 
three peptides consist of 36 amino acids with C-terminal amidation and share considerable 
sequence homologies.1-3 
NPY  YPSKPDNPGEDAPAEDMARYYSALRHYINLITRQRY-NH2 
PYY  YPIKPEAPGEDASPEELNRYYASLRHYLNLVTRQRY-NH2  
PP  APLEPVYPGDNATPEQMAQYAADLRRYINMLTRPRY-NH2 
Figure 1: Amino acid sequences of human NPY, PYY and PP 
NPY, PYY and PP interact with the same family of rhodopsin-like (class 1) G-protein coupled 
receptors (GPCRs), referred to as NPY receptors (NPYR). Until now five different subtypes 
have been identified (Y1R, Y2R, Y4R, Y5R, y6R).
4-12 The y6R is a functional receptor in rabbit and 
mouse, but non-functional in most mammalian species. It is an inactive pseudogene in 
human and pig and is absent in rat.13 NPY receptors act via Gi/o-proteins mediating the 
inhibition of cAMP accumulation.14,15 Furthermore, NPYRs were reported to activate 
phospholipase C resulting in subsequent elevation of intracellular Ca2+ levels.6,7,16-21 The 
intensity of this effect is highly dependent on the investigated cell type.14 NPY and PYY bind 
with high affinity to Y1, Y2 and Y5 receptors, but exhibit only low affinity to the Y4R. The latter 
is addressed by PP. Therefore, the Y4R was originally designated as PP1R.
8 
The tertiary structure of the three peptide hormones was studied by several spectroscopic 
methods. The crystal structure of chicken (avian) pancreatic polypeptide was resolved by x-
ray analysis.22 PP comprises an extended polyproline-like helix (residues 1-8), followed by a 
β-turn (9-ϭϯͿ aŶd aŶ α-helix (14-31) that runs roughly antiparallel to the polyproline-like 
helix, bringing N-terminus and C-terminus into close proximity. The helices are stabilized by 
hǇdƌophoďiĐ iŶteƌaĐtioŶs ďetǁeeŶ pƌoliŶes Ϯ, ϱ aŶd ϴ aŶd hǇdƌophoďiĐ side ĐhaiŶs of the α-
helix. The amidated C-terminus (32-36), which comprises the most crucial residues for 
receptor binding, was reported to be rather flexible. The hairpin-like conformation which is 
formed between the polyproline-like heliǆ aŶd the α-helix, the so called PP-fold, was later 
also proposed for porcine NPY (Figure 2) since the homology between aPP and NPY 
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preserves all of the residues which are essential for the maintenance of the tertiary 
structure.23  
 
Figure 2: tertiary structure of porcine NPY according to Allen et al.23 
The tertiary structure of NPY in solution was intensively investigated using NMR and CD 
spectroscopy as well as FRET-based approaches with contradictory results. Some of these 
studies confirmed the PP-fold structure.24,25 Otheƌ gƌoups ƌepoƌted oŶ α-helical structures of 
the C-terminus, rather flexible N-termini and the formation of dimers through hydrophobic 
ĐoŶtaĐts of the ƌepoƌted α-helices.26 Major disadvantages of conformational studies using 
NMR spectroscopy are the required high concentrations of the protein, which are 
physiologically irrelevant, and the pH values considerably lower than 7.4 to increase the 
solubility of the peptide. CD spectroscopy revealed that NPY exists in different states, 
depending on the concentration, pH value and the temperature. Under physiological 
conditions, the monomeric form with the PP-fold seems to be the most favored one.27 A 
comparable tertiary structure in solution could later be verified for PYY too.28 
Over the last years methods to determine the tertiary structure of GPCRs including x-ray 
analysis of GPCR crystals, NMR spectroscopy, mutagenesis based approaches and molecular 
modeling have clearly advanced. Several groups described structures of NPY receptors in 
complex with the respective endogenous ligands using NMR spectroscopy, NPY receptor 
mutants and homology models based on crystal structures of related GPCRs. Merten et al. 
published a model outlining the importance of Asp6.59, an amino acid that is highly conserved 
throughout all NPY receptors. In Y1R and Y4R, Asp
6.59 was identified to interact with Arg35 of 
NH2 
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PP or NPY. However, in Y2R and Y5R, Asp
6.59 interacts with Arg33.29 Xu et al. reported on a 
alternative model of the Y2R. The two C-terminal arginines in NPY and PYY, Arg
33 and Arg35 
were found to form a double salt bridge with both Glu5.24 and Asp6.59 on the Y2R. Several 
additional amino acids, e.g. Gln3.32, Leu6.51 and His7.39 were identified to contribute to the 
orthosteric binding site.30 This model was basically verified very recently by NMR 
measurements of specific isotope-labeled NPY in complex with the Y2R.
31 Based on all 
available class A GPCR crystal structures and data from mutagenesis studies, a model of the 
Y4R in complex with PP was constructed.
32 In addition to the above-mentioned interaction 
between Asp6.59 and Arg35, several residues were found to contribute to a complex network 
of ionic or hydrophobic interactions and hydrogen binding. Specifically, Tyr2.64 undergoes 
hydrophobic interactions with Tyr27, and Asn7.32 interacts with Arg33 via hydrogen bonding. 
Requiring rather artificial conditions, every method for the structure determination of GPCRs 
has its own limitations. However, three-dimensional models of NPY receptors might still 
facilitate the rational design of NPY receptor ligands, agonists and antagonists, with 
increased affinity and selectivity.  
The neuropeptide Y receptor family is involved in the regulation of numerous physiological 
and pathophysiological processes33 including energy metabolism and the development of 
obesity,34-39 mental and psychiatric disorders,40-44 neurodegeneration44-47 or the regulation 
of blood pressure.48,49 A summary of important biological functions is shown in Table 1.  
Table 1. Overview of biological effects mediated by the stimulation of NPY receptors. 
Y1R 
Food iŶtake ;↑Ϳ aŶd eŶeƌgǇ ŵetaďolisŵ ;↓Ϳ, depƌessioŶ, anxiolysis, alcohol 
ĐoŶsuŵptioŶ ;↓Ϳ, seizuƌes ;↑Ϳ, paiŶ seŶsitiǀitǇ ;↑Ϳ,  ƌegulatioŶ of ďlood 
pressure (vasoconstriction) 
Y2R 
Food iŶtake ;↓Ϳ aŶd eŶeƌgǇ ŵetaďolisŵ ;↑Ϳ, aŶǆietǇ ;due to ƌeduĐed NPY 
release), schizophrenia-ƌeleǀaŶt sǇŵptoŵs ;↑Ϳ, seizuƌes ;↓Ϳ, ŶeuƌopƌoteĐtioŶ iŶ 
patieŶts ǁith HuŶtiŶgtoŶs͛ disease, ďoŶe foƌŵatioŶ, hǇpoǆia-induced tumor 
gƌoǁth, ƌegulatioŶ of ďlood pƌessuƌe ;sloǁiŶg of the heaƌt ƌateͿ, NPY ƌelease ;↓, 
presynaptic autoreceptor) 
Y4R Food iŶtake ;↓Ϳ, gastƌoiŶtestiŶal ŵotilitǇ ;↑) 
Y5R Food iŶtake aŶd oďesitǇ ;↑Ϳ, hǇpoǆia-induced tumor growth 
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1.2  NPY Y1, Y2 and Y5 Receptor Ligands 
Modifications of the flexible C-terminal part resulted in Y1R agonists with selectivity over the 
Y2R, e.g. [Leu
31, Pro34]NPY.50 Mullins et al. reported on a series of D-peptides with increased 
Y1R selectivity. [D-Arg
25, D-His26]NPY displayed a 40-fold selectivity over the Y2R and a 300-
fold selectivity over the Y5R, respectively.
51 A further increase in selectivity and affinity was 
achieved with centrally truncated analogs such as Des-AA11-18[Cys7,21, D-Lys9 (Ac), D-His26, 
Pro34]NPY. The incorporation of artificial amino acids such as norleucine or L-4-
benzoylphenylalanine (Bpa) into the C-terminal part of NPY led to the identification of the 
first selective Y1R agonists with reduced size. The nonapeptide [Pro
30, Nle31, Bpa32, 
Leu34]NPY(28-36) binds to the Y1R with an affinity in the two-digit nanomolar range and was 
proposed as a precursor for diagnostic agents to specifically label Y1R expressing tumors.
52 
The first selective non-peptide Y1R antagonist, the (R)-argininamide BIBP 3226, was 
described in 1994.53 The structure was designed as a mimic of the C-terminal moiety in NPY 
since an alanine scan for NPY revealed arginine residues 33 and 35 to be essential for Y1R 
binding.54 The affinity of the (S)-configured enantiomer, BIBP 3435, was lower by a factor of 
1000.55 Replacement of the phenolic hydroxyl group with an ureidomethyl moiety gave 
another potent Y1R antagonist, BIBO 3304 (Ki = 0.4 nM).
56 Even though BIBP 3226 was never 
considered as an appropriate candidate for clinical trials due to the lack of drug like 
properties, it was used as a starting point in the development of numerous pharmacological 
tools, e.g. radiolabelled and fluorescent ligands.57-60 Very recently, [3H]UR-MK299, a Y1R 
radioligand with a Kd value in the two-digit picomolar range was described.
60 Apart from 
superior Y1R affinity, a considerably increased target-residence time was characteristic of 
[3H]UR-MK299. An overview about further structurally diverse Y1R antagonists is given in 
Figure 3. 
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Figure 3: Structures of several selective Y1R antagonists: a: Kanatani et al
61; b: Rudolf et al53; c: 
Wieland et al56; d: Griffith et al62 ; f: Hipskind et al63; g: Zarrinmayeh et al64; h: Sit et al65; I: Leslie et 
al66. 
In contrast to the Y1R, N-terminal truncations of NPY are well tolerated with respect to Y2R 
affinity. For example, NPY(18-36) showed an only 6-fold lower affinity to the Y2R than NPY, 
but the affinity to the Y1R was reduced by the factor of 70.
67 A peptidomimetic comprising 
four C-terminal NPY fragments (33-ϯϲͿ liŶked to a ĐǇĐliĐ teŵplate ŵoleĐule ŵiŵiĐkiŶg tǁo β-
turns was identified as a selective Y2R antagonist
68 illustrating that the C-terminus is the 
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most crucial part for interaction with the Y2R, whereas the N-terminus seems to be less 
important. In 1999, the (S)-argininamide BIIE 0246 was described as the first non-peptide Y2R 
antagonist with a Ki value in the lower nanomolar range.
69 Growing interest in the Y2R as a 
potential target for the treatment of obesity led to the identification of several structurally 
diverse Y2R antagonists. A selection of different, more drug-like compounds is shown in 
Figure 4. Recently, [3H]UR-PLN196 was reported as the first non-peptide radioligand for the 
Y2R.
70 By analogy with the development of BIBP 3226 derived pharmacological tools, 
electron-withdrawing residues such as acyl or carbamoyl moieties carrying a terminal amino 
group were attached to the guanidine group of BIIE 0246.70 
 
Figure 4: Structures of selective Y2R antagonists: a: Doods et al
69; b: Andres et al71; c: Mittapalli et 
al72; d: Bonaventure et al73 ; e: Shoblock et al74 ; f: Brothers et al75. 
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A selective Y5R agonist was obtained by incorporationg the turn inducing sequence Ala-Aib 
into positions 31 and 32 of porcine NPY. Y5R affinity could be further improved by 
introducing the Ala-Aib motif into NPY/PP chimeras.76 The search for new anti-obesity drugs 
led to the identification of numerous small-molecule Y5R antagonists (Figure 5). The first Y5R 
antagonist, CGP 71683A, was reported by Novartis in 1997.19 Some compounds entered 
clinical trials, e.g. MK-0557 (Merck & Co., Inc.),77 but none of these drug candidates reached 
the market. 
 
Figure 5: Structures of selective Y5R antagonists: a: Criscione et al
19; b: Walker et al78 ; c: Erondu et 
al77 ; d: Itani et al79 ; e: Norman et al80 ; f: Block et al81 ; g: Kawanishi et al82; h: Sato et al83. 
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1.3  Y4R Ligands 
In contrast to the other NPY receptors, only few selective Y4R ligands are known so far 
(Figures 6+7). Surprisingly, among a series of dimeric Y1R peptide antagonists, some 
compounds turned out to act as Y4R agonists.
84-86 The compound with the highest affinity, 
GW1229 (also designated as GR231118 and 1229U91) (Ki (Y1R) = 0.51 nM), binds to the Y4R 
with picomolar affinity (Ki (Y4R) = 0.36 nM). In 2006 Balasubramaniam et al. prepared a series 
of dimeric peptides with improved Y4R selectivity by connecting the C-terminal 
pentapeptides of GW1229 (Tyr-Arg-Leu-Arg-Tyr-NH2) via aliphatic dicarboxylic acids with 
different chain lengths.87 Highest activity was achieved with 2,7-D/L-diaminosuberic acid as a 
linker (BVD74-D). In vivo studies describe a regulatory effect of BVD74-D on food intake in 
mice35 suggesting Y4R agonists as potential agents for the treatment of obesity. One 
pentapeptide sequence of BVD-74D instead of the crosslinked compound was reported to 
bind to the Y4R as well (1: Ki (Y4R) = 50 nM, EC50 = 65 nM). Whereas 1 was a full agonist in a 
[γ-33P]GTPase assay, analogs containing the cyclic beta amino acid cis-ĐǇĐlopeŶtaŶe β-amino 
aĐid ;βĐpeͿ iŶstead of Leu3 were partial agonists (2: Ki (Y4R) = 105 nM, EC50 = 94 nM, Emax = 
73%).88  
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Figure 6: Y4R agonists and partial agonists: a: Daniels et al
84; b: Balasubramaniam et al87; c: Berlicki et 
al88; d: Oestergaard et al89. 
As the endogenous ligand PP already displays moderate Y4R selectivity over the other 
receptor subtypes, approaches to stabilize PP against enzymatic degradation might result in 
peptides with improved suitability for in vivo applications. The lipidated analog [K30(E-
Prop)]PP2-36 (EC50 (Y4R) = 1.3 nM, EC50 (Y5R) = 937 nM) is equipotent with PP (EC50 (Y4R) = 1.3 
nM, EC50 (Y5R) = 11.4 nM) at the Y4R, but has a better selectivity over the Y5R. Moreover, 
[K30(E-Prop)]PP2-36 displayed a prolonged half-life in human plasma.
90 Novo Nordisk reported 
on a series of selective Y4R or Y2/4R dual agonists (3, 4) that were able to reduce the 
cumulative food intake in fasted lean mice for 48 h after subcutaneous injection.89 Prolonged 
terminal half-lives in plasma were achieved by attaching fatty acids to the peptides enabling 
reversible binding to albumin. Whereas the half-life of PP was only around 2 min, 4 showed a 
prolonged half-life of 55 h. 
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The only Y4R antagonists with an affinity in the nanomolar range derive from a series of 
bivalent NG-acylated BIBP 3226 derivatives, which were initially designed as dimeric Y1R 
antagonists (Figure 6).91 Several structures with linkers modified in chemical nature, length, 
rigidity and attachment position where synthesized resulting in UR-MK188, the Y4R 
antagonist with the highest affinity known so far.92 The selectivity profile of these dimeric 
antagonists could be shifted towards the Y4R by replacement of the R-configured 
argininamide moieties with the S-configured enantiomers, that is, UR-MEK388 had about the 
same affinity and antagonist activity as UR-MK188 at the Y4R, but was inactive at the Y1R.
92  
 
Figure 7: Bivalent NG-carbamoylated BIBP 3226 derived Y4R antagonists and Y4‘ ͚ŵodulatoƌs͛. a: 
Keller et al91; b: Keller et al92; c: Sliwoski et al93; d: Ewing et al94. 
  
 
12  Chapter 1 
 
Very recently, several small molecules were described as Y4R positive allosteric modulators. 
The antiparasitic drug niclosamide and structural variations thereof were reported to 
potentiate the EC20 signal of PP with an EC50 value in the three-digit nanomolar range in a 
Ca2+ assay and an inositol phosphate accumulation assay.93 Several compounds within a 
series of substituted diaminocyclohexanes were described as Y4R ligands(6, 7).
94 However, 
the information about the functional assays and the interpretation of the functional data is 
very sparse. The investigated compounds were declared as agonists, partial agonists or 
modulators, although the described setup of the functional assay (suppression of forskolin-
induced cAMP formation) would have only allowed the identification of agonists. In general, 
small molecule positive allosteric Y4R modulators which enhance the biological effect of the 
endogenous ligand PP represent an interesting new approach to address the Y4R and 
harbour a potential for the treatment of metabolic disorders and obesity. However, the 
clinical relevance of such compounds remains still unclear. 
 
1.4  Scope of the Thesis 
The neuropeptide Y family contributes to the regulation of numerous physiological 
processes. Especially, the involvement in the development of metabolic disorders has 
attracted the attention of scientists in academia and industry. 
Over the last decades, obesity has emerged to a serious global health problem being linked 
with secondary diseases such as diabetes type II, arthrosis or cardiovascular diseases. 
Research on the implication of NPY in obesity has led to an amount of information, for 
example, on the occurrence of the receptor subtypes in brain and periphery, cellular 
signalling and interactions with numerous other neurotransmitters and hormones. However, 
the physiological role of both, the different NPY receptors and their endogenous ligands, is 
still far from being understood due to the complex and in part opposite effects of receptor-
subtype stimulation. For instance, even though peripheral administration of PP has been 
shown to reduce food intake in rodents and humans,95-97 Y4R knockout in mice resulted in 
lean phenotypes.98 
Whereas many peptide agonists and non-peptide antagonists for Y1, Y2 and Y5 receptors 
were reported, only few Y4R ligands are known so far. Even though Y4R agonists should have 
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the higher clinical potential, high-affinity antagonists are required as well to investigate the 
physiological and pathophysiological role of the Y4R in more detail. 
UR-MK188, a bivalent ligand composed of two NG-carbamoylated BIBP 3226 derived 
moieties connected via a linker, is the most potent Y4R antagonist known to date (Ki = 130 
nM, Kb = 20 nM).
92 Previous investigations on such dimeric argininamides, initially designed 
as bivalent Y1R antagonists, suggest that the linker length should be reduced. Taking UR-
MK188 as a lead structure, one objective of this thesis is to optimize the linker of bivalent 
Y4R ligands aiming at Y4R antagonists with increased affinity and reduced size.  
Furthermore, the incorporation of cyclic beta amino acids such as cis-ĐǇĐlopeŶtaŶe β-amino 
acid into the C-terminal part of Y4R full agonists resulted in partial agonism.
88 This effect had 
to be further investigated and complementary possibilities of backbone modifications had to 
be applied to more suitable agonist precursors. Based on the working hypothesis that the 
rigidization of the backbone of Y4R peptide agonists may result in a change of the quality of 
action, various modifications, e.g. the incorporation of D-amino acids or aza-amino acids and 
backbone cyclization should be applied to Y4R peptide agonists. 
The availability of selective Y4R radioligands for binding studies is very limited. [
125I]-labeled 
compounds suffer from a short half-life of only 60 days, but have the broadest 
application.87,99-101 Due to their longer half-life, tritiated radioligands are highly preferred in 
our laboratory. To explore the applicability of reported Y4R ligands as precursors for the 
attachment of a radioactive (tritiated) moiety was another aim of the thesis. Compounds 
with an amino group enabling acylation with commercially available N-succinimidyl-[2,3-
3H]propi onate should be preferred as precursors. A selective Y4R radioligand is anticipated 
to be a useful pharmacological tool for the detection of Y4 receptors, autoradiographic 
studies or the determination of Y4R binding data of non-labelled compounds. 
  
  
 
14  Chapter 1 
 
1.5  References 
(1) Balasubramaniam, A. A. Neuropeptide Y family of hormones: receptor subtypes and 
antagonists. Peptides 1997, 18, 445-457. 
(2) Cerda-Reverter, J. M.; Larhammar, D. Neuropeptide Y family of peptides: structure, 
anatomical expression, function, and molecular evolution. Biochem. Cell Biol. 2000, 78, 371-
392. 
(3) Cabrele, C.; Beck-Sickinger, A. G. Molecular characterization of the ligand-receptor 
interaction of the neuropeptide Y family. J. Pept. Sci. 2000, 6, 97-122. 
(4) Larhammar, D.; Blomqvist, A. G.; Yee, F.; Jazin, E.; Yoo, H.; Wahlested, C. Cloning and 
functional expression of a human neuropeptide Y/peptide YY receptor of the Y1 type. J. Biol. 
Chem. 1992, 267, 10935-10938. 
(5) Herzog, H.; Hort, Y. J.; Ball, H. J.; Hayes, G.; Shine, J.; Selbie, L. A. Cloned human 
neuropeptide Y receptor couples to two different second messenger systems. Proc. Natl. 
Acad. Sci. U. S. A. 1992, 89, 5794-5798. 
(6) Gerald, C.; Walker, M. W.; Vaysse, P. J.; He, C.; Branchek, T. A.; Weinshank, R. L. 
Expression cloning and pharmacological characterization of a human hippocampal 
neuropeptide Y/peptide YY Y2 receptor subtype. J. Biol. Chem. 1995, 270, 26758-26761. 
(7) Bard, J. A.; Walker, M. W.; Branchek, T. A.; Weinshank, R. L. Cloning and functional 
expression of a human Y4 subtype receptor for pancreatic polypeptide, neuropeptide Y, and 
peptide YY. J. Biol. Chem. 1995, 270, 26762-26765. 
(8) Lundell, I.; Blomqvist, A. G.; Berglund, M. M.; Schober, D. A.; Johnson, D.; Statnick, M. 
A.; Gadski, R. A.; Gehlert, D. R.; Larhammar, D. Cloning of a human receptor of the NPY 
receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 
1995, 270, 29123-29128. 
(9) Gerald, C.; Walker, M. W.; Criscione, L.; Gustafson, E. L.; Batzl-Hartmann, C.; Smith, K. 
E.; Vaysse, P.; Durkin, M. M.; Laz, T. M.; Linemeyer, D. L.; Schaffhauser, A. O.; Whitebread, S.; 
Hofbauer, K. G.; Taber, R. I.; Branchek, T. A.; Weinshank, R. L. A receptor subtype involved in 
neuropeptide-Y-induced food intake. Nature 1996, 382, 168-171. 
(10) Weinberg, D. H.; Sirinathsinghji, D. J.; Tan, C. P.; Shiao, L. L.; Morin, N.; Rigby, M. R.; 
Heavens, R. H.; Rapoport, D. R.; Bayne, M. L.; Cascieri, M. A.; Strader, C. D.; Linemeyer, D. L.; 
MacNeil, D. J. Cloning and expression of a novel neuropeptide Y receptor. J. Biol. Chem. 
1996, 271, 16435-16438. 
  
 
  General Introduction 15 
 
 
(11) Gregor, P.; Feng, Y.; DeCarr, L. B.; Cornfield, L. J.; McCaleb, M. L. Molecular 
characterization of a second mouse pancreatic polypeptide receptor and its inactivated 
human homologue. J. Biol. Chem. 1996, 271, 27776-27781. 
(12) Matsumoto, M.; Nomura, T.; Momose, K.; Ikeda, Y.; Kondou, Y.; Akiho, H.; Togami, J.; 
Kimura, Y.; Okada, M.; Yamaguchi, T. Inactivation of a novel neuropeptide Y/peptide YY 
receptor gene in primate species. J. Biol. Chem. 1996, 271, 27217-27220. 
(13) Starback, P.; Wraith, A.; Eriksson, H.; Larhammar, D. Neuropeptide Y receptor gene 
y6: multiple deaths or resurrections? Biochem. Biophys. Res. Commun. 2000, 277, 264-269. 
(14) Holliday, N. D.; Michel, M. C.; Cox, H. M. In Neuropeptide Y and Related Peptides, Ed. 
Michel, M. C., Springer: Heidelberg, 2004; Vol. 162, pp 45-73. 
(15) Michel, M. C.; Beck-Sickinger, A.; Cox, H.; Doods, H. N.; Herzog, H.; Larhammar, D.; 
Quirion, R.; Schwartz, T.; Westfall, T. XVI. International Union of Pharmacology 
recommendations for the nomenclature of neuropeptide Y, peptide YY, and pancreatic 
polypeptide receptors. Pharmacol. Rev. 1998, 50, 143-150. 
(16) Michel, M. C. Concomitant regulation of Ca2+ mobilization and G13 expression in 
human erythroleukemia cells. Eur. J. Pharmacol. 1998, 348, 135-141. 
(17) Grouzmann, E.; Meyer, C.; Burki, E.; Brunner, H. Neuropeptide Y Y2 receptor 
signalling mechanisms in the human glioblastoma cell line LN319. Peptides 2001, 22, 379-
386. 
(18) Selbie, L. A.; Darby, K.; Schmitz-Peiffer, C.; Browne, C. L.; Herzog, H.; Shine, J.; Biden, 
T. J. Synergistic interaction of Y1-neuropeptide Y and alpha 1b-adrenergic receptors in the 
regulation of phospholipase C, protein kinase C, and arachidonic acid production. J. Biol. 
Chem. 1995, 270, 11789-11796. 
(19) Criscione, L.; Rigollier, P.; Batzl-Hartmann, C.; Rueger, H.; Stricker-Krongrad, A.; Wyss, 
P.; Brunner, L.; Whitebread, S.; Yamaguchi, Y.; Gerald, C.; Heurich, R. O.; Walker, M. W.; 
Chiesi, M.; Schilling, W.; Hofbauer, K. G.; Levens, N. Food intake in free-feeding and energy-
deprived lean rats is mediated by the neuropeptide Y5 receptor. J. Clin. Invest. 1998, 102, 
2136-2145. 
(20) Motulsky, H. J.; Michel, M. C. Neuropeptide Y mobilizes Ca2+ and inhibits adenylate 
cyclase in human erythroleukemia cells. Am. J. Physiol. 1988, 255, E880-885. 
  
 
16  Chapter 1 
 
(21) Aakerlund, L.; Gether, U.; Fuhlendorff, J.; Schwartz, T. W.; Thastrup, O. Y1 receptors 
for neuropeptide Y are coupled to mobilization of intracellular calcium and inhibition of 
adenylate cyclase. FEBS Lett. 1990, 260, 73-78. 
(22) Blundell, T. L.; Pitts, J. E.; Tickle, I. J.; Wood, S. P.; Wu, C. W. X-ray analysis (1. 4-A 
resolution) of avian pancreatic polypeptide: Small globular protein hormone. Proc. Natl. 
Acad. Sci. U. S. A. 1981, 78, 4175-4179. 
(23) Allen, J.; Novotny, J.; Martin, J.; Heinrich, G. Molecular structure of mammalian 
neuropeptide Y: analysis by molecular cloning and computer-aided comparison with crystal 
structure of avian homologue. Proc. Natl. Acad. Sci. U. S. A. 1987, 84, 2532-2536. 
(24) Darbon, H.; Bernassau, J. M.; Deleuze, C.; Chenu, J.; Roussel, A.; Cambillau, C. 
Solution conformation of human neuropeptide Y by 1H nuclear magnetic resonance and 
restrained molecular dynamics. Eur. J. Biochem. 1992, 209, 765-771. 
(25) Boulanger, Y.; Chen, Y.; Commodari, F.; Senecal, L.; Laberge, A. M.; Fournier, A.; St-
Pierre, S. Structural characterizations of neuropeptide tyrosine (NPY) and its agonist analog 
[Ahx5-17]NPY by NMR and molecular modeling. Int. J. Pept. Protein Res. 1995, 45, 86-95. 
(26) Bettio, A.; Dinger, M. C.; Beck-Sickinger, A. G. The neuropeptide Y monomer in 
solution is not folded in the pancreatic-polypeptide fold. Protein Sci. 2002, 11, 1834-1844. 
(27) Nordmann, A.; Blommers, M. J.; Fretz, H.; Arvinte, T.; Drake, A. F. Aspects of the 
molecular structure and dynamics of neuropeptide Y. Eur. J. Biochem. 1999, 261, 216-226. 
(28) Keire, D. A.; Kobayashi, M.; Solomon, T. E.; Reeve, J. R., Jr. Solution structure of 
monomeric peptide YY supports the functional significance of the PP-fold. Biochemistry 
2000, 39, 9935-9942. 
(29) Merten, N.; Lindner, D.; Rabe, N.; Rompler, H.; Mörl, K.; Schöneberg, T.; Beck-
Sickinger, A. G. Receptor subtype-specific docking of Asp6.59 with C-terminal arginine 
residues in Y receptor ligands. J. Biol. Chem. 2007, 282, 7543-7551. 
(30) Xu, B.; Fallmar, H.; Boukharta, L.; Pruner, J.; Lundell, I.; Mohell, N.; Gutierrez-de-
Teran, H.; Aqvist, J.; Larhammar, D. Mutagenesis and computational modeling of human G-
protein-coupled receptor Y2 for neuropeptide Y and peptide YY. Biochemistry 2013, 52, 
7987-7998. 
(31) Kaiser, A.; Muller, P.; Zellmann, T.; Scheidt, H. A.; Thomas, L.; Bosse, M.; Meier, R.; 
Meiler, J.; Huster, D.; Beck-Sickinger, A. G.; Schmidt, P. Unwinding of the C-Terminal 
  
 
  General Introduction 17 
 
 
Residues of Neuropeptide Y is critical for Y2 Receptor Binding and Activation. Angew. Chem. 
Int. Ed. Engl. 2015, 54, 7446-7449. 
(32) Pedragosa-Badia, X.; Sliwoski, G. R.; Dong Nguyen, E.; Lindner, D.; Stichel, J.; 
Kaufmann, K. W.; Meiler, J.; Beck-Sickinger, A. G. Pancreatic polypeptide is recognized by 
two hydrophobic domains of the human Y4 receptor binding pocket. J. Biol. Chem. 2014, 
289, 5846-5859. 
(33) Brothers, S. P.; Wahlestedt, C. Therapeutic potential of neuropeptide Y (NPY) 
receptor ligands. EMBO Mol Med 2010, 2, 429-439. 
(34) Zhang, L.; Lee, I. C.; Enriquez, R. F.; Lau, J.; Vahatalo, L. H.; Baldock, P. A.; Savontaus, 
E.; Herzog, H. Stress- and diet-induced fat gain is controlled by NPY in catecholaminergic 
neurons. Mol Metab 2014, 3, 581-591. 
(35) Li, J. B.; Asakawa, A.; Terashi, M.; Cheng, K.; Chaolu, H.; Zoshiki, T.; Ushikai, M.; 
Sheriff, S.; Balasubramaniam, A.; Inui, A. Regulatory effects of Y4 receptor agonist (BVD-74D) 
on food intake. Peptides 2010, 31, 1706-1710. 
(36) Loh, K.; Herzog, H.; Shi, Y. C. Regulation of energy homeostasis by the NPY system. 
Trends Endocrinol. Metab. 2015, 26, 125-135. 
(37) Zhang, L.; Nguyen, A. D.; Lee, I. C.; Yulyaningsih, E.; Riepler, S. J.; Stehrer, B.; Enriquez, 
R. F.; Lin, S.; Shi, Y. C.; Baldock, P. A.; Sainsbury, A.; Herzog, H. NPY modulates PYY function in 
the regulation of energy balance and glucose homeostasis. Diabetes Obes Metab 2012, 14, 
727-736. 
(38) Qi, Y.; Fu, M.; Herzog, H. Y2 receptor signalling in NPY neurons controls bone 
formation and fasting induced feeding but not spontaneous feeding. Neuropeptides 2016, 
55, 91-97. 
(39) Olza, J.; Gil-Campos, M.; Leis, R.; Ruperez, A. I.; Tojo, R.; Canete, R.; Gil, A.; Aguilera, 
C. M. Influence of variants in the NPY gene on obesity and metabolic syndrome features in 
Spanish children. Peptides 2013, 45, 22-27. 
(40) Giesbrecht, C. J.; Mackay, J. P.; Silveira, H. B.; Urban, J. H.; Colmers, W. F. 
Countervailing modulation of Ih by neuropeptide Y and corticotrophin-releasing factor in 
basolateral amygdala as a possible mechanism for their effects on stress-related behaviors. J. 
Neurosci. 2010, 30, 16970-16982. 
  
 
18  Chapter 1 
 
(41) Stadlbauer, U.; Langhans, W.; Meyer, U. Administration of the Y2 receptor agonist 
PYY3-36 in mice induces multiple behavioral changes relevant to schizophrenia. 
Neuropsychopharmacology 2013, 38, 2446-2455. 
(42) Pleil, K. E.; Rinker, J. A.; Lowery-Gionta, E. G.; Mazzone, C. M.; McCall, N. M.; Kendra, 
A. M.; Olson, D. P.; Lowell, B. B.; Grant, K. A.; Thiele, T. E.; Kash, T. L. NPY signaling inhibits 
extended amygdala CRF neurons to suppress binge alcohol drinking. Nat. Neurosci. 2015, 18, 
545-552. 
(43) LaCrosse, A. L.; Olive, M. F. Neuropeptide systems and schizophrenia. CNS Neurol 
Disord Drug Targets 2013, 12, 619-632. 
(44) Reichmann, F.; Holzer, P. Neuropeptide Y: A stressful review. Neuropeptides 2016, 55, 
99-109. 
(45) Kloster, E.; Saft, C.; Akkad, D. A.; Epplen, J. T.; Arning, L. Association of age at onset in 
Huntington disease with functional promoter variations in NPY and NPY2R. J Mol Med (Berl) 
2014, 92, 177-184. 
(46) Duarte-Neves, J.; Pereira de Almeida, L.; Cavadas, C. Neuropeptide Y (NPY) as a 
therapeutic target for neurodegenerative diseases. Neurobiol. Dis. 2016, 95, 210-224. 
(47) Croce, N.; Gelfo, F.; Ciotti, M. T.; Federici, G.; Caltagirone, C.; Bernardini, S.; 
Angelucci, F. NPY modulates miR-30a-5p and BDNF in opposite direction in an in vitro model 
of Alzheimer disease: a possible role in neuroprotection? Mol. Cell. Biochem. 2013, 376, 189-
195. 
(48) Guo, X. W.; Wang, X. L.; Gao, Z. L. [Effect of neuropeptide Y and neurotensin on 
diurnal rhythm of blood pressure and target organ damage for essential hypertension]. 
Zhonghua Xin Xue Guan Bing Za Zhi 2005, 33, 1006-1009. 
(49) Capurro, D.; Huidobro-Toro, J. P. The involvement of neuropeptide Y Y1 receptors in 
the blood pressure baroreflex: studies with BIBP 3226 and BIBO 3304. Eur. J. Pharmacol. 
1999, 376, 251-255. 
(50) Beck-Sickinger, A. G.; Jung, G. Structure-activity relationships of neuropeptide Y 
analogues with respect to Y1 and Y2 receptors. Biopolymers 1995, 37, 123-142. 
(51) Mullins, D.; Kirby, D.; Hwa, J.; Guzzi, M.; Rivier, J.; Parker, E. Identification of potent 
and selective neuropeptide Y Y(1) receptor agonists with orexigenic activity in vivo. Mol. 
Pharmacol. 2001, 60, 534-540. 
  
 
  General Introduction 19 
 
 
(52) Zwanziger, D.; Bohme, I.; Lindner, D.; Beck-Sickinger, A. G. First selective agonist of 
the neuropeptide Y1-receptor with reduced size. J. Pept. Sci. 2009, 15, 856-866. 
(53) Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H. A.; Willim, K. D.; Entzeroth, M.; 
Wienen, W.; Beck-Sickinger, A. G.; Doods, H. N. The first highly potent and selective non-
peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 1994, 271, R11-
13. 
(54) Beck-Sickinger, A. G.; Wieland, H. A.; Wittneben, H.; Willim, K. D.; Rudolf, K.; Jung, G. 
Complete L-alanine scan of neuropeptide Y reveals ligands binding to Y1 and Y2 receptors 
with distinguished conformations. Eur. J. Biochem. 1994, 225, 947-958. 
(55) Wieland, H. A.; Willim, K. D.; Entzeroth, M.; Wienen, W.; Rudolf, K.; Eberlein, W.; 
Engel, W.; Doods, H. N. Subtype selectivity and antagonistic profile of the nonpeptide Y1 
receptor antagonist BIBP 3226. J. Pharmacol. Exp. Ther. 1995, 275, 143-149. 
(56) Wieland, H. A.; Engel, W.; Eberlein, W.; Rudolf, K.; Doods, H. N. Subtype selectivity of 
the novel nonpeptide neuropeptide Y Y1 receptor antagonist BIBO 3304 and its effect on 
feeding in rodents. Br. J. Pharmacol. 1998, 125, 549-555. 
(57) Keller, M.; Pop, N.; Hutzler, C.; Beck-Sickinger, A. G.; Bernhardt, G.; Buschauer, A. 
Guanidine-acylguanidine bioisosteric approach in the design of radioligands: synthesis of a 
tritium-labeled N(G)-propionylargininamide ([3H]-UR-MK114) as a highly potent and 
selective neuropeptide Y Y1 receptor antagonist. J. Med. Chem. 2008, 51, 8168-8172. 
(58) Keller, M.; Bernhardt, G.; Buschauer, A. [(3)H]UR-MK136: a highly potent and 
selective radioligand for neuropeptide Y Y(1) receptors. ChemMedChem 2011, 6, 1566-1571. 
(59) Keller, M.; Erdmann, D.; Pop, N.; Pluym, N.; Teng, S.; Bernhardt, G.; Buschauer, A. 
Red-fluorescent argininamide-type NPY Y1 receptor antagonists as pharmacological tools. 
Bioorg. Med. Chem. 2011, 19, 2859-2878. 
(60) Keller, M.; Weiss, S.; Hutzler, C.; Kuhn, K. K.; Mollereau, C.; Dukorn, S.; Schindler, L.; 
Bernhardt, G.; König, B.; Buschauer, A. N(omega)-carbamoylation of the argininamide 
moiety: an avenue to insurmountable NPY Y1 receptor antagonists and a radiolabeled 
selective high-affinity molecular tool ([(3)H]UR-MK299) with extended residence time. J. 
Med. Chem. 2015, 58, 8834-8849. 
(61) Kanatani, A.; Kanno, T.; Ishihara, A.; Hata, M.; Sakuraba, A.; Tanaka, T.; Tsuchiya, Y.; 
Mase, T.; Fukuroda, T.; Fukami, T.; Ihara, M. The novel neuropeptide Y Y(1) receptor 
  
 
20  Chapter 1 
 
antagonist J-104870: a potent feeding suppressant with oral bioavailability. Biochem. 
Biophys. Res. Commun. 1999, 266, 88-91. 
(62) Griffith, D. A.; Hargrove, D. M.; Maurer, T. S.; Blum, C. A.; De Lombaert, S.; 
Inthavongsay, J. K.; Klade, L. E.; Mack, C. M.; Rose, C. R.; Sanders, M. J.; Carpino, P. A. 
Discovery and evaluation of pyrazolo[1,5-a]pyrimidines as neuropeptide Y1 receptor 
antagonists. Bioorg. Med. Chem. Lett. 2011, 21, 2641-2645. 
(63) Hipskind, P. A.; Lobb, K. L.; Nixon, J. A.; Britton, T. C.; Bruns, R. F.; Catlow, J.; 
Dieckman-McGinty, D. K.; Gackenheimer, S. L.; Gitter, B. D.; Iyengar, S.; Schober, D. A.; 
Simmons, R. M.; Swanson, S.; Zarrinmayeh, H.; Zimmerman, D. M.; Gehlert, D. R. Potent and 
selective 1,2,3-trisubstituted indole NPY Y-1 antagonists. J. Med. Chem. 1997, 40, 3712-3714. 
(64) Zarrinmayeh, H.; Zimmerman, D. M.; Cantrell, B. E.; Schober, D. A.; Bruns, R. F.; 
Gackenheimer, S. L.; Ornstein, P. L.; Hipskind, P. A.; Britton, T. C.; Gehlert, D. R. Structure-
activity relationship of a series of diaminoalkyl substituted benzimidazole as neuropeptide Y 
Y1 receptor antagonists. Bioorg. Med. Chem. Lett. 1999, 9, 647-652. 
(65) Sit, S. Y.; Huang, Y.; Antal-Zimanyi, I.; Ward, S.; Poindexter, G. S. Novel 
dihydropyrazine analogues as NPY antagonists. Bioorg. Med. Chem. Lett. 2002, 12, 337-340. 
(66) Leslie, C. P.; Di Fabio, R.; Bonetti, F.; Borriello, M.; Braggio, S.; Dal Forno, G.; Donati, 
D.; Falchi, A.; Ghirlanda, D.; Giovannini, R.; Pavone, F.; Pecunioso, A.; Pentassuglia, G.; Pizzi, 
D. A.; Rumboldt, G.; Stasi, L. Novel carbazole derivatives as NPY Y1 antagonists. Bioorg. Med. 
Chem. Lett. 2007, 17, 1043-1046. 
(67) Gehlert, D. R.; Beavers, L. S.; Johnson, D.; Gackenheimer, S. L.; Schober, D. A.; Gadski, 
R. A. Expression cloning of a human brain neuropeptide Y Y2 receptor. Mol. Pharmacol. 
1996, 49, 224-228. 
(68) Grouzmann, E.; Buclin, T.; Martire, M.; Cannizzaro, C.; Dorner, B.; Razaname, A.; 
Mutter, M. Characterization of a selective antagonist of neuropeptide Y at the Y2 receptor. 
Synthesis and pharmacological evaluation of a Y2 antagonist. J. Biol. Chem. 1997, 272, 7699-
7706. 
(69) Doods, H.; Gaida, W.; Wieland, H. A.; Dollinger, H.; Schnorrenberg, G.; Esser, F.; Engel, 
W.; Eberlein, W.; Rudolf, K. BIIE0246: a selective and high affinity neuropeptide Y Y(2) 
receptor antagonist. Eur. J. Pharmacol. 1999, 384, R3-5. 
  
 
  General Introduction 21 
 
 
(70) Pluym, N.; Baumeister, P.; Keller, M.; Bernhardt, G.; Buschauer, A. [(3)H]UR-PLN196: 
a selective nonpeptide radioligand and insurmountable antagonist for the neuropeptide Y 
Y(2) receptor. ChemMedChem 2013, 8, 587-593. 
(71) Andres, C. J.; Antal Zimanyi, I.; Deshpande, M. S.; Iben, L. G.; Grant-Young, K.; 
Mattson, G. K.; Zhai, W. Differentially functionalized diamines as novel ligands for the NPY2 
receptor. Bioorg. Med. Chem. Lett. 2003, 13, 2883-2885. 
(72) Mittapalli, G. K.; Vellucci, D.; Yang, J.; Toussaint, M.; Brothers, S. P.; Wahlestedt, C.; 
Roberts, E. Synthesis and SAR of selective small molecule neuropeptide Y Y2 receptor 
antagonists. Bioorg. Med. Chem. Lett. 2012, 22, 3916-3920. 
(73) Bonaventure, P.; Nepomuceno, D.; Mazur, C.; Lord, B.; Rudolph, D. A.; Jablonowski, J. 
A.; Carruthers, N. I.; Lovenberg, T. W. Characterization of N-(1-Acetyl-2,3-dihydro-1H-indol-6-
yl)-3-(3-cyano-phenyl)-N-[1-(2-cyclopentyl-eth yl)-piperidin-4yl]acrylamide (JNJ-5207787), a 
small molecule antagonist of the neuropeptide Y Y2 receptor. J. Pharmacol. Exp. Ther. 2004, 
308, 1130-1137. 
(74) Shoblock, J. R.; Welty, N.; Nepomuceno, D.; Lord, B.; Aluisio, L.; Fraser, I.; Motley, S. 
T.; Sutton, S. W.; Morton, K.; Galici, R.; Atack, J. R.; Dvorak, L.; Swanson, D. M.; Carruthers, N. 
I.; Dvorak, C.; Lovenberg, T. W.; Bonaventure, P. In vitro and in vivo characterization of JNJ-
31020028 (N-(4-{4-[2-(diethylamino)-2-oxo-1-phenylethyl]piperazin-1-yl}-3-fluorophenyl)-2- 
pyridin-3-ylbenzamide), a selective brain penetrant small molecule antagonist of the 
neuropeptide Y Y(2) receptor. Psychopharmacology (Berl). 2010, 208, 265-277. 
(75) Brothers, S. P.; Saldanha, S. A.; Spicer, T. P.; Cameron, M.; Mercer, B. A.; Chase, P.; 
McDonald, P.; Wahlestedt, C.; Hodder, P. S. Selective and brain penetrant neuropeptide y y2 
receptor antagonists discovered by whole-cell high-throughput screening. Mol. Pharmacol. 
2010, 77, 46-57. 
(76) Cabrele, C.; Wieland, H. A.; Koglin, N.; Stidsen, C.; Beck-Sickinger, A. G. Ala31-Aib32: 
identification of the key motif for high affinity and selectivity of neuropeptide Y at the Y5-
receptor. Biochemistry 2002, 41, 8043-8049. 
(77) Erondu, N.; Gantz, I.; Musser, B.; Suryawanshi, S.; Mallick, M.; Addy, C.; Cote, J.; Bray, 
G.; Fujioka, K.; Bays, H.; Hollander, P.; Sanabria-Bohorquez, S. M.; Eng, W.; Langstrom, B.; 
Hargreaves, R. J.; Burns, H. D.; Kanatani, A.; Fukami, T.; MacNeil, D. J.; Gottesdiener, K. M.; 
Amatruda, J. M.; Kaufman, K. D.; Heymsfield, S. B. Neuropeptide Y5 receptor antagonism 
  
 
22  Chapter 1 
 
does not induce clinically meaningful weight loss in overweight and obese adults. Cell Metab 
2006, 4, 275-282. 
(78) Walker, M. W.; Wolinsky, T. D.; Jubian, V.; Chandrasena, G.; Zhong, H.; Huang, X.; 
Miller, S.; Hegde, L. G.; Marsteller, D. A.; Marzabadi, M. R.; Papp, M.; Overstreet, D. H.; 
Gerald, C. P.; Craig, D. A. The novel neuropeptide Y Y5 receptor antagonist Lu AA33810 [N-
[[trans-4-[(4,5-dihydro[1]benzothiepino[5,4-d]thiazol-2-yl)amino]cyclohexyl]me thyl]-
methanesulfonamide] exerts anxiolytic- and antidepressant-like effects in rat models of 
stress sensitivity. J. Pharmacol. Exp. Ther. 2009, 328, 900-911. 
(79) Itani, H.; Ito, H.; Sakata, Y.; Hatakeyama, Y.; Oohashi, H.; Satoh, Y. Novel potent 
antagonists of human neuropeptide Y Y5 receptors. Part 2: substituted 
benzo[a]cycloheptene derivatives. Bioorg. Med. Chem. Lett. 2002, 12, 757-761. 
(80) Norman, M. H.; Chen, N.; Chen, Z.; Fotsch, C.; Hale, C.; Han, N.; Hurt, R.; Jenkins, T.; 
Kincaid, J.; Liu, L.; Lu, Y.; Moreno, O.; Santora, V. J.; Sonnenberg, J. D.; Karbon, W. Structure-
activity relationships of a series of pyrrolo[3,2-d]pyrimidine derivatives and related 
compounds as neuropeptide Y5 receptor antagonists. J. Med. Chem. 2000, 43, 4288-4312. 
(81) Block, M. H.; Boyer, S.; Brailsford, W.; Brittain, D. R.; Carroll, D.; Chapman, S.; Clarke, 
D. S.; Donald, C. S.; Foote, K. M.; Godfrey, L.; Ladner, A.; Marsham, P. R.; Masters, D. J.; Mee, 
C. D.; O'Donovan, M. R.; Pease, J. E.; Pickup, A. G.; Rayner, J. W.; Roberts, A.; Schofield, P.; 
Suleman, A.; Turnbull, A. V. Discovery and optimization of a series of carbazole ureas as 
NPY5 antagonists for the treatment of obesity. J. Med. Chem. 2002, 45, 3509-3523. 
(82) Kawanishi, Y.; Takenaka, H.; Hanasaki, K.; Okada, T. Preparation of sulfonamides and 
sulfinamides as NPY Y5 antagonists. WO 2001037826, 2001, Chem. Abstr. 135:19547. 
(83) Sato, N.; Takahashi, T.; Shibata, T.; Haga, Y.; Sakuraba, A.; Hirose, M.; Sato, M.; 
Nonoshita, K.; Koike, Y.; Kitazawa, H.; Fujino, N.; Ishii, Y.; Ishihara, A.; Kanatani, A.; Fukami, T. 
Design and synthesis of the potent, orally available, brain-penetrable arylpyrazole class of 
neuropeptide Y5 receptor antagonists. J. Med. Chem. 2003, 46, 666-669. 
(84) Daniels, A. J.; Matthews, J. E.; Slepetis, R. J.; Jansen, M.; Viveros, O. H.; Tadepalli, A.; 
Harrington, W.; Heyer, D.; Landavazo, A.; Leban, J. J.; Spaltenstein, A. High-affinity 
neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 9067-9071. 
(85) Parker, E. M.; Babij, C. K.; Balasubramaniam, A.; Burrier, R. E.; Guzzi, M.; Hamud, F.; 
Mukhopadhyay, G.; Rudinski, M. S.; Tao, Z.; Tice, M.; Xia, L.; Mullins, D. E.; Salisbury, B. G. 
GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent 
  
 
  General Introduction 23 
 
 
neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur. J. 
Pharmacol. 1998, 349, 97-105. 
(86) Matthews, J. E.; Jansen, M.; Lyerly, D.; Cox, R.; Chen, W. J.; Koller, K. J.; Daniels, A. J. 
Pharmacological characterization and selectivity of the NPY antagonist GR231118 (1229U91) 
for different NPY receptors. Regul. Pept. 1997, 72, 113-119. 
(87) Balasubramaniam, A.; Mullins, D. E.; Lin, S.; Zhai, W.; Tao, Z.; Dhawan, V. C.; Guzzi, 
M.; Knittel, J. J.; Slack, K.; Herzog, H.; Parker, E. M. Neuropeptide Y (NPY) Y4 receptor 
selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective 
agonist with picomolar affinity. J. Med. Chem. 2006, 49, 2661-2665. 
(88) Berlicki, L.; Kaske, M.; Gutierrez-Abad, R.; Bernhardt, G.; Illa, O.; Ortuno, R. M.; 
Cabrele, C.; Buschauer, A.; Reiser, O. Replacement of Thr32 and Gln34 in the C-terminal 
neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane beta-amino acids 
shifts selectivity toward the Y(4) receptor. J. Med. Chem. 2013, 56, 8422-8431. 
(89) Oestergaard, S.; Knudsen, S. M.; Spetzler, J.; Joergensen, R.; Kofoed, J. Long-acting Y2 
and/or Y4 receptor agonists, PYY or PP peptide derivs. with serum albumin binding side 
chains comprising a distal tetrazole or carboxylic acid group. WO 2009138511, 2009, Chem. 
Abstr. 151:577542. 
(90) Made, V.; Bellmann-Sickert, K.; Kaiser, A.; Meiler, J.; Beck-Sickinger, A. G. Position and 
length of fatty acids strongly affect receptor selectivity pattern of human pancreatic 
polypeptide analogues. ChemMedChem 2014, 9, 2463-2474. 
(91) Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent argininamide-type 
neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation. 
ChemMedChem 2009, 4, 1733-1745. 
(92) Keller, M.; Kaske, M.; Holzammer, T.; Bernhardt, G.; Buschauer, A. Dimeric 
argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 
and Y4 receptors. Bioorg. Med. Chem. 2013, 21, 6303-6322. 
(93) Sliwoski, G.; Schubert, M.; Stichel, J.; Weaver, D.; Beck-Sickinger, A. G.; Meiler, J. 
Discovery of Small-Molecule Modulators of the Human Y4 Receptor. PLoS One 2016, 11, 
e0157146. 
(94) Ewing, W. R.; Zhu, Y.; Sun, C.; Huang, Y.; Karatholuvhu, M. S.; Bolton, S. A.; Pasunoori, 
L.; Mandal, S. K.; Sher, P. M. Diaminocyclohexane compounds as NPY Y4 receptor modulator 
and their preparation. US 20130184284, 2013, Chem. Abstr. 159:245258. 
  
 
24  Chapter 1 
 
(95) Batterham, R. L.; Le Roux, C. W.; Cohen, M. A.; Park, A. J.; Ellis, S. M.; Patterson, M.; 
Frost, G. S.; Ghatei, M. A.; Bloom, S. R. Pancreatic polypeptide reduces appetite and food 
intake in humans. J. Clin. Endocrinol. Metab. 2003, 88, 3989-3992. 
(96) Akerberg, H.; Meyerson, B.; Sallander, M.; Lagerstedt, A. S.; Hedhammar, A.; 
Larhammar, D. Peripheral administration of pancreatic polypeptide inhibits components of 
food-intake behavior in dogs. Peptides 2010, 31, 1055-1061. 
(97) Sainsbury, A.; Shi, Y. C.; Zhang, L.; Aljanova, A.; Lin, Z.; Nguyen, A. D.; Herzog, H.; Lin, 
S. Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and 
brain-derived neurotropic factor dependent pathways. Neuropeptides 2010, 44, 261-268. 
(98) Sainsbury, A.; Baldock, P. A.; Schwarzer, C.; Ueno, N.; Enriquez, R. F.; Couzens, M.; 
Inui, A.; Herzog, H.; Gardiner, E. M. Synergistic effects of Y2 and Y4 receptors on adiposity 
and bone mass revealed in double knockout mice. Mol. Cell. Biol. 2003, 23, 5225-5233. 
(99) Gehlert, D. R.; Schober, D. A.; Gackenheimer, S. L.; Beavers, L.; Gadski, R.; Lundell, I.; 
Larhammar, D. [125I]Leu31, Pro34-PYY is a high affinity radioligand for rat PP1/Y4 and Y1 
receptors: evidence for heterogeneity in pancreatic polypeptide receptors. Peptides 1997, 
18, 397-401. 
(100) Berglund, M. M.; Lundell, I.; Eriksson, H.; Soll, R.; Beck-Sickinger, A. G.; Larhammar, D. 
Studies of the human, rat, and guinea pig Y4 receptors using neuropeptide Y analogues and 
two distinct radioligands. Peptides 2001, 22, 351-356. 
(101) Dumont, Y.; Moyse, E.; Fournier, A.; Quirion, R. Distribution of peripherally injected 
peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the CNS: 
enrichment in the area postrema. J. Mol. Neurosci. 2007, 33, 294-304. 
  
 
  High Affinity Agonists of the NPY Y4 Receptor 25 
 
 
 
Chapter 2 
High Affinity Agonists of the Neuropeptide Y 
(NPY) Y4 Receptor Derived from the C-
terminal Pentapeptide of Human Pancreatic 
Polypeptide (hPP): Synthesis, Stereochemical 
Discrimination and Radiolabeling 
 
 
 
Note: Prior to the submission of this thesis, parts of this chapter were published in 
cooperation with partners: 
Kuhn, K.; Ertl, T.; Dukorn, S., Keller, M.; Bernhardt, G.; Reiser, O.; Buschauer, A. High affinity 
agonists of the neuropeptide Y (NPY) Y4 receptor derived from the C-terminal pentapeptide 
of human pancreatic polypeptide (hPP): synthesis, stereochemical discrimination and 
radiolabeling. J. Med. Chem. 2016, 59, 6045-6058. 
The following experiments were performed by co-authors: 
T.E.: Synthesis of 2.6, 2.7 and 2.8 
S.D.: Luciferase assay on HEK293-hY4-CRE Luc cells 
M.K.: Synthesis of 2.11 and support in the radio synthesis of [3H]2.10 and [3H]2.18 
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2.1  Introduction 
Neuropeptide Y (NPY), peptide YY (PYY) and pancreatic polypeptide (PP) consist of 36 amino 
acids and share considerable sequence similarities (Figure 1).1-3 NPY, PYY and PP activate 
NPY receptors, in humans comprising four functional subtypes of G-protein coupled 
receptors (Y1R, Y2R, Y4R, Y5R), which are involved in the regulation of numerous central and 
peripheral biological processes.4 The Y4R shares only low sequence identity with the other 
subtypes (e.g. 42% sequence identity of hY4R with hY1R
5) and is an exception as it prefers PP 
over NPY and PYY.5 The Y4R is considered to play a role, for example, in feeding behavior and 
the regulation of energy metabolism.6,7 Recently, Y4R agonists were proposed as putative 
anti-obesity agents.8,9 Therefore, there is a need for high affinity Y4R ligands, agonists as well 
as antagonists, to explore the potential of the Y4R as a biological target. 
Previous work from different groups suggests that connecting two pharmacophoric moieties 
favors Y4R binding, in particular, in case of peptidic agonists such as GW1229 and 2.2 (BVD-
74D) (Figure 2), which are derived from the C-terminal pentapeptide of hNPY or hPP, 
respectively. UR-MK18810 is an example of a Y4R antagonist, composed of two molecules of 
an argininamide-type Y1R antagonist ((R)-4-guanidino-1-({[(4-hydroxyphenyl)methyl]amino}-
carbonyl)butyl-α-phenylbenzeneacetamide, BIBP3226),11 which are connected via the 
guanidine groups. Generally, the arginine residues in positions 33 and 35 of the endogenous 
peptides are important for NPY receptor binding.12 Similarly, the arginine moieties are 
considered crucial structural features of the Y4R ligands mentioned above. The ͞diŵeƌic 
peptide͟ GW1229 (also known as GR23118 or 1229U91)13 is both, a high-affinity antagonist 
at the Y1R and an agonist at the Y4R.
14 The pentapeptide sequence Tyr-Arg-Leu-Arg-Tyr-NH2 
in GW1229 is very similar to the C-teƌŵiŶal seƋueŶĐe of hPP ;…Thƌ32-Arg33-Pro34-Arg35-Tyr36-
NH2). D/L-2,7-diaminooctanedioyl-bis(YRLRY-NH2) (BVD-74D, 2.2),
15 comprising the same 
pentapeptide moieties as GW1229, but a different linker, is more selective for the Y4R. Data 
reported for 2.2 refer to the diastereomeric mixture of (2R,7R)-2.2 and (2S,7S)-2.2,15 not to a 
single stereoisomer (note: in the following, positions 2 and 7 refer to the stereo centers in 
the 2,7-diaminosuberic acid moiety). 
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Figure 1. Amino acid sequences of human NPY, PYY and PP 
 
 
Figure 2. Structures of the described NPY Y1R antagonist/Y4R agonist GW1229, the Y4R agonist 2.2, 
and the Y1R/Y4R antagonist UR-MK188. Dpr: L-2,3-diaminopropionic acid; 2.2 was previously 
described as a mixture of two diastereomers due to (2R,7R)- and (2S,7S)-configuration of the 2,7-
diaminosuberic acid linker. 
Here we report on the synthesis and pharmacological characterization of the pure 
stereoisomers (2R,7R)-2.2 and (2S,7S)-2.2. Very recently, a pilot study from our laboratory 
suggested that the amino groups in the linker of 2.2 are dispensable.16 Therefore, we 
synthesized a set of analogues using octanedioic acid instead of 2,7-diaminosuberic acid as 
linker. To investigate the contribution of the individual arginines to the Y4R affinity of the 
dimers, we prepared compounds in which one or two Arg moieties in the pentapeptide 
ďuildiŶg ďloĐk ǁeƌe ƌeplaĐed ďǇ Ala. Fuƌtheƌŵoƌe, the suitaďilitǇ of the ͚diŵeƌiĐ͛ 
pentapeptides as precursors for the preparation of radiolabeled compounds was explored, 
the target compounds were characterized in functional assays, and two tritiated derivatives 
were synthesized and used to perform Y4R binding studies. 
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2.2  Results and Discussion 
2.2.1  Chemistry 
The enantiopure 2,7-diaminooctanedioic acids were synthesized from (S)- and (R)-2-
allylglycine via the N-Boc protected esters (S)-2.5 and (R)-2.5 (Scheme 1) by analogy with 
procedures from the literature.17,18 The enantiomers of 2.5 were submitted to a cross-
ŵetathesis ƌeaĐtioŶ, eŵploǇiŶg Gƌuďďs͛ II ĐatalǇst to ďuild up the Đoƌe stƌucture 2.6. After 
exchanging the solvent (DCM) with ethanol, compound 2.6 was not isolated, but 
hydrogenated at 20 bar in the presence of the same catalyst,19,20 in contrast to reported 
procedures requiring workup of 2.6 and Pd/C catalyzed hydrogenation.21 Besides the 
convenience of this protocol, overall yields were improved, affording (2R,7R)-2.7 and (2S,7S)-
2.7 in 95% and 74% yield, respectively, over two steps. Hydrolysis of the ethyl ester 
quantitatively provided the diacids (2R,7R)-2.8 and (2S,7S)-2.8. 
 
Scheme 1. Enantioselective synthesis of the diacids (2R,7R)-2.8 and (2S,7S)-2.8a 
 
a(2S,7S)-2.8 was prepared according to the same protocol using (S)-2-allylglycine as starting material. 
Reagents and conditions: (a) Boc2O, 1 M NaOH/dioxane (2:1), 0 °C to rt, 18 h; (b) DCC, 4-DMAP, EtOH, 
DCM, Ϭ °C to ƌt, ϭϮ h; ;ĐͿ Ϭ.ϭ eƋuiǀ Gƌuďďs͛ II ĐatalǇst, aŶhǇdƌous DCM, N2 atmosphere, reflux, 12 h; 
compd. 2.6 ǁas Ŷot isolated, ďut suďjeĐted to hǇdƌogeŶatioŶ iŶ the Ŷeǆt step; ;dͿ Ϭ.ϭ eƋuiǀ Gƌuďďs͛ II 
catalyst (from reaction step (c)), ethanol, H2 (20 bar), rt, 15 h (95% for (R,R)-2.7, 74% for (S,S)-2.7 
over two steps, (c) and (d)); (e) 1 M NaOH, EtOH, rt, 21 h (quant.). 
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Peptide synthesis was carried out manually on a Sieber-amide resin applying an Fmoc 
pƌotoĐol aŶd ͚douďle͛ ĐoupliŶg pƌoĐeduƌes ǁith HBTU/HOBt/DIPEA ;“Đheŵe ϮͿ. Afteƌ 
cleavage from the resin, two equivalents of the protected pentapeptide 2.916 were cross-
linked with the in situ activated (R,R)- and (S,S)-configured enantiomers of 2,7-
diaminosuberic acid (2.8) to obtain the corresponding peptides (2R,7R)-2.2 and (2S,7S)-2.2 
after deprotection. Subsequent acylation (monitored by HPLC) of an excess of precursor with 
succinimidyl propionate gave the propionamides (2R,7R)-2.10 (for preparation of [3H]-
labeled form see below) and (2S,7S)-2.10. With respect to labeling of compounds devoid of 
amino groups in the linker (Scheme 3), we introduced the recently reported arginine 
derivative 2.11 (Figure 3), in which the guanidine group is replaced by a nonclassical 
bioisostere, a functionalized carbamoylguanidine moiety.16 
Scheme 2. Synthesis of (2R,7R)-2.2 and (2S,7S)-2.2 and the propionylated analogues (2R,7R)-2.10 and 
(2S,7S)-2.10a 
 
aReagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), 
solǀeŶt: DMF/NMP ;ϴ:ϮͿ, ͚douďle͛ ĐoupliŶg at ƌt, ϲϬ ŵiŶ; Fmoc deprotection was carried out with 
20% piperidine in DMF/NMP (8:2), rt, 2 × 10 min; (b) DCM/TFA (97:3), 10 × 6 min; (c) HBTU, HOBt, 
DIPEA, anhydrous DMF, 35 °C, 16 h; (d) TFA/H2O (95:5), rt, 2.5 h; (e) succinimidyl propionate, 3% 
DIPEA in anhydrous DMF, rt, 2 h. 
 
 
Figure 3. Structure of the Nω-carbamoylated arginine building block 2.11.16 
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For the preparation of the homodimeric ligands (2.16, 2.19, 2.21, 2.27-2.30) shown in 
Scheme 3, octanedioic acid, activated as di-succinimidyl ester (2.1222), was used for cross-
linking (Scheme 3). By contrast, as a building block for the synthesis of heterodimeric ligands 
(2.17,16 2.18,16 2.20, 2.22,), compound 2.1316 was prepared by coupling suberic acid 
monomethyl ester to the resin-bound peptide sequence Tyr(tBu)-Arg(Pbf)-Leu-Arg(Pbf)-
Tyr(tBu). The side-chain protected peptides 2.14, 2.15 and 2.23-2.26 were treated with 2.12 
to give 2.16,16 2.19 and 2.21 and 2.27-2.30), whereas in situ activated 2.13 was coupled to 
the side-chain protected peptides 2.14 and 2.15 for the preparation of the heterodimeric 
ligands 2.20 and 2.22, respectively. By analogy with the synthesis of the potential 
radioligands (2S,7S)-2.10 and (2R,7R)-2.10, the precursor 2.1716 was treated with 
succinimidyl propionate to give 2.18 as described very recently.16 
 
  
 
Scheme 3. Synthesis of homo- and heterodimeric Y4R ligands
a
 
 
  
 
a
Reagents and conditions: (a) cf. legend to Scheme 2; (b) DCM/TFA (97:3), 10 × 6 min; (c) 1 equiv of 2.12 in 1% DIPEA in anhydrous DMF, followed by 2.5 equiv of 2.9, 2.14, 
15, or 2.23-2.26, 35 °C, 16 h; (d) TFA/H2O (95:5), rt, 2.5 h; (e) suberic acid monomethyl ester/HBTU/HOBt/DIPEA (4/4/4/8 equiv), solvent: DMF/NMP (8:2), single coupling at 
30 °C, 14 h; (f) 0.5 M NaOH/MeOH (1:5), reflux, 3 h; (g) 2.11/HBTU/HOBt/DIPEA (3/3/3/6 equiv), solvent: DMF/NMP (8:2), single coupling at 35 °C, 16 h; (h) 
2.13/HBTU//HOBt/DIPEA (1/1/1/2 equiv), solvent: DMF/NMP (8:2), single coupling at 35 °C, 16 h; (i) succinimidyl propionate, DMF, DIPEA, rt, 2 h; (j) 
2.13/HBTU/HOBt/DIPEA (1/1/1/3.5 equiv), solvent: DMF, rt, 5 min, subsequent addition of 1.1 equiv of 2.14 or 2.15, rt, 17 h. 
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2.2.2  Synthesis of the Radiolabeled Ligands [
3
H]2.10 and [
3
H]2.18 
Based on the results obtained in the functional assays (see below), (2R,7R)-2.10 and 2.18 
were selected for the synthesis of the corresponding tritiated versions. An 8-fold excess of 
the precursor peptides (2R,7R)-2.2 and 2.1716 was treated with commercially available 
succinimidyl [3H]propionate (Scheme 4). The radioligands were obtained in high 
radiochemical purities (Figure 4A and Figure 4C). After storage of the radioligands in a 
mixture of EtOH/H2O (1:1) at -20 °C over 9 months, approximately 10% were decomposed 
(Figure 4B and Figure 4D). No decomposition was observed after an incubation period of 48 
h, ǁheŶ the ͚Đold͛ aŶalogues, ;ϮR,7R)-2.10 and 2.18, were investigated for stability (Figure 
5A and Figure 5B) in a HEPES buffer (buffer I, pH 7.4). 
 
 
Scheme 4. Synthesis of the radioligands [3H]2.10 and [3H]2.18 by propionylation of the precursors 
(2R,7R)-2.2 and 2.17a 
 
 
 aRadiochemical yield: 34% ([3H]2.10), 30% ([3H]2.18). 
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Figure 4. Purity, identity control and long-term stability of the radiolabeled peptides [3H]2.10 and 
[3H]2.18. (A) HPLC analysis of [3H]2.10 (ca. 0.35 µMͿ spiked ǁith ͚Đold͛ ;ϮR,7R)-2.10 (5 µM), analyzed 
3 days after synthesis. Radiochemical purity > 99%. (B) HPLC analysis of [3H]2.10 (ca. 0.25 µM) spiked 
ǁith ͚Đold͛ ;2R,7R)-2.10 (13 µM), analyzed after 9 months of storage at -20 °C in EtOH/H2O (1:1). 
Radiochemical purity: 87%. (C) HPLC analysis of [3H]2.18 (ca. 0.35 µMͿ spiked ǁith ͚Đold͛ 2.18 (5 µM), 
analyzed 10 days after synthesis. Radiochemical purity > 99%. (D) HPLC analysis of [3H]2.18 (ca. 0.25 
µMͿ spiked ǁith ͚Đold͛ 2.18 (13 µM), analyzed after 9 months of storage at -20 °C in EtOH/H2O (1:1). 
Radiochemical purity: 90%. The minor differences in tR result from serial detection of the UV and 
radiometric signals. 
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Figure 5. HPLC aŶalǇsis of ͚Đold͛ ;ϮR,7R)-2.10 (A) and 2.18 (B) after incubation in buffer I (HEPES 
buffer, sodium-free) (pH 7.4) for up to 48 h. Both compounds showed no decomposition. Peaks 
between 0 and 5 min correspond to buffer components. 
 
2.2.3  Functional Studies at the hY4R 
The target compounds were investigated for Y4R agonism in an aequorin Ca
2+ assay23 and a 
luciferase gene reporter assay on genetically engineered CHO and HEK293 cells, respectively 
(data cf. Table 1 and Figure 6). The configuration of the stereo centers in the 2,7-
diaminosuberic acid linker in 2.2 had an impact on Y4R potency. In the luciferase assay 
(2R,7R)-2.2 (EC50 = 1.6 nM) was 12 times more potent than (2S,7S)-2.2 (EC50 = 19 nM). In the 
aequorin assay the difference in potency was less pronounced (EC50 values: 6.9 nM ((2R,7R)-
2.2) vs. 18 nM ((2S,7S)-2.2)). The same tendency became obvious for the propionylated 
analogues (2R,7R)-2.10 and (2S,7S)-2.10 in both assays. Generally, propionylation of an 
amino group of the linker did only slightly (by a factor of two) affect Y4R potency in both 
assays. 
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Table 1. NPY Y4R agonist potencies (EC50) and intrinsic activities (αͿ of ͛diŵeƌiĐ͚ peŶtapeptides aŶd 
reference compounds PP and GW1229. 
 Aequorin assay
 a
  Luciferase assay
b
  
Compd. EC50 [nM]
 α EC50 [nM] α 
PP 9.7 ± 0.4 1 0.73 ± 0.2 1 
GW1229 8.5c 0.62 5.5 ± 0.8 1.01 
(2R,7R)-2.2 6.9 ± 0.6 0.75 1.6 ± 0.6 1.03 
(2S,7S)-2.2 18 ± 1.6 0.78 19 ± 4.8 1.07 
(2R,7R)-2.10 14 ± 2.0 0.76 4.0 ± 0.9 1.00 
(2S,7S)-2.10 59 ± 5.6 0.70 27 ± 4.6 0.98 
2.16 49 ± 13 0.73 86 ± 16 0.93 
2.17 6.4 ± 1.3 0.80 1.7 ± 0.2 1.06 
2.18 13 ± 1.1 0.67 7.1 ± 1.9 1.05 
2.19 >3000 - >3000 - 
2.20 290 ± 33 0.85 160 ± 29 0.98 
2.21 >3000 - >3000 - 
2.22 310 ± 38 0.85 150 ± 18 0.99 
2.27 >3000 - - - 
2.28 >3000 - - - 
2.29 486 ± 45 0.41 - - 
2.30 >3000 - - - 
aAequorin calcium mobilization assay on CHO-hY4-Gqi5-mtAEQ cells.
23 bCRE-luciferase reporter gene 
assay on HEK293 cells stably co-expressing the hY4R and the CRE-controlled luciferase gene reporter. 
Y4R agonist potency was determined from the inhibition of forskolin (2 µM) stimulated luciferase 
activity. The maximal response (intrinsic activity, α) is referred to the effect of PP set to α = 1.0. cEC50 
value reported by Ziemek et al.23 
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Figure 6. Y4R agonism of PP, GW1229, 2.2, 2.10, 2.16-2.22 and 2.29 determined in a calcium 
(aequorin) assay and a luciferase reporter gene assay. (A), (B) and (C) Concentration-response curves 
(CRCs) from an aequorin assay on CHO-hY4R-mtAEQ-Gqi5 cells. Mean values ± SEM were from at least 
3 independent experiments (performed in triplicate). (D), (E) and (F) Inhibition of forskolin-stimulated 
(2 µM) luciferase activity (corresponding to 100%) in hY4R expressing HEK293 cells by PP, GW1229, 
2.2, 2.10 and 2.16-2.22 with the maximum inhibitory effect of the endogenous ligand PP which is set 
to 0% luciferase activity and corresponds to full agonism (α = 1.0). Data points shown are the mean ± 
SEM of at least three independent experiments performed in triplicate. 
Except for 2.17 and 2.18, compounds devoid of an amino group in the linker were 
significantly less potent Y4‘ agoŶists. IŶteƌestiŶglǇ, ƌeplaĐeŵeŶt of oŶe of the ͛iŶŶeƌ 
aƌgiŶiŶes͚ iŶ 2.16 by the NG-carbamoylated arginine 2.11 considerably increased Y4R agonist 
potency (2.17, EC50: 6.4 nM and 1.7 nM in the aequorin assay and the luciferase assay, 
respectively), that is, 2.17 was equipotent with (2R,7R)-2.2. As observed for the 
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stereoisomers of 2.2 and 2.10, propionylation of 2.17, resulting in the derivative 2.18, led 
only to a minor decrease in Y4R potency. 
The homodimeric compounds 2.19, 2.21, 2.27 and 2.28 in which two amino acids were 
replaced by alanine, proved to be inactive at the Y4R. Only 2.29 in which the tyrosine 
adjacent to the linker was replaced with alanine was still active at the Y4R (EC50 = 486 nM in 
the aequorin assay), suggesting that the presence of at least one unaltered tetrapeptide 
sequence Arg-Leu-Arg-Tyr-NH2 is indispensable. Compounds 2.20 and 2.22, in which only 
one Arg was replaced by Ala, were less potent than 2.16 by a factor of 5 to 6 in the aequorin 
assay and by a factor of 2 in the luciferase assay. Considering the high affinity of the 
endogenous ligand PP, the C-terminal pentapeptide of PP was applied as a putatively 
superior scaffold for dimeric Y4R agonists. However, compound 2.30, a dimer of the C-
terminal pentapeptide of PP, was inactive at the Y4R. Except for the homodimeric 
compounds that were inactive at the Y4R, all investigated compounds were partial agonists 
in the aequorin assay (intrinsic activities between 40% and 85% referred to hPP), but full 
agonists in the luciferase assay. Moreover, the potencies obtained in the luciferase assay 
were on average slightly higher than those obtained in the aequorin assay, presumably due 
to more pronounced signal amplification in the gene reporter assay.24 
 
2.2.4  Characterization of [
3
H]2.10 and [
3
H]2.18 
Saturation binding experiments with the tritiated radioligands (Figure 7A and Figure 8A), 
performed on intact CHO-hY4-Gqi5-mtAEQ cells in buffer I (HEPES, sodium-free) as used by 
Balasubramaniam et al.15 to investigate the diastereomeric mixture 2.2, revealed a Kd value 
of 0.67 ± 0.1 nM for both compounds, [3H]2.10 and [3H]2.18. The number of specific binding 
sites per cell, determined with [3H]2.10 or [3H]2.18, was 320,000 ± 20,000 and 340,000 ± 
15,000, respectively. At concentrations around the Kd value, unspecific binding amounted to 
10% ([3H]2.10) and 20% ([3H]2.18), respectively, of the total binding. Association to the 
receptor was complete after 100 min (Figure 7B and Figure 8B). Dissociation from the 
receptor was biphasic (Figure 7C and Figure 8C) with a fast koff (0.0329 min
-1 for [3H]2.10 and 
0.0309 min-1 for [3H]2.18) and a slow koff (0.0024 min
-1 for [3H]2.10 and 0.0026 min-1 for 
[3H]2.18). 
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Figure 7. Y4R binding characteristics of the radioligand [
3H]2.10 determined at live CHO-hY4-Gqi5-
mtAEQ cells at 22 °C in buffer I (HEPES, sodium-free). (A) Representative saturation binding 
experiment with [3H]2.10. (B) Y4R association kinetics of [
3H]2.10 (c = 1.5 nM). Inset: Linearization 
ln[Beq/(Beq-Bt)] versus time. (C) Y4R dissociation kinetics of [
3H]2.10 (c = 1.5 nM, pre-incubation time: 
2 h) determined in the presence of a 200-fold excess of (2R,7R)-2.2. Fitting of the data according to a 
biphasic exponential decay (black curve, B = B0(1) ·e
-koff(1)t + B0(2) · e
-koff(2)t, R2 = 0.9532) resulted in a 
much better correlation than an analysis according to a monophasic exponential decay (blue dotted 
curve, B = B0· e
-kofft, R2 = 0.8321). Inset: Linearization ln[B/B0] versus time.  
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Figure 8. Y4R binding characteristics of the radioligand [
3H]2.18 determined at live CHO-hY4-Gqi5-
mtAEQ cells at 22 °C in buffer I (HEPES, sodium-free). (A) Representative saturation binding 
experiment with [3H]2.18. (B) Y4R association kinetics of [
3H]2.18 (c = 1.5 nM). Inset: Linearization 
ln[Beq/(Beq-Bt)] versus time. (C) Y4R dissociation kinetics [
3H]2.18 (c = 1.5 nM, pre-incubation time: 2 
h) determined in presence of 200-fold excess of 2.17. Fitting of the data according to a biphasic 
exponential decay (black curve, B = B0(1) · e
-koff(1)t + B0(2) · e
-koff(2)t, R2 = 0.9819) resulted in a much 
better correlation than an analysis according to a monophasic exponential decay (blue dotted curve, 
B = B0 · e
-kofft, R2 = 0.9166). Inset: Linearization ln[B/B0] versus time. 
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Table 2. Binding data of [3H]2.10 and [3H]2.18.  
 Saturation binding Binding kinetics 
radioligand Kd [nM] kobs [s
-1]c koff1 [s
-1]d koff2 [s
-1]e 
[3H]2.10 0.67 ± 0.1a 9.8  ± 2.5b 0.0467 0.0329 0.0024 
[3H]2.18 0.67 ± 0.1a  0.0262 0.0391 0.0032 
aEquilibrium dissociation constant determined on CHO-hY4-Gqi5-mtAEQ cells in buffer I; mean ± SEM 
from at least 4 independent experiments (performed in triplicate). bEquilibrium dissociation constant 
determined on CHO-hY4-Gqi5-ŵtAEQ Đells iŶ Leiďoǀitz͛ L-15 medium; mean ± SEM from at least 4 
independent experiments (performed in triplicate). cApparent association constant, mean from 3 
independent experiments (performed in triplicate). dFast dissociation constant, mean from 3 
independent experiments (performed in triplicate), calculated according to a four-parameter 
equation describing a biphasic exponential decay. eSlow dissociation constant, mean from 3 
independent experiments (performed in triplicate), calculated according to a four-parameter 
equation describing a biphasic exponential decay. Note: A kinetically derived dissociation constant 
Kd(kin) and the association rate constant kon was not calculated, as koff was ambiguous due to a fast 
(koff1) and a slow (koff2) component. 
2.2.5  Competition Binding Studies at NPY Receptor Subtypes 
Ki ǀalues of the ͚diŵeƌiĐ͛ peŶtapeptides ǁeƌe deteƌŵiŶed iŶ ĐoŵpetitioŶ ďiŶdiŶg 
experiments on live cells expressing human Y1, Y2, Y4 or Y5 receptors to determine the NPY 
receptor subtype selectivity. The unspecific binding at the respective NPY receptor 
expressing cells was low, and there was no hint to an internalization of the used 
radioligands, which might lead to a misinterpretation of the binding data. Therefore, 
investigations on a potential internalization, e. g. by acid wash experiments,16  were not 
considered necessary. 
2.2.5.1  Y4R Binding 
The ďiŶdiŶg data of the ͚diŵeƌiĐ͛ peŶtapeptides aŶd the ƌefeƌeŶĐe ĐoŵpouŶds PP, GW1229 
and UR-MK188, were determined at the Y4R, using the new radioligands [
3H]2.10 and 
[3H]2.18 (Figure 9, Figure 11). The Ki value of PP (0.65 nM) was in good agreement with 
published data (Ki: 0.50 nM,
16 0.53 nM25), whereas the affinity of UR-MK188 (Ki = 660 nM) 
was slightly lower than reported (Ki = 130 nM
10Ϳ. IŶ Đase of the ͚Đold͛ aŶalogues of the 
radioligands, (2R,7R)-2.10 (0.87 nM) and 2.18 (1.2 nM), the Ki values were in good 
agreement with the Kd values (cf. Figure 9, Figure 11, Table 2). Generally, the Ki values of the 
͚diŵeƌiĐ͛ peŶtapeptides at the Y4R were by a factor of approximately 10 lower than the EC50 
values determined in the functional assays (aequorin or luciferase assay, Table 1). 
Nevertheless, the Y4R affinities correlated with the order of potency. 
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Figure 9. Radioligand displacement curves from competition binding experiments performed with 
[3H]2.10 at CHO-hY4R-Gqi5-mtAEQ cells in buffer I. (A), (B) and (C) Displacement of [
3H]2.10 (Kd = 0.67 
nM, c = 0.6 nM). Data represent mean values ± SEM of at least 3 independent experiments, each 
performed in triplicate. 
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The diastereomeric mixture of 2.2 was previously reported15 to show Y4R agonism in the 
two-digit nM range (EC50 = 14.8 nM, cAMP assay), but much higher affinity (Ki = 0.05 nM, 
radioligand [125I]PP) determined in sodium-free HEPES buffer (buffer I), which has a broad 
application in binding experiments in the NPY field. Experiments performed with different 
buffers in our laboratory revealed that the discrepancies between functional and binding 
data aƌe, at least iŶ paƌt, Đaused ďǇ the aďseŶĐe ;ďuffeƌ IͿ oƌ pƌeseŶĐe ;Leiďoǀitz͛ L-15 
medium) of sodium ions. An exchange of the sodium-free buffer I with the Na+ containing L-
15 medium led to an increase in the Kd value of [
3H]2.10 from 0.67 nM to 9.8 nM (cf. Table 2, 
footnote b). Similarly, Ki values determined in competition binding experiments using 
[3H]2.10 in L-15 medium were by a factor of almost 10 higher (Ki values, (2R,7R)-2.2: 2.0 nM; 
(2S,7S)-2.2: 17 nM; (2R,7R)-2.10: 6.3 nM). It should be stressed that the binding constants 
determined in L-15 medium were in good agreement with the agonist potencies determined 
in the functional assays using Na+ containing buffer III or DMEM. 
 
Figure 10. Radioligand displacement curves from competition binding experiments performed with 
[3H]2.10 at CHO-hY4R-Gqi5-mtAEQ cells in Leiďoǀitz͛ Lϭϱ ŵediuŵ. Displacement of [3H]2.10 (Kd = 9.8 
nM, c = 10 nM). Data represent mean values ± SEM of at least 2 independent experiments, each 
performed in triplicate. 
 
Interestingly, the affinity of the Y4R antagonist UR-MK188 was not affected in the same way 
by an exchange of the binding buffer. The Ki value of UR-MK188 in competition binding 
experiments using the L-15 medium was even lower (Ki = 150 nM) than in experiments using 
buffer I. These results are compatible with recent insights obtained from GPCR crystal 
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stabilizers of inactive-state receptor conformations.26,27 Therefore, Na+ is expected to reduce 
the affinity of agonists binding to the active state. 
As an alternative to [3H]2.10, the radioligand [3H]2.18 is also suited for competition binding. 
The Ki values determined by displacement of [
3H]2.18 were on average slightly lower (Table 
3). 
 
Figure 11. Radioligand displacement curves from competition binding experiments performed with 
[3H]2.18 at CHO-hY4R-Gqi5-mtAEQ cells in buffer I. Displacement of [
3H]2.18 (Kd = 0.67 nM, c = 1 nM). 
Data represent mean values ± SEM of at least 3 independent experiments, each performed in 
triplicate. 
 
2.2.5.2 NPY Receptor Subtype Selectivity 
The Ki values of (2R,7R)-2.10 and 2.18, the ͛Đold͛ aŶalogues of the Ŷeǁ Y4R radioligands at 
the Y1R, Y2R and Y5R were in the three-digit ŶaŶoŵolaƌ ƌaŶge ;Taďle ϯͿ. The ͚heteƌodiŵeƌiĐ͛ 
ligands 2.20 and 2.22 were comparable with (2R,7R)-2.10 and 2.18 at the Y1R and Y5R, but 
only very weak binders at the Y2R. Ki ǀalues ǁeƌe Ŷot deteƌŵiŶed foƌ the ͚hoŵodiŵeƌiĐ͛ 
ligand 2.21, 2.27, 2.28 and 2.30 at all NPY receptors due to low affinity. The same holds for 
compound 2.19 with exception of the Y5R. Peptide dimers derived from the C-terminus of 
NPY such as GW1229 were among the first high affinity Y1R antagonists described in 
literature.13,28 Therefore, we selected (2R,7R)-2.2 and 2.17 as examples for functional 
investigations at the Y1R. In a standard Y1R model, the Fura-2 calcium assay on HEL cells, 
both compounds revealed antagonism with Kb values of 9.5 nM and 25.3 nM, respectively 
(Table 3, footnote, and Figure 12).  
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Figure 12: Inhibition of the pNPY (10 nM, EC50 = 0.87 nM) induced intracellular Ca
2+ mobilization in 
HEL cells in a Fura-2 assay. (A) Inhibition of the pNPY induced Ca2+ signal by 2.17 (Kb = 25.3 ± 3.8 nM). 
Mean ± SEM from two independent experiments. (B) Logit transformed inhibition of the pNPY 
induced Ca2+ signal by (2R,7R)-2.2 (Kb = 9.5 ± 0.12 nM). Mean ± SEM from two independent 
experiments. 
 
In case of (2R,7R)-2.2 the result disagrees with published data for the diastereomeric 
mixture 2.2, which was reported to be an agonist in a cAMP assay on Y1R expressing HEK 293 
cells.15 It may be speculated, whether the opposing qualities of action are related to the 
specific repertoire of Gq and Gi coupling
29 in HEL cells, endogenously expressing the Y1R, 
compared to genetically engineered HEK293 cells. 
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Table 3. NPY receptor binding data. 
 Y1R  Y2R   Y4R, Ki [nM]  Y5R 
 
Compd. Ki [nM]
a 
Ki [nM]
b [3H]2.10c [3H]2.10d [3H]2.18e Ki [nM]
f 
PP 440g >5000g 0.65 ± 0.13 - 0.37 ± 0.02 17g 
GW1229 - - 1.6 ± 0.34 - 1.3 ± 0.78 - 
2.2 
7.5h 1100h 1.06 ± 0.47 
(0.05h) 
- - >1000h 
(2R,7R)-2.2 440 ± 81i 830 ± 250 0.45 ± 0.14 2.0 ± 0.04 0.18 ± 0.02 1500 ± 300 
(2S,7S)-2.2 930 ± 270 950 ± 520 2.3 ± 0.16 17 ± 4.3 - 2100 ± 980 
UR-MK188 24j 920j 660 ± 140 150 ± 36 630 ± 80 >5000j 
(2R,7R)-2.10 400 ± 46 420 ± 50 0.87 ± 0.16 6.3 ± 0.8 0.32 ± 0.02 710 ± 96 
(2S,7S)-2.10 290 ± 110 750 ± 380 2.8 ± 0.44 - - 400 ± 71 
2.16 720 ± 100 1700 ± 70 3.5 ± 0.59k - - 280 ± 40 
2.17 410 ± 150l 730 ± 150 1.2 ± 0.37k - - 140 ± 1.4 
2.18 360 ± 46 1300 ± 760 1.2 ± 0.49k - 0.66 ± 0.13 220 ± 40 
2.19 >3000 >10000 >3000 - - 550 ± 5.5 
2.20 1400 ± 270 >3000 12 ± 1.6 - - 220 ± 40 
2.21 >10000 >10000 >3000 - - >10000 
  
 
2.22 1600 ± 30 >3000 11 ± 1.4 - - 460 ± 50 
2.27 >5000 >5000 >5000 - - >5000 
2.28 >5000 >5000 724 ± 168 - - 2820 ± 217 
2.29 3230 ± 690 1750 ± 394 12.2 ± 5.1 - - 3440 ± 207 
2.30 >5000 >5000 622 ± 150 - - >5000 
aRadioligand competition binding assay with [3H]UR-MK13630 (Kd = 6.2 nM, c = 4 nM) using MCF-7-hY1 cells in buffer II.
31 bRadioligand competition binding 
assay with [3H]propionyl-pNPY32 (Kd = 1.4 nM, c = 1 nM) using CHO-hY2-Gqi5-mtAEQ cells in buffer I.
33 cRadioligand competition binding assay with [3H]2.10 (Kd 
= 0.67 nM, c = 0.6 nM) using CHO-hY4R-Gqi5-mtAEQ cells in buffer I. 
dRadioligand competition binding assay with [3H]2.10 (Kd = 9.8 nM, c = 10 nM) using CHO-
hY4R-Gqi5-mtAEQ cells in L-15 medium. 
eRadioligand competition binding assay with [3H]2.18 (Kd = 0.67 nM, c = 1 nM) using CHO-hY4R-Gqi5-mtAEQ cells in 
buffer I. fRadioligand competition binding assay with [3H]propionyl-pNPY (Kd = 4.83 nM, c = 4 nM) using HEC-1b hY5R cells in buffer II.
34 gKi value reported by 
Berlicki et al.25 hKi value reported by Balasubramaniam et al.;
15 these authors used [125I]PYY (Y1R expressed in HEK 293 cells, Y2R or Y5R expressed in CHO 
cells) and [125I]PP (Y4R expressing CHO cells) for the determination of the binding data. 
iY1R antagonism at HEL cells (Fura-2 calcium assay): Kb = 9.5 ± 0.12 nM 
(Figure 12); in contrast to data reported in ref.15 for the diastereomeric mixture 2.2 (cAMP assay, Y1R expressing HEK 293 cells), no Y1R agonist activity. 
j
Ki 
value reported by Keller et al.10 kRef.16: Ki values determined by flow cytometry using fluorescence-labeled K
4-hPP in buffer I: 2.16: 7.4 nM, 2.17: 1.5 nM, 
2.18: 3.6 nM. l Y1R antagonism at HEL cells (Fura-2 calcium assay): Kb = 25.3 ± 3.8 nM (Figure 12). 
 2.3  Conclusions 
The synthesis of the enantiopure diaminosuberic acids (R,R)-2.8 and (S,S)-2.8, accomplished 
iŶ eǆĐelleŶt Ǉield ǀia Gƌuďďs͛ II ĐatalǇzed ĐoupliŶg, gaǀe aĐĐess to the iŶdiǀidual 
diastereomers of compound 2.2 with (2R,7R)- or (2S,7S)-configuration in the linker. In the 
same way, octanedioic acid was used as an achiral linker to combine two identical or two 
different pentapeptide moieties, in which the Arg residues were either retained or replaced 
at one or two positions by Ala or by an amino-functionalized carbamoylated Arg. 
Interestingly, the latter turned out to compensate for the absence of the two amino groups 
in the connecting diacid with respect to affinity and potency (cf. compound 2.17). Moreover, 
propionylation of one amino group in the linker of 2.2 (cf. compound 10) or at the primary 
amino group in 2.17 gave access to the corresponding tritiated high affinity radioligands. 
[3H]2.10 ([3H]UR-KK193) and [3H]2.18 ([3H]UR-KK200) are useful new pharmacological tools 
for the Y4R. (2R,7R)-2.2 was superior to (2S,7S)-2.2 and, in contrast to published data for the 
mixture 2.2, affinities and agonist potencies were essentially in the same range. As 
demonstrated by saturation and competition binding experiments, the composition of the 
buffer may account for discrepancies between functional and binding data. It should be kept 
in mind that the affinity of peptidic Y4R agonists may be considerably higher in the absence 
of sodium ions, conditions widely used for the investigation of NPY receptor ligands.  
 
2.4  Experimental Section 
2.4.1  General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers and used without further 
purification unless otherwise indicated. MeCN for HPLC (gradient grade) was obtained from 
Merck (Darmstadt, Germany). DMF for peptide synthesis, NMP for peptide synthesis and 
HOBt hydrate were obtained from Acros Organics/Fisher Scientific (Nidderau, Germany). 
Fmoc-Sieber-PS resin (0.61 mmol/g), (S)-allylglycine, (R)-allylglycine, Fmoc-Arg(Pbf)-OH, 
Fmoc-Tyr(tBu)-OH and HBTU were purchased from Iris Biotech (Marktredwitz, Germany). 
Fmoc-Ala-OH, Fmoc-Leu-OH, Fmoc-Thr(tBu)-OH, Fmoc-Pro-OH, dicyclohexylcarbodiimide, 
dioxane, sodium hydroxide and methanol were obtained from Merck (Darmstadt, Germany). 
Trifluoroacetic acid, dichloromethane, diethyl ether, ethanol and Triton X-100 were obtained 
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from Sigma Aldrich (Deisenhofen, Germany), N,N-diisopropylethylamine (DIPEA) (99%) was 
from ABCR (Karlsruhe, Germany), di-tert-butyl dicarbonate (>97%) and 8-methoxy-8-
oxooctanoic acid (98%) were from Alfa Aesar (Karlsruhe, Germany). Bovine serum albumin 
and bacitracin were purchased from Serva (Heidelberg, Germany), coelenterazin h was 
obtained from Biotrend (Cologne, Germany), human pancreatic polypeptide and porcine 
neuropeptide Y were synthesized by Prof. Dr. C. Cabrele (University Salzburg, Salzburg, 
Austria). GW1229 was a gift from Dr. A. J. Daniels (Glaxo Wellcome, NC, USA). The synthesis 
of UR-MK188,10 2.11,16 2.12,22 and [3H]propionyl-pNPY32 was previously described. (4,5-
DihydroIMES)(PCy3)Cl2‘u=CHPh ;Gƌuďďs͛ II ĐatalǇstͿ ǁas sǇŶthesized aĐĐoƌdiŶg to liteƌatuƌe 
procedure.35 Millipore water was used throughout for the preparation of buffers and HPLC 
eluents. Polypropylene reaction vessels (1.5 or 2 mL) with screw cap (Süd-Laborbedarf, 
Gauting, Germany) were used for the synthesis of the radioligands [3H]2.10 and [3H]2.18, for 
small scale reactions (e.g. the preparation of 2.16 ), the investigation of chemical stabilities 
and for the storage of stock solutions. TL chromatography was performed on Merck silica gel 
60 F254 TLC aluminum plates, silica gel 60 (40-63 µm, Merck) was used for column 
chromatography. Visualization was accomplished by UV light ( = 254 nm or 366 nm) and 
ninhydrin/acetic acid solution. NMR-spectra were recorded on a Bruker Avance 300 (7.05 T, 
1H: 300.1 MHz, 13C: 75.5 MHz) or a Bruker Avance 600 instrument with cryogenic probe (14.1 
T, 1H: 600.3 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany). ATR-IR spectroscopy was 
performed on a Biorad Excalibur FTS 3000 spectrometer (Biorad, Munich, Germany), 
equipped with a Specac Golden Gate Diamond Single Reflection ATR-System. Mass spectra 
were recorded on a Finnigan MAT95 (EI-MS 70eV) or a Finnigan MAT SSQ 710 A (CI-MS 
(NH3)). For HRMS an Agilent Q-TOF 6540 UHD (Agilent, Waldbronn, Germany) equipped with 
an ESI source was used. Optical rotations (given as specific rotation [α]20, [° cm3 dm-1 g-1], 
concentrations (c) given as g/100 mL) were determined in an MCP 500 (Anton Paar, 
Ostfildern-Scharnhausen, Germany) or a 241 polarimeter (Perkin Elmer, Rodgau, Germany) 
at 589 nm in a 1.0-dm cuvette. Preparative HPLC was performed on a system from Knauer 
(Berlin, Germany) consisting of two K-1800 pumps, a K-2001 detector and a RP-column 
(Kinetex-XB C18, 5 µm, 250 mm × 21 mm, Phenomenex, Aschaffenburg, Germany) at a flow-
rate of 15 mL/min using mixtures of acetonitrile and 0.1% aqueous TFA solution as mobile 
phase. A detection wavelength of 220 nm was used throughout. The collected fractions were 
lyophilised using an alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany) 
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equipped with a RZ 6 rotary vane vacuum pump (vacuubrand, Wertheim, Germany). 
Analytical HPLC analysis was performed on a system from Merck-Hitachi (Hitachi, Düsseldorf, 
Germany) composed of a L-6200-A pump, a AS-2000A autosampler, a L-4000A UV detector, 
a D-6000 interface and a RP-column Kinetex-XB C18, 5 µm, 250 mm × 4.6 mm (Phenomenex, 
Aschaffenburg, Germany) at a flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.1% 
aqueous TFA solution (B) were used as mobile phase. The following gradient was applied: 
A/B: 0-25 min: 10:90 - 60:40, 25-35 min: 60:40 - 95:5, 35-45 min: 95:5. Detection was 
performed at 220 nm, the oven temperature was 30 °C. 
 
2.4.2  Chemistry: Experimental Protocols and Analytical data 
General procedure for solid phase peptide synthesis. Peptides were synthesized by manual 
SPPS using the Fmoc strategy on an Fmoc-Sieber-PS resin. 5-ml or 20-ml Discardit II syringes 
(Becton Dickinson, Heidelberg, Germany) were equipped with 35 µm polyethylene frits 
(Roland Vetter Laborbedarf, Ammerbuch, Germany) and used as reaction vessels. DMF/NMP 
(8:2) was used as solvent. Protected standard L-amino acids (5 equiv) were pre-activated 
with HBTU (5 equiv)/HOBt (5 equiv)/DIPEA (10 equiv) for 5 min and added to the resin. 
͚Douďle͛ ĐoupliŶg at ƌt ǁas peƌfoƌŵed foƌ all staŶdaƌd aŵiŶo aĐids foƌ ϰϱ ŵiŶ. Afteƌ 
completed coupling of an Fmoc-aa, the resin was washed with DMF/NMP and treated with 
20% piperidine in DMF/NMP (8:2) at rt (2×) for 10 min to remove the Fmoc group, followed 
by thorough washing of the resin. 
General procedure for cleavage of protected peptides from the resin. After the last 
coupling step and Fmoc deprotection, the resin was washed with DCM. Side-chain protected 
peptides were cleaved from the resin with CH2Cl2/TFA (97:3) (rt, 10 × 6 min). The peptides 
were separated from the resin by filtration. The combined filtrates were collected in a round 
bottom flask containing water (10 times the volume of the combined filtrates). The organic 
solvent was removed on a rotary evaporator; the aqueous phase was lyophilised followed by 
purification by preparative HPLC. 
(2R,7R)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) 
hexakis(hydrotrifluoroacetate) ((2R,7R)-2.2). (R,R)-2.8 (4.3 mg, 10.7 µmol), HBTU (8.5 mg, 
2.1 equiv) and HOBt (3.5 mg, 2.1 equiv) were dissolved in anhydrous DMF (400 µL). DIPEA 
(10 µL, 5 equiv) was added and the mixture was stirred at room temperature for 5 min 
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followed by the addition of a solution of 2.9 (40 mg, 2.5 equiv). The resulting mixture was 
stirred at 35 °C for 16 h. Water (10 mL) was added and the protected intermediate was 
extracted with DCM (2 × 10 mL). The combined organic layers were evaporated, and the 
residue was dried in vacuo. TFA/water (95:5, 2 mL) was added and the mixture was stirred at 
room temperature for 2.5 h. Water (100 mL) was added followed by lyophilisation. The 
product was purified by preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 
0–20 min: MeCN/0.1% aq TFA 10:90–35:65, tR = 15.8 min). Lyophilisation of the eluate 
afforded (2R,7R)-2.2 as a white fluffy solid (7.5 mg, 29.3%). HRMS (m/z): [M+4H]4+ calcd. for 
C80H128N26O16, 427.2495; found, 427.2510. RP-HPLC (220 nm): 96% (tR = 18.93 min, k = 5.6). 
C80H124N26O16 · C12H6F18O12 (1706.04 + 684.14). 
(2S,7S)-Diaminooctanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) hexakis(hydrotrifluoroacetate) 
((2S,7S)-2.2). (2S,7S)-2.2 was prepared in analogy to (2R,7R)-2.2 by using (S,S)-2.8 (4.3 mg, 
10.7 µmol). The product was purified by preparative HPLC (column: Kinetex-XB C18 250 × 21 
mm; gradient: 0–20 min: MeCN/0.1% aq TFA 10:90–35:65, tR = 15.5 min). Lyophilisation of 
the eluate afforded (2S,7S)-2.2 as a white fluffy solid (8.6 mg, 33.6%). HRMS (m/z): [M+4H]4+ 
calcd. for C80H128N26O16, 427.2495; found, 427.2508. RP-HPLC (220 nm): 98% (tR = 18.37 min, 
k = 5.4). C80H124N26O16 · C12H6F18O12 (1706.04 + 684.14). 
(R)-2-[(tert-Butoxycarbonyl)amino]pent-4-enoic acid ((R)-2.4).
36 
(R)-2-Allylglycine, 1.0 g, 8.69 mmol) was dissolved in 1 M NaOH (20 mL) and dioxane (10 mL). 
Boc anhydride (2.32 g, 1.23 equiv.) was added under ice-cooling. The reaction mixture was 
allowed to warm up to ambient temperature, and stirring was continued for 18 h. After 
completion of the reaction, the mixture was concentrated under reduced pressure, and the 
aqueous phase was washed with diethyl ether to remove the excess of Boc anhydride. The 
pH was adjusted to 2.5 with 0.5 M hydrochloric acid, and the mixture was extracted with 
EtOAc (3 x 20 mL). The combined organic layers were dried over MgSO4 and concentrated 
under reduced pressure. The desired compound was obtained as viscous colorless oil (1.78 g, 
95.2%). 1H-NMR (300 MHz, [D6]DMSO): δ 1.38 (s, 9H), 2.20 – 2.47 (m, 2H), 3.57 (s, 2H), 3.86 – 
3.97 (m, 1H), 4.99 – 5.15 (m, 2H), 5.67 – 5.85 (m, 1H), 7.07 (d, 1H, J 8.24). LRMS (ESI): m/z = 
140.04 [M-H-C4H10O]
-, 214.11 [M-H]-. 
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(S)-2-[(tert-Butoxycarbonyl)amino]pent-4-enoic acid ((S)-2.4).
37 
Compound (S)-2.4 was synthesized from (S)-2-allylglycine (1.0 g, 8.69 mmol) by analogy with 
the procedure for the preparation of (R)-2.4. The desired compound was obtained as viscous 
colorless oil (1.72 g, 92.0%). 1H-NMR (300 MHz, [D6]DMSO): δ 1.37 (s, 9H), 2.20 – 2.47 (m, 
2H), 3.57 (s, 2H), 3.87 – 3.97 (m, 1H), 4.99 – 5.15 (m, 2H), 5.68 – 5.84 (m, 1H), 7.07 (d, 1H, J 
8.09). LRMS (ESI): m/z = 140.04 [M-H-C4H10O]
-, 214.11 [M-H]-. 
Ethyl (R)-2-[(tert-butoxycarbonyl)amino]pent-4-enoate ((R)-2.5).
38 
(R)-2.4 (350 mg, 1.63 mmol) and 4-(dimethylamino)pyridine (39.7 mg, 0.2 equiv.) were 
dissolved in DCM and EtOH (300 µL, 3 equiv.) was added. A solution of 
dicyclohexylcarbodiimide (352 mg, 1.05 equiv.) in DCM (5 mL) was added drop wise under 
ice-cooling. The mixture was allowed to warm up to ambient temperature and was stirred 
for 12 h. After completion of the reaction, the mixture was filtered and concentrated under 
reduced pressure. The residue was taken up in PE/EtOAc (10:1, 5 mL) and subjected to 
column chromatography (eluent: PE/EtOAc 10:1). The desired compound was obtained as 
viscous colorless oil (280 mg, 70.9%). TLC (PE/EtOAc 10:1): Rf = 0.32. 
1H-NMR (300 MHz, 
[D6]DMSO): δ 1.17 (t, 3H, J 7.08), 1.33 (s, 1H), 1.37 (s, 8H), 2.22 – 2.47 (m, 2H), 3.91 – 4.16 
(m, 3H), 4.99 – 5.14 (m, 2H), 5.68 – 5.84 (m, 1H), 7.24 (d, 1H, J 7.69). LRMS (ESI): m/z = 
144.10 [M-Boc+H]+, 266.14 [M+NaH]+. 
Ethyl (S)-2-[(tert-butoxycarbonyl)amino]pent-4-enoate ((S)-2.5). 
Compound (S)-2.5 was synthesized from (S)-2.4 (350 mg, 1.63 mmol) by analogy with the 
procedure for the preparation of (R)-2.5. The desired compound was obtained as viscous 
colorless oil (295 mg, 74.7%). TLC (PE/EtOAc 10:1): Rf = 0.32. 
1H-NMR (300 MHz, [D6]DMSO): 
δ ϭ.ϭϳ ;t, ϯH, J ϳ.ϭϯͿ, ϭ.ϯϯ ;s, ϭHͿ, ϭ.ϯϴ ;s, ϴHͿ, Ϯ.Ϯϲ – 2.45 (m, 2H), 3.92 – 4.16 (m, 3H), 4.97 – 
5.15 (m, 2H), 5.68 – 5.85 (m, 1H), 7.23 (d, 1H, J 7.78). LRMS (ESI): m/z = 144.10 [M-Boc+H]+, 
266.14 [M+Na]+. 
(2R,7R)-Diethyl 2,7-bis[(tert-butoxycarbonyl)amino]oct-4-enedioate ((R,R)-2.6). According 
to literature procedure39 in a flame-dried Schlenk flask (R)-2.5 (106 mg, 0.43 mmol, 2 equiv) 
was dissolved in anhydrous DCM (8 mL) under N2-atŵospheƌe. Gƌuďďs͛ II ĐatalǇst seĐoŶd 
generation (18.5 mg, 0.022 mmol, 0.1 equiv) was added and the reaction mixture was stirred 
under reflux for 11 h until all starting material had been consumed. The solvent was 
removed under reduced pressure and the crude product was purified by column 
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chromatography (PE/EtOAc 5:1) to obtain (R,R)-6 (89 mg, 0.19 mmol, 89%) as colorless oil. Rf 
= 0.23 (PE/EtOAc 5:1). 1H-NMR (300 MHz, CDCl3Ϳ: δ (ppm) 1.21 (t, 6H, J 7.1 Hz), 1.38 (s, 18H), 
2.31 - 2.49 (m, 4H), 4.13 (qd, 4H, J 1.8 Hz, 7.1 Hz), 4.2 – 4.31 (m, 2H), 5.01 – 5.11 (m, 2H), 
5.31 – 5.44 (m, 2H). 13C-NMR (75 MHz, CDCl3Ϳ: δ (ppm) 14.2, 28.3, 35.5, 53.1, 61.3, 79.8, 
128.5, 155.2, 171.9. IR (neat) 3369, 2978, 2937, 1703, 1498, 1367, 1330, 1248, 1159, 1095, 
1051, 1021, 969, 857, 779 cm-1. [α]20�  -27.0 (c 1, chloroform). LRMS (ESI): m/z [M+H]+ 459.3, 
[M+Na]+ 481.3, [2M+Na]+ 939.5. HRMS (ESI): m/z [M+H]+ calcd. for [C22H39N2O8]
+  459.2701, 
found: 459.2711. C22H38N2O8 (458.55). 
(2S,7S)-Diethyl 2,7-bis[(tert-butoxycarbonyl)amino]oct-4-enedioate ((S,S)-2.6). Compound 
(S,S)-(+)-2.6 was prepared according to (R,R)-2.6 from (S)-2.5 (105 mg, 0.43 mmol, 2 equiv) 
as starting material to obtain the product as a colorless oil (47.3 mg, 0.1 mmol, 49%). The 
spectroscopic data were identical to those for the enantiomer (R,R)-(-)-2.6. [α]20�  +27.9 (c 1, 
chloroform). 
(2R,7R)-Diethyl 2,7-bis[(tert-butoxycarbonyl)amino]octanedioate ((R,R)-2.7). In a flame 
dried Schlenk flask under nitrogen atmosphere (R)-2.5 (300 mg, 1.23 mmol, 2 equiv) was 
dissolǀed iŶ aŶhǇdƌous DCM ;ϭϴ ŵLͿ. Gƌuďďs͛ II ĐatalǇst ;ϱϮ ŵg, Ϭ.Ϭϲ ŵŵol, Ϭ.ϭ eƋuiǀͿ ǁas 
added, and the reaction mixture was stirred under reflux for 12 h. After all starting material 
was consumed, the solvent was removed under reduced pressure, and EtOH (10 mL) was 
added. The mixture was transferred into an autoclave and stirred under hydrogen at 20 bar 
at room temperature for 15 h. The reaction mixture was filtrated, and the solvent was 
removed under reduced pressure. The crude product was purified by column 
chromatography (PE/EtOAc 3:1) to yield (R,R)-2.7 (268 mg, 0.58 mmol, 95% over two steps) 
as colorless oil. Rf = 0.3 (PE/EtOAc 3:1). 
1H-NMR (300 MHz, CDCl3Ϳ: δ (ppm) 1.21 (t, 6H, J 7.1 
Hz), 1.24 – 1.33 (m, 4 H), 1.37 (s, 18H), 1.46 – 1.79 (m, 4 H), 4.05-4.24 (m, 4H + 2H), 4.94 – 
5.04 (m, 2H). 13C-NMR (75 MHz, CDCl3Ϳ: δ (ppm) 14.2, 24.9, 28.3, 32.6, 53.3, 61.3, 79.8, 
155.4, 172.8. IR (neat) 3354, 2978, 2937, 2870, 1699, 1505, 1457, 1367, 1248, 1159, 1021, 
861, 779 cm-1. [α]20�  -14.8 (c 1, chloroform). LRMS (ESI): m/z [M+H]+ 461.3, [M+Na]+ 483.3, 
[2M+Na]+ 943.5. HRMS (ESI): m/z [M+H]+ calcd. for [C22H41N2O8]
+ 461.2857, found: 461.2865. 
C22H40N2O8 (460.56). 
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(2S,7S)-Diethyl 2,7-bis[(tert-butoxycarbonyl)amino]octanedioate ((S,S)-2.7). Compound 
(S,S)-(+)-2.7 was prepared according to (R,R)-2.7 by using (S)-2.5 (303 mg, 1.2 mmol, 2 equiv) 
as starting material to obtain the product as a colorless oil (212 mg, 0.46 mmol, 74% over 
two steps). The spectroscopic data were identical to those for its enantiomer (R,R)-(-)-2.7.  
[α]20�  +16.9 (c 1, chloroform). 
(2R,7R)-2,7-bis[(tert-butoxycarbonyl)amino]octanedioic acid ((R,R)-2.8).
40 (R,R)-2.7 (268 
mg, 0.58 mmol, 1 equiv) was dissolved in EtOH (8 mL) and 1M NaOH solution (1.2 mL, 1.16 
mmol, 2 equiv) was added dropwise. The reaction was stirred at room temperature for 21 h. 
When all the starting material had been consumed, the solution was adjusted to pH 2 by 
addition of 1M HCl solution. Water and EtOAc were added, and the phases were separated. 
The aqueous layer was extracted with EtOAc, and the combined organic phases were dried 
over MgSO4, filtered and concentrated in vacuo to yield the product as a white solid (238 
mg, 0.58 mmol, quant.). 1H-NMR (300 MHz, CD3ODͿ: δ (ppm) 1.35 – 1.50 (m, 22H), 1.57 – 
1.71 (m, 2H), 1.72 – 1.96 (m, 2H), 3.91 – 4.13 (m, 2H). 13C-NMR (75 MHz, CD3ODͿ: δ (ppm) 
26.5, 28.8, 32.7, 54.9, 80.5, 158.1, 176.5. IR (neat) 3295, 2978, 2933, 2363, 1789, 1707, 1680, 
1509, 1449, 1394, 1370, 1312, 1244, 1159, 1077, 1047, 1017, 946, 846, 790, 758, 697 cm-1. 
[α]20�  +11.2 (c 1, DMF). LRMS (ESI): m/z = 403.2 [M-H]-, 807.4 [2M-H]-. HRMS (ESI): m/z [M-H]- 
calcd. for [C18H31N2O8]
- 403.2086, found: 403.2096. C18H32N2O8 (404.46). 
(2S,7S)-2,7-bis[(tert-butoxycarbonyl)amino]octanedioic acid ((S,S)-2.8).
41 Compound (S,S)-
(+)-2.8 was prepared according to (R,R)-2.8 by using (S,S)-2.7 (212 mg, 0.46 mmol, 2 equiv) 
as starting material to obtain the product as a white solid (190 mg, 0.46 mmol, quant.). The 
spectroscopic data were identical to those for the enantiomer (R,R)-2.8. [α]20�  -9.8 (c 1, DMF, 
ref.41 -15.2, 5% in DMF). 
H-Tyr(tBu)-Arg(Pbf)-Leu-Arg(Pbf)-Tyr(tBu)-NH2 hydrotrifluoroacetate (2.9).
16
 The side chain 
protected pentapeptide 2.9 was prepared on a Sieber resin (loading: 0.61 mmol/g) according 
to the general procedure. The product was purified by preparative HPLC (column: Kinetex-XB 
C18 250 × 21 mm; gradient: 0–16 min: MeCN/0.1% aq TFA 52:48–81:19, tR = 11 min). 
Lyophilisation of the eluate afforded 2.9 as a white solid (200 mg, 56%). HRMS (ESI): m/z 
[M+3H]3+ calcd. for [C70H107N12O13S2]
3+ 462.5835, found 462.5838. C70H104N12O13S2 · C2HF3O2 
(1385.79 + 114.02). 
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(2R,7R)-2-Amino-7-(propionylamino)octanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) 
pentakis(hydrotrifluoroacetate) ((2R,7R)-2.10). (2R,7R)-2.2 (4 mg, 1.67 µmol) was dissolved 
in 3% DIPEA in anhydrous DMF (400 µL). A solution of succinimidyl propionate in anhydrous 
DMF (10 mg/mL) was added in small portions (a total of 17 µL (0.98 µmol)). To prevent two-
fold acylation, the reaction was monitored by HPLC and stopped when approximately 35% of 
the starting material was consumed. Water (5 mL) was added and the product was purified 
by preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% 
aq TFA 10:90–35:65, tR = 17.2 min). Lyophilisation of the eluate afforded (2R,7R)-2.10 as a 
white fluffy solid (1.1 mg, 0.47 µmol). HRMS (m/z): [M+4H]4+ calcd. for C83H132N26O17, 
441.2560; found, 441.2575. RP-HPLC (220 nm): 97% (tR = 20.00 min, k = 6.0). C83H124N26O17 · 
C10H5F15O10 (1762.10 + 570.12). 
(2S,7S)-2-Amino-7-(propionylamino)octanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) 
pentakis(hydrotrifluoroacetate) ((2S,7S)-2.10). (2S,7S)-2.10 was prepared by analogy with 
(2R,7R)-2.10 using (2S,7S)-2.2 (4 mg, 1.67 µmol) as starting material. The product was 
purified by preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: 
MeCN/0.1% aq TFA 10:90–35:65, tR = 17.0 min). Lyophilisation of the eluate afforded (2S,7S)-
2.10 as a white fluffy solid (1.0 mg, 0.43 µmol). HRMS (m/z): [M+4H]4+ calcd. for 
C83H132N26O17, 441.2560; found, 441.2577. RP-HPLC (220 nm): 97% (tR = 19.56 min, k = 5.8). 
C83H124N26O17 · C10H5F15O10 (1762.10 + 570.12). 
HOOC-(CH2)6-C(=O)-Tyr-Arg-Leu-Arg-Tyr-NH2 (2.13).
16
 Compound 2.13 was synthesized on a 
Sieber resin (loading: 0.61 mmol/g). Fmoc-amino acids were coupled according to the 
general procedure. The coupling of suberic acid monomethyl ester (196 mg, 1.04 mmol) was 
performed at 30 °C for 14 h (single coupling) using the solvent and coupling reagent as for 
Fmoc-amino acids. The peptide was cleaved from the resin according to the general 
procedure. The residue obtained after lyophilisation was dissolved in MeOH (5 mL), 0.5 M aq 
NaOH (1 mL) was added and the mixture was kept under reflux for 3 h. An aequous solution 
of citric acid (0.1 g/ml) (20 mL) was added causing the formation of a white precipitate. The 
suspension was stored in the refrigerator overnight, the solid was separated by filtration and 
purified by preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–18 min: 
MeCN/0.1% aq TFA 52:48–90:10, tR = 17 min). Lyophilisation of the eluate afforded 2.13 as a 
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white solid (120 mg, 30%). HRMS (ESI): m/z [M+2H]2+ calcd. for [C78H118N12O16S2]
2+ 771.411, 
found 771.4124. C78H116N12O16S2 (1541.97). 
Tyr(tBu)-Ala-Leu-Arg(Pbf)-Tyr(tBu)-amide hydrotrifluoroacetate (2.14). The side chain 
protected pentapeptide 2.14 was synthesized according to the general procedure (0.1 mmol 
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC was 
performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–24 min: MeCN/0.1% aq TFA 
38:62–90:10, tR = 11 min). Lyophilisation of the eluate afforded 2.14 as a white solid (51 mg, 
49%). HRMS (m/z): [M+2H]2+ calcd. for C54H83N9O10S, 524.7986; found, 524.7999. 
C54H81N9O10S · C2HF3O2 (1048.36 + 114.02). 
Tyr(tBu)-Arg(Pbf)-Leu-Ala-Tyr(tBu)-amide hydrotrifluoroacetate (2.15). The side chain 
protected pentapeptide 2.15 was synthesized according to the general procedure (0.1 mmol 
Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC was 
performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–24 min: MeCN/0.1% aq TFA 
38:62–90:10, tR = 10.5 min). Lyophilisation of the eluate afforded 2.15 as a white solid (58 
mg, 55%). HRMS (m/z): [M+2H]2+ calcd. for C54H83N9O10S, 524.7986; found, 524.7999. 
C54H81N9O10S · C2HF3O2 (1048.36 + 114.02). 
Octanedioyl-bis(Tyr-Arg-Leu-Arg-Tyr-amide) tetrakis(hydrotrifluoroacetate) (2.16).
16 
Compound 2.9 (20 mg, 13.3 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 
µL). Compound 2.12 (1.96 mg, 5.3 µmol) was added and the mixture was stirred at 35 °C for 
16 h. Water (10 mL) was added and the protected intermediate extracted with CH2Cl2 (2 × 10 
ml). The combined extracts were evaporated and the residue dried in vacuo. TFA/water 
(95:5 v/v) (2 mL) was added and the mixture was stirred at rt for 2.5 h. Water (100 mL) was 
added followed by lyophilisation. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 14:86–52:48, tR = 11 
min). Lyophilisation of the eluate afforded 16 as a white fluffy solid (5.7 mg, 51%). 1H-NMR 
(600 MHz, [D6]DMSO): δ 0.83 (d, 6H, J 6.5 Hz), 0.87 (d, 6H, J 6.5 Hz), 1.03 (br s, 4H), 1.30 (br 
s, ϰHͿ, ϭ.ϯϳ−ϭ.ϱϲ ;ŵ, ϭϲHͿ, ϭ.ϱϲ−ϭ.ϳϯ ;ŵ, ϲHͿ, ϭ.ϵϱ−Ϯ.Ϭϱ ;ŵ, ϰHͿ, Ϯ.ϱϳ−Ϯ.ϲϱ ;ŵ, ϮHͿ, 
Ϯ.ϲϴ−Ϯ.ϳϱ ;ŵ, ϮHͿ, Ϯ.ϴϭ−Ϯ.ϴϵ ;ŵ, ϰHͿ, ϯ.ϬϮ−ϯ.ϭϯ ;ŵ, ϴHͿ, ϰ.ϭϳ−ϰ.Ϯϰ ;ŵ, ϮHͿ, ϰ.Ϯϰ−ϰ.ϯϲ ;ŵ, 
ϲHͿ, ϰ.ϯϵ−ϰ.ϰϲ ;ŵ, ϮHͿ, ϲ.ϱϵ−ϲ.ϲϱ ;ŵ, ϴHͿ, ca ϲ.ϵ ;ďƌ s, ϴHͿ, ϲ.ϵϱ−ϲ.ϵϵ ;ŵ, ϰHͿ, ϲ.ϵϵ−ϳ.Ϭϯ ;ŵ, 
4H), 7.05 (s, 2H), ca 7.3 (br s, ϴHͿ, ϳ.ϯϲ ;s, ϮHͿ, ϳ.ϰϵ−ϳ.ϱϳ ;ŵ, ϰHͿ, ϳ.ϳϰ ;d, ϮH, J 7.9 Hz), 
ϳ.ϴϱ−ϳ.ϵϰ ;ŵ, ϰHͿ, ϴ.Ϭϯ ;d, ϮH, J 7.7 Hz), 8.17 (d, 2H, J 7.8 Hz), 9.16 (s, 2H), 9.17 (s, 2H). 13C-
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NMR (150 MHz, [D6]DMSO): δ 21.4 (2 carb.), 23.1 (2 carb.), 24.1 (2 carb.), 24.9 (2 carb.), 25.0 
(2 carb.), 25.1 (2 carb.), 28.4 (2 carb.), 28.9 (2 carb.), 29.0 (2 carb.), 35.2 (2 carb.), 36.6 (2 
carb.), 36.8 (2 carb.), 40.4 (4 carb.), 40.7 (2 carb.), 50.9 (2 carb.), 52.1 (2 carb.), 52.2 (2 carb.), 
53.9 (2 carb.), 54.1 (2 carb.), 114.8 (4 carb.), 114.9 (4 carb.), 127.5 (2 quat. carb.), 127.9 (2 
quat. carb.), 129.9 (4 carb.), 130.0 (4 carb.), 155.7 (2 quat. carb.), 155.8 (2 quat. carb.), 155.6 
(2 quat. carb.), 155.7 (2 quat. carb.), 170.8 (2 quat. carb.), 171.1 (2 quat. carb.), 171.8 (2 
quat. carb.), 172.0 (2 quat. carb.), 172.3 (2 quat. carb.), 172.7 (2 quat. carb.). HRMS (ESI): 
m/z [M+4H]4+ calcd. for [C80H126N24O16]
4+ 419.7440, found 419.7452. RP-HPLC (220 nm): 98% 
(tR = 20.2 min, k = 6.0). C80H122N24O16 · C8H4F12O8 (1676.01 + 456.09). 
At position Arg
2
 N
ω
-[N-(4-aminobutyl)aminocarbonyl]-monosubstituted octanedioyl 
bis(Tyr-Arg-Leu-Arg-Tyr-amide) pentakis(hydrotrifluoroacetate) (2.17).
16 Compound 2.17 
was synthesized on a Sieber resin (loading: 0.61 mmol/g). Fmoc-amino acids and arginine 
building block 2.11 were coupled according to the general procedure in the order Fmoc-
Tyr(tBu)-OH, Fmoc-Arg(Pbf)-OH, Fmoc-Leu-OH, 2.11 and Fmoc-Tyr(tBu)-OH followed by the 
coupling of building block 2.13 (50 mg, 32 µmol) using HBTU/HOBt/DIPEA (1/1/2 equiv. to 
2.13) and anhydrous DMF (800 µl) as solvent (35 °C, 16 h). The peptide was cleaved from the 
resin according to the general procedure. The residue obtained after lyophilisation was 
dissolved in TFA/water (95:5 v/v) (2 mL), the mixture was stirred at rt for 2.5 h and poured 
into ice-cold diethyl ether (15 mL) causing the precipitation of the crude product, which was 
separated from the organic solvent by centrifugation and decantation. Purification by 
preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq 
TFA 13:87–43:57, tR = 16 min) afforded 2.17 as a white fluffy solid (22 mg, 41%). 1H-NMR 
(600 MHz, [D6]DMSO): δ 0.83 (d, 6H, J 6.5 Hz), 0.87 (d, 6H, J 6.5 Hz), 1.03 (br s, 4H), 1.30 (br 
s, ϰHͿ, ϭ.ϯϲ−ϭ.ϱϳ ;ŵ, ϮϬHͿ, ϭ.ϱϳ−ϭ.ϳϱ ;ŵ, ϲHͿ, ϭ.ϵϰ−Ϯ.Ϭϲ ;ŵ, ϰHͿ, Ϯ.ϱϳ−Ϯ.ϲϱ ;ŵ, ϮHͿ, 
Ϯ.ϲϴ−Ϯ.ϳϱ ;ŵ, ϮHͿ, Ϯ.ϳϱ−Ϯ.ϴϮ ;ŵ, ϮHͿ, Ϯ.ϴϮ−Ϯ.ϵϬ ;ŵ, ϰHͿ, ϯ.ϬϮ−ϯ.ϭϰ ;ŵ, ϴHͿ, ϯ.Ϯϰ ;ďƌ s, ϮHͿ, 
ϰ.ϭϳ−ϰ.Ϯϯ ;ŵ, ϮHͿ, ϰ.Ϯϰ−ϰ.ϯϲ ;ŵ, ϲHͿ, ϰ.ϯϵ−ϰ.ϰϲ ;ŵ, ϮHͿ, ϲ.ϱϵ−ϲ.ϲϱ ;ŵ, ϴHͿ, ca 6.95 (br s, 
ϲHͿ, ϲ.ϵϱ−ϲ.ϵϵ ;ŵ, ϰHͿ, ϲ.ϵϵ−ϳ.Ϭϯ ;ŵ, ϰHͿ, ϳ.Ϭϱ ;s, ϮHͿ, ca ϳ.ϯ ;ďƌ s, ϲHͿ, ϳ.ϯϯ−ϳ.ϯϵ ;ŵ, ϮHͿ, 
ϳ.ϱϮ−ϳ.ϲϯ ;ŵ, ϰHͿ, ϳ.ϲϳ−ϳ.ϳϵ ;ŵ, ϰHͿ, ϳ.ϴϰ−ϳ.ϵϱ ;ŵ, ϰHͿ, ϳ.ϵϵ−ϴ.Ϭϴ ;ŵ, ϮHͿ, ϴ.ϭϳ ;d, ϭH, J 7.8 
Hz), 8.20 (d, 1H, J 7.8 Hz), 8.45 (br s, 2H), 9.00 (s, 1H), 9.17 (br s, 4H), 10.38 (s, 1H). 13C-NMR 
(150 MHz, [D6]DMSO): δ 21.4 (2 carb.), 23.1, 23.1, 24.1 (2 carb.), 24.4, 24.9 (3 carb.), 25.0, 
25.1 (2 carb.), 26.0, 28.4 (2 carb.), 28.9, 29.0 (3 carb.), 35.2 (2 carb.), 36.6 (2 carb.), 36.8 (2 
carb.), 38.5, 38.6, 40.4 (3 carb.), 40.5, 40.7 (2 carb.), 51.0 (2 carb.), 50.1 (2 carb.), 52.26, 
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52.29, 53.89, 53.92, 54.1, 54.2, 114.8 (4 carb.), 114.9 (4 carb.), 115.6 (TFA), 117.6 (TFA), 
127.5 (2 quat. carb.), 127.89, 127.91, 130.02 (4 carb.), 130.04 (4 carb.), 153.7, 153.8, 155.75 
(2 quat. carb.), 155.82 (2 quat. carb.), 156.71 (2 quat. carb.), 156.73, 158.5 (q, J 33 Hz) (TFA), 
170.81, 170.84, 171.08, 171.13, 171.8, 171.9, 172.0 (2 quat. carb.), 172.31, 172.34, 172.7 (2 
quat. carb.). HRMS (ESI): m/z [M+4H]4+ calcd. for [C85H136N26O17]
4+ 448.2639, found 
448.2652. RP-HPLC (220 nm): 96%, (tR = 19.3 min, k = 5.7). C85H132N26O17 · C10H5F15O10 
(1790.16 + 570.11). 
At position Arg
2
 N
ω
-[N-(4-propanoylaminobutyl)aminocarbonyl]-monosubstituted 
octanedioyl bis(Tyr-Arg-Leu-Arg-Tyr-amide) tetrakis(hydrotrifluoroacetate) (2.18).
16 
Compound 2.17 (10 mg, 4.24 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 
µL). Succinimidyl propionate (0.8 mg, 4.7 µmol) was added and the mixture was stirred at rt 
for 2 h. 0.2% aq TFA (9 mL) was added and the product was purified by preparative HPLC 
(column: Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 12:88–43:57, 
tR = 18 min). Lyophilisation of the eluate afforded 2.18 as a white fluffy solid (5.7 mg, 58%). 
1H-NMR (600 MHz, [D6]DMSO): δ 0.83 (d, 6H, J 6.5 Hz), 0.87 (d, 6H, J 6.6 Hz), 0.98 (t, 3H, 7.7 
HzͿ, ϭ.Ϭϯ ;ďƌ s, ϰHͿ, ϭ.ϯϬ ;ďƌ s, ϰHͿ, ϭ.ϯϰ−ϭ.ϱϳ ;ŵ, ϮϬHͿ, ϭ.ϱϳ−ϭ.ϳϱ ;ŵ, ϲHͿ, ϭ.ϵϰ−Ϯ.Ϭϳ ;ŵ, ϲHͿ, 
2.ϱϳ−Ϯ.ϲϰ ;ŵ, ϮHͿ, Ϯ.ϲϵ−Ϯ.ϳϱ ;ŵ, ϮHͿ, Ϯ.ϴϮ−Ϯ.ϴϴ ;ŵ, ϰHͿ, Ϯ.ϵϵ−ϯ.ϭϯ ;ŵ, ϭϬHͿ, ϯ.Ϯϯ ;ďƌ s, ϮHͿ, 
ϰ.ϭϳ−ϰ.Ϯϰ ;ŵ, ϮHͿ, ϰ.Ϯϰ−ϰ.ϯϲ ;ŵ, ϲHͿ, ϰ.ϰϬ−ϰ.ϰϲ ;ŵ, ϮHͿ, ϲ.ϱϵ−ϲ.ϲϱ ;ŵ, ϴHͿ, ca 6.85 (br s, 
ϲHͿ, ϲ.ϵϱ−ϲ.ϵϵ ;ŵ, ϰHͿ, ϲ.ϵϵ−ϳ.Ϭϯ ;ŵ, ϰHͿ, ϳ.Ϭϱ ;s, ϮHͿ, ca 7.3 (br s, 6H), 7.37 (s, 2H), 
ϳ.ϰϲ−ϳ.ϱϯ ;ŵ, ϰHͿ, ϳ.ϲϵ−ϳ.ϳϳ ;ŵ, ϯHͿ, ϳ.ϴϰ−ϳ.ϵϯ ;ŵ, ϰHͿ, ϴ.Ϭϯ ;ŵ, ϮHͿ, ϴ.ϭϴ ;ŵ, ϮHͿ, ϴ.ϰϬ ;ďƌ 
s, 2H), 8.96 (s, 1H), 9.16 (s, 4H), 9.87 (s, 1H). HRMS (ESI): m/z [M+4H]4+ calcd. for 
[C88H140N26O18]
4+ 462.2704, found 462.2717. RP-HPLC (220 nm): 96%, (tR = 21.1 min, k = 6.3). 
C88H136N26O18 · C8H4F12O8 (1846.22 + 456.09). 
Octanedioyl-bis(Tyr-Ala-Leu-Arg-Tyr-amide) bis(hydrotrifluoroacetate) (2.19). Compound 
2.14 (16 mg, 13.8 µmol) was dissolved in anhydrous DMF/DIPEA (99:1, 600 µL). Compound 
2.12 (2.5 mg, 6.78 µmol) was added and the mixture was stirred at 35 °C for 16 h. Water (10 
mL) was added and the protected intermediate was extracted with DCM (2 × 10 mL). The 
combined organic layers were evaporated, and the residue was dried in vacuo. TFA/water 
(95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was 
added followed by lyophilisation. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 10:90–62:38, tR = 15.5 
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min). Lyophilisation of the eluate afforded 2.19 as a white fluffy solid (5.7 mg, 48.5%). 1H-
NMR (600 MHz, [D6]DM“OͿ: δ Ϭ.ϴϮ ;d, ϲH, J 6.4 Hz), 0.86 (d, 6H, J 6.6 Hz), 1.03 (t, 4H, J 6.3 
Hz), 1.15 (d, 6H, J 7.0 Hz), 1.26-1.34 (m, 4H), 1.38-1.56 (m, 10H), 1.56-1.63 (m, 2H), 1.63-1.71 
(m, 2H), 1.94-2.03 (m, 4H), 2.56-2.63 (m, 2H), 2.67-2.73 (m, 2H), 2.81-2.88 (m, 4H), 3.04-3.12 
(m, 4H), 4.14-4.21 (m, 2H), 4.24-4.32 (m, 6H), 4.38-4.45 (m, 2H), 6.57-6.64 (m, 8H), ca 6.8 (br 
s, 4H), 6.94-6.98 (m, 4H), 6.98-7.02 (m, 4H), 7.04 (s, 2H), ca 7.2 (br s, 4H), 7.31 (s, 2H), 7.43 (t, 
2H, J 5.6 Hz), 7.65 (d, 2H, J 7.9 Hz), 7.88 (d, 2H, J 8.3 Hz), 7.91 (d, 2H, J 8.0 Hz), 8.02 (d, 2H, J 
7.1 Hz), 8.11 (d, 2H, J 7.8 Hz), 9.13 (s, 4H). HRMS (m/z): [M+3H]3+ calcd. for C74H111N18O16, 
502.6136; found, 502.6146. RP-HPLC (220 nm): 96% (tR = 23.27 min, k = 7.1). C74H108N18O16 · 
C4H2F6O4 (1505.79 + 228.04). 
Octanedioyl-1-(Tyr-Arg-Leu-Arg-Tyr-amide)-8-(Tyr-Ala-Leu-Arg-Tyr-amide)  
tris(hydrotrifluoroacetate) (2.20). Compound 2.13 (37.0 mg, 24.1 µmol), HOBt (3.69 mg, 1 
equiv) and HBTU (9.14 mg, 1 equiv) were dissolved in 500 µL of DMF. DIPEA (14.5 µL, 3.5 
equiv) was added, and the mixture was stirred for 5 min prior to the addition of a solution of 
2.14 (30.6 mg, 1.1 equiv) in DMF (400 µL). The mixture was stirred at room temperature for 
17 h, water (15 mL) was added, and the protected intermediate was extracted with DCM (2 
×20 mL). The combined organic layers were evaporated, and the residue was dried in vacuo. 
TFA/H2O (95:5, 3 mL) was added and the mixture was stirred at rt for 2.5 h. Water (150 mL) 
was added followed by lyophilisation. The product was purified by preparative HPLC 
(column: Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 10:90–62:38, 
tR = 14.1 min). Lyophilisation of the eluate afforded 20 as a white fluffy solid (16.6 mg, 
35.6%). 1H-NMR (600 MHz, [D6]DM“OͿ: δ Ϭ.ϴϯ ;d, ϲH, J 6.6 Hz), 0.86 (d, 6H, J 6.5 Hz), 1.00-
1.07 (m, 4H), 1.19 (d, 3H, J 7.0 Hz), 1.25-1.34 (m, 4H), 1.36-1.55 (m, 13H), 1.56-1.72 (m, 5H), 
1.95-2.03 (m, 4H), 2.55-2.63 (m, 2H), 2.67-2.74 (m, 2H), 2.81-2.89 (m, 4H), 3.01-3.12 (m, 6H), 
4.16-4.23 (m, 2H), 4.23-4.35 (m, 6H), 4.37-4.44 (m, 2H), 6.57-6.65 (m, 8H), 6.94-7.02 (m, 8H), 
ca. 6.95 (br s, 6H), 7.04 (d, 2H, J 7.8 Hz), ca. 7.3 (br s, 6H), 7.34 (d, 2H, J 5.9 Hz), 7.53 (t, 1H, J 
5.6 Hz), 7.56 (t, 2H, J 5.5 Hz), 7.74 (d, 1H, J 7.9 Hz), 7.77 (d, 1H, J 7.9 Hz), 7.85-7.95 (m, 5H), 
8.01 (d, 1H, J 7.9 Hz), 8.11 (d, 1H, J 7.4 Hz), 8.15 (d, 1H, J 7.8 Hz), 9.16 (s, 4H). 13C-NMR (150 
MHz, [D6]DM“OͿ: δ  ϭϳ.ϴϴ, Ϯϭ.ϯϳ, Ϯϭ.ϰϲ, Ϯϯ.Ϭϳ, Ϯϯ.ϭϭ, Ϯϰ.ϭϮ ;Ϯ Đaƌď.Ϳ, Ϯϰ.ϳϵ, Ϯϰ.ϴϴ, Ϯϱ.ϬϮ ;Ϯ 
carb.), 25.06, 28.32 (2 carb.), 28.92, 28.96, 29.06, 35.14 (2 carb.), 36.53, 36.64, 36.75, 36.78, 
40.41 (3 carb.), 40.53, 40.68, 48.06, 50.97, 51.07, 52.07, 52.09, 52.25, 53.92 (2 carb.), 54.03, 
54.19, 114.75 (2 carb.), 114.77 (2 carb.), 114.85 (4 carb.), 127.48, 127.56, 127.90, 127.97, 
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129.97 (2 carb.), 130.01 (6 carb.), 155.69, 155.73, 155.79, 155.80, 156.68, 156.71 (2 quat. 
carb.), 170.76, 170.82, 171.13, 171.47, 171.86, 171.98, 171.99, 172.10, 172.25, 172.35, 
172.68, 172.69. HRMS (m/z): [M+3H]3+ calcd. for C77H118N21O16, 530.9683; found, 530.9692. 
RP-HPLC (220 nm): 99% (tR = 19.57 min, k = 5.8). C77H115N21O16 · C6H3F9O6 (1590.90 + 342.06). 
Octanedioyl-bis(Tyr-Arg-Leu-Ala-Tyr-amide) bis(hydrotrifluoroacetate) (2.21). Compound 
2.15 (12 mg, 10.4 µmol) was dissolved in anhydrous DMF/DIPEA (99:1, 400 µL). Compound 
2.12 (1.9 mg, 5.1 µmol) was added and the mixture was stirred at 35 °C for 16 h. Water (10 
mL) was added and the protected intermediate was extracted with DCM (2 × 10 mL). The 
combined organic layers were evaporated, and the residue was dried in vacuo. TFA/water 
(95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was 
added followed by lyophilisation. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 10:90–62:38, tR = 15.3 
min). Lyophilisation of the eluate afforded 21 as a white fluffy solid (3.7 mg, 41.8%). 1H-NMR 
(600 MHz, [D6]DM“OͿ: δ Ϭ.ϴϮ ;d, ϲH, J 6.7 Hz), 0.86 (d, 6H, J 6.5 Hz), 1.03 (t, 4H, J 6.5 Hz), 
1.19 (d, 6H, J 7.1 Hz), 1.26-1.34 (m, 4H), 1.35-1.53 (m, 10H), 1.54-1.68 (m, 4H), 1.98 (t, 4H, J 
7.3 Hz), 2.56-2.62 (m, 2H), 2.67-2.73 (m, 2H), 2.81-2.88 (m, 4H), 3.02-3.08 (m, 4H), 4.19-4.29 
(m, 6H), 4.30-4.35 (m, 2H), 4.37-4.43 (m, 2H), 6.57-6.64 (m, 8H), ca 6.7 (br s, 4H), 6.94-6.98 
(m, 4H), 6.99-7.02 (m, 4H), 7.03 (s, 2H), ca 7.2 (br s, 4H), 7.34 (s, 2H), 7.41 (t, 2H, J 5.7 Hz), 
7.76 (d, 2H, J 7.9 Hz), 7.85-7.93 (m, 6H), 8.09 (d, 2H, J 7.2 Hz), 9.13 (s, 4H). HRMS (m/z): 
[M+3H]3+ calcd. for C74H111N18O16, 502.6136; found, 502.6143. RP-HPLC (220 nm): 97% (tR = 
22.17 min, k = 6.7). C74H108N18O16 · C4H2F6O4 (1505.79 + 228.04). 
Octanedioyl-1-(Tyr-Arg-Leu-Arg-Tyr-amide)-8-(Tyr-Arg-Leu-Ala-Tyr-amide) 
tris(hydrotrifluoroacetate) (2.22). Compound 2.13 (28.1 mg, 18.3 µmol), HOBt (2.8 mg, 1 
equiv) and HBTU (6.94 mg, 1 equiv) were dissolved in 500 µL DMF. DIPEA (11 µL, 3.5 equiv) 
was added, and the mixture was stirred for 5 min followed by the addition of a solution of 
2.15 (23.2 mg, 1.1 equiv) in DMF (400 µL). The mixture was stirred at room temperature for 
18 h, water (15 mL) was added and the protected intermediate was extracted with DCM (2 x 
20 mL). The combined organic layers were evaporated, and the residue was dried in vacuo. 
TFA/water (95:5, 3 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (150 
mL) was added followed by lyophilisation. The product was purified by preparative HPLC 
(column: Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 10:90–62:38, 
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tR = 14.2 min). Lyophilisation of the eluate afforded 2.22 as a white fluffy solid (12.5 mg, 
35.3%). 1H-NMR (600 MHz, [D6]DM“OͿ: δ Ϭ.ϴϮ ;d, ϲH, J 6.5 Hz), 0.86 (d, 6H, J 6.6 Hz), 0.99-
1.07 (m, 4H), 1.15 (d, 3H, J 7.1 Hz), 1.25-1.35 (m, 4H), 1.36-1.55 (m, 13H), 1.56-1.73 (m, 5H), 
1.94-2.04 (m, 4H), 2.55-2.64 (m, 2H), 2.66-2.74 (m, 2H), 2.80-2.89 (m, 4H), 3.01-3.12 (m, 6H), 
4.14-4.22 (m, 2H), 4.23-4.34 (m, 6H), 4.38-4.45 (m, 2H), 6.58-6.65(m, 8H), ca. 6.9 (br s, 6H), 
6.93-7.02 (m, 8H), 7.04 (s, 2H), ca. 7.3 (br s, 6H), 7.31 (s, 1H), 7.35 (s, 1H), 7.52 (t, 1H, J 5.6 
Hz), 7.53-7.57 (m, 2H), 7.66 (d, 1H, J 8.0 Hz), 7.74 (d, 1H, J 7.9 Hz), 7.85-7.95 (m, 4H), 7.99-
8.05 (m, 2H), 8.11 (d, 1H, J 7.7 Hz), 8.15 (d, 1H, J 7.8 Hz), 9.16 (s, 4H). 13C-NMR (150 MHz, 
[D6]DM“OͿ: δ ϭϳ.ϵϮ, Ϯϭ.ϯϲ, Ϯϭ.ϰϭ, Ϯϯ.Ϭϵ, Ϯϯ.ϭϭ, Ϯϰ.ϭϬ, Ϯϰ.ϭϭ, Ϯϰ.ϴϳ, Ϯϰ.ϵϲ, Ϯϱ.ϬϮ, Ϯϱ.Ϭϰ ;Ϯ 
carb.), 28.32 (2 carb.), 29.93, 28.97, 29.07, 35.15 (2 carb.), 36.56, 36.59, 36.71, 36.78, 40.42 
(3 carb.), 40.59, 40.69, 48.38, 50.79, 50.95, 52.02, 52.08, 52.24, 53.91 (2 carb.), 54.07, 54.14, 
114.75 (2 carb.), 114.76 (2 carb.), 114.82 (2 carb.), 114.85 (2 carb.), 127.47, 127.59, 127.89, 
127.92, 129.98 (4 carb.), 130.01 (2 carb.), 130.05 (2 carb.), 155.70, 155.72, 155.76, 155.80, 
156.67, 156.69, 156.70, 170.08, 171.06, 171.11, 171.64, 171.68 (2 quat. carb.), 171.98, 
172.24, 172.33, 172.66, 172.67. HRMS (m/z): [M+3H]3+ calcd. for C77H118N21O16, 530.9683; 
found, 530.9689. RP-HPLC (220 nm): 99% (tR = 19.97 min, k = 6.0) C77H115N21O16 · C6H3F9O6 
(1590.90 + 342.06). 
H-Tyr(tBu)-Arg(Pbf)-Leu-Arg(Pbf)-Ala-NH2 hydrotrifluoroacetate (2.23). The side chain 
protected pentapeptide 2.23 was prepared on a Sieber resin (loading: 0.61 mmol/g) 
according to the general procedure. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 43:57–81:19, tR = 11.8 
min). Lyophilisation of the eluate afforded 2.23 as a white solid (47 mg, 63%). HRMS (ESI): 
m/z [M+2H]2+ calcd. for [C60H94N12O12S2]
2+ 619.3272, found 619.3276. C60H92N12O12S2 · 
C2HF3O2 (1239.60 + 114.02). 
H-Tyr(tBu)-Arg(Pbf)-Ala-Arg(Pbf)-Tyr(tBu)-NH2 hydrotrifluoroacetate (2.24). The side chain 
protected pentapeptide 2.24 was prepared on a Sieber resin (loading: 0.61 mmol/g) 
according to the general procedure. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–16 min: MeCN/0.1% aq TFA 43:57–81:19, tR = 14.5 
min). Lyophilisation of the eluate afforded 2.24 as a white solid (47 mg, 29%). HRMS (ESI): 
m/z [M+2H]2+ calcd. for [C67H100N12O13S2]
2+ 672.3492, found 462.5838. C67H98N12O13S2 · 
C2HF3O2 (1385.79 + 114.02). 
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H-Ala-Arg(Pbf)-Leu-Arg(Pbf)-Tyr(tBu)-NH2 hydrotrifluoroacetate (2.25). The side chain 
protected pentapeptide 2.25 was prepared on a Sieber resin (loading: 0.61 mmol/g) 
according to the general procedure. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–18 min: MeCN/0.1% aq TFA 43:57–81:19, tR = 12.4 
min). Lyophilisation of the eluate afforded 2.25 as a white solid (36 mg, 48%). HRMS (ESI): 
m/z [M+2H]2+ calcd. for [C60H94N12O12S2]
2+ 619.3272, found 619.3278. C60H92N12O12S2 · 
C2HF3O2 (1239.60 + 114.02). 
H-Thr(tBu)-Arg(Pbf)-Pro-Arg(Pbf)-Tyr(tBu)-NH2 hydrotrifluoroacetate (2.26). The side chain 
protected pentapeptide 2.26 was prepared on a Sieber resin (loading: 0.61 mmol/g) 
according to the general procedure. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–18 min: MeCN/0.1% aq TFA 43:57–81:19, tR = 12.3 
min). Lyophilisation of the eluate afforded 2.26 as a white solid (76 mg, 87%). HRMS (ESI): 
m/z [M+2H]2+ calcd. for [C64H100N12O13S2]
2+ 654.3482, found 654.3489. C64H98N12O13S2 · 
C2HF3O2 (1307.68 + 114.02). 
Octanedioyl-bis(Tyr-Arg-Leu-Arg-Ala-amide) tetrakis(hydrotrifluoroacetate) (2.27). 
Compound 2.23 (16.6 mg, 12.2 µmol) was dissolved in anhydrous DMF/DIPEA (99:1, 400 µL). 
Compound 2.12 (1.8 mg, 4.9 µmol) was added and the mixture was stirred at 35 °C for 16 h. 
Water (10 mL) was added and the protected intermediate was extracted with DCM (2 × 10 
mL). The combined organic layers were evaporated, and the residue was dried in vacuo. 
TFA/water (95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 
mL) was added followed by lyophilisation. The product was purified by preparative HPLC 
(column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–42:58, 
tR = 16.6 min). Lyophilisation of the eluate afforded 2.27 as a white fluffy solid (4.1 mg, 43%). 
HRMS (m/z): [M+3H]3+ calcd. for C68H117N24O14, 497.9722; found, 497.9738. RP-HPLC (220 
nm): 98% (tR = 18.97 min, k = 5.6). C68H114N24O14 · C8H4F12O8 (1491.81 + 456.08). 
Octanedioyl-bis(Tyr-Arg-Ala-Arg-Tyr-amide) tetrakis(hydrotrifluoroacetate) (2.28). 
Compound 2.24 (19.5 mg, 13 µmol) was dissolved in anhydrous DMF/DIPEA (99:1, 400 µL). 
Compound 2.12 (2.0 mg, 5.2 µmol) was added and the mixture was stirred at 35 °C for 16 h. 
Water (10 mL) was added and the protected intermediate was extracted with DCM (2 × 10 
mL). The combined organic layers were evaporated, and the residue was dried in vacuo. 
TFA/water (95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 
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mL) was added followed by lyophilisation. The product was purified by preparative HPLC 
(column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–42:58, 
tR = 15.2 min). Lyophilisation of the eluate afforded 2.28 as a white fluffy solid (5.2 mg, 49%). 
HRMS (m/z): [M+3H]3+ calcd. for C74H113N24O16, 531.2917; found, 531.2932. RP-HPLC (220 
nm): 99% (tR = 16.8 min, k = 4.9). C74H110N24O16 · C8H4F12O8 (1591.85 + 456.08). 
Octanedioyl-bis(Ala-Arg-Leu-Arg-Tyr-amide) bis(hydrotrifluoroacetate) (2.29). Compound 
2.25 (20.3 mg, 15 µmol) was dissolved in anhydrous DMF/DIPEA (99:1, 400 µL). Compound 
2.12 (2.2 mg, 6.0 µmol) was added and the mixture was stirred at 35 °C for 16 h. Water (10 
mL) was added and the protected intermediate was extracted with DCM (2 × 10 mL). The 
combined organic layers were evaporated, and the residue was dried in vacuo. TFA/water 
(95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was 
added followed by lyophilisation. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–42:58, tR = 16.4 
min). Lyophilisation of the eluate afforded 2.29 as a white fluffy solid (6.0 mg, 51%). HRMS 
(m/z): [M+3H]3+ calcd. for C68H117N24O14, 497.9722; found, 497.9736. RP-HPLC (220 nm): 99% 
(tR = 18.62 min, k = 5.5). C68H114N24O14 · C8H4F12O8 (1491.81 + 456.08). 
Octanedioyl-bis(Thr-Arg-Pro-Ala-Tyr-amide) bis(hydrotrifluoroacetate) (2.30). Compound 
2.26 (38.2 mg, 26.9 µmol) was dissolved in anhydrous DMF/DIPEA (99:1, 700 µL). Compound 
2.12 (4.0 mg, 10.5 µmol) was added and the mixture was stirred at 35 °C for 16 h. Water (15 
mL) was added and the protected intermediate was extracted with EtOAc (2 × 15 mL). The 
combined organic layers were evaporated, and the residue was dried in vacuo. TFA/water 
(95:5, 2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water (100 mL) was 
added followed by lyophilisation. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–42:58, tR = 13.0 
min). Lyophilisation of the eluate afforded 2.30 as a white fluffy solid (11.4 mg, 56%). HRMS 
(m/z): [M+3H]3+ calcd. for C68H113N24O16, 507.2917; found, 507.2932. RP-HPLC (220 nm): 99% 
(tR = 14.33 min, k = 4.0). C68H110N24O16 · C8H4F12O8 (1519.78 + 456.08). 
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2.4.3  Synthesis of the Radioligands [
3
H]2.10 and [
3
H]2.18 
The radiolabeled peptides [3H]2.10 and [3H]2.18 were prepared by [3H]propionylation of the 
precursor peptides (2R,7R)-2.2 and 2.17, respectively. A solution of succinimidyl 
[3H]propionate (specific activity: 80 Ci/mmol, purchased from American Radiolabeled 
Chemicals, St. Louis, MO via Hartman Analytics, Braunschweig, Germany) (2.5 mCi, 5.5 µg, 32 
nmol) in hexane/EtOAc (9:1) was transferred from the delivered ampoule into a 1.5 mL 
reaction vessel with screw cap, and the solvent was removed in a vacuum concentrator (30 
°C, 30 min). A solution of the precursor peptide ((2R,7R)-2.2: 0.6 mg, 260 nmol, or 2.17: 0.8 
mg, 260 nmol) in anhydrous DMF containing 3% DIPEA (60 µL) was added, and the vessel 
was vigorously shaken at rt for 3 h. The mixture was acidified by addition of 2% aqueous TFA 
(80 µL) followed by addition of MeCN/H2O (10:90) (400 µL). [
3H]2.10 and [3H]2.18 were 
purified using a HPLC system from Waters (Eschborn, Germany) consisting of two 510 
pumps, a pump control module, a 486 UV/VIS detector and a Flow-one beta series A-500 
radiodetector (Packard, Meriden, USA). A Luna C18(2) column (3 µm, 150 × 4.6 mm, 
Phenomenex, Aschaffenburg, Germany) was used as stationary phase at a flow rate of 0.8 
mL/min. Mixtures of acetonitrile supplemented with 0.04% TFA (A) and 0.05% aq TFA (B) 
were used as mobile phase. The following linear gradient was applied: A/B: 0–20 min: 8:92 – 
33:67, 20–22 min: 33:67 – 95:5, 22–32 min: 95:5. For the purification of each radiolabeled 
peptide four HPLC runs were performed. The radioligands (tR = 17.3 min ([
3H]2.10) and tR = 
19.8 min ([3H]2.18)) were collected in 2-mL reaction vessels with screw cap, and the volumes 
of the combined eluates were reduced by evaporation to approximately 600 µL. The same 
volume of ethanol (600 µL) was added, and the solution was diluted with 50% ethanol to a 
volume of 1500 µL for each radioligand. For the quantification of the radioligands, a four-
point calibration was performed with (2R,7R)-2.10 (0.15, 0.3, 0.45 and 0.6 µM; injection 
volume: 100 µL, UV-detection: 225 nm) or 2.18 (0.1, 0.2, 0.3 and 0.4 µM; injections volume: 
100 µL, UV-detection: 225 nm) using the above mentioned HPLC system and gradient. 
Aliquots ([3H]2.10: 2 µL, [3H]2.18: 2 µL) of the respective radioligand solutions were added to 
acetonitrile/0.05% aqueous TFA (10:90) (128 µL). 100 µL of the resulting solutions were 
analyzed by HPLC and 5 × 3 µL were counted in 3 mL of liquid scintillator (Rotiszint eco plus, 
Carl Roth, Karlsruhe, Germany) with a LS 6500 liquid scintillation counter (Beckman Coulter, 
Krefeld, Germany). To determine the radiochemical purity and to prove the identity of the 
radioligands, a solution of the radiolabeled peptide (100 µL, 0.35 µMͿ, spiked ǁith ͚Đold͛ 
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(2R,7R)-2.10 (5 µM) or 2.18 (5 µM), was analyzed using the same HPLC system as for 
quantification and simultaneous radiometric detection (Rotiszint eco plus/acetonitrile, 85:15 
(v/v), flow rate: 4.0 mL/min). The radiochemical purities were > 99%. Analyses repeated 
after storage at -20 °C for 9 months revealed a radiochemical purities of 87% ([3H]2.10) and 
90% ([3H]2.18), respectively. Calculated specific activity: 0.960 TBq/mmol (25.94 Ci/mmol, 
[3H]2.10) or 0.976 TBq/mmol (26.37 Ci/mmol, [3H]2.18). The activity concentration was 
adjusted to 15.00 MBq/ml by the addition of 50% ethanol amounting to final concentrations 
of 15.6 µM [3H]2.10) and 15.4 µM ([3H]2.18), respectively. Chemical yields: 
penta(hydrotrifluoroacetate) of [3H]2.10: 75.6 µg, 32.4 nmol, and 
tetra(hydrotrifluoroacetate) of [3H]2.18: 64.7 µg, 28.1 nmol. Radiochemical yields: [3H]2.10: 
0.842 mCi (31.14 MBq), 34%, [3H]2.18: 0.741 mCi (27.39 MBq), 30%. 
 
2.4.4  Investigation of the Chemical Stability 
The chemical staďilitǇ of ͚Đold͛ ;ϮR,7R)-2.10 aŶd ͚Đold͛ 2.18 was investigated in buffer I at 22 
± 1 °C. The incubation was started by addition of 20 µL of a 1 mM aqueous solution of 
(2R,7R)-2.10 or 2.18 to the buffer (780 µL or 580 µL) to give final concentrations of 25 µM 
((2R,7R)-2.10) and 33.35 µM (2.18), respectively. After 0, 12 and 48 h, aliquots (100 µL) were 
taken, and 100 µL of 1% aqueous TFA were added. The resulting solutions were analyzed by 
RP-HPLC (cf. general experimental conditions). 
 
2.4.5 Pharmacological Assays 
Cells. The HEC-1B human endometrial cancer cell line and the MCF-7 (HTB 22) human breast 
cancer cells were from the American Type Culture Collection (Rockville, MD). A subclone of 
the MCF-7 cell line that shows higher Y1R expression was established in our laboratory and 
used for binding experiments.31 Human erythroleukemia (HEL) cells were kindly provided by 
Dr. M. C. Michel (Universitätsklinikum Essen, Germany). Human embryonal kidney cells 
(HEK-293 cells) and chinese hamster ovarian (CHO) cells were from Deutsche Sammlung für 
Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, Germany). Genetically engineered 
cells, used for binding and functional assays, were generated and cultured as described (cf. 
brief description of protocols). 
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HEK293-hY4-CRE Luc cells. HEK293 cells were stably co-transfected with the 
pGL4.29[luc2P/CRE/Hygro] plasmid (Promega, Mannheim, Germany) encoding hygromycin B 
resistance and the firefly luciferase, the transcription of which is controlled by the cAMP 
responsive element (HEK293-CRE Luc cells, ref.24) and pcDNA3.1 hY4 vector (cDNA Resource 
Center; Bloomsberg, PA, USA) encoding the hY4R (HEK293-hY4-CRE Luc cells) and neomycin 
resistance. For transfection, the cells were seeded into a 24 well-plate (Becton Dickinson), so 
that they reached 60–70% confluency on the next day. The transfection mixture containing 2 
µg of the DNA and 8 µL of FuGene HD transfection reagent (Roche Diagnostics, Mannheim, 
GeƌŵaŶǇͿ ǁas pƌepaƌed aĐĐoƌdiŶg to the ŵaŶufaĐtuƌeƌ͛s pƌotoĐol aŶd added to the Đells, 
followed by an incubation period of 48 h at 37 °C and 5% CO2 in a water-saturated 
atmosphere.  
Routinely performed examinations for mycoplasma contamination using the Venor GeM 
Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany) were negative for all cell 
types. 
Cell Culture. Cells were cultured in 25- or 75-cm2 flasks (Sarstedt, Nümbrecht, Germany) in a 
humidified atmosphere (95% air, 5% CO2) at 37 °C. MCF-7-Y1 cells,
30 HEL cells,42 CHO-hY2-
Gqi5-mtAEQ cells
23 and CHO-hY4-Gqi5-mtAEQ cells
23 were cultured as described previously. 
HEK293T-hY4-CRE Luc cells were cultured in Dulbecco`s Modified Eagle Medium (DMEM) 
(Sigma-Aldrich, Deisenhofen, Germany) containing L-glutamine (Sigma-Aldrich), 4500 mg/L 
glucose, 3.7 g/L NaHCO3 (Merck, Darmstadt, Germany), 110 mg/L sodium pyruvate (Serva, 
Heidelberg, Germany), 10 % fetal calf serum (FCS) (Biochrom, Berlin, Germany) and the 
selection antibiotics G418 (600 μg/mL) (Biochrom) and hygromycin B (250 μg/mL) (MoBiTec 
GmbH, Göttingen, Germany). HEC-1B cells expressing the human Y5R were cultured as 
previously described.34 
Buffers and Media Used in Binding and Functional Experiments. Buffer I. A sodium-free 
HEPES buffer (25 mM HEPES, 2.5 mM CaCl2, 1 mM MgCl2, pH 7.4) was used in binding 
experiments at the Y2R and Y4R. Buffer II. Binding experiments at the Y1R and Y5R were 
performed in a buffer containing 150 mM NaCl, 10 mM HEPES, 25 mM NaHCO3, 2.5 mM 
CaCl2, 5 mM KCl.  Buffer III. For the aequorin assay on CHO cells stably expressing the Y4R the 
buffer contained 120 mM NaCl, 25 mM HEPES, 1.5 mM CaCl2, MgCl2, 5 mM KCl, 10 mM D-
glucose. Leiďovitz’ L-15 medium (containing 140 mM NaCl, 1.3 mM CaCl2, 1 mM MgCl2, 
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amino acids, vitamins, pH 7.4) was used to perform additional binding experiments with 
selected compounds at the Y4R. DMEM (without phenol red, containing 110 mM NaCl, 44 
mM NaHCO3, 1.8 mM CaCl2, 0.8 mM MgCl, 5.6 mM D-glucose, vitamins, amino acids, pH 7.4) 
was used to perform the luciferase assay. 
Radioligand Binding Assays. Y1R binding. Radioligand binding assays for all receptor 
subtypes were performed at 22 ± 1 °C. Competition binding experiments with the 
radioligand [3H]UR-MK136 (Kd = 6.2 nM, c = 4 nM) were performed at intact MCF-7-Y1 cells 
as previously described30 with the following modifications: Experiments were carried out in 
96-well plates with clear bottom (Corning Incorporated Life Sciences, Tewksbury, MA; 
Corning cat. no. 3610), and the volume per well was reduced to 100 µL. After incubation, the 
cells were washed with buffer II (200 µL) twice and covered with lysis solution (25 µL) 
consisting of urea, acetic acid and Triton-X-100 in water. The plates were shaken for 30 min 
prior to addition of liquid scintillator (Optiphase Supermix, PerkinElmer, Überlingen, 
Germany) (200 µL). The wells were sealed with a transparent film (permanent seal for 
microplates, PerkinElmer, prod. no. 1450–461). The plates were shaken to mix the 
scintillator and the aqueous phase and kept in the dark for at least 30 min. Radioactivity 
(dpm) was measured with a MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany). 
Y2R binding. Competition binding experiments were performed at CHO-hY2R-Gqi5-mtAEQ 
cells33 with [3H]propionyl-pNPY (Kd = 1.4 nM, c = 1 nM).
32 One day prior to the experiment, 
the Đells ǁeƌe adjusted to a deŶsitǇ of appƌoǆiŵatelǇ ϭϳϬ ϬϬϬ peƌ ŵL iŶ Haŵ͛s FϭϮ ;“igŵa 
Aldrich) supplemented with 10 % FCS. 200 μL per well were seeded into 96-well plates with 
clear bottom (Corning Incorporated Life Sciences, Tewksbury, MA; cat. no. 3610). The cells 
were allowed to attach overnight at 37 °C, 5% CO2 in a water-saturated atmosphere. On the 
day of the experiment, the confluency of the cells was >90%. The culture medium was 
removed by suction, the cells were washed with buffer I (200 µL) and covered with binding 
buffer (buffer I supplemented with 1% BSA and 0.1 mg/mL bacitracin) (80 µL). For 
radioligand displacement experiments, binding buffer containing the competitor 10-fold 
concentrated (10 µL) and binding buffer containing the radioligand 10-fold concentrated 
were added. The cells were incubated for 90 min, the buffer was removed by suction, and 
the cells were washed twice with ice-cold buffer I (200 µL), before 25 µL of lysis solution (25 
mM tricine; glycerol 10 % (v/v); EGTA, 2 mM; 1% (v/v) Triton X-100; MgSO4 · 7 H2O, 5 mM; 
  
 
68  Chapter 2 
 
DTT, 1 mM) were added. The plates were shaken for 30 min prior to addition of liquid 
scintillator (Optiphase Supermix, 200 µL). The sealed plates were processed as described 
above. 
Y4R binding. Binding assays with the radioligands [
3H]2.10 or [3H]2.18 were performed at 
intact CHO-hY4R-Gqi5-mtAEQ cells.
23 For saturation and competition binding experiments, 
cells were grown to 80% - 100% confluency, scraped off the culture flask and centrifuged for 
5 min at 300 g. The culture medium was discarded, and the cells were resuspended at a 
deŶsitǇ of ϱϬϬ,ϬϬϬ Đells/ŵL iŶ ďuffeƌ I oƌ Leiďoǀitz͛ L-15 medium, both supplemented with 
1% BSA and 0.1 mg/mL bacitracin. Both, saturation and competition experiments were 
performed in a final volume of 200 µL in Primaria 96-well plates (Corning Life Sciences, 
Oneonta, NY). Saturation binding experiments were performed in a concentration range of 
0.14 - 11 nM, when using buffer I, or 0.5 - 30 nM, when using L-15 medium. Competition 
binding experiments were performed with increasing concentrations of unlabeled 
compounds and radioligand concentrations in the range of the respective Kd value (0.6 nM in 
case of [3H]2.10 in buffer I (sodium-free HEPES buffer), 10 nM of [3H]2.10 in L-15 medium, 1 
nM of [3H]2.18 in buffer I). Nonspecific binding was determined in the presence of a 200-fold 
excess of (2R,7R)-2.2 (when using [3H]2.10) or 2.17 (when using [3H]2.18), respectively. 
Incubation period was 90 min. Bound and free radioligand were separated by filtration 
through 0.3% polyethyleneimine pre-treated GF/C filters (Whatman, Maidstone, UK) using a 
Brandel Harvester (Brandel, Gaithersburg, MD, USA). Filter pieces for each well were 
punched out and transferred into 96-well plates 1450-401 (PerkinElmer) and scintillation 
cocktail (200 µL, Rotiscint eco plus) was added. After incubation in the dark for 60 min, 
radioactivity (dpm) was measured with a MicroBeta2 plate counter (PerkinElmer).  
For kinetic experiments, the cells were adjusted to a density of approximately 170,000 per 
ŵL iŶ Haŵ͛s FϭϮ ;“igŵa AldƌiĐhͿ suppleŵeŶted ǁith ϭϬ % FC“. Cells ǁeƌe seeded iŶ a ǀoluŵe 
of ϮϬϬ μL peƌ ǁell iŶto Primaria 96-well plates one day before the experiment. The cells 
were allowed to attach overnight at 37 °C, 5% CO2 in a water-saturated atmosphere. On the 
day of the experiment, confluency of the cells was approximately 90%. The culture medium 
was removed by suction, the cells were washed with 200 µL of buffer I and covered with 160 
µL of binding buffer (buffer I supplemented with 1% BSA and 0.1 mg/mL bacitracin) per well. 
Unspecific binding was determined in the presence of (2R,7R)-2.2 in experiments with 
[3H]2.10 or 2.17 in experiments with [3H]2.18. For association experiments, the radioligand 
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concentration was 1.5 nM. The incubation of the cells was stopped after different periods of 
time (2 – 180 min) by removing the radioligand-containing medium, and cells were washed 
twice with ice-cold buffer I (200 µL). In case of dissociation experiments, cells were pre-
incubated with [3H]2.10 or [3H]2.18 at a concentration of 1.5 nM for 120 min. The solution 
was removed by suction and the cells were covered with binding buffer (200 µL) containing 
(2R,7R)-2.2 (300 nM) or 2.17 (300 nM). After different periods of time (2 – 360 min) the cells 
were washed with ice-cold buffer I. After addition of lysis solution (25 µL), the plates were 
shaken for 30 min, and the content of the wells was transferred into 96-well plates 1450-
401, followed by the addition of 200 µL of liquid scintillator (Optiphase Supermix). The plates 
were sealed and processed as described above.  
Y5R binding. Competition binding experiments were performed at HEC-1B-hY5 cells
34 with 
[3H]propionyl-pNPY (Kd = 4.8 nM, c = 4 nM).
32 One or two days prior to the experiment, the 
cells were seeded into 96-well plates with clear bottom (Corning cat. no. 3610). The cells 
were allowed to attach overnight at 37 °C, 5% CO2 in a water-saturated atmosphere. On the 
day of the experiment, confluency of the cells was approximately 90%. The culture medium 
was removed by suction and the cells were washed with buffer II (200 µL) and covered with 
80 µL of binding buffer (buffer II supplemented with 1% BSA and 0.1 mg/mL bacitracin). For 
displacement experiments, 10 µL of binding buffer containing the competitor (10-fold 
concentrated) and 10 µL of binding buffer containing the radioligand (10-fold concentrated) 
were added. The cells were incubated for 120 min. The solution was removed by suction and 
the cells were washed with ice-cold buffer II (2 × 200 µL) followed by the addition of lysis 
solution (25 µL). The plates were shaken for 30 min followed by the addition of 200 µL of 
liquid scintillator (Optiphase Supermix). The plates were sealed and processed as described 
above. 
Functional Assays. Fura-2 Calcium Assay. The assay was performed for the functional 
characterization of selected ligands at the human Y1 receptor using HEL cells and a LS-50B 
luminescence spectrometer (Perkin Elmer, Überlingen, Germany) as previously 
described.42,43 
Aequorin Calcium Assay. The assay was performed on CHO-hY4-Gqi5-mtAEQ cells in buffer III 
as previously described23 using a GENios Pro plate reader (Tecan, Salzburg, Austria). Areas 
under the curve were calculated using SigmaPlot 12.5 software (Systat Software Inc., 
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Chicago, IL). Luminescence data were normalized to the effect caused by 1 µM PP (measured 
in triplicate on every 96-well plate). 
Luciferase Assay. The Luciferase assay was performed on HEK293-hY4-CRE Luc cells. One day 
prior to the experiment, the cells were adjusted to a density of approximately 800,000 per 
mL in DMEM without phenol red supplemented with 5 % FCS. Cells were seeded in a volume 
of 160 μL per well into 96-well plates with clear bottom (Corning cat. no. 3610), and allowed 
to attach overnight at 37 °C, 5% CO2 in a water-saturated atmosphere. A stock solution (10 
mM) of forskolin (Sigma) in DMSO was used to prepare feed solutions in DMEM without 
phenol red (final DMSO concentration in the assay was 0.02%). After addition of 20 µL of 
forskolin solution (final concentration 2 µM), 20 µL of a 10-fold concentrated solution of the 
respective test compound were added. The cells were incubated at 37 °C in water saturated 
atmosphere containing 5 % CO2 for 4.5 h. Afterwards, the medium was discarded, and 80 μL 
of lysis solution (pH adjusted to 7.8 with hydrochloric acid) were added to each well. The 
plates were shaken at 600 rpm for 30 min. Afterwards, 40 μL of the lysate were transferred 
into white 96-well plates (Greiner, Frickenhausen, Germany). Luminescence was measured 
with a GENios Pro microplate reader. Light emission was induced by injecting 80 μL of the 
luciferase assay buffer (25 mM Gly-Gly; MgSO4 · 7 H2O, 15 mM; KH2PO4, 15 mM; EGTA, 4 
mM; ATP disodium salt, 2 mM; DTT, 2 mM; D-luciferin potassium salt (Synchem, Felsberg, 
Germany), 0.2 mg/mL; pH was adjusted to 7.8 with hydrochloric acid). Luminescence [RLU] 
was measured for 10 s.  
  
  
 
  High Affinity Agonists of the NPY Y4 Receptor 71 
 
 
2.5  References 
(1) Balasubramaniam, A. A. Neuropeptide Y family of hormones: receptor subtypes and 
antagonists. Peptides 1997, 18, 445-457. 
(2) Cerda-Reverter, J. M.; Larhammar, D. Neuropeptide Y family of peptides: structure, 
anatomical expression, function, and molecular evolution. Biochem. Cell Biol. 2000, 78, 371-
392. 
(3) Cabrele, C.; Beck-Sickinger, A. G. Molecular characterization of the ligand-receptor 
interaction of the neuropeptide Y family. J. Pept. Sci. 2000, 6, 97-122. 
(4) Zhang, L.; Bijker, M. S.; Herzog, H. The neuropeptide Y system: pathophysiological 
and therapeutic implications in obesity and cancer. Pharmacol. Ther. 2011, 131, 91-113. 
(5) Lundell, I.; Blomqvist, A. G.; Berglund, M. M.; Schober, D. A.; Johnson, D.; Statnick, M. 
A.; Gadski, R. A.; Gehlert, D. R.; Larhammar, D. Cloning of a human receptor of the NPY 
receptor family with high affinity for pancreatic polypeptide and peptide YY. J. Biol. Chem. 
1995, 270, 29123-29128. 
(6) Sainsbury, A.; Shi, Y. C.; Zhang, L.; Aljanova, A.; Lin, Z.; Nguyen, A. D.; Herzog, H.; Lin, 
S. Y4 receptors and pancreatic polypeptide regulate food intake via hypothalamic orexin and 
brain-derived neurotropic factor dependent pathways. Neuropeptides 2010, 44, 261-268. 
(7) Lin, S.; Shi, Y. C.; Yulyaningsih, E.; Aljanova, A.; Zhang, L.; Macia, L.; Nguyen, A. D.; Lin, 
E. J.; During, M. J.; Herzog, H.; Sainsbury, A. Critical role of arcuate Y4 receptors and the 
melanocortin system in pancreatic polypeptide-induced reduction in food intake in mice. 
PLoS One 2009, 4, e8488. 
(8) Kamiji, M. M.; Inui, A. NPY Y2 and Y4 receptors selective ligands: promising anti-
obesity drugs? Curr. Top. Med. Chem. 2007, 7, 1734-1742. 
(9) Li, J. B.; Asakawa, A.; Terashi, M.; Cheng, K.; Chaolu, H.; Zoshiki, T.; Ushikai, M.; 
Sheriff, S.; Balasubramaniam, A.; Inui, A. Regulatory effects of Y4 receptor agonist (BVD-74D) 
on food intake. Peptides 2010, 31, 1706-1710. 
(10) Keller, M.; Kaske, M.; Holzammer, T.; Bernhardt, G.; Buschauer, A. Dimeric 
argininamide-type neuropeptide Y receptor antagonists: chiral discrimination between Y1 
and Y4 receptors. Bioorg. Med. Chem. 2013, 21, 6303-6322. 
(11) Rudolf, K.; Eberlein, W.; Engel, W.; Wieland, H. A.; Willim, K. D.; Entzeroth, M.; 
Wienen, W.; Beck-Sickinger, A. G.; Doods, H. N. The first highly potent and selective non-
  
 
72  Chapter 2 
 
peptide neuropeptide Y Y1 receptor antagonist: BIBP3226. Eur. J. Pharmacol. 1994, 271, R11-
13. 
(12) Merten, N.; Lindner, D.; Rabe, N.; Rompler, H.; Mörl, K.; Schöneberg, T.; Beck-
Sickinger, A. G. Receptor subtype-specific docking of Asp6.59 with C-terminal arginine 
residues in Y receptor ligands. J. Biol. Chem. 2007, 282, 7543-7551. 
(13) Daniels, A. J.; Matthews, J. E.; Slepetis, R. J.; Jansen, M.; Viveros, O. H.; Tadepalli, A.; 
Harrington, W.; Heyer, D.; Landavazo, A.; Leban, J. J.; Spaltenstein, A. High-affinity 
neuropeptide Y receptor antagonists. Proc. Natl. Acad. Sci. U. S. A. 1995, 92, 9067-9071. 
(14) Parker, E. M.; Babij, C. K.; Balasubramaniam, A.; Burrier, R. E.; Guzzi, M.; Hamud, F.; 
Mukhopadhyay, G.; Rudinski, M. S.; Tao, Z.; Tice, M.; Xia, L.; Mullins, D. E.; Salisbury, B. G. 
GR231118 (1229U91) and other analogues of the C-terminus of neuropeptide Y are potent 
neuropeptide Y Y1 receptor antagonists and neuropeptide Y Y4 receptor agonists. Eur. J. 
Pharmacol. 1998, 349, 97-105. 
(15) Balasubramaniam, A.; Mullins, D. E.; Lin, S.; Zhai, W.; Tao, Z.; Dhawan, V. C.; Guzzi, 
M.; Knittel, J. J.; Slack, K.; Herzog, H.; Parker, E. M. Neuropeptide Y (NPY) Y4 receptor 
selective agonists based on NPY(32-36): development of an anorectic Y4 receptor selective 
agonist with picomolar affinity. J. Med. Chem. 2006, 49, 2661-2665. 
(16) Keller, M.; Kuhn, K. K.; Einsiedel, J.; Hubner, H.; Biselli, S.; Mollereau, C.; Wifling, D.; 
Svobodova, J.; Bernhardt, G.; Cabrele, C.; Vanderheyden, P. M.; Gmeiner, P.; Buschauer, A. 
Mimicking of arginine by functionalized N(omega)-carbamoylated arginine as a new broadly 
applicable approach to labeled bioactive peptides: high affinity angiotensin, neuropeptide Y, 
neuropeptide FF and neurotensin receptor ligands as examples. J. Med. Chem. 2016, 59, 
ϭϵϮϱ−ϭϵϰϱ. 
(17) Moffat, D. F. C.; Patel, S. R.; Davies, S. J.; Baker, K. W. J.; Philps, O. J. Preparation of 
tetrahydropteridinylaminomethoxybenzoylamino acids as polo-like kinase (PLK1) inhibitors 
useful in the treatment of cancer. WO 2008/050096, 2008, Chem. Abstr. 148:517974. 
(18) Hupp, C. D.; Tepe, J. J. 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride-
mediated oxazole rearrangement: gaining access to a unique marine alkaloid scaffold. J. Org. 
Chem. 2009, 74, 3406-3413. 
(19) Louie, J.; Bielawski, C. W.; Grubbs, R. H. Tandem catalysis: the sequential mediation 
of olefin metathesis, hydrogenation, and hydrogen transfer with single-component Ru 
complexes. J. Am. Chem. Soc. 2001, 123, 11312-11313. 
  
 
  High Affinity Agonists of the NPY Y4 Receptor 73 
 
 
(20) Watson, M. D.; Wagener, K. B. Tandem homogeneous metathesis/heterogeneous 
hydrogenation: preparing model ethylene/CO2 and ethylene/CO copolymers. 
Macromolecules 2000, 33, 3196-3201. 
(21) Passarella, D.; Peretto, B.; Blasco y Yepes, R.; Cappelletti, G.; Cartelli, D.; Ronchi, C.; 
Snaith, J.; Fontana, G.; Danieli, B.; Borlak, J. Synthesis and biological evaluation of novel 
thiocolchicine-podophyllotoxin conjugates. Eur. J. Med. Chem. 2010, 45, 219-226. 
(22) Keller, M.; Teng, S.; Bernhardt, G.; Buschauer, A. Bivalent argininamide-type 
neuropeptide y y(1) antagonists do not support the hypothesis of receptor dimerisation. 
ChemMedChem 2009, 4, 1733-1745. 
(23) Ziemek, R.; Schneider, E.; Kraus, A.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, G.; 
Buschauer, A. Determination of affinity and activity of ligands at the human neuropeptide Y 
Y4 receptor by flow cytometry and aequorin luminescence. J. Recept. Signal Transduct. 2007, 
27, 217-233. 
(24) Nordemann, U.; Wifling, D.; Schnell, D.; Bernhardt, G.; Stark, H.; Seifert, R.; 
Buschauer, A. Luciferase reporter gene assay on human, murine and rat histamine H4 
receptor orthologs: correlations and discrepancies between distal and proximal readouts. 
PLoS One 2013, 8, e73961. 
(25) Berlicki, L.; Kaske, M.; Gutierrez-Abad, R.; Bernhardt, G.; Illa, O.; Ortuno, R. M.; 
Cabrele, C.; Buschauer, A.; Reiser, O. Replacement of Thr32 and Gln34 in the C-terminal 
neuropeptide Y fragment 25-36 by cis-cyclobutane and cis-cyclopentane beta-amino acids 
shifts selectivity toward the Y(4) receptor. J. Med. Chem. 2013, 56, 8422-8431. 
(26) Liu, W.; Chun, E.; Thompson, A. A.; Chubukov, P.; Xu, F.; Katritch, V.; Han, G. W.; Roth, 
C. B.; Heitman, L. H.; AP, I. J.; Cherezov, V.; Stevens, R. C. Structural basis for allosteric 
regulation of GPCRs by sodium ions. Science 2012, 337, 232-236. 
(27) Huang, W.; Manglik, A.; Venkatakrishnan, A. J.; Laeremans, T.; Feinberg, E. N.; 
Sanborn, A. L.; Kato, H. E.; Livingston, K. E.; Thorsen, T. S.; Kling, R. C.; Granier, S.; Gmeiner, 
P.; Husbands, S. M.; Traynor, J. R.; Weis, W. I.; Steyaert, J.; Dror, R. O.; Kobilka, B. K. 
Structural insights into micro-opioid receptor activation. Nature 2015, 524, 315-321. 
(28) Daniels, A. J.; Heyer, D.; Spaltenstein, A. In Neuropeptide Y and Drug Development, 
Ed. Grundemar, L.; Bloom, S. R., Academic Press: London, 1996; pp 127-155. 
(29) Holliday, N. D.; Michel, M. C.; Cox, H. M. In Neuropeptide Y and Related Peptides, Ed. 
Michel, M. C., Springer: Heidelberg, 2004; Vol. 162, pp 45-73. 
  
 
74  Chapter 2 
 
(30) Keller, M.; Bernhardt, G.; Buschauer, A. [(3)H]UR-MK136: a highly potent and 
selective radioligand for neuropeptide Y Y(1) receptors. ChemMedChem 2011, 6, 1566-1571. 
(31) Memminger, M.; Keller, M.; Lopuch, M.; Pop, N.; Bernhardt, G.; Von Angerer, E.; 
Buschauer, A. The Neuropeptide Y Y1 receptor: a diagnostic marker? Expression in MCF-7 
breast cancer cells is down-regulated by antiestrogens in vitro and in xenografts. PLoS One 
2012, 7, e51032. 
(32) Keller, M.; Weiss, S.; Hutzler, C.; Kuhn, K. K.; Mollereau, C.; Dukorn, S.; Schindler, L.; 
Bernhardt, G.; König, B.; Buschauer, A. N(omega)-carbamoylation of the argininamide 
moiety: an avenue to insurmountable NPY Y1 receptor antagonists and a radiolabeled 
selective high-affinity molecular tool ([(3)H]UR-MK299) with extended residence time. J. 
Med. Chem. 2015, 58, 8834-8849. 
(33) Ziemek, R.; Brennauer, A.; Schneider, E.; Cabrele, C.; Beck-Sickinger, A. G.; Bernhardt, 
G.; Buschauer, A. Fluorescence- and luminescence-based methods for the determination of 
affinity and activity of neuropeptide Y2 receptor ligands. Eur. J. Pharmacol. 2006, 551, 10-18. 
(34) Moser, C.; Bernhardt, G.; Michel, J.; Schwarz, H.; Buschauer, A. Cloning and functional 
expression of the hNPY Y5 receptor in human endometrial cancer (HEC-1B) cells. Can. J. 
Physiol. Pharmacol. 2000, 78, 134-142. 
(35) Garber, S. B.; Kingsbury, J. S.; Gray, B. L.; Hoveyda, A. H. Efficient and recyclable 
monomeric and dendritic Ru-based metathesis catalysts. J. Am. Chem. Soc. 2000, 122, 8168-
8179. 
(36) Gao, Y.; Lane-Bell, P.; Vederas, J. C. Stereoselective Synthesis of meso-2,6-
Diaminopimelic Acid and Its Selectively Protected Derivatives. J. Org. Chem. 1998, 63, 2133-
2143. 
(37) Duggan, H. M.; Hitchcock, P. B.; Young, D. W. Synthesis of 5/7-, 5/8- and 5/9-bicyclic 
lactam templates as constraints for external beta-turns. Org. Biomol. Chem. 2005, 3, 2287-
2295. 
(38) Saniere, L.; Leman, L.; Bourguignon, J.-J.; Dauban, P.; Dodd, R. H. Iminoiodane 
mediated aziƌidiŶatioŶ of α-allylglycine: access to a novel rigid arginine derivative and to the 
natural amino acid enduracididine. Tetrahedron 2004, 60, 5889-5897. 
(39) Ward, M. D.; Zhu, Z. Compounds as L-cystine crystallization inhibitors and uses 
thereof. US 2012/0316236, 2012, Chem. Abstr. 158:66920. 
  
 
  High Affinity Agonists of the NPY Y4 Receptor 75 
 
 
(40) Aguilera, B.; Wolf, L. B.; Nieczypor, P.; Rutjes, F. P.; Overkleeft, H. S.; van Hest, J. C.; 
Schoemaker, H. E.; Wang, B.; Mol, J. C.; Furstner, A.; Overhand, M.; van der Marel, G. A.; van 
Boom, J. H. Synthesis of diaminosuberic acid derivatives via ring-closing alkyne metathesis. J. 
Org. Chem. 2001, 66, 3584-3589. 
(41) Hiebl, J.; Blanka, M.; Guttman, A.; Kollmann, H.; Leitner, K.; Mayrhofer, G.; Rovenszky, 
F.; Winkler, K. A detailed investigation of the preparation of 2,7-diaminosuberic acid and 2,5-
diaminoadipic acid derivatives using Kolbe electrolysis. Tetrahedron 1998, 54, 2059-2074. 
(42) Weiss, S.; Keller, M.; Bernhardt, G.; Buschauer, A.; König, B. Modular synthesis of 
non-peptidic bivalent NPY Y1 receptor antagonists. Bioorg. Med. Chem. 2008, 16, 9858-9866. 
(43) Keller, M.; Schindler, L.; Bernhardt, G.; Buschauer, A. Toward labeled argininamide-
type NPY Y1 receptor antagonists: Identification of a favorable propionylation site in 
BIBO3304. Arch. Pharm. (Weinheim). 2015, 348, 390-398. 
  
  
  
 
  Investigations with [3H]UR-KK193 at rY4R and gpY4R 77 
 
 
 
Chapter 3 
IŶǀestigatioŶs ǁith [ϯH]UR-KKϭϵϯ at Rat aŶd 
GuiŶea Pig Yϰ Receptors 
  
 
78  Chapter 3 
 
3.1  Introduction 
Among the NPY receptors, the Y4R shows the lowest degree of sequence identity across 
different species. For example, the rat Y4R only shares a sequence identity of 75% with the 
human ortholog,1 whereas the amino acid identity between human and rat Y1Rs is 94%. The 
sequence of guinea pig Y4R is much more similar to that of the human Y4R (84% identity) 
than to the sequence of the rat Y4R.
2 This correlates with the preferred ligand of the Y4Rs, 
PP, for which rodents show the highest divergence of all known mammalian PP sequences.3 
Previously, the high-affinity agonist BVD-74D4 (Figure 1) was described to have a regulatory 
effect on the food intake in fasted mice, suggesting BVD74-D as potential agent for the 
treatment of obesity.5 However, due to the above-mentioned strong differences between 
human and rodent Y4Rs, it is highly questionable whether these results can be transferred to 
humans. Binding studies with BVD-74D should be carried out at rodent Y4Rs to be able to 
better assess the potential of BVD-74D to reduce the food intake in humans. Furthermore, 
by analogy with GPCR mutants, orthologous Y4Rs might serve as a template to identify 
putative interaction partners between a peptide ligand and the human Y4R.   
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Figure 1: Structures of the Y4‘ ͚diŵeƌiĐ͛ peŶtapeptide agoŶists, the peŶtapeptide agoŶist 4.3 and the 
Y1R/Y4R antagonist UR-MK188. 
aBalasubramaniam et al4; bKuhn et al6; cKeller et al7; dBerlicki et al8; 
Keller et al9. 
 
3.2  Results and Discussion 
3.2.1  Saturation Binding of [
3
H]UR-KK193 at Rat and Guinea Pig Y4Rs 
Saturation binding experiments with the tritiated radioligand [3H]UR-KK193 were performed 
on homogenates of CHO cells stably expressing either the rY4R or the gpY4R in a sodium-free 
HEPES buffer. The affinity of [3H]UR-KK193 at the rY4R (Kd = 0.18 ± 0.01 nM) was higher than 
at the gpY4R (Kd = 2.64 ± 0.5 nM) by a factor of 14. The number of specific binding sites per 
cell were 86500 ± 5700 (rY4R) or 105500 ± 9200 (gpY4R). At concentrations around the Kd 
values, nonspecific binding amounted to 10% (rY4R) and 36% (gpY4R), respectively, of the 
  
 
80  Chapter 3 
 
total binding. Due to the high affinity of [3H]UR-KK193 at the rY4R and the low unspecific 
binding associated therewith, binding experiments at the rY4R were especially robust. 
 
Figure 2: Representative saturation binding experiments with [3H]UR-KK193 at CHO-rY4R (A) and 
CHO-gpY4R (B) cell homogenates. (C) Comparison of saturation binding experiments with [
3H]UR-
KK193 at rY4R (red), hY4R (black) and gpY4‘ ;ďlueͿ. MeaŶ ± “EM of ≥ ϯ iŶdepeŶdeŶt eǆpeƌiŵeŶts 
performed in triplicate. 
 
3.2.2  Competition Binding Studies with [
3
H]UR-KK193 at Rat and 
Guinea Pig Y4Rs 
The Ki ǀalues of seǀeƌal ͚diŵeƌiĐ͛ peŶtapeptides aŶd ƌefeƌeŶĐe ĐoŵpouŶds ǁeƌe deteƌŵiŶed 
in competition binding experiments at the rY4R and gpY4R, respectively (Figure 3, for results 
see Table 1). The determination of Ki values at the hY4R is described in chapter 2 (hPP, UR-
MK188, (2R,7R)-2.2, (2S,7S)-2.2, (2R,7R)-2.10, 2.16, 2.17, 2.19, 2.20, 2.21, 2.22) and chapter 
4 (4.3). The affinity of the endogenous ligand hPP to rY4R and gpY4R was nearly identical (Ki 
(rY4R) = 0.15 nM, Ki (gpY4R) = 0.17 nM). As observed for the radioligand [
3H]UR-KK193, the 
affiŶitǇ of all iŶǀestigated ͚diŵeƌiĐ͛ peŶtapeptides to the ƌY4R is higher than the affinity to 
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the gpY4R by a factor of 10 to 20. For example, (2R,7R)-2.2 showed Ki values in the picomolar 
range at the rY4R (Ki = 0.044 nM) and substantially lower affinity to the gpY4R (Ki = 1.08 nM). 
The same holds for the (2S,7S)-configured isomer (Ki (rY4R) = 0.38 nM, Ki (gpY4R) = 9.90 nM). 
The order of affinity within the investigated seƌies of ͚diŵeƌiĐ͛ peŶtapeptides ǁas the saŵe 
at all three Y4‘ oƌthologs, that is, the affiŶitǇ of eaĐh ͚diŵeƌiĐ͛ peŶtapeptide to the hY4R was 
in between those to the rY4R and the gpY4R. In contrast to the dimeric peptides, the 
difference in affinity to human, guinea pig and rat Y4R was lower in case of peptide 4.3 and 
the dimeric antagonist UR-MK188. Compound 4.3 and UR-MK188 display similar affinities to 
the human and guinea pig Y4Rs (4.3: Ki (hY4R) = 337 nM, Ki (gpY4R) = 267 nM; UR-MK188: Ki 
(hY4R) = 660 nM, Ki (gpY4R) = 643 nM). The affinity to the rY4R was approximately 5 times 
higher for both compounds (4.3: Ki (rY4R) = 55.6 nM, UR-MK188: Ki (rY4R) = 124 nM).   
Recently, a model of the hY4R in complex with PP was constructed based on all available 
class A GPCR crystal structures. Several amino acids in the top of transmembrane helixes 2 
(Tyr2.64, Asp2.68 and Trp2.70), 6 (Asn6.55 and Asp6.59) and 7 (Asn7.32 and Phe7.35) were reported to 
form the core of the peptide binding pocket (Figure 4).10 The reported amino acids and 
neighboring regions are highly conserved among human, guinea pig and rat Y4Rs. Therefore 
it appeaƌs ƌatheƌ suƌpƌisiŶg that the affiŶitǇ of the ͚diŵeƌiĐ͛ peptides to ƌat aŶd guiŶea pig 
Y4Rs differs by a factor of 10 to 20, whereas the affinity of the endogenous ligand hPP is 
nearly identical. The different binding profiles could be explained by not or only partially 
oǀeƌlappiŶg ďiŶdiŶg sites. Fuƌtheƌŵoƌe, ǁith ƌespeĐt to theiƌ size, the ͚diŵeƌiĐ͛ peptides 
might occupy an additional allosteric interaction site that is less conserved among different 
Y4 orthologous receptors. Glu
5.24 was reported to be crucial for the interaction of the hY2R 
with the endogenous ligand NPY.11 Like Asp6.59, Glu5.24 is highly conserved among 
mammalian Y4Rs with exception of rat and mouse Y4Rs (Figure 4). Due to the high affinity of 
all investigated compounds to the rY4R, a contribution of Glu
5.24 to either the orthosteric 
binding pocket or an allosteric interaction site can be excluded in case of the Y4R.  
Taking into consideration the different affinity of (2R,7R)-2.2 and (2S,7S)-2.2 to hY4R and 
rY4R (Table 1), it remains a matter of speculation whether the regulatory effect of BVD-74D 
on food intake in mice (note: the rY4R and mY4R display a high sequence identity of 92%) can 
be extrapolated to humans. In addition, (2R,7R)-2.2 is a weak antagonist at the hY1R as well, 
whereas the affinity of BVD-74D to rodent Y1, Y2 and Y5 receptors is unknown. Furthermore, 
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the y6R is functionally expressed in mice.
12 As the y6R is an inactive pseudogene in humans, it 
is often neglected in the interpretation of data from in vivo studies. In principal, the effect of 
BVD-74D on food intake in mice might be regulated via Y1R, Y2R, Y5R or y6R as well. 
 
 
Figure 3:  Radioligand displacement curves from competition binding experiments performed with 
[3H]UR-KK193 at CHO-rY4R (red, Kd = 0.18 nM, c = 0.2 nM) and CHO-gpY4R (blue, Kd = 2.64 nM, c = 2 
nM) cell homogenates or CHO-hY4R-Gqi5-mtAEQ cells (Kd = 0.67 nM, c = 0.6 nM). 
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Figure 4: Alignment of Y4R sequences that were reported to contribute to the Y4R binding pocket.
10 
Table 1. NPY receptor binding data. 
 hY4R rY4R gpY4R 
Compd. Ki [nM]
a Ki [nM]
b Ki [nM]
c 
[3H]UR-KK193 0.67 ± 0.1 (Kd) 0.18 ± 0.01 (Kd) 2.64 ± 0.5 (Kd) 
hPP 0.65 ± 0.13 0.15 ± 0.01 0.17 ± 0.02 
UR-MK188 660 ± 140 124 ± 5.4 643 ± 5.7 
4.3 337 ± 110 55.6 ± 20 267 ± 36 
(2R,7R)-2.2 0.45 ± 0.14 0.044 ± 0.004 1.08 ± 0.13 
(2S,7S)-2.2 2.3 ± 0.16 0.38 ± 0.16 9.90 ± 1.6 
(2R,7R)-2.10 0.87 ± 0.16 0.16 ± 0.06 1.57 ± 0.06 
2.16 3.5 ± 0.59 0.23 ± 0.02 19.8 ± 4.5 
2.17 1.2 ± 0.37 0.21 ± 0.09 7.08 ± 1.1 
2.19 >3000 >5000 >5000 
2.20 12 ± 1.6 2.63 ± 0.27 47.6 ± 11 
2.21 >3000 971 ± 180 >5000 
2.22 11 ± 1.4 2.46 ± 0.64 110 ± 35 
aRadioligand competition binding assay with [3H]UR-KK1936 (Kd = 0.18 nM, c = 0.2 nM) at CHO-rY4R
13 
cell homogenates. bRadioligand competition binding assay with [3H]UR-KK193 (Kd = 0.67 nM, c = 0.6 
nM) at CHO-hY4R-Gqi5-mtAEQ cells.
14 cRadioligand competition binding assay with [3H]UR-KK193 (Kd = 
0.18 nM, c = 0.2 nM) at CHO-gpY4R
2 cell homogenates. 
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3.3  Conclusions 
The tritiated radioligand [3H]UR-KK193 is a useful tool for binding studies at rat and guinea 
pig Y4‘s. IŶ ĐoŶtƌast to the eŶdogeŶous ligaŶd hPP, the iŶǀestigated ͚diŵeƌiĐ͛ peptides ďind 
with higher affinities to the rY4R than to human and guinea pig Y4Rs. Therefore, it is unclear 
whether the regulatory effect of BVD-74D on food intake in mice is reproducible in humans. 
 
3.4  Experimental Section 
3.4.1  Cell Culture 
CHO-rY4R
13 and CHO-gpY4R
2 cells were cultured in 55- or 152-cm2 dishes in a humidified 
atmosphere (95% air, 5% CO2) at 37 °C in Dulbecco`s Modified Eagle Medium (DMEM) 
(Invitrogen) containing 10% FCS (Invitrogen), penicillin-streptomycin (100 IU/mL and 100 
µg/mL) (Gibco) and amphotericin B (2.5 µg/mL) (Invitrogen). 
 
3.4.2  Radioligand Binding Assays 
Binding assays with the radioligand [3H]UR-KK193 were performed at CHO-rY4R or CHO-
gpY4R cell homogenates. Cells were grown to 90% - 100% confluency in 152 cm
2 dishes, 
scraped of the culture flask and centrifuged for 5 min at 300 g. The culture medium was 
discarded and the cells were resuspended in buffer (1 mL) (25 mM HEPES, 2.5 mM CaCl2, 1.0 
mM MgCl2, pH 7.4) containing 0.1 mg/mL bacitracin. The cells were homogenized using an 
Ultra-Turrax homogenizer under ice-cooling and subsequently diluted with buffer containing 
0.1 mg/mL bacitracin and 1% BSA to a final volume of 22 mL. Both, saturation and 
competition experiments, were performed in a final volume of 200 µL in 96-well plates 1450-
401 (PerkinElmer). Saturation binding experiments were performed in a concentration range 
from 0.03 to 7.5 nM. Competition binding experiments were performed with increasing 
concentrations of unlabeled compounds using the radioligand at a concentration in the 
range of the respective Kd value (0.2 nM in case of rY4R, 2 nM in case of gpY4R). Nonspecific 
binding was determined in the presence of a 200-fold excess of (2R,7R)-2.2. The incubation 
period was 90 min. Bound and free radioligand were separated by filtration through 
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polyethylenimine pre-treated GF/C filters (Whatman, Maidstone, UK) using a TOMTEC cell 
harvester (Orange, CT, USA), and the filters were dried at 60 °C. The dried filters were 
treated with MeltiLex A (Perkin Elmer) melt-on szintillator sheets and the remaining 
radioactivity was counted using a Wallac 1450 Betaplate counter (Perkin Elmer). 
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Chapter 4 
The IŶcorporatioŶ of Aza-AŵiŶo Acids or D-
AŵiŶo Acids iŶto NPY YϰR Peptide LigaŶds 
TurŶs AgoŶists iŶto AŶtagoŶists 
 
 
 
 
 
 
 
 
 
 
 
 
Note: Prior to the submission of this thesis, parts of this chapter were submitted to 
publication in cooperation with partners: 
The following experiments were performed by co-authors: 
Tiŵo LittŵaŶŶ: ChaƌaĐteƌizatioŶ of fiŶal ĐoŵpouŶds iŶ the β-aƌƌestiŶ ϭ aŶd β-arrestin 2 assay 
Stefanie Dukorn: Characterization of (2R,7R)-26 and 27 in the luciferase reporter gene assay 
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4.1  Introduction 
Among the neuropeptide Y (NPY) receptors, designated Y1R, Y2R, Y4R and Y5R,
1 the Y4R plays 
a special role, because it preferentially binds pancreatic polypeptide.2 Compared to the Y1R, 
Y2R and Y5R subtypes, by far less ligands (examples cf. Figure 1) are reported for the Y4R, in 
particular, high-affinity Y4R antagonists are still lacking.
3-6 
 
Figure 1: Amino acid sequence of human PP and structures of the described NPY Y4R agonists 4.1, 4.2 
and 4.3 and the Y1R/Y4R antagonist UR-MK188. 
 
Y4R agonists are considered as potential anti-obesity agents.
7,8 The diastereomeric mixture of 
the cross-liŶked ;͞diŵeƌiĐ͟Ϳ pentapeptide 4.1 (BVD-74D), a mimic of the C-terminus of 
pancreatic polypeptide, was described as a high-affinity Y4R agonist,
4 having an effect on the 
food intake in mice.9 As reported previously, (2R,7R)-4.1 (note: in the following, positions 2 
and 7 refer to the stereo centers in the 2,7-diaminosuberic acid moiety) was by a factor of 3-
10 more potent than (2S,7S)-4.1, depending on the type of assay.10,11 Even though Y4R 
agonists should come up with the higher clinical potential, antagonists are of interest as well, 
in particular, as pharmacological tools. The pentapeptide 4.3,6 a Y4R agonist with an affinity 
in the two-digit nanomolar range (Ki = 50 nM), shares the same amino acid sequence with 
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the peptide moieties of 1. The iŶĐoƌpoƌatioŶ of ĐǇĐliĐ β-amino acids such as (1R,2S)-2-
aminocyclopentane-1-carboxylic acid resulted in partial agonism.6 
To investigate the impact of backbone modifications in Y4R agonists on functional activity in 
more detail, additional analogs of (2R,7R)-4.1, 4.211 and 4.3 were prepared. Here we report 
on the synthesis of Y4R ligands in which aza-amino acids or D-amino acids were introduced. 
The title compounds were characterized in binding and functional cellular assays with 
complementary readouts. 
 
4.2  Results and Discussion 
4.2.1  Chemistry 
Aza-peptides ĐoŶtaiŶ at least oŶe aŵiŶo aĐid iŶ ǁhiĐh the α-carbon atom is replaced by 
nitrogen.12 The semicarbazide substructure reduces conformational flexibility.13,14 Several 
studies revealed that the incorporation of aza-amino acids into bioactive peptides may result 
in a longer duration of action or higher potencies compared to the parent peptide.15-17 Aza-
peptides can be prepared by the reaction of an N-protected N͛-substituted hydrazine with an 
isocyanate.12 However, the synthesis of aza-peptides on solid phase is compromised by an 
intramolecular side-reaction of resin-bound isocyanates resulting in the formation of 
hydantoins (Figure 2, A), lowering the yields of the target compounds and requiring time-
consuming purification.18 To circumvent hydantoin formation, N-Fmoc-aza1-dipeptides were 
prepared from N-protected N͛-substituted hydrazines and benzyl ester protected amino 
acids, followed by hydrogenolytic debenzylation in solution (Figure 2, B).19 
Two different Fmoc-protected hydrazines were synthesized to mimic the side chains of Orn 
or Leu, respectively (Scheme 1). 3-Aminopropan-1-ol was Boc-protected and subsequently 
oxidized under Parikh-Döring conditions using dimethyl sulfoxide as an oxidant to form the 
aldehyde 4.7. Condensation of (9H-fluoren-9-yl)methyl hydrazinecarboxylate 4.8 and the 
aldehyde 4.7 or isobutyric aldehyde resulted in hydrazones 4.9 and 4.10. Subsequent 
reduction using sodium cyanotrihydridoborate gave access to the substituted hydrazines 
4.10 and 4.12. 
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Figure 2: Synthesis of aza-peptides on a solid phase (A) or in solution (B). 
 
Scheme 1. Synthesis of the hydrazines 4.10 and 4.12a 
 
aReagents and conditions: (a) Boc2O, Na2CO3, THF, 0 °C, 10 min, followed by rt, 14 h; (b) Sulfur 
trioxide pyridine complex, DMSO, TEA, CH2Cl2, 0 °C, 1 h, followed by rt, 3 h; (c) Fmoc-Cl, MeCN/H2O 
(1:1), 0 °C, 10 min, followed by rt, 12 h; (d) 4.7, CH2Cl2, 14 h; (e) isobutyraldehyde, CH2Cl2, 50 h; (f) 
sodium cyanotrihydridoborate, CH2Cl2/MeOH (4:3), 2 M HCl (pH 2-3), rt, 2-6 h. 
Benzyl ester protected amino acids 4.14-4.16 were treated with triphosgene to give the 
respective isocyanates in situ (Scheme 2). Without purification, the isocyanates were treated 
with hydrazines 4.10 and 4.12 affording the benzyl protected N-Fmoc-aza1-dipeptides in 
yields >70%. Subsequent ester cleavage by hydrogenation gave access to the N-Fmoc-aza1-
dipeptides Fmoc-aza-Leu-Arg(Pbf)-OH (4.17), Fmoc-aza-Orn(Boc)-Tyr(tBu)-OH (4.18) and 
Fmoc-aza-Orn(Boc)-Leu-OH (4.19). Dipeptides 4.17-4.19 were employed in solid phase 
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synthesis under the same conditions as for standard Fmoc-protected amino acids resulting in 
quantitative coupling efficiencies. 
Scheme 2. Synthesis of N-Fmoc-aza1-dipeptides 4.17-4.19a 
 
aReagents and conditions: (a) Benzyl alcohol, 4-DMAP, DCC, CH2Cl2, rt, 14 h, followed by DEA/CH2Cl2 
(1:8), rt; (b) Triphosgene, DIPEA, CH2Cl2, rt, 90 min, followed by Pd/C, H2, MeOH, rt, 1 h; (c) 
Triphosgene, DIPEA, CH2Cl2, rt, 90 min, followed by Pd/C, H2, MeOH, rt, 1 h. 
 
To optimize the coupling of a resin-bound aza1-peptide, the model peptide H-Ala-aza-Leu-
Arg(Pbf)-NH2 (4.20) was synthesized under various conditions (Scheme 3). When HBTU/HOBt 
was used as coupling reagent at 35 °C only 5 to 10% of the desired products were formed. 
The same holds for the application of the succinimidyl ester, Fmoc-Ala-OSu. The coupling 
efficiency was increased to approximately 50%, when the 7-azabenzotriazole derivative 
HATU was used as coupling reagent. The best results (> 50% coupling efficiency) were 
achieved by in situ activation of Fmoc-Ala-OH to the corresponding acyl chloride using 
triphosgene in THF. Surprisingly, when CH2Cl2 was used as a solvent instead of THF, only 
minor amounts of 4.20 were detected. 
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Scheme 3. Incorporation of aza-Leu into the model peptide 4.20 via SPPS.a 
 
aReagents and conditions: (a) SPPS (Fmoc strategy), 4.17/HBTU/HOBt/DIPEA (3/3/3/6 equiv), solvent 
DMF, 35 °C, 14 h; Fmoc deprotection was carried out with 20% piperidine in DMF/NMP (8:2), rt, 2 × 
10 min; (b) variation of the conditions according to the table; Fmoc deprotection as under (a); (c) 
CH2Cl2/TFA (97:3), 10 × 6 min. 
  
 
Scheme 4. Synthesis of ͞hoŵodiŵeƌiĐ͟ aza-peptides 4.26-4.31a 
 
aReagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), solvent DMF/NMP ;ϴ:ϮͿ, ͚douďle͚ ĐoupliŶg at ƌt, ϲϬ ŵiŶ oƌ 
dipeptide (4.17, 4.18 or 4.19)/HBTU/HOBt/DIPEA (3/3/3/6), solvent: DMF, 35 °C, 14 h; Fmoc deprotection as under (a) in Scheme 3; (b) triphosgene, DIPEA, 
THF, 35 °C, 14 h; Fmoc deprotection as under (a) in Scheme 3; (c) CH2Cl2/TFA (97:3), 10 × 6 min; (d) HBTU, HOBt, DIPEA, anhydrous DMF, 35 °C, 16 h; (e) 1 
equiv of 4.25 in 1% DIPEA in anhydrous DMF, followed by 2.5 equiv of 4.21, 4.22 or 4.23, 35 °C, 16 h; (f) TFA/H2O (95:5), rt, 2.5 h; (g) N,N'-di-Boc-1H-
pyrazole-1-carboxamidine, DMF, DIPEA, rt, 4 h; Boc-deprotection, TFA/CH2Cl2/H2O (10/10/1), rt, 3 h. 
  
 
96  Chapter 4 
 
The ͞diŵeƌiĐ͟ aza-peptide (2R,7R)-4.26, an aza-Leu analog of (2R,7R)-4.1, was prepared from 
the protected pentapeptide 4.21 and the diacid (R,R)-4.24 (Scheme 4). For the preparation 
of the aza-peptides 4.27-4.31, octanedioic acid disuccinimidyl ester (4.25) was used for 
cross-linking. Cross-linking of 4.21 with 4.25 Ǉielded the ͞diŵeƌiĐ͟ aza-peptide 4.27, an aza-
Leu analog of 4.2. Dimerization of the protected peptides 4.22 and 4.23 resulted in aza-
peptides 4.28 and 4.30 containing ornithine instead of arginine. Subsequently, 
guanidinylation was performed with N,N'-di-Boc-1H-pyrazole-1-carboxamidine resulting in 
4.29 and 4.31, aza-Arg containing analogs of 4.2. 
 
Figure 3: Structure of the Nω-carbamoylated arginine building block 4.32.20 
 
Very recently, we reported that the replacement of Arg2 with the Nω-carbamoylated arginine 
4.32 (Figure 3) in one of the pentapeptide chains of 2 led to increased Y4R affinity.
11 
Similarly, 4.32 was used for the preparation of peptides 4.33-4.42 (Figure 4), which are 
analogs of the pentapeptide 4.3, on an Fmoc-Sieber-PS resin by manual SPPS according to 
the Fmoc strategy. 
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Figure 4: Primary structures of the synthesized peptides 4.33-4.42 ;Đf. ͞geŶeƌal pƌoĐeduƌe foƌ solid 
phase peptide sǇŶthesis͟Ϳ. 
Finally, the applicability of 4.32 to the preparation of cyclic peptides via head-to-side-chain 
cyclization was investigated. The formation of head-to-tail cyclic peptides is often 
compromised by rather rigid backbones. However, the side-chain of 4.32 is very flexible, 
facilitating an approximation of the activated C-terminus and the terminal amino group. The 
hexapeptide 4.43 was prepared on an H-L-Tyr(tBu)-2-CT resin followed by global side-chain 
deprotection (Scheme 5). Cyclization was achieved at a peptide concentration of 1 mM using 
PyBOP as coupling reagent. Under these conditions, the formation of peptide dimers was 
not observed. 
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Scheme 5. Synthesis of the head-to-side-chain cyclic peptide 4.43.a 
 
aReagents and conditions: (a) SPPS (Fmoc strategy), Fmoc-aa/HBTU/HOBt/DIPEA (5/5/5/10 equiv), 
solǀeŶt DMF/NMP ;ϴ:ϮͿ, ͚douďle͚ ĐoupliŶg at ƌt, ϲϬ ŵiŶ oƌ 4.32/HBTU/HOBt/DIPEA (3/3/3/6), 
solvent: DMF, 35 °C, 14 h; Fmoc deprotection as under (a) in Scheme 3; (b) CH2Cl2/TFA (97:3), 10 × 6 
min; (c) TFA/H2O (95:5), rt, 2.5 h; (d) PyBOP, HOBt, DIPEA, DMF, rt, 24 h. 
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4.2.2  Competition Binding Studies at NPY Receptor Subtypes 
4.2.2.1 Y4R Binding 
 
Figure 5: Structures of the Y4R radioligand [
3H]UR-KK193 (4.45) and the Y1R radioligand [3H]UR-
MK136 (4.46). 
 
Ki values of all target compounds were determined in competition binding studies on live 
cells expressing the Y4R (CHO-hY4R-Gqi5-mtAEQ cells) using the radioligand [
3H]UR-KK193 
(4.45, Figure 5) (Table 1, Figure 6).11 The affinities of the aza-peptides 4.27 (Ki = 134 nM), 
4.29 (Ki = 52.7 nM) and 4.31 (Ki = 113 nM) were lower than the affinity of the respective 
reference compound 4.2 (Ki = 3.5 nM). (R,R)-2,7-diaminosuberic acid was superior to 
octanedioic acid as a linker in dimeric aza-peptides (cf. (2R,7R)-4.26: Ki = 30.8 nM) as in case 
of peptide 1 compared to 4.2. The aza-Orn precursors of 4.29 and 4.31, compounds 4.28 (Ki 
= 130 nM) and 4.30 (Ki = 385 nM) bind to the Y4R as well, though with lower affinities 
compared to their aza-Arg counterparts. 
Among the structural modifications of pentapeptide 4.3, replacement of the N-terminal 
acetic acid with octanoic acid resulted in an increase in Y4R affinity by a factor of almost six. 
The replacement of Arg2 in 4.3 with the carbamoylated arginine 4.32 was even more 
favorable: The affinity of 4.34 (Ki = 19.5 nM) was 17-fold higher than the affinity of its parent 
compound 4.3. Extension of the N-terminus by an additional arginine led to a further 
increase in affinity: the Ki value of compound 4.35 was in the single-digit nanomolar range (Ki 
= 2.87 nM). Up to now, comparable binding data were achieved only in case of cross-linked 
or significantly longer linear peptides. Furthermore, the introduction of an additional N-
terminal arginine could compensate for the absence of the carbamoylated arginine 4.32, 
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that is, 4.36 (Ki = 3.43 nM) showed nearly the same affinity as peptide 4.35. Interestingly, the 
replacement of the arginine adjacent to the C-terminus with the modified arginine building 
block 4.32 was not tolerated (4.37: Ki = 501 nM). 
Following the structural optimization of 4.3, a D-amino acid scan was performed with the 
hexapeptide 4.35. Whereas replacement of Arg1 or Tyr2 with D-Arg or D-Tyr, respectively, 
was tolerated (cf. 4.41, 4.42), replacement of Leu4, Arg5 or Tyr6 by the corresponding D-
amino acid led to a marked decrease in Y4R affinity (cf. 4.38-4.40). 
Previous studies revealed that C-terminal amidation is crucial for Y4R binding of the 
endogenous ligand hPP.21 Similarly, the affinity of the carboxylic acid 4.43 (IC50 > 5000 nM) 
was by far lower than the affinity of the amide 4.35. Cyclization of 4.43 resulted in an 
increase in Y4R affinity. However, the cyclic peptide 4.44 (Ki = 1650 nM) was only a weak 
binder compared to the linear analog 4.35. 
 
4.2.3.2 NPY Receptor Subtype Selectivity 
Ki values of all target compounds were also determined at Y1, Y2 and Y5 receptors using the 
radioligands [3H]propionyl-pNPY (Y2R and Y5R) or [
3H]UR-MK136 (4.46, Y1R, Figure 5). Neither 
the linear peptides 4.34-4.43 nor the cyclic peptide 4.44 displayed remarkable affinity to Y1, 
Y2 or Y5 receptors. Having a more than 1000-fold selectivity for the Y4R over the other NPY 
receptors, peptide 4.35 proved to be superior to (2R,7R)-4.1 and 4.2. Only the pentapeptide 
4.33 bound to the Y1R with a Ki value in the submicromolar range (Ki (Y1R) = 589 nM), that is, 
the lipophilic N-terminal octanoyl residue is disadvantageous with respect to Y4R selectivity. 
The cross-linked aza-peptides (2R,7R)-4.26, 4.27 and 4.28 displayed only low Y1R, Y2R and 
Y5R affinities, whereas the affinity of 4.31 (Ki = 53 nM) at the Y1R was markedly higher than 
that of the peptide analog 4.2. In a Fura-2 Ca2+ assay on HEL cells, 4.31 revealed Y1R 
antagonism (Figure 7) with a Kb value of 11.5 nM. 
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Figure 6. Competition binding performed with the radioligand 4.45 at CHO-hY4R-Gqi5-mtAEQ cells. 
(A), (B) and (C) Displacement of 4.45 (Kd = 0.67 nM, c = 0.6 nM). Data represent mean values ± SEM 
of at least 3 independent experiments, each performed in triplicate. 
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Figure 7. Y1R antagonism of 4.31. Inhibition of the pNPY (c = 10 nM, EC50 = 0.87 nM) induced 
intracellular Ca2+ mobilization in HEL cells by 4.31 (Kb = 11.5 ± 1.1 nM), determined in a Fura-2 assay. 
Mean ± SEM from three independent experiments. 
Table 1. NPY receptor binding data. 
 Y1R Y2R Y4R Y5R 
Compd. Ki [nM]
a Ki [nM]
b Ki [nM]
c Ki [nM]
d 
hPP 440e >5000e 0.65f 17e 
(2R,7R)-4.1 440f 830 f 0.45f 1500f 
4.2 720f 1700f 3.5f 280f 
4.3 > 5000 > 5000 337 ± 110 > 5000 
4.4 24g 920g 660f > 5000g 
(2R,7R)-4.26 1840 ± 380 > 5000 30.8 ± 7.5 > 5000 
4.27 574 ± 49 > 5000 134 ± 20 2700 ± 490 
4.28 n.d. n.d. 130 ± 39  n.d. 
4.29 3730 ± 350 > 5000 52.7 ± 7.1 3560 ± 440 
4.30 n.d. n.d. 385 ± 127 n.d. 
4.31 53 ± 12 3270 ± 870 113 ± 14 2100 ± 240 
4.33 589 ± 120 > 5000 56.9 ± 5.3 3440 ± 210 
4.34 > 5000 > 5000 19.5 ± 2.6 > 5000 
4.35 4830 ± 1400 > 5000 2.87 ± 0.78 > 5000 
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4.36 1180 ± 380 > 5000 3.43 ± 1.3 > 5000 
4.37 1120 ± 270 > 5000 501 ± 200 > 5000 
4.38 > 5000 > 5000 724 ± 140 > 5000 
4.39 > 5000 > 5000 568 ± 76 > 5000 
4.40 > 5000 > 5000 248 ± 23 > 5000 
4.41 > 5000 > 5000 10.4 ± 3.3 > 5000 
4.42 > 5000 > 5000 40.5± 15 > 5000 
4.43 > 5000 > 5000 > 5000 > 5000 
4.44 > 5000 > 5000 1650 ± 290 > 5000 
aRadioligand competition binding assay with 4.4622 (Kd = 6.2 nM, c = 4 nM) using MCF-7-hY1 cells.
23 
bRadioligand competition binding assay with [3H]propionyl-pNPY24 (Kd = 1.4 nM, c = 1 nM) using CHO-
hY2-Gqi5-mtAEQ cells
25. cRadioligand competition binding assay with 4.4511 (Kd = 0.67 nM, c = 0.6 nM) 
using CHO-hY4R-Gqi5-mtAEQ cells.
26 dRadioligand competition binding assay with [3H]propionyl-pNPY 
(Kd = 4.83 nM, c = 4 nM) using HEC-1b hY5R cells
27. eKi value reported by Berlicki et al.
6 fKi value 
reported by Kuhn et al.11 gKi value reported by Keller et al.
5 
 
4.2.3  Functional Studies at the Y4R 
The target compounds were investigated for Y4R functional activity in an aequorin Ca
2+ assay 
as ǁell as β-aƌƌestiŶ ϭ aŶd β-arrestin 2 recruitment assays on genetically engineered CHO or 
HEK293T cells, respectively (data cf. Table 2, Figure 7 and Figure 8). (2R,7R)-4.1 was a partial 
agonist in both, the Ca2+ assaǇ aŶd the β-arrestin recruitment assays (α = 0.62, (Ca2+ assay), α 
= Ϭ.ϱϰ ;β-aƌƌestiŶ ϭͿ oƌ Ϭ.ϱϴ ;β-arrestin 2)). The incorporation of aza-amino acids into the 
cross-linked peptides (2R,7R)-4.1 and 4.2 had an impact on the quality of action in both 
assaǇs. The ͞diŵeƌiĐ͟ aza-peptides (2R,7R)-4.26, 4.27, 4.29 and 4.31 were Y4R antagonists, 
able to suppress the response elicited by the endogenous ligand hPP (note: The aza-peptide 
4.29 displayed very weak partial agonism with negligible efficacy (α = 0.07, EC50 = 542 nM 
(Ca2+ assay), α = Ϭ.Ϭϵ, EC50 = ϴϳϱ ŶM ;β-aƌƌestiŶ ϭͿ, α = Ϭ.ϭϮ, EC50 = ϰϳϯ ;β-arrestin 2)). 
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Figure 8. Y4R functional activity of (2R,7R)-4.1, (2R,7R)-4.26 and 4.27 determined in a calcium 
;aeƋuoƌiŶͿ assaǇ, a β-arrestin recruitment assay and a luciferase reporter gene assay. (A) Induced 
intracellular Ca2+ mobilization ((2R,7R)-4.1, plotted on left Y-axis) or inhibition of the hPP (EC50 = 9.7 
nM, c = 100 nM) induced Ca2+ mobilization ((2R,7R)-4.26, 4.27, plotted on right Y-axis) in CHO-hY4R-
mtAEQ-Gqi5 cells. (BͿ IŶduĐed β-arrestin 1,2 recruitment ((2R,7R)-4.1, plotted on left Y-axis) or 
inhibition of the hPP (EC50 (Arr1) = 3.54 nM, EC50 (Arr2) = 2.74 nM, c = 3 nM) induĐed β-arrestin 1,2 
recruitment ((2R,7R)-4.26, 4.27, plotted on right Y-axis) in HEK293T-ARRB1-Y4R cells (shown in dark 
colors) and HEK293T-ARRB2-Y4R cells (shown in light colors). (C) Inhibition of the forskolin-stimulated 
(2 µM) luciferase activity (corresponding to 100%) in hY4R expressing HEK293 cells with the maximum 
inhibitory effect of the endogenous ligand hPP which is set to 0% luciferase activity and corresponds 
to full agonism (α = 1.0). Data points shown for (A), (B), and (C) are the mean ± SEM of at least three 
independent experiments performed in triplicate. 
Compounds (2R,7R)-4.26 and 4.27 were also investigated for Y4R agonism in a luciferase 
reporter gene assay. Surprisingly, both aza-peptides displayed partial agonism in this assay 
(α = 0.81, EC50 = 176 nM ((2R,7R)-4.26), α = 0.75, EC50 = 220 nM (4.27)). This can be 
explained by amplification of the signal in the luciferase assay, uncovering weak partial 
agonism which is elusive in assays with proximal readouts, a phenomenon demonstrated, for 
example, for histamine H4 receptor ligands.
28  This becomes also obvious from the fact that 
the partial agonist (2R,7R)-1 was a full agonist in this assay.11 The pentapeptides 4.33, 4.34 
and the hexapeptides 4.35 and 4.36 were partial agonists achieving between 44 and 78% of 
the maximal response of hPP in both, the calcium and the arrestin assay. The introduction of 
D-amino acids into the C-terminal tripeptide of 4.35 led to Y4R antagonism. Compound 4.40 
in which Leu4 was replaced by D-Leu displayed the highest antagonistic activity (Kb = 531 nM, 
Ca2+ assay). By contrast, Y4R agonism was retained, though at a lower level, when D-amino 
acids were introduced into the N-terminal part of 4.35 (cf. 4.41, 4.42). Compound 4.37, in 
which Arg5 was replaced by the carbamoylated arginine 4.32, and the cyclic hexapeptide 
4.44 were identified as weak Y4R antagonists. 
In summary, the modification of the C-terminal part of the monomeric and crosslinked 
peptide partial agonists by the introduction of aza-amino acids or D-amino acids as well as 
the rigidization of the backbone by head-to-side-chain cyclization gave access to Y4R 
antagonists. Unfortunately, these modifications went along with a decrease in Y4R affinity. 
The antagonistic activities determined in the aequorin Ca2+ assaǇ aŶd the β-arrestin assays 
were in good agreement with the respective binding constants with exception of the Kb 
value of (2R,7R)-4.26 iŶ the β-arrestin assays. The EC50 values of the reported Y4R partial 
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agonists were substantially higher than the Ki values. This effect was previously discussed 
and can be attributed to the presence or absence of sodium ions in the buffers.11 
 
 
Figure 9. Y4R functional activity of 4.35, 4.38 and 4.44 determined in a calcium (aequorin) assay and a 
β-arrestin recruitment assay. (A) Induced intracellular Ca2+ mobilization (4.35, plotted on left Y-axis) 
or inhibition of the hPP (EC50 = 9.7 nM, c = 100 nM) induced intracellular Ca
2+ mobilization (4.38, 
4.44, plotted on right Y-axis) in in CHO-hY4R-mtAEQ-Gqi5 cells. (BͿ IŶduĐed β-arrestin 1,2 recruitment 
(4.35, plotted on left Y-axis) or inhibition of the hPP (EC50 (Arr1) = 3.54 nM, EC50 (Arr2) = 2.74 nM, c = 
ϯ ŶMͿ iŶduĐed β-arrestin 1,2 recruitment (4.38, 4.44, plotted on right Y-axis) in HEK293T-ARRB1-Y4R 
cells (shown in dark colors) and HEK293T-ARRB2-Y4R cells (shown in light colors). Data points shown 
for (A) and (B) are the mean ± SEM of at least three independent experiments performed in 
triplicate. 
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Table 2. NPY Y4R agonist potencies (EC50Ϳ aŶd iŶtƌiŶsiĐ aĐtiǀities ;αͿ oƌ antagonistic activities (Kb 
values). 
 Aequorin Ca
2+,a
  β-Arrestin 1b  β-Arrestin 2c  
Compd. EC50/Kb [nM]
 α EC50/Kb [nM] α EC50/Kb [nM] α 
hPP 9.7d 1 3.54 ± 0.59 1 2.74 ± 0.23 1 
(2R,7R)-4.1 6.9d 0.62 40.4 ± 11 0.54 31.8 ± 12 0.58 
4.3 6390 ± 450 0.55 n.d. n.d. n.d. n.d. 
4 20
e n.a. 102 ± 40 n.a. 96.3 ± 37 n.a. 
(2R,7R)-4.26f 34.3 ± 4.5 n.a. 2940 ± 190 n.a. 632 ± 110 n.a. 
4.27
g
 127 ±26 n.a. 591 ± 190 n.a. 340 ± 42 n.a. 
4.29 
542 ± 110 0.07 875 ± 260 0.09 473 ±65 0.12 
50.6 ± 0.2 n.a. n.d. n.d. n.d. n.d. 
4.31 118.4 ± 47 n.a. n.d. n.d. n.d. n.d. 
4.33 2050 ± 84 0.44 2200 ± 130 0.56 1790 ± 1070 0.61 
4.34 1460 ± 83 0.61 1070 ± 520 0.62 568 ± 120 0.60 
4.35 187 ± 23 0.58 144 ± 28 0.48 124.1 ± 24 0.55 
4.36 303 ± 68 0.78 187 ± 40 0.51 140 ± 45 0.54 
4.37 847 ± 180 n.a. 3590 ± 429 n.a. 3840 ± 55 n.a. 
4.38 1660 ± 570 n.a. 708 ± 210 n.a. 533 ± 120 n.a. 
4.39 737 ± 360 n.a. n.d. n.d. n.d. n.d. 
4.40 531 ± 230 n.a. n.d. n.d. n.d. n.d. 
4.41 608 ± 140 0.61 2050 ± 780 0.46 710 ± 200 0.49 
4.42 756 ± 230 0.63 2160 ± 600 0.45 624 ± 150 0.56 
4.44 1100 ± 520 n.a. 2920 ± 880 n.a. 1880 ± 320 n.a. 
aAequorin calcium mobilization assay on CHO-hY4-Gqi5-mtAEQ cells.
26 Antagonistic activities (Kb values 
given in italics) were determined in the presence of 100 nM hPP. b,cβ-Arrestin 1,2 recruitment assay 
on HEK293T cells stably expressing the Y4R and ARRB1 or ARRB2. Antagonistic activities (Kb values 
given in italics) were determined in the presence of 3 nM hPP. dEC50 value reported by Kuhn et al.
11 
e
Kb value reported by Keller et al.
5 fY4R agonism on HEK293-hY4R-CRE Luc cells (luciferase reporter 
gene assay): EC50 = ϭϳϲ ± ϱϬ ŶM, α = Ϭ.ϴϭ. gY4R agonism on HEK293-hY4R-CRE Luc cells (luciferase 
reporter gene assay): EC50 = ϮϮϬ ± ϳϯ ŶM, α = Ϭ.ϳϱ. 
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4.3  Conclusions 
The affinity and potency of the Y4R partial agonist 4.3 was considerably increased by the 
replacement of Arg2 with the carbamoylated arginine 4.32 and the introduction of an 
additional arginine at the N-terminus. The latter turned out to compensate for the absence 
of the carbamoylated arginine. Several backbone modifications of the C-terminal tripeptide 
(e.g. the introduction of aza-amino acids or D-amino acids) as well as a rigidization via head-
to-side-ĐhaiŶ ĐǇĐlizatioŶ ĐhaŶged the ƋualitǇ of aĐtioŶ of liŶeaƌ oƌ ͞diŵeƌiĐ͟ Y4R peptide 
ligands from partial agonism to antagonism. The resulting antagonists displayed lower Y4R 
antagonistic activities than the reported Y4R antagonist 4.4. However, due to their extremely 
facile synthetic accessibility, linear peptides containing D-amino acids (e.g. 4.40 (Ki = 248 nM, 
Kb = 531 nM (aequorin Ca
2+ assay)) are promising building blocks for further structural 
modifications and might pave the way for the development of peptide Y4R antagonists with 
increased affinity and antagonistic activity. 
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4.4  Experimental Section 
4.4.1  General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers and used without further 
purification unless otherwise indicated. DMF for peptide synthesis, NMP for peptide 
synthesis, 4-DMAP, sodium cyanotrihydroborate and HOBt hydrate were from Acros 
Organics/Fisher Scientific (Nidderau, Germany). Fmoc-Sieber-PS resin (0.61 mmol/g), Fmoc-
Arg(Pbf)-OH, Fmoc-Tyr(tBu)-OH, H-L-Tyr(tBu)-2-CT resin (0.68 mmol/g), PyBOP and HBTU 
were from Iris Biotech (Marktredwitz, Germany). MeCN for HPLC (gradient grade), Fmoc-
Leu-OH, DCC, sulfur trioxide pyridine complex, hydrazine hydroxide and methanol were from 
Merck (Darmstadt, Germany). Trifluoroacetic acid, triethylamin (TEA), triphosgene, Fmoc 
chloride, isobutyraldehyde, diethylamin (DEA), CH2Cl2, diethyl ether and Triton X-100 were 
from Sigma Aldrich (Deisenhofen, Germany), di-tert-butyl dicarbonate (>97%) and 3-
aminopropan-1-ol were from Alfa Aesar (Karlsruhe, Germany). N,N-diisopropylethylamine 
(DIPEA) (99%) was from ABCR (Karlsruhe, Germany), and Fmoc-Ala-OSu was from Advanced 
Chemtech (Louisville, KY). Bovine serum albumin and bacitracin were from Serva 
(Heidelberg, Germany) and coelenterazin h was obtained from Biotrend (Cologne, Germany). 
Human pancreatic polypeptide and porcine neuropeptide Y were from Synpeptide 
(Shanghai, China). The synthesis of (2R,7R)-4.1,11 4.3,6 4.4,5 4.24,11 4.25,29 4.32,20 4.45,11 
4.46
22 and [3H]propionyl-pNPY24 was previously described. Millipore water was used 
throughout for the preparation of buffers and HPLC eluents. Polypropylene reaction vessels 
(1.5 or 2 mL) with screw cap (Süd-Laborbedarf, Gauting, Germany) were used for small scale 
reactions (e.g. the preparation of 4.44) and for the storage of stock solutions. TL 
chromatography was performed on Merck silica gel 60 F254 TLC aluminum plates, silica gel 60 
(40-63 µm, Merck) was used for column chromatography. Visualization was accomplished by 
UV light ( = 254 nm or 366 nm) and with ninhydrin/acetic acid solution. NMR-spectra were 
recorded on a Bruker Avance 300 (7.05 T, 1H: 300.1 MHz, 13C: 75.5 MHz) or a Bruker Avance 
600 instrument with cryogenic probe (14.1 T, 1H: 600.3 MHz, 13C: 150.9 MHz) (Bruker, 
Karlsruhe, Germany). Mass spectra were recorded on a Finnigan MAT95 (EI-MS 70eV) or a 
Finnigan MAT SSQ 710 A (CI-MS (NH3)). For HRMS an Agilent Q-TOF 6540 UHD (Agilent, 
Waldbronn, Germany) equipped with an ESI source was used. Preparative HPLC was 
performed on a system from Knauer (Berlin, Germany) consisting of two K-1800 pumps, a K-
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2001 detector and a RP-column (Kinetex-XB C18, 5 µm, 250 mm × 21 mm, Phenomenex, 
Aschaffenburg, Germany) at a flow-rate of 15 mL/min using mixtures of acetonitrile and 
0.1% aqueous TFA solution as mobile phase. A detection wavelength of 220 nm was used 
throughout. The collected fractions were lyophilised using an alpha 2-4 LD apparatus (Martin 
Christ, Osterode am Harz, Germany) equipped with a RZ 6 rotary vane vacuum pump 
(vacuubrand, Wertheim, Germany). Analytical HPLC analysis was performed on a system 
from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of a L-6200-A pump, a AS-
2000A autosampler, a L-4000A UV detector, a D-6000 interface and a RP-column Kinetex-XB 
C18, 5 µm, 250 mm × 4.6 mm (Phenomenex, Aschaffenburg, Germany) at a flow rate of 0.8 
mL/min. Mixtures of acetonitrile (A) and 0.1% aqueous TFA solution (B) were used as mobile 
phase. The following gradient was applied: A/B: 0-25 min: 10:90 - 60:40, 25-35 min: 60:40 - 
95:5, 35-45 min: 95:5. Detection was performed at 220 nm, the oven temperature was 30 °C. 
 
4.4.2  Chemistry: Experimental Protocols and Analytical Data 
General procedure for solid phase peptide synthesis. Peptides were synthesized by manual 
SPPS using the Fmoc strategy on an Fmoc-Sieber-PS resin or an H-L-Tyr(tBu)-2CT resin (4.43). 
5-mL Discardit II syringes (Becton Dickinson, Heidelberg, Germany) were equipped with 35 
µm polyethylene frits (Roland Vetter Laborbedarf, Ammerbuch, Germany) and used as 
reaction vessels. For the coupling of standard D- or L-amino acid to the N-terminus of an 
amino acid or the amino group of the Fmoc-Sieber-PS resin, DMF/NMP (8:2) was used as 
solvent. Fmoc amino acids (5-fold excess) were preactivated with HBTU/HOBt/DIPEA (5/5/10 
eƋuiǀͿ foƌ ϱ ŵiŶ aŶd added to the ƌesiŶ. ͚Douďle͛ ĐoupliŶg at ƌt ǁas peƌfoƌŵed foƌ all 
standard amino acids for 45 min. The coupling of the arginine building block 4.32 and the 
dipeptides 4.17, 4.18 and 4.19  (3-fold excess, preactivated with HBTU/HOBt/DIPEA (3/3/6 
eƋuiǀͿ ǁas peƌfoƌŵed at ϯϱ °C foƌ ϭϰ h ;͚siŶgle ĐoupliŶg͛Ϳ usiŶg aŶhǇdƌous DMF as solǀeŶt. 
For the coupling of Fmoc amino acids to a resin bound aza-amino acid, triphosgene was used 
as coupling reagent. Triphosgene (1.75 equiv) was dissolved in anhydrous THF and cooled to 
0 °C. A solution of Fmoc amino acid (5 equiv) and DIPEA (15 equiv) in anhydrous THF was 
added dropwise causing the formation of a white precipitate. After addition, stirring was 
continued for 5 min. The suspension was centrifuged and the supernatant was added to the 
resin. Coupling was performed at 35 °C for 12 h. 
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After completed coupling, the resin was washed with DMF/NMP and treated with 20% 
piperidine in DMF/NMP (8:2) at rt (2 ×) for 10 min to remove the Fmoc group, followed by 
thorough washing of the resin. 
General procedure for cleavage of protected peptides from the resin. After the last 
coupling step and Fmoc deprotection, the resin was washed with CH2Cl2. Side-chain 
protected peptides were cleaved from the resin with CH2Cl2/TFA (97:3) (rt, 10 × 6 min). The 
peptides were separated from the resin by filtration. The combined filtrates were collected 
in a round bottom flask containing water (10 times the volume of the combined filtrates). 
The organic solvent was removed on a rotary evaporator; the aqueous phase was lyophilised 
followed by purification by preparative HPLC. 
tert-Butyl (3-hydroxypropyl)carbamate (4.6).30 3-Aminopropan-1-ol (5 g, 66.5 mmol) was 
dissolved in THF (50 mL). An aqueous solution of Na2CO3 (8.42 g, 1.2 equiv, 10 mL) was 
added, and the mixture was cooled to 0 °C. Boc anhydride (14.82 g, 1.02 equiv) was added 
dropwise, and the mixture was stirred at room temperature for 14 h. The mixture was 
filtered over a pad of celite, and the volume of the filtrate was reduced to approximately 15 
mL under reduced pressure. The residue was diluted with water (50 mL) and extracted with 
EtOAc (3 × 100 mL). The combined organic layers were dried over MgSO4 followed by the 
removal of the solvent under reduced pressure. The desired compound was obtained as 
viscous oil (10.47 g, 80.8%). 1H-NMR (400 MHz, [D6]aĐetoŶeͿ: δ (ppm) 1.40 (s, 9H), 1.59 – 
1.70 (m, 2H), 3.18 (dd, 2H, J 14.3 Hz, 6.6 Hz), 3.58 (dd, 2H, J 13.1 Hz, 5.8 Hz), 3.61 – 3.67 (m, 
1H), 5.99 (br s, 1H). HRMS (ESI): m/z [M+Na]+ calcd. for [C8H17NNaO3]
+ 198.1101, found: 
198.1097. C8H17NO3 (175.23). 
tert-Butyl (3-oxopropyl)carbamate (7).
31
 Compound 4.6 (10.3 g, 58.8 mmol), trimethylamine 
(28 mL) and DMSO (30 mL) were mixed with CH2Cl2 (100 mL). Sulfur trioxide pyridine 
complex (21 g, 132 mmol) was added under ice-cooling, and the mixture was stirred at 0 °C 
for 1 h and at room temperature for additional 3 h. Water (500 mL) was added, and the 
mixture was extracted with EtOAc (2 × 300 mL). The combined organic layers were dried 
over MgSO4, and the solvent was removed on a rotary evaporator. The residue was taken up 
in hexane/EtOAc (3:1, 30 mL) and subjected to column chromatography (eluent: 
hexane/EtOAc: 3:1  1:1). The title compound was obtained as colorless oil (5.3 g, 58%). TLC 
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(light petroleum/EtOAc 2:1) Rf = 0.36. 
1H-NM R (300 MHz, [D6]aĐetoŶeͿ: δ (ppm) 1.39 (s, 9H), 
2.59 – 2.67 (m, 2H), 3.36 – 3.43 (m, 2H), 6.01 (br s, 1H), 9.75 (t, 1H, J 1.7 Hz). HRMS (ESI): m/z 
[M+Na]+ calcd. for [C8H15NNaO3]
+ 196.0944, found: 196.0945. C8H15NO3 (173.21). 
(9H-Fluoren-9-yl)methyl hydrazinecarboxylate (4.8).
32
 Hydrazine hydroxide (0.97 g, 19.4 
mmol) was dissolved in MeCN/H2O (1:1, 10 mL). A solution of Fmoc-Cl (1 g, 3.9 mmol) in 
MeCN (20 mL) was added dropwise under ice-cooling causing the formation of a white 
precipitate. The mixture was stirred at room temperature for additional 12 h and filtered to 
yield the desired compound as a white solid (900 mg, 91.3%). 1H-NMR (300 MHz, [D6]DMSO): 
δ (ppm) 4.08 (br s, 2H), 4.16 – 4.34 (m, 3H), 7.27 – 7.48 (m, 4H), 7.69 (d, 2H, J 7.40 Hz), 7.89 
(d, 2H, J 7.40 Hz), 8.36 (br s, 1H). HRMS (ESI): m/z [2M+H]+ calcd. for [C30H29N4O4]
+ 509.2183, 
found: 509.2183. C15H14N2O2 (254.29). 
(9H-Fluoren-9-yl)methyl 2-{3-[(tert-butoxycarbonyl)amino]propylidene}hydrazine-1-
carboxylate (4.9).
33
 Compound 6 (2.7 g, 10.5 mmol) was suspended in CH2Cl2 (120 mL). A 
solution of 4.8 (1.82 g, 10.5 mmol) in CH2Cl2 (20 mL) was added which in turn led to the 
dissolution of 4.6. While stirring at room temperature for 14 h, a white, voluminous 
precipitate was formed. The volume of the mixture was reduced to approximately 50 mL and 
the precipitate was collected by filtration to yield 4.9 as white solid (3.6 g, 83.7%). 1H-NMR 
(300 MHz, [D6]DM“OͿ: δ (ppm) 1.36 (s, 9H), 2.18 – 2.40 (m, 2H), 2.95 – 3.20 (m, 2H), 4.25 (t, 
1H, J 6.3 Hz), 4.32 – 4.50 (m, 2H), 6.88 (t, 1H, J 5.6 Hz), 7.25 – 7.47 (m, 5H), 7.71 (d, 2H, J 7.3 
Hz), 7.90 (d, 2H, J 7.3 Hz), 10.83 (s, 1H). HRMS (ESI): m/z [M+Na]+ calcd. for [C23H27N3NaO4]
+ 
432.1894, found: 432.1892. C23H27N3O4 (409.49). 
(9H-Fluoren-9-yl)methyl 2-{3-[(tert-butoxycarbonyl)amino]propyl}hydrazine-1-carboxylate 
(4.10).
33
 Compound 4.9 (2.75 g, 6.72 mmol) was dissolved in CH2Cl2/MeOH (3:2, 50 mL) and 
sodium cyanotrihydridoborate (550 mg, 8.74 mmol) was added. The pH was slowly adjusted 
to a value of 2-3 with 2 M aqueous HCl, and the mixture was stirred at room temperature for 
6 h. After completion of the reaction (monitored by TLC (light petroleum/EtOAc 1:1): Rf = 
0.44), the mixture was basified with Na2CO3. The precipitate was filtered off, and the volume 
of the filtrate was reduced to approximately 5 mL. The residue was taken up in 
hexane/EtOAc (1:2, 10 mL) and subjected to column chromatography (eluent: 
hexane/EtOAc: 4:3). After removal of the solvent on a rotary evaporator, the residue was 
triturated with EtOAc (3 mL), and the desired compound was obtained as white, crystalline 
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solid (1.05 g, 40%). 1H-NMR (300 MHz, [D6]acetone): δ (ppm) 1.40 (s, 9H), 1.55 – 1.72 (m, 
2H), 2.80 – 2.94 (m, 2H), 3.10 – 3.23 (m, 2H), 4.24 (t, 1H, J 6.7 Hz), 4.28 – 4.44 (m, 3H), 5.99 
(br s, 1H), 7.28 – 7.45 (m, 4H), 7.70 (d, 2H, J 7.3 Hz), 7.86 (d, 2H, J 7.5 Hz), 7.99 (br s, 1H). 
HRMS (ESI): m/z [M+H]+ calcd. for [C23H30N3O4]
+ 412.2231, found: 412.2235. C23H29N3O4 
(411.50). 
(9H-Fluoren-9-yl)methyl 2-(2-methylpropylidene)hydrazine-1-carboxylate (4.11).
34
 
Compound 4.6 (890 mg, 3.45 mmol) was suspended in CH2Cl2 (20 mL). After addition of 
isobutyraldehyde (315 µL, 1 equiv) compound 4.6 dissolved, and the mixture was stirred for 
50 h. The title compound was obtained as a white solid after removal of the volatiles under 
reduced pressure (1.06 g, quant). 1H-NMR (300 MHz, [D6]aĐetoŶeͿ: δ (ppm) 1.00 – 1.20 (m, 
6H), 2.39 – 2.59 (m, 1H), 4.27 (t, 1H, J 7.0 Hz), 4.42 (d, 2H, J 7.0 Hz), 7.27 – 7.48 (m, 5H), 7.75 
(br s, 2H), 7.87 (d, 2H, J 7.4 Hz), 9.72 (br s, 1H). HRMS (ESI): m/z [M+Na]+ calcd. for 
[C19H20N2NaO2]
+ 331.1417, found: 331.1421. C19H20N2O2 (308.38). 
(9H-Fluoren-9-yl)methyl 2-isobutylhydrazine-1-carboxylate (4.12).
32
 Compound 4.11 (980 
mg, 3.2 mmol) was dissolved in CH2Cl2/MeOH (4:3, 35 mL) and sodium 
cyanotrihydridoborate (260 mg, 4.1 mmol) was added. The pH was adjusted to a value of 2-3 
with 2 M aqueous HCl and the mixture was stirred at room temperature for 2 h. After 
completion of the reaction, the mixture was basified with Na2CO3. The solids were removed 
by filtration, and the filtrate was extracted with EtOAc (150 mL). The organic layer was 
washed with water (2 ×) and brine. The title compound was obtained as a greyish solid (970 
mg, 98%) after removal of the solvents. 1H-NMR (300 MHz, [D6]aĐetoŶeͿ: δ (ppm) 0.90 (d, 
6H, J 6.6 Hz), 1.58 – 1.80 (m, 1H), 2.62 (br s, 2H), 4.13 – 4.28 (m, 2H), 4.35 (d, 2H, J 6.8 Hz), 
7.26 – 7.45 (m, 4H), 7.69 (d, 2H, J 7.4 Hz), 7.85 (d, 2H, J 7.4 Hz), 7.96 (br s, 1H). HRMS (ESI): 
m/z [M+H]+ calcd. for [C19H23N2O2]
+ 311.1754, found: 311.1757. C19H22N2O2 (310.40). 
Benzyl N
ω
-[(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl]-L-argininate 
(4.14).
35
 Fmoc-Arg(Pbf)-OH (3 g, 4.62 mmol, 1 equiv), 4-dimethylaminopyridine (57 mg, 0.1 
equiv) and benzyl alcohol (1 mL, 2 equiv) were dissolved in CH2Cl2 (25 mL), and a solution of 
DCC (1 g, 1.05 equiv) in CH2Cl2 (10 mL) was added dropwise under ice-cooling. The reaction 
mixture was stirred at room temperature for 14 h. After completion of the reaction 
(monitored by TLC (light petroleum/EtOAc 1:2): Rf = 0.40), the mixture was filtered, and the 
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filtrate was washed with 0.1 M HCl solution (30 mL) and brine (20 mL). The volume of the 
organic layer was adjusted to 160 mL with CH2Cl2, and diethylamine (20 mL) was added for 
removal of the Fmoc group. After all starting material had been consumed, the volatiles 
were removed on a rotary evaporator The residue was taken up in light petroleum/EtOAc 
(1:1, 10 mL) and subjected to column chromatography (eluent: light petroleum/EtOAc 1:1  
EtOAc/MeOH 4:1). The desired compound was obtained as a white, sticky solid (1.89 mg, 
79.2%). 1H-NMR (300 MHz, [D6]DM“OͿ: δ (ppm) 1.33–1.62 (m, 10H), 1.89 (br s, 2H), 1.99 (s, 
3H, overlap with EtOAc), 2.42 (s, 3H), 2.47 (s, 3H), 2.93 (s, 2H), 2.97-3.10 (m, 2H), 3.26-3.34 
(m, 1H), 5.06 (s, 2H), 6.43 (br s, 2H), 6.70 (br s, 1H), 7.27-7.42 (m, 5H). HRMS (ESI): m/z 
[M+H]+ calcd. for [C26H37N4O5S]
+  517.2479, found: 517.2543. C26H36N4O5S (516.66). 
Benzyl (S)-2-amino-3-[4-(tert-butoxy)phenyl]propanoate (4.15). Fmoc-Tyr(tBu)-OH (2 g, 
4.35 mmol, 1 equiv), 4-dimethylaminopyridine (53.2 mg, 0.1 equiv) and benzyl alcohol (1 mL, 
2.2 equiv) were dissolved in CH2Cl2 (25 mL) and a solution of DCC (943 mg, 1.05 equiv) in 
CH2Cl2 (6 mL) was added dropwise under ice-cooling. The mixture was stirred at room 
temperature for 14 h. After completion of the reaction (monitored by TLC (light 
petroleum/EtOAc 2:1): Rf = 0.76), the mixture was filtered, and the filtrate was washed with 
0.1 M HCl solution (30 mL) and brine (20 mL). The volume of the organic layer was adjusted 
to 70 mL with CH2Cl2, and diethylamine (12 mL) was added for removal of the Fmoc group. 
After all starting material had been consumed, the volatiles were removed on a rotary 
evaporator, and the residue was taken up in light petroleum/EtOAc (1:1, 10 mL) and 
subjected to column chromatography (eluent: light petroleum/EtOAc 1:1  EtOAc/MeOH 
4:1). The desired compound was obtained as a yellowish highly viscous oil (1.05 g, 73.7%). 
1H-NMR (300 MHz, [D6]DM“OͿ: δ (ppm) 1.26 (s, 9H), 1.80 (br s, 2H), 2.71 – 2.89 (m, 2H), 3.60 
(t, 2H, J 6.9 Hz), 5.05 (s, 2H), 6.84 (d, 2H, J 8.5 Hz), 7.06 (d, 2H, J 8.4 Hz), 7.25 – 7.39 (m, 5H). 
13C-NMR (100.6 MHz, [D6]DM“OͿ: δ (ppm) 29.0 (3 carb), 56.4, 66.0, 78.0, 123.8 (2 carb), 
128.40 (2 carb), 128.43, 128.8 (2 carb), 130.2 (2 carb), 132.9, 136.5, 153.9, 175.4. HRMS 
(ESI): m/z [M+H]+ calcd. for [C20H26NO3]
+ 328.1907, found: 328.1915. C20H25NO3 (327.42). 
Benzyl L-leucinate (4.16).
36
 Fmoc-Leu-OH (1.54 g, 4.35 mmol, 1 equiv), 4-
dimethylaminopyridine (53.2 mg, 0.1 equiv) and benzyl alcohol (1 mL, 2.2 equiv) were 
dissolved in CH2Cl2 (25 mL), and a solution of DCC (943 mg, 1.05 equiv) in CH2Cl2 (6 mL) was 
added dropwise under ice-cooling. The mixture was stirred at room temperature for 14 h. 
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After completion of the reaction (monitored by TLC (light petroleum/EtOAc 2:1): Rf = 0.80), 
the mixture was filtered and the filtrate was washed with 0.1 M HCl (30 mL) and brine (20 
mL). The volume of the organic layer was adjusted to 70 mL with CH2Cl2, and diethylamine 
(12 mL) was added for removal of the Fmoc group. After all starting material had been 
consumed, the volatiles were removed on a rotary evaporator, the residue was taken up in 
light petroleum/EtOAc (1:1, 10 mL) and subjected to column chromatography (eluent: light 
petroleum/EtOAc 1:1  EtOAc/MeOH 4:1). Compound 4.16 was obtained as a yellowish 
highly viscous oil (750 mg, 77.9%). 1H-NMR (300 MHz, [D6]DM“OͿ: δ (ppm) 0.83 (d, 3H, J 6.6 
Hz), 0.86 (d, 3H, J 6.6 Hz), 1.24–1.47 (m, 2H), 1.62–1.74 (m, 1H), 1.80 (br s, 2H), 3.28–3.42 
(m, 1H), 5.10 (s, 2H), 7.28 – 7.43 (m, 5H). HRMS (ESI): m/z [M+H]+ calcd. for [C13H20NO2]+ 
222.1489, found: 222.1495. C13H19NO2 (221.30). 
N
2
-(2-{[(9H-fluoren-9-yl)methoxy]carbonyl}-1-isobutylhydrazine-1-carbonyl)-N
ω
-[(2,2,4,6,7-
pentamethyl-2,3-dihydrobenzofuran-5-yl)sulfonyl]-L-arginine (4.17). Triphosgene (152 mg, 
0.4 equiv) was dissolved in CH2Cl2 (5 mL). A solution of 4.14 (145 mg, 0.442 mmol) and DIPEA 
(450 µL, 2 equiv) in CH2Cl2 (5 mL) was added dropwise under ice-cooling. The mixture was 
allowed to warm to ambient temperature under stirring for 30 min. A solution of 4.12 (200 
mg, 1.1 equiv) in CH2Cl2 (2 mL) was added and stirring was continued for 90 min. The mixture 
was diluted with EtOAc (60 mL) and washed with water. The volatiles were removed under 
reduced pressure, the residue was taken up in EtOAc/hexane (2:1, 10 mL) and subjected to 
column chromatography (eluent: EtOAc/hexane (2:1)). The protected intermediate was 
dissolved in MeOH (10 mL), and Pd/C-catalyst (50 mg) was added. The mixture was stirred 
vigorously under hydrogen. After completion of the hydrogenation, the solids were removed 
by filtration through celite, the volume was reduced on a rotary evaporator. The desired 
compound was purified via column chromatography (eluent: CH2Cl2/MeOH (10:1)  
CH2Cl2/MeOH (1:1) + 0.5% TFA). Removal of the volatiles under reduced pressure and by 
lyophilisation afforded 4.14 as white lyophilisate (370 mg, 88.5%). TLC (CH2Cl2/MeOH 
(10:0.6) + 1% AcOH): Rf = 0.28. 
1H-NMR (400 MHz, [D4]ŵethaŶolͿ: δ ;ppŵͿ Ϭ.ϴϱ ;s, ϲHͿ, ϭ.ϰϭ 
(s, 6H), 1.47-1.69 (m, 3H), 1.69-1.79 (m, 1H), 1.79-1.92 (m, 1H), 2.06 (s, 3H), 2.49 (s, 3H), 2.56 
(s, 3H), 2.95 (s, 2H), 3.15 (s, 2H), 4.12-4.30 (m, 2H), 4.52 (s, 2H), 7.28 (t, 2H, J 7.3 Hz), 7.37 (t, 
2H, J 7.3 Hz), 7.54-7.70 (m, 2H), 7.77 (d, 2H, J 7.5 Hz). HRMS (ESI): m/z [M+H]+ calcd. for 
[C39H51N6O8S]
+ 763.3484, found: 763.3494. C39H50N6O8S (762.92). 
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(S)-5-({[(9H-Fluoren-9-yl)methoxy]carbonyl}amino)-2-[4-(tert-butoxy)benzyl]-12,12-
dimethyl-4,10-dioxo-11-oxa-3,5,9-triazatridecanoic acid (4.18). Triphosgene (52.5 mg, 0.4 
equiv) was dissolved in CH2Cl2 (2 mL). A solution of 4.15 (145 mg, 0.442 mmol) and DIPEA 
(150 µL, 2 equiv) in CH2Cl2 (2 mL) was added dropwise under ice-cooling. The mixture was 
allowed to warm to ambient temperature under stirring for 30 min. A solution of 4.10 (200 
mg, 1.1 equiv) in CH2Cl2 (2 mL) was added, and stirring was continued for 90 min. The 
mixture was diluted with EtOAc (40 mL) and washed with water. The volatiles were removed 
under reduced pressure, the residue was taken up in EtOAc/hexane (1:1, 10 mL) and 
subjected to column chromatography (eluent: EtOAc/hexane (1:1), Rf = 0.57). The protected 
intermediate was dissolved in MeOH (10 mL), and Pd/C-catalyst (30 mg) was added. The 
mixture was stirred vigorously under hydrogen. After completion of the hydrogenation, the 
solids were removed by filtration through celite, the volume was reduced on a rotary 
evaporator. The desired compound was purified via column chromatography (eluent: 
CH2Cl2/MeOH (10:0.5)  CH2Cl2/MeOH (10:0.6) + 1% AcOH). Removal of the volatiles under 
reduced pressure and by lyophilisation afforded 4.18 as a white lyophilisate (221 mg, 74.1%). 
TLC (CH2Cl2/MeOH (10:0.6) + 0.5% AcOH): Rf = 0.35. 
1H-NMR (400 MHz, [D4]ŵethaŶolͿ: δ 
(ppm) 1.20 (s, 9H), 1.42 (s, 9H), 1.51-1.66 (m, 2H), 2.81-3.20 (m, 5H), 3.69 (br s, 1H), 4.21 (s, 
1H), 4.35-4.60 (m, 3H), 6.79 (s, 2H), 7.04 (s, 2H), 7.24-7.35 (m, 2H), 7.39 (t, 2H, J 7.2 Hz), 
7.54-7.73 (m, 2H), 7.80 (d, 2H, J 7.5 Hz). HRMS (ESI): m/z [M+H]+ calcd. for [C37H47N4O8]
+ 
675.3388, found: 675.3403. C37H46N4O8 (674.80). 
{[1-(9H-Fluoren-9-yl)-12,12-dimethyl-3,10-dioxo-2,11-dioxa-4,5,9-triazatridecan-5-
yl]carbonyl}-L-leucine (4.19). Triphosgene (52.5 mg, 0.4 equiv) was dissolved in CH2Cl2 (2 
mL). A solution of 4.16 (97.7 mg, 0.442 mmol) and DIPEA (150 µL, 2 equiv) in CH2Cl2 (2 mL) 
was added dropwise under ice-cooling. The mixture was allowed to warm to ambient 
temperature under stirring for 30 min. A solution of 4.10 (200 mg, 1.1 equiv) in CH2Cl2 (2 mL) 
was added and stirring was continued for 90 min. The mixture was diluted with EtOAc (40 
mL) and washed with water. The volatiles were removed under reduced pressure and the 
residue was taken up in EtOAc/hexane (1:1, 10 mL) and subjected to column 
chromatography (eluent: EtOAc/hexane (1:1), Rf = 0.71). The protected intermediate was 
dissolved in MeOH (10 mL), and Pd/C-catalyst (30 mg) was added. The mixture was stirred 
vigorously under hydrogen. After completion of the hydrogenation, the solids were removed 
by filtration through celite, and the volume was reduced on a rotary evaporator. The desired 
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compound was purified via column chromatography (eluent: CH2Cl2/MeOH (10:0.4)  
CH2Cl2/MeOH (10:0.6) + 0.1% TFA). Removal of the volatiles afforded 4.19 as a sticky solid 
(132 mg, 52.5%). TLC (CH2Cl2/MeOH (10:0.6) + 0.5% AcOH): Rf = 0.55. 
1H-NMR (400 MHz, 
[D4]ŵethaŶolͿ: δ ;ppŵͿ Ϭ.ϵϬ ;d, ϲH, J 4.4 Hz), 1.42 (s, 9H), 1.52-1.77 (m, 5H), 3.03 (s, 2H), 
3.35-3.95 (m, 2H), 4.23 (t, 1H, J 6.3 Hz), 4.29 (t, 1H, J 7.0 Hz), 4.52 (s, 2H), 7.31 (t, 2H, J 7.3 
Hz), 7.39 (t, 2H, J 7.4 Hz), 7.59-7.71 (m, 2H), 7.79 (d, 2H, J 7.5 Hz). HRMS (ESI): m/z [M+H]+ 
calcd. for [C30H41N4O7]
+ 569.2970, found: 569.2969. C30H40N4O7 (568.67). 
Tyr(tBu)-Arg(Pbf)-azaLeu-Arg(Pbf)-Tyr(tBu)-amide Hydrotrifluoroacetate (4.21). The side-
chain protected pentapeptide 4.21 was synthesized according to the general procedure (100 
mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC was 
performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min MeCN/0.1% aq TFA 
42:58–78:22, tR = 14.9 min). Lyophilisation of the eluate afforded 4.21 as a white solid (39 
mg, 42.6%). HRMS (ESI): m/z [M+2H]2+ calcd. for [C69H105N13O13S2]
2+ 693.8693, found: 
693.8708. C69H103N13O13S2∙C2HF3O2 (1386.06 + 114.02). 
Tyr(tBu)-Arg(Pbf)-Leu-azaOrn(Boc)-Tyr(tBu)-amide Hydrotrifluoroacetate (4.22). The side-
chain protected pentapeptide 4.22 was synthesized according to the general procedure (100 
mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC was 
performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–20 min MeCN/0.1% aq TFA 
42:58–78:22, tR = 14.2 min). Lyophilisation of the eluate afforded 4.22 as a white solid (42 
mg, 52.7%). HRMS (ESI): m/z [M+2H]2+ calcd. for [C60H95N11O12S]
2+ 596.8436, found: 
596.8445. C60H93N11O12“∙C2HF3O2 (1192.53 + 114.02). 
Tyr(tBu)-azaOrn(Boc)-Leu-Arg(Pbf)-Tyr(tBu)-amide Hydrotrifluoroacetate (4.23). The side-
chain protected pentapeptide 4.23 was synthesized according to the general procedure (100 
mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by preparative HPLC was 
performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–20 min MeCN/0.1% aq TFA 
42:58–78:22, tR = 14.6 min). Lyophilisation of the eluate afforded 4.23 as a white solid (36 
mg, 45.2%). HRMS (ESI): m/z [M+2H]2+ calcd. for [C60H95N11O12S]
2+ 596.8436, found: 
596.8446. C60H93N11O12“∙C2HF3O2 (1192.53 + 114.02). 
(2R,7R)-Diaminooctanedioyl-bis(Tyr-Arg-azaLeu-Arg-Tyr-amide) 
Hexakis(hydrotrifluoroacetate) ((2R,7R)-4.26). Compound 4.24 (2.08 mg, 5.1 µmol), HBTU 
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(4.1 mg, 2.1 equiv) and HOBt (1.57 mg, 2 equiv) were dissolved in anhydrous DMF (400 µL). 
DIPEA (10 µL, 5 equiv) was added, and the mixture was stirred at room temperature for 5 
min followed by the addition of a solution of 4.21 (19.3 mg, 12.8 µmol). The resulting 
mixture was stirred at 35 °C for 16 h. Water (10 mL) was added and the protected 
intermediate was extracted with CH2Cl2 (2 × 10 mL). The combined organic layers were 
evaporated, and the residue was dried in vacuo. Subsequently, TFA/water (95:5, 2 mL) was 
added, and the mixture was stirred at room temperature for 2.5 h. Water (100 mL) was 
added followed by lyophilisation. The product was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–42:58, tR = 15.6 
min). Lyophilisation of the eluate afforded (2R,7R)-4.26 as a white fluffy solid (3.45 mg, 
28.3%). HRMS (ESI): m/z [M+4H]4+ calcd. for [C78H126N28O16]
4+ 427.7471, found: 427.7485. 
RP-HPLC (220 nm): 99% (tR = 17.72 min, k = 5.2). C78H122N28O16∙C12H6F18O12 (1708.01 + 
684.12). 
Octanedioyl-bis(Tyr-Arg-azaLeu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (4.27). 
Compound 4.21 (28.8 mg, 19.2 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 
µL). Compound 4.25 (2.83 mg, 7.7 µmol) was added, and the mixture was stirred at 35 °C for 
16 h. Water (10 mL) was added, and the protected intermediate was extracted with CH2Cl2 
(2 × 10 ml). The combined extracts were evaporated, and the residue was dried in vacuo. 
TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water 
(100 mL) was added followed by lyophilisation. The product was purified by preparative 
HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–
42:58, tR = 16.5 min). Lyophilisation of the eluate afforded 4.27 as a white fluffy solid (6.3 
mg, 38.3%). HRMS (ESI): m/z [M+4H]4+ calcd. for C78H124N26O16 420.2417, found: 420.2433. 
RP-HPLC (220 nm): 95% (tR = 19.13 min, k = 5.7). C78H120N26O16∙C8H4F12O8 (1677.98 + 456.08). 
Octanedioyl-bis(Tyr-Arg-Leu-azaOrn-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (4.28). 
Compound 4.22 (16.7 mg, 12.8 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 
µL). Compound 4.25 (1.9 mg, 5.1 µmol) was added, and the mixture was stirred at 35 °C for 
16 h. After addition of water (10 mL), the protected intermediate was extracted with CH2Cl2 
(2 × 10 ml). The combined extracts were evaporated, and the residue was dried in vacuo. 
TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water 
(100 mL) was added followed by lyophilisation. The product was purified by preparative 
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HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 3:97–
42:58, tR = 16.1 min). Lyophilisation of the eluate afforded 4.28 as a white fluffy solid (4.2 
mg, 40.2%). HRMS (ESI): m/z [M+4H]4+ calcd. for C76H120N22O16 399.2308, found: 399.2327. 
RP-HPLC (220 nm): 99% (tR = 19.55 min, k = 5.8). C76H116N22O16∙C8H4F12O8 (1593.90 + 456.08). 
Octanedioyl-bis(Tyr-Arg-Leu-azaArg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (4.29). 
Compound 4.28 (3.7 mg, 2.05 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (300 
µL). A solution of N,N'-di-Boc-1H-pyrazole-1-carboxamidine (1 mg/10 µL, 16 µL, 2.5 equiv) 
was added, and the mixture was stirred at room temperature for 4 h. After addition of water 
(5 mL) the protected intermediate was purified by preparative HPLC (column: Kinetex-XB 
C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 3:97–52:48, tR = 26.4 min). The 
eluates were subjected to lyophilisation, and the residue was taken up in TFA/ CH2Cl2/H2O 
(5:5:0.5, 3 mL). The resulting mixture was stirred for 3 h. The volatiles were removed on a 
rotary evaporator and by lyophilisation. 4.29 was obtained as a white fluffy solid (1.62 mg, 
37.0%). HRMS (ESI): m/z [M+4H]4+ calcd. for C78H124N26O16 420.2417, found: 420.2434. RP-
HPLC (220 nm): > 99% (tR = 20.15 min, k = 6.0). C78H120N26O16∙C8H4F12O8 (1677.98 + 456.08). 
Octanedioyl-bis(Tyr-azaOrn-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (4.30). 
Compound 4.23 (16.7 mg, 12.8 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (600 
µL). Compound 4.25 (1.88 mg, 5.1 µmol) was added, and the mixture was stirred at 35 °C for 
16 h. After addition of water (10 mL), the protected intermediate was extracted with CH2Cl2 
(2 × 10 ml). The combined extracts were evaporated, and the residue was dried in vacuo. 
TFA/water (95:5 v/v) (2 mL) was added, and the mixture was stirred at rt for 2.5 h. Water 
(100 mL) was added followed by lyophilisation. The product was purified by preparative 
HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 6:94–
37:63, tR = 17.4 min). Lyophilisation of the eluate afforded 4.30 as a white fluffy solid (3.9 
mg, 37.3%). HRMS (ESI): m/z [M+4H]4+ calcd. for C76H120N22O16 399.2308, found: 399.2317. 
RP-HPLC (220 nm): 98% (tR = 20.13 min, k = 6.0). C76H116N22O16∙C8H4F12O8 (1593.90 + 456.08). 
Octanedioyl-bis(Tyr-azaArg-Leu-Arg-Tyr-amide) Tetrakis(hydrotrifluoroacetate) (4.31). 
Compound 4.30 (3.0 mg, 1.66 µmol) was dissolved in anhydrous DMF/DIPEA (99:1 v/v) (300 
µL). A solution of N,N'-di-Boc-1H-pyrazole-1-carboxamidine (1 mg/10 µL, 13 µL, 2.5 equiv) 
was added, and the mixture was stirred at room temperature for 4 h. After addition of water 
(5 mL), the protected intermediate was purified by preparative HPLC (column: Kinetex-XB 
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C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 3:97–52:48, tR = 26.1 min). The 
solvents were removed by lyophilisation, the residue was taken up in TFA/ CH2Cl2/H2O 
(5:5:0.5, 3 mL), and the resulting mixture was stirred for 3 h. The volatiles were removed on 
a rotary evaporator and by lyophilisation. The title compound was obtained as a white fluffy 
solid (1.50 mg, 42.3%). HRMS (ESI): m/z [M+4H]4+ calcd. for C78H124N26O16 420.2417, found: 
420.2437. RP-HPLC (220 nm): 96% (tR = 20.86 min, k = 6.3). C78H120N26O16∙C8H4F12O8 (1677.98 
+ 456.08). 
Octanoyl-Tyr-Arg-Leu-Arg-Tyr-amide Bis(hydrotrifluoroacetate) (4.33). The pentapeptide 
4.33 was synthesized according to the general procedure (82 mg Fmoc-Sieber-PS resin 
(loading: 0.61 mmol/g)). Purification by preparative HPLC was performed with a Kinetex-XB 
C18 250 × 21 mm (gradient: 0–18 min MeCN/0.1% aq TFA 22:78–51:49, tR = 13.2 min). 
Lyophilisation of the eluate afforded 4.33 as a white solid (33.4 mg, 59.5%). HRMS (ESI): m/z 
[M+2H]2+ calcd. for [C44H72N12O8]
2+ 448.2793, found: 448.2800. RP-HPLC (220 nm): 99% (tR = 
28.04 min, k = 8.8). C44H70N12O8∙C4H2F6O4 (895.13 + 228.04). 
Ac-Tyr-N
ω
-[(4-aminobutyl)aminocarbonyl]Arg-Leu-Arg-Tyr-amide 
Tris(hydrotrifluoroacetate) (4.34). The pentapeptide 4.34 was synthesized according to the 
general procedure (18.8 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 14.4 min). Lyophilisation of the eluate afforded 4.34 as a 
white solid (7.7 mg, 53.0%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C43H71N14O9]
3+ 309.1837, 
found: 309.1850. RP-HPLC (220 nm): 97% (tR = 16.96 min, k = 4.9). C43H68N14O9∙C6H3F9O6 
(925.12 + 342.06). 
Ac-Arg-Tyr-N
ω
-[(4-aminobutyl)aminocarbonyl]Arg-Leu-Arg-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.35). The hexapeptide 4.35 was synthesized according to 
the general procedure (18.8 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification 
by preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.6 min). Lyophilisation of the eluate afforded 4.35 as a 
white solid (9.3 mg, 52.7%). HRMS (ESI): m/z [M+4H]4+ calcd. for [C49H84N18O10]
4+ 271.1649, 
found: 217.1657. RP-HPLC (220 nm): 97% (tR = 15.22 min, k = 4.3). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
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Ac-Arg-Tyr-Arg-Leu-Arg-Tyr-amide Tris(hydrotrifluoroacetate) (4.36). The hexapeptide 4.36 
was synthesized according to the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 
0.61 mmol/g)). Purification by preparative HPLC was performed with a Kinetex-XB C18 250 × 
21 mm (gradient: 0–18 min MeCN/0.1% aq TFA 3:97–42:58, tR = 13.7 min). Lyophilisation of 
the eluate afforded 4.36 as a white solid (18.3 mg, 65.5%). HRMS (ESI): m/z [M+3H]3+ calcd. 
for [C44H70N16O9]
3+ 323.1910, found: 323.1927. RP-HPLC (220 nm): 99% (tR = 15.98 min, k = 
4.6). C44H70N16O9∙C6H3F9O6 (967.15 + 342.06). 
Ac-Arg-Tyr-Arg-Leu-N
ω
-[(4-aminobutyl)aminocarbonyl]Arg-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.37). The hexapeptide 4.37 was synthesized according to 
the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.6 min). Lyophilisation of the eluate afforded 4.37 as a 
white solid (7.2 mg, 21.9%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C49H83N18O10]
3+ 361.2174, 
found: 361.2187. RP-HPLC (220 nm): 99% (tR = 15.17 min, k = 4.3). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
Ac-Arg-Tyr-N
ω
-[(4-aminobutyl)aminocarbonyl]Arg-Leu-Arg-D-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.38). The hexapeptide 4.38 was synthesized according to 
the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.6 min). Lyophilisation of the eluate afforded 4.38 as a 
white solid (5.7 mg, 17.4%). HRMS (ESI): m/z [M+4H]4+ calcd. for [C49H84N18O10]
4+ 271.1649, 
found: 217.1666. RP-HPLC (220 nm): 98% (tR = 15.25 min, k = 4.3). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
Ac-Arg-Tyr-N
ω
-[(4-aminobutyl)aminocarbonyl]Arg-Leu-D-Arg-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.39). The hexapeptide 4.39 was synthesized according to 
the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.3 min). Lyophilisation of the eluate afforded 4.39 as a 
white solid (6.0 mg, 18.3%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C49H83N18O10]
3+ 361.2174, 
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found: 361.2190. RP-HPLC (220 nm): 95% (tR = 14.77 min, k = 4.1). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
Ac-Arg-Tyr-N
ω
-[(4-aminobutyl)aminocarbonyl]Arg-D-Leu-Arg-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.40). The hexapeptide 4.40 was synthesized according to 
the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.4 min). Lyophilisation of the eluate afforded 4.40 as a 
white solid (6.6 mg, 20.1%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C49H83N18O10]
3+ 361.2174, 
found: 361.2189. RP-HPLC (220 nm): 96% (tR = 14.33 min, k = 4.0). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
Ac-Arg-D-Tyr-{N
ω
-[N-(4-aminobutyl)aminocarbonyl]}Arg-Leu-Arg-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.41). The hexapeptide 4.41 was synthesized according to 
the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.5 min). Lyophilisation of the eluate afforded 4.41 as a 
white solid (6.7 mg, 20.5%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C49H83N18O10]
3+ 361.2174, 
found: 361.2190. RP-HPLC (220 nm): 95% (tR = 15.1 min, k = 4.3). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
Ac-D-Arg-Tyr-{N
ω
-[N-(4-aminobutyl)aminocarbonyl]}Arg-Leu-Arg-Tyr-amide 
Tetrakis(hydrotrifluoroacetate) (4.42). The hexapeptide 4.42 was synthesized according to 
the general procedure (35 mg Fmoc-Sieber-PS resin (loading: 0.61 mmol/g)). Purification by 
preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
MeCN/0.1% aq TFA 3:97–42:58, tR = 13.5 min). Lyophilisation of the eluate afforded 4.42 as a 
white solid (7.0 mg, 21.4%). HRMS (ESI): m/z [M+3H]3+ calcd. for [C49H83N18O10]
3+ 361.2174, 
found: 361.2190. RP-HPLC (220 nm): 99% (tR = 14.94 min, k = 4.2). C49H80N18O10∙C8H4F12O8 
(1081.31 + 456.08). 
Ac-Arg-Tyr-{N
ω
-[N-(4-aminobutyl)aminocarbonyl]}Arg-Leu-Arg-Tyr-OH 
Tetrakis(hydrotrifluoroacetate) (4.43). The hexapeptide 4.43 was synthesized according to 
the general procedure (44.1 mg, H-L-Tyr(tBu)-2 CT resin (loading: 0.68 mmol/g)). Purification 
by preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm (gradient: 0–18 min 
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MeCN/0.1% aq TFA 13:87–42:58, tR = 10.7 min). Lyophilisation of the eluate afforded 4.43 as 
a white solid (15.2 mg, 32.9 %). HRMS (ESI): m/z [M+4H]4+ calcd. for [C49H83N17O11]
4+ 
271.4109, found: 271.4124. RP-HPLC (220 nm): 95% (tR = 16.28 min, k = 4.7). 
C49H79N17O11∙C8H4F12O8 (1082.28 + 456.08). 
(S)-2-Acetamido-N-((S)-1-{[(12S,15S,18S,21S)-2-amino-15-(3-guanidinopropyl)-12-(4-
hydroxybenzyl)-18-isobutyl-4,11,14,17,20-pentaoxo-1,3,5,10,13,16,19-
heptaazacyclotetracos-2-en-21-yl]amino}-3-(4-hydroxyphenyl)-1-oxopropan-2-yl)-5-
guanidinopentanamide Tris(hydrotrifluoroacetate) (4.44). Compound 4.43 (9.0 mg, 5.85 
µmol), HOBt (1.79 mg, 2 equiv) and DIPEA (0.9 µL, 8 equiv) were dissolved in anhydrous DMF 
(5850 µL) to give a 1 mM solution. A solution of PyBOP (3.65 mg, 1.2 equiv) was added 
dropwise. After stirring at room temperature for 24 h, 0.1% aq TFA (20 mL) was added and 
purification by preparative HPLC was performed with a Kinetex-XB C18 250 × 21 mm 
(gradient: 0–18 min MeCN/0.1% aq TFA 3:97–42:58, tR = 15.9 min). Lyophilisation of the 
eluate afforded 4.44 as a white solid (3.9 mg, 47.4 %). HRMS (ESI): m/z [M+3H]3+ calcd. for 
[C49H80N17O10]
3+ 355.5419, found: 355.5434. RP-HPLC (220 nm): 95% (tR = 18.4 min, k = 5.4). 
C49H77N17O10∙C6H3F9O6 (1064.27 + 342.06). 
 
4.4.3  Pharmacological Assays 
Cells. HEC-1B (HTB-113) human endometrial cancer cells, MCF-7 (HTB-22) human breast 
cancer cells were from the American Type Culture Collection (Rockville, MD). A subclone of 
the MCF-7 cell line that shows higher Y1R expression was established in our laboratory and 
used for binding experiments.23 Human erythroleukemia (HEL) cells were kindly provided by 
Dr. M. C. Michel (Universitätsklinikum Essen, Germany) and chinese hamster ovarian (CHO-
K1, ACC-110) cells and human embryonal kidney cells (HEK-293T, 293T, ACC 635) cells were 
from Deutsche Sammlung für Mikroorganismen und Zellkulturen (DSMZ, Braunschweig, 
Germany). Genetically engineered cells, used for binding and functional assays, were 
generated and cultured as described (cf. brief description of protocols). 
Routinely performed examinations for mycoplasma contamination using the Venor GeM 
Mycoplasma Detection Kit (Minerva Biolabs, Berlin, Germany) were negative for all cell 
types. 
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HEK293T-ARRB1-hY4R and HEK293T-ARRB2-hY4R cells. The β-arrestin recruitment was 
quantified by a luciferase complementation assay based on the emerald luciferase (ELuc) 
from brazilian click-beetle Pyrearinus termitilluminans. The fusion construct of the human 
hY4R (the hY4R cDNA was from cDNA Resource Center, Bloomsburg, PA, USA) and the C-
terminal luciferase fragment (hY4R-ELucC) was generated using the previously described 
construct SSTR2-ELucC37,38 by replacing the cDNA of SSTR2 by the cDNA of the hY4R. HEK293T 
cells were stably transfected with the pcDNA3.1/myc-HIS (B) vector encoding the β-arrestin 
isoform 1 or 2, N-terminally fused with the N-terminus of the luciferase (ELucN-ARRB1 or 
ELucN-ARRB2, respectively)37 and the pcDNA4/V5-HIS (B) vector encoding hY4R-ELucC. Cells 
transfected with pcDNA3.1/myc-HIS (B) were cultivated in the presence of G418 (600 µg/mL) 
for up to 3 weeks until stable growth was observed. Afterwards, the cells were co-
transfected with the pcDNA4/V5-HIS (B) vector encoding hY4R-ELucC and selection pressure 
was applied using zeocin (40 µg/mL). To determine the hY4R-ELucC expression, saturation 
binding studies were performed with both, HEK293T-ARRB1- hY4R cells and HEK293T-ARRB2-
hY4R cells using the radioligand 45 (cf. Figure S6, S7, Supporting Information). 
Cell Culture. Cells were cultured in 25- or 75-cm2 flasks (Sarstedt, Nümbrecht, Germany) in a 
humidified atmosphere (95% air, 5% CO2) at 37 °C. MCF-7-Y1 cells,
22 HEL cells,39 CHO-hY2-
Gqi5-mtAEQ cells,
25 CHO-hY4-Gqi5-mtAEQ cells
26 and HEK293T-hY4R-CRE Luc cells
11 were 
cultured as described previously. HEK293T-ARRB1-hY4R and HEK293T-ARRB2-hY4R cells were 
maintained in DMEM containing 10% FCS, 600 µg/mL G418 and 40 µg/mL zeocin. 
Radioligand Binding Assays. Y1R binding. The Radioligand binding assay was performed at 
intact MCF-7-Y1 cells as previously described
22 with the following modifications: Experiments 
were carried out in 96-well plates with clear bottom (Corning Incorporated Life Sciences, 
Tewksbury, MA; Corning cat. no. 3610), and the volume per well was reduced to 100 µL. 
After incubation, the cells were washed with buffer (200 µL) twice and covered with lysis 
solution (25 µL) consisting of urea (8 M), acetic acid (3 M) and Triton-X-100 (1%) in water. 
The plates were shaken for 30 min prior to addition of liquid scintillator cocktail (Optiphase 
Supermix, PerkinElmer, Überlingen, Germany) (200 µL). The wells were sealed with a 
transparent film (permanent seal for microplates, PerkinElmer, prod. no. 1450–461). The 
plates were shaken and kept in the dark for at least 30 min. Radioactivity (dpm) was 
measured with a MicroBeta2 plate counter (PerkinElmer, Rodgau, Germany). 
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Y2R binding. Competition binding experiments were performed at CHO-hY2R-Gqi5-mtAEQ 
cells25 with [3H]propionyl-pNPY24 (Kd = 1.4 nM, c = 1 nM) in a hypotonic HEPES buffer (25 mM 
HEPES, 2.5 mM CaCl2, 1 mM MgCl2, pH 7.4) as previously described.
11 
Y4R binding. Competition binding experiments were performed at CHO-hY4R-Gqi5-mtAEQ 
cells26 with 4.45 (Kd = 0.67 nM, c = 0.6 nM) in a hypotonic HEPES buffer (25 mM HEPES, 2.5 
mM CaCl2, 1 mM MgCl2, pH 7.4) as described in Chapter 2.4.5.
 
Y5R binding. Competition binding experiments were performed at HEC-1B-hY5 cells
27 with 
[3H]propionyl-pNPY24 (Kd = 4.8 nM, c = 4 nM) in an isotonic HEPES buffer (150 mM NaCl, 10 
mM HEPES, 25 mM NaHCO3, 2.5 mM CaCl2, 1.2 mM KH2PO4, 1.2 mM MgSO4, 5 mM KCl) as 
previously described.11 
 
Fura-2 Calcium Assay. The assay was performed for the functional characterization of 
selected ligands at the human Y1 receptor using human erythroleukemia (HEL) cells and a LS-
50B luminescence spectrometer (Perkin Elmer, Überlingen, Germany) as previously 
described.39,40 
Aequorin Calcium Assay. The assay was performed on CHO-hY4-Gqi5-mtAEQ cells as 
previously described26 using a GENios Pro plate reader (Tecan, Salzburg, Austria). Areas 
under the curve were calculated using SigmaPlot 12.5 software (Systat Software Inc., 
Chicago, IL). 
Luciferase Assay. The Luciferase assay was performed on HEK293-hY4-CRE Luc cells as 
previously described.11 
β-Arrestin Recruitment Assay. The ƌeĐƌuitŵeŶt of β-arrestin was measured via split-
luciferase complementation technique. The N-terminal part of a green light-emitting 
luĐifeƌase ǁas fused to β-arrestin and the C-terminal part was fused to Y4R. One day before 
the experiment, HEK293T-ARRB1-Y4R and HEK293T-ARRB2-Y4R cells were trypsinized (0.05% 
trypsin, 0.02% EDTA in PBS) and centrifuged (400 g, 5 min). The cells were re-suspended in 
DMEM without phenol red (Sigma, Steinheim, Germany) supplemented with 5% FCS, and 90 
µL of the cell suspension were seeded in white, TC-treated, flat bottom 96-well microtiter 
plates (VWR, Ismaning, Germany) at a density of approximately 100,000 cells/well. The cells 
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were cultivated at 37 °C overnight in a water-saturated atmosphere containing 5% CO2. 
Shortly before the experiment, the cells were removed from the incubator and allowed to 
equilibrate to room temperature, before 10 µL of agonist solution were added per well. The 
plates were shaken at 25 °C for 60 min. At the end of the incubation period, 50 µL of 
medium were replaced by 50 µL of Bright-Glo luciferase assay reagent (Promega, Mannheim, 
Germany). The plates were vigorously shaken (800 rpm) for 5 min. Bioluminescence was 
recorded for 1 s per well using the GENios Pro microplate reader (Tecan, Salzburg, Austria). 
For the determination of antagonistic activities, the cells were pre-incubated in the presence 
of the antagonist for 15 min. 10 µL of an hPP solution (30 nM, final concentration 3 nM) 
were added and incubation was continued at 25 °C for 60 min. The plates were further 
processed as in case of the agonist mode. 
 
Data Analysis. All data are presented as mean ± SEM from at least 3 independent 
experiments performed in triplicate. Concentration response curves from the aequorin, β-
arrestin or luciferase assay and concentration displacement curves from radioligand binding 
experiments were analyzed by four-parameter sigmoidal fits (GraphPad Prism 5.0, San 
Diego, CA). Agonist potencies are given as EC50 values, maximal responses (efficacies) are 
expressed as α value referred to the effect of 1 µM hPP (α = 1.0). Ki values were calculated 
from IC50 values using the Cheng-Prusoff equation.
41 
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Diŵeric ArgiŶiŶaŵide-type Neuropeptide Y 
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CoŶforŵatioŶally CoŶstraiŶed LiŶkers oŶ YϰR 
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5.1  Introduction 
Whereas many non-peptide Y1R and Y5R antagonists and a few Y2R antagonists with drug like 
properties have been reported (cf. general introduction (1.2)), highly potent and selective 
small molecule Y4R antagonists are not known so far. Such compounds are required as 
pharmacological tools to further investigate the physiological and pathophysiological role of 
the Y4R. 
Surprisingly, within a series of bivalent NG-acylated BIBP 3226 derivates which were initially 
designed as dimeric Y1R antagonists, several compounds proved to possess Y4R affinities and 
antagonistic activities in the two- to three-digit nanomolar range.1 Modifications of the 
linkers regarding chemical nature, length, rigidity and attachment position resulted in the 
dimeric NG-carbamoylated BIBP 3226 derivate UR-MK188.2 Y4R selectivity could be improved 
by changing the stereo configuration of UR-MK188. The S,S-configured enantiomer, UR-
MEK388, binds to the Y4R with an affinity comparable to that of the R,R-configured UR-
MK188, but is inactive at the Y1R.  
 
Figure 1: Dimeric NG-carbamoylated argininamides UR-MK188 and UR-MEK388 and the parent 
compound BIBP 3226. 
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Previous investigations on such dimeric argininamides, initially designed as bivalent Y1R 
antagonists, suggest that the linker length should be reduced. Taking UR-MK188 as a lead 
structure, a series of bivalent Y4R ligands with truncated, conformationally constrained 
linkers was prepared. 
 
5.2  Retrosynthetic Analysis of Dimeric N
G
-Carbamoylated 
Argininamides 
Two series of bivalent BIBP 3226 derived ligands were planned, one containing an extended 
core structure, the other one containing a bent one. Each series comprised three ligands 
with linkers of different lengths. As an example, (R,R)-5.1 is shown in Figure 2. (R,R)-5.1 can 
be devided into four different substructures. 
 
Figure 2: Retrosynthetic analysis of bivalent ligand (R,R)-5.1. 
Building block A was prepared from Fmoc-Orn(Cbz)-OH in a four step synthesis. The rather 
flexible substructure B was attached to A ďǇ guaŶidiŶǇlatioŶ of the δ-amino group of the 
ornithinamide A. The NG-carbamoylated argininamide (A + B) comprises the pharmacophoric 
moiety (BIBP 3226) and a rather flexible part to allow optimal spatial orientation of the 
pharmacophoric moieties when binding to the receptor. This part was kept identical 
throughout this series of bivalent ligands. 
A connecting moiety C, consisting of one or three glycine residues was optionally used for 
the extension of the linkers. In the last step, the rigid core structure D, was coupled to the 
portion A-C containing the argininamide residues. 
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5.3  Results and Discussion 
5.3.1  Chemistry 
5.3.1.1 Synthesis of the N
G
-(3-aminopropylcarbamoyl)argininamide     
(R)-5.13 
Carbamoylguanidines can be prepared from amines and N-protected, carbamoylated S-
methylisothioureas. The amines (R)-5.7 and (S)-5.7, which were used for guanidinylation, 
were prepared in a four step synthesis as previously described.1,3 To allow for selective 
deprotection, three orthogonal protecting groups, Fmoc, Cbz and tert-butyl, were 
introduced. Amide coupling and deprotection were carried out by analogy with standard 
protocols (DEA for Fmoc cleavage, Pd/C, H2 in MeOH for Cbz cleavage; CDI or succinimidyl 
esters for amide coupling). 
Scheme 1: Preparation of the D-ornithinamide (R)-5.7.a 
 
a(S)-5.7 was prepared according to the same protocol using (S)-5.1 as starting material. Reagents and 
conditions: (a) CDI, DIPEA, THF, rt, 60 min, followed by 5.2, rt, 18 h. (b) DEA, CH2Cl2, rt, 24 h. (c) 5.5, 
DME/THF (85:15), 35 °C, 20 h. (d) H2, Pd/C (10%), MeOH, rt, 20 h. 
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Scheme 2: Synthesis of guanidinylating reagent 5.12 and amine (R)-5.13a 
 
a(S)-5.13 was prepared according to the same protocol using (S)-5.7 as starting material. Reagents 
and conditions: (a) Boc2O, TEA, chloroform, rt, 20 h. (b) Boc2O, TEA, chloroform, rt, 40 h. (c) 
Triphosgene, CH2Cl2, DIPEA, rt, 45 min, followed by 5.1, rt, 3 h. (d) HgCl2, DIPEA, DMF, rt, 16 h, 
followed by TFA/ CH2Cl2/H2O (10:10:1), rt, 2.5 h. 
As guanidinylating reagent a carbamoylated S-methylisothiourea was used, which was 
prepared as outlined in Scheme 2. The mono-Boc-protected diamine 5.10 was in situ 
converted into the corresponding isocyanate with triphosgene and used for carbamoylation 
of the mono-Boc-protected isothiourea 5.9. Subsequently, amines (R)-5.7 and (S)-5.7 were 
treated with the carbamoylated S-methyl isothiourea 5.12 in the presence of mercury(II) 
chloride to give the respective carbamoylated guanidines. Removal of the tert-butyl and Boc 
protecting groups under acidic conditions yielded the building blocks (R)-5.13 and (S)-5.13. 
 
5.3.1.2 Synthesis of the Bent Core Structure in Bivalent Ligands 
(R,R)/(S,S)-5.1, (R,R)/(S,S)-5.31 and (R,R)-5.32 
Two different dicarboxylic acids with aromatic scaffolds were selected as rigid core 
structures of the linker. Biphenyl-4,4'-dicarboxylic acid (5.14) was commercially available. In 
search for a central core structure that sets the whole linker of the bivalent ligands into a 
bent conformation, 1,7-dihydroimidazo[4,5-f]benzimidazole (5.15) was chosen. The 
compound was easily accessible by heating benzene-1,2,4,5-tetraamine tetrahydrochloride 
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in formic acid at 100 °C. Subsequent alkylation of 5.15 with tert-butyl bromoacetate gave a 
1:1 mixture of the desired 1,7-disubstituted product (5.17) and the 1,5-disubstituted isomer 
(5.16). The two isomers 5.16 and 5.17 could be easily separated by column chromatography 
using mixtures of CH2Cl2 and MeOH as mobile phases. Finally, the dicarboxylic acid 5.18 was 
obtained after cleavage of the tert-butyl protecting groups under acidic conditions. 
Scheme 3: Structure of Biphenyl-4,4'-dicarboxylic acid (5.14) and the synthesis of dicarboxylic acid 
5.18
a 
 
aReagents and conditions: (a) Formic acid, 100 °C, 30 h. (b) NaH, anhydrous DMF, 80 °C, followed by 
tert-butyl bromoacetate, 30 min, 50 °C, 3 h. (c) TFA/ CH2Cl2/H2O (10:10:1), rt, 4 h. 
 
5.3.1.3 Synthesis of Intermediates for the Preparation of Bivalent Ligands 
with Extended Linkers 
For the preparation of dimeric ligands with extended linkers, the intended glycine or 
triglycine moieties had to be attached either to the amines (R)-5.13 and (S)-5.13 or to the 
central rigid core structures 5.14 and 5.18, respectively. In a first attempt glycine was 
protected as methyl ester and coupled to 5.14 using standard amide coupling protocols. The 
resulting dicarboxylic acid 5.19 could be isolated after cleavage of the methyl ester under 
basic conditions. However, due to poor solubility of both, starting material and product, in 
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various organic solvents, the purification of 5.19 was rather inconvenient. Therefore, the 
strategy for extension of the linker was changed. Instead of coupling ester-protected glycine 
or triglycine to the central part of the linker, Boc-protected glycine (5.20) and triglycine 
(5.21) were coupled to the amines (R)-5.13 or (S)-5.13, respectively. In this way (R)-5.22, (S)-
5.22 and (R)-5.23, extended analogs of 5.13, were obtained in acceptable yields. 
Scheme 4: Synthesis of dicarboxylic acid 5.19 and amines (R)-5.22 and (R)-5.23, extended analogs of 
5.13.a 
 
a(S)-5.22 was prepared according to the same protocol using (S)-5.13 as starting material. Reagents 
and conditions: (a) SOCl2, MeOH, 0 °C, 10 min, reflux, 2 h. (b) Biphenyl-4,4'-dicarboxylic acid, CDI, 
DIPEA, anhydrous DMF, rt, 10 min, 70 °C, 3 h, followed by 10% NaOH, MeOH, 0 °C, 3 h. (c) Boc2O, 
DIPEA, H2O/dioxane (1:1), rt, 6 h. (d) CDI, DIPEA, DMF, (R)-5.13, 80 °C, 2 h, followed by 
CH2Cl2/TFA/H2O (10:10:1), rt, 3 h. (e) TBTU, DIPEA, DMF, (R)-5.13, 70 °C (microwave conditions), 2 h, 
followed by TFA/ CH2Cl2/H2O (10:10:1), rt, 3 h. 
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5.3.1.4 BIBP 3226 Derived Dimeric Ligands with Alternative Linker 
Attachment Positions 
In addition to bivalent ligands like UR-MK188 in which the linker is attached to the guanidine 
nitrogen of BIBP 3226, bivalent ligands with different attachment positions should be 
considered. In this way, the size of the compounds can be reduced while maintaining the 
distance between the guanidine residues. Furthermore, the attachment of the linker to 
another substructure of BIBP 3226 increases the flexibility of the guanidine groups which 
might be favorable for the interaction with the receptor. Several different positions within 
BIBP 3226 are worth considering (cf. Figure 3). 
 
Figure 3: Possible positions of linker attachment for BIBP 3226 derived dimeric ligands. 
Scheme 5 shows the synthesis of building blocks for the preparation of bivalent ligands in 
which the linker is attached to the carboxylic acid of the arginine in BIBP 3226. As the stereo 
discrimination of this set of bivalent ligands cannot be predicted, final compounds were 
prepared as racemic mixtures. Benzyl protected D/L-Arg(Pbf)-OH was acylated with 
diphenylacetic acid. Subsequent cleavage of the benzyl ester gave the carboxylic acid (R/S)-
5.24. Mono-Cbz-protected 1,4-bis(aminomethyl)benzene (5.25) was coupled to Fmoc-D/L-
Arg(Pbf)-OH. Subsequent Fmoc-deprotection with diethylamine resulted in the amine (R/S)-
5.26 which was acylated with N-succinimidyl diphenylacetate. The racemic mixture of amine 
5.27 was obtained after Fmoc-deprotection. 
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Scheme 5: Preparation of building blocks for bivalent ligands with modified linker attachment sitesa 
 
aReagents and conditions: (a) Diphenylacetic acid, TBTU, DIPEA, CH2Cl2/DMF (5:3), rt, 14 h, followed 
by H2, Pd/C, MeOH, rt. (b) Benzyl chloroformate, DIPEA, CH2Cl2, rt, 14 h. (c) 5.25, N,N͛-
diisopropylcarbodiimide, DMF, 0 °C, 10 min, rt, 14 h, followed by CH2Cl2/DEA (8:1). (d) 5.5, DIPEA, 
DME/THF (3:1), rt, 14 h, followed by, H2, Pd/C, MeOH, rt. 
 
5.3.1.5 Synthesis of Homo- and Heterodimeric Ligands 
Finally, the dimeric argininamide-type potential Y4R ligands (R,R)-5.28-5.32, (R,R)/(S,S)-5.1 
and (S,S)-5.31 were prepared by amidation of the dicarboxylic acids 5.14, 5.19 or 5.18 with 
the respective amine precursors (R)/(S)-5.13, (R)/(S)-5.22 or (R)-5.23 (Scheme 6). Satisfactory 
yields were achieved with TBTU as a coupling reagent under microwave irradiation at 70 °C. 
The bivalent ligands (R/S)-5.34 and (R/S)-5.35 were prepared from the acid (R/S)-5.24 and 
the amine (R/S)-5.27 or the diacid 5.19 and (R/S)-5.27, respectively, using the same coupling 
conditions as mentioned above (note: R/S denotes the mixture of R,R, S,S, and R,S-
configured stereoisomers resulting from the coupling the the racemic argininamide 
derivative as building block). The hybrid compound all-S-5.33 was prepared by coupling the 
amine (S)-5.13 to the protected pentapeptide building block 2.13 and subsequent final 
deprotection under acidic conditions. 
  
Scheme 6: Preparation of homodimeric ligands (R,R)-5.28-5.32, (R,R)/(S,S)-5.1, (S,S)-5.31, (R/S)-5.34, (R/S)-5.35 and hybrid compound all-S-5.33a 
 
aReagents and conditions: (a) TBTU, DIPEA, DMF, rt 15 min, 70 °C, 30 min (microwave conditions). (b) HBTU, HOBt, DIPEA, DMF, rt, 10 min, 70 °C, 30 min, 
followed by TFA/H2O (95:5), rt, 2.5 h. 
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5.3.2  Pharmacology: Binding and Functional Assays 
Ki values of the dimeric ligands and all-S-5.33 were determined in competition binding 
experiments on live cells expressing human Y1, Y2, Y4 or Y5 receptors to determine the NPY 
receptor affinity and subtype selectivity (data cf. Table 1). 
The synthesized bivalent ligands (R,R)-5.1 and (R,R)-5.28-5.32 show binding to both Y1R and 
Y4R. The affinity to the Y1R was considerable higher than to the Y4R for all compounds 
mentioned above. The compounds with the highest Y1R affinities, (R,R)-5.31 and (R,R)-
5.32,had Ki values of 41 nM and 80 nM, respectively, which is a 30- to 60-fold decrease in 
Y1R affinity compared to the parent compound BIBP 3226 (Ki = 1.3 nM). 
The monomeric parent compound BIBP 3226 is a high-affinity Y1R antagonist, but inactive at 
the Y4R. The bivalent ligand approach resulted in a tremendous increase in Y4R binding. At 
the Y4R, the compounds that share 5.18 as central rigid core were slightly superior to those 
comprising 5.14. For example, compound (R,R)-5.1 (Y4R: Ki = 859 nM) had a higher affinity 
than (R,R)-5.28 (Y4R: Ki = 2020 nM). This trend was also observed for compounds (R,R)-5.29 
and (R,R)-5.31 or (R,R)-5.30 and (R,R)-5.32, respectively. 
However, it is questionable whether the increase in affinity in case of compounds (R,R)-5.1, 
(R,R)-5.31 and (R,R)-5.32 is due to a bent conformation of the central core structure. For 
example, the biphenyl moiety in compounds (R,R)-5.28-5.30 can rotate around the C-C bond 
between the benzene rings. This goes along with a higher loss of entropy upon binding, 
which could also be a reason for the lower affinity. Furthermore, the influence of the core 
structure on the spatial orientation of the whole linker should not be overestimated. The 
glycine chains are more rigid than previously used alkyl or glycol ether chains. However, 
when combined with the part adjacent to the pharmacophoric moieties, there is a high level 
of conformational flexibility. 
In addition to rigidisation, variation of the linker length was performed to test the working 
hypothesis. Having a linker length of 41 atoms, UR-MK188 is among the dimeric 
argininamides with the longest linkers. Conformational analysis of the central part of the 
linker suggests a bent, V- or U-shaped conformation for this substructure. Considering the 
bent conformation of the central structure of UR-MK188, the argininamide moieties would 
bind to the receptor in much closer proximity than expected from a compound in an 
extended conformation. Furthermore, structures with shorter linkers (17 or 33 atoms) 
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revealed affinities in the nanomolar range as well. Recent observations suggest that linker 
lengths of 40 atoms and more are not necessary.2 This is in line with the binding data of the 
bivalent ligands described herein. For instance, the three compounds from the series with 
bent linkers, compounds (R,R)-5.1, (R,R)-5.31 and (R,R)-5.32, only show minor differences 
regarding Y4R affinities, although they strongly differ in linker lengths (21 atoms, 27 atoms or 
even 39 atoms). The reduction of the linker length would be generally favorable for 
improving drug like properties of these molecules. 
 
Figure 4: Radioligand displacement curves from competition binding experiments at Y1R or Y4R. (A) 
Displacement of ([3H]UR-KK1934 (Kd = 9.8 nM, c = 10 nM)) using CHO-hY4R-Gqi5-mtAEQ cells
5 in L15 
medium. Data represent mean values ± SEM of at least 3 independent experiments, each performed 
in triplicate. (B) Displacement of [3H]UR-MK1366 (Kd = 6.2 nM, c = 4 nM) using MCF-7-Y1 cells. Data 
represent mean values ± SEM of at least 3 independent experiments, each performed in triplicate. 
The S-configured enantiomer of BIBP 3226, BIBP 3435, was reported to bind to the Y1R with 
a substantially lower affinity than the R-configured eutomer.7 In order to exploit the 
stereodiscrimination of the Y1R to gain Y4R selectivity, an S-configured version of 5.1 and 
5.31 was prepared. By analogy with the parent compound BIBP 3435, the Y1R affinity of the 
S-configured dimeric ligands (Ki (Y1R, (S,S)-5.1) = 3380 nM; Ki (Y1R, (S,S)-5.31) = 5320 nM) was 
significantly lower than the affinity of the R-configured counterparts. In contrast, Y2R, Y4R 
and Y5R affinity remained essentially unaffected (S,S)-5.1 (Ki (Y4R) = 614 nM) and (S,S)-5.31 
(Ki (Y4R) = 725 nM) proved to be equipotent with the R-configured enantiomers (R,R)-5.1 and 
(R,R)-5.31, respectively.  
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Figure 5: Inhibition of the PP (100 nM) stimulated Ca2+ response on CHO-hY4R-mtAEQ-Gqi5 cells. Mean 
values ± SEM were from at least 3 independent experiments (performed in triplicate).  
Additionally, (S,S)-5.31 and (R,R)-5.31 were investigated for Y4R antagonism in an aequorin 
Ca2+ assay. Like UR-MK188, both compounds antagonized the effect of PP at the Y4R. The Kb 
values were 453 nM ((R,R)-5.31) or 368 nM ((S,S)-5.31), respectively. In summary, the 
replacement of the R-configured argininamide moieties by the S-configured enantiomers is a 
convenient way to shift the selectivity of this type of ligands from Y1R to Y4R. 
The Ki values determined for the bivalent ligands (R/S)-5.34 and (R/S)-5.35 at the Y4R were in 
the one-digit micromolar range. Moreover, (R/S)-5.34 was not Y4R selective, as the affinity to 
the Y2R (Ki = 864 nM) was increased. The Ki value of (R/S)-5.35 (Ki (Y4R) = 1460 nM) was in 
the same range as those of the UR-MK188 derived bivalent ligands ((R,R)/(S,S)-5.1, (S,S)-
5.31, (R,R)-5.28-5.32). Apparently, carbamoylation of the guanidine residues as well as the 4-
(aminomethyl)phenol moieties are not crucial for interaction with the receptor. Y4R affinity 
was not increased by the exchange of the linker attachment position. However, the synthetic 
accessibility was improved, simplifying structural variations at the diphenylacetic acid 
residues. 
The heterodimeric ligand all-S-5.33 (Figure 6) takes a special role among the investigated 
compounds. All-S-5.33 comprises two different pharmacophores: a part that is derived from 
the antagonist UR-MK188 and a peptide that was described as Y4R agonist.
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Figure 6: Heterodimeric Y4R ligand all-S-5.33 
The affinity of all-S-5.33 (Ki (Y4R) = 332 nM) was slightly lower than that of UR-MK188. 
Functional experiments revealed that all-S-5.33 is an agonist that elicits a higher maximal 
response (EMax = 2.15 (aequorin assay), EMax = 1.95 (DMR assay)) than the endogenous ligand 
PP (aequorin assay) or the modified endogenous ligand K4hPP (dynamic mass redistribution 
assay). In both cases, EC50 values (EC50 = 488 nM (Aequorin assay), EC50 = 483 nM (DMR 
assay)) were in good agreement with the Ki value.  
 
Figure 7: Y4R agonism of all-S-5.33 and PP or K
4hPP determined in an aequorin Ca2+ assay and a 
dynamic mass redistribution (DMR) assay. (A) Concentration response curves from an aequorin assay 
on CHO-hY4R-mtAEQ-Gqi5 cells. Mean values ± SEM were from at least 3 independent experiments 
(performed in triplicate). (B) Concentration response curves from a dynamic mass redistribution 
assay on CHO-hY4R-mtAEQ-Gqi5 cells. Mean values ± SEM were from at least 3 independent 
experiments (performed in triplicate). 
Compounds eliciting a higher maximal functional response than the endogenous agonists are 
referred to as superagonists. Superagonism is a phenomenon that has been rarely described 
for GPCR ligands9-11. Overall, GPCRs should have substantial conformational freedom to 
achieve degrees of activation that are higher than the natural state that is formed by the 
complex of receptor and endogenous ligand. However, it remains unclear whether the 
occurance of superagonism in cell based functional assays has any physiological relevance, 
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since the activation of only a fraction of receptors might be sufficient to elicit the full 
response in vivo. 
Recently we demonstrated that the affinity of Y4R ligands is affected by the concentration of 
sodium ions in the binding buffer.4 The affinity of Y4R agonists was increased in the absence 
of sodium ions, whereas the affinity of the antagonist UR-MK188 was reduced. The same 
trend was observed for all UR-MK188 derived bivalent ligands and the homodimeric 
compounds (R/S)-5.34 and (R/S)-5.35 described in this chapter. For example, the Ki values of 
(R,R)-5.1 (Ki = 859 nM (L-15 medium), Ki = 3270 nM (sodium free buffer)) or (R/S)-5.35 (Ki = 
1460 nM (L-15 medium), Ki = 3470 nM (sodium free buffer)) were lower in the sodium 
containing L-15 medium than in the sodium free buffer. In contrast, the superagonist all-S-
5.33 had a three-fold higher affinity in sodium free buffer compared to L-15 medium. 
 
  
Table 1. NPY receptor binding and functional dataa 
 Y1R Y2R Y4R 
 
  Y5R 
Linker length
h 
Compd. Ki [nM]
a 
Ki [nM]
b 
Ki [nM]
c
 Ki [nM]
d 
Kb [nM]
e EC50 [nM]
f 
Ki [nM]
g 
UR-MK188 24i 1100i 150k 660k 20i - >5000i 41 
(R,R)-5.28 225 ± 80 >10000 2020 ± 240 2980 ± 1800 - - >10000 22 
(R,R)-5.29 500 ± 188 >10000 1300 ± 260 3750 ± 500 - - >10000 28 
(R,R)-5.1 82 ± 38 4950 ± 1100 859 ± 99 3270 ± 1300 - - >10000 21 
(S,S)-5.1 3880 ± 810 2690 ± 1000 614 ± 58 1890 ± 220 - - >10000 21 
(R,R)-5.30 99 ± 3 >10000 2960 ± 340 >10000 - - >10000 40 
(R,R)-5.31 41 ± 6 5570 ± 1500 577 ± 100 3750 ± 540 453 ± 140 - >10000 27 
(S,S)-5.31 5320 ± 950 5540 ± 2200 725 ± 100 2960 ± 380 368 ± 110 - >10000 27 
(R,R)-5.32 80 ± 14 >10000 1090 ± 130  6100 ± 3600 - - >10000 39 
(R/S)-5.34 1510 ± 340 864 ± 210 4030 ± 1300 >10000 - - >10000 20 
(R/S)-5.35 683 ± 180 9420 ± 4000 1460 ± 370 3470 ± 1800 - - >10000 37 
All-S-5.33 2060 ± 490 4950 ± 870 332 ± 100 116 ± 33 488 ± 49 (EC50) 483 ± 167 1290 ± 150 - 
aRadioligand competition binding assay with [3H]UR-MK1366 (Kd = 6.2 nM, c = 4 nM) using MCF-7-hY1 cells.
 1212 bRadioligand competition binding assay with 
[3H]propionyl-pNPY13 (Kd = 1.4 nM, c = 1 nM) using CHO-hY2-Gqi5-mtAEQ cells.
14 cRadioligand competition binding assay with [3H]2.10 4 (Kd = 9.8 nM, c = 10 
nM) using CHO-hY4R-Gqi5-mtAEQ cells
5 in L-15 medium. dRadioligand competition binding assay with [3H]2.10 (Kd = 0.67 nM, c = 0.6 nM) using CHO-hY4R-Gqi5-
mtAEQ cells in buffer I. eAequorin calcium mobilization assay on CHO-hY4-Gqi5-mtAEQ cells.
5 fDynamic mass redistribution assay on CHO-hY4-Gqi5-mtAEQ 
cells. gRadioligand competition binding assay with [3H]propionyl-pNPY (Kd = 4.83 nM, c = 4 nM) using HEC-1b hY5R cells
15. hNumber of atoms separating the 
guanidine moieties of the bivalent ligands. iKi value reported by Berlicki et al.
8 kKi value reported by Kuhn et al.
4 
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5.4  Conclusions 
The most potent Y4R antagonist UR-MK188 known so far was used as a lead structure to 
explore the potential of dimeric ligands with truncated, conformationally constrained 
linkers. Aromatic substructures in the core of the linker were tolerated, and a truncation of 
the linker length from 39 to 21 atoms did not affect Y4R affinity. An exchange of the linker 
attachment position from the guanidine group to the carboxylic acid of the arginine was 
tolerated with respect to Y4R affinity. All-S-5.33 is the first Y4R agonist capable of activating 
the receptor with a higher efficacy than the endogenous ligand PP. However, additional 
experiments, e.g. cytotoxicity assays, functional assays with different readouts in the 
presence or absence of an antagonist as well as functional assays at wild type cells should be 
performed to confirm superagonism and to exclude off-target effects. 
 
5.5  Experimental Section 
5.5.1  General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers and used without further 
purification unless otherwise indicated. MeCN for HPLC (gradient grade), mercury(II) 
chloride, glycine, thionyl chloride, formic acid and 1,4-benzenedimethanamine were 
purchased form Merck (Darmstadt, Germany), HOBt (98%, contains 11-16% H2O) and 
diphenylacetic acid were from Acros Organics/Fisher Scientific (Nidderau, Germany). 
Trifluoroacetic acid, palladium on activated charcoal (loading 10%), trimethylamine, 
triphosgene, carbonyldiimidazole, tert-butyl bromoacetate and diisopropyl carbodiimide 
were obtained from Sigma Aldrich (Deisenhofen, Germany), N,N-diisopropylethylamine 
(DIPEA) (99%) was from ABCR (Karlsruhe, Germany). Triglycine (99%) and boc anhydride 
were from Alfa Aesar (Karlsruhe, Germany). Fmoc-Arg(Pbf)-OH, Fmoc-D-Arg(Pbf)-OH, HBTU 
and TBTU were from Iris Biotech (Marktredwitz, Germany). Bovine serum albumin and 
bacitracin were from Serva (Heidelberg, Germany), human pancreatic polypeptide and 
porcine neuropeptide Y were from Synpeptide (Shanghai, China). Compounds 5.23 and 5.53 
were synthesized and provided by Dr. Max Keller (University of Regensburg, Germany). The 
synthesis of [3H]2.104 and [3H]propionyl-pNPY13 was previously described. Millipore water 
was used throughout for the preparation of buffers and HPLC eluents. Polypropylene 
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reaction vessels (1.5 or 2 mL) with screw cap (Süd-Laborbedarf, Gauting, Germany) were 
used for the storage of stock solutions. TL chromatography was performed on Merck silica 
gel 60 F254 TLC aluminum plates, silica gel 60 (40-63 µm, Merck) was used for column 
chromatography. Visualization was accomplished by UV light ( = 254 nm or 366 nm). NMR-
spectra were recorded on a Bruker Avance 300 (7.05 T, 1H: 300.1 MHz, 13C: 75.5 MHz), a 
Bruker Avance III HD 400 (1H: 400 MHz, 13C: 101 MHz) or a Bruker Avance 600 instrument 
with cryogenic probe (14.1 T, 1H: 600.3 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany). 
Mass spectra were recorded on a Finnigan MAT95 (EI-MS 70eV) or a Finnigan MAT SSQ 710 
A (CI-MS (NH3)). For HRMS an Agilent Q-TOF 6540 UHD (Agilent, Waldbronn, Germany) 
equipped with an ESI source was used. Preparative HPLC was performed on a system from 
Knauer (Berlin, Germany) consisting of two K-1800 pumps, a K-2001 detector and a RP-
column (Kinetex-XB C18, 5 µm, 250 mm × 21 mm, Phenomenex, Aschaffenburg, Germany or 
Nucleodur-100 C18, 250 mm × 21 mm, Macherey-Nagel, Düren) at a flow-rate of 15 mL/min 
using mixtures of acetonitrile and 0.1% aqueous TFA solution as mobile phase. A detection 
wavelength of 220 nm was used throughout. The collected fractions were lyophilised using 
an alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany) equipped with a RZ 6 
rotary vane vacuum pump (vacuubrand, Wertheim, Germany). Analytical HPLC analysis was 
performed on a system from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of a L-
6200-A pump, a AS-2000A autosampler, a L-4000A UV detector, a D-6000 interface and a RP-
column (Kinetex-XB C18, 5 µm, 250 mm × 4.6 mm, Phenomenex, Aschaffenburg, Germany or 
Eurospher-100 C18 column, 250 mm × 4 mm, 5 µm, Knauer, Berlin) at a flow rate of 0.8 
mL/min. Mixtures of acetonitrile (A) and 0.1% aqueous TFA solution (B) were used as mobile 
phase. The following gradient was applied: A/B: 0-25 min: 20:80 - 95:5, 25-35 min: 95:5 - 
95:5. Detection was performed at 220 nm, the oven temperature was 30 °C. 
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5.5.2  Chemistry: Experimental Protocols and Analytical Data 
(2R)-2-(2,2-Diphenylacetamido)-5-{[({[3-(2-{7-[({3-[({N-[(4R)-4-(2,2-diphenylacetamido)-4-
{[(4-hydroxyphenyl)methyl]carbamoyl}butyl]carbamimidoyl}carbamoyl)amino]propyl}-
carbamoyl)methyl]-1H,7H-imidazo[4,5-f]benzimidazol-1-yl}acetamido)propyl]carbamoyl}-
amino)methanimidoyl]amino}-N-[(4-hydroxyphenyl)methyl]pentanamide ((R,R)-5.1). 5.18 
(9.7 mg, 25 µmol) was suspended in anhydrous DMF (0.6 mL). TBTU (18 mg, 2.2 equiv) and 
DIPEA (9 µL, 2 equiv) were added, and the mixture was stirred for 15 min leading to the 
dissolution of the suspended starting material. A solution of (R)-5.13 (50 mg, 2.5 equiv) and 
DIPEA (23 µL, 5 equiv) in anhydrous DMF (0.4 mL) was added and the mixture was subjected 
to microwave irradiation (70 °C, 30 min). The desired compound was purified by preparative 
HPLC (column: Nucleodur-100 C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 
14:86–62:38, tR = 14.7 min). Lyophilisation of the eluate afforded (R,R)-5.13 as a white fluffy 
solid (6 mg, 15%). 1H-NMR (600 MHz, COSY, [D4]methanol): δ (ppm) 1.45 – 1.60 (m, 4H), 1.66 
– 1.76 (m, 6H), 1.78 – 1.86 (m, 2H), 3.13 – 3.24 (m, 8H), 3.27 – 3.34 (m, overlap with solvent, 
4H), 4.22 (q, 4H, J 14.6 Hz, 10.8 Hz), 4.41 (q, 2H, J 5.8 Hz, 2.7 Hz), 5.07 (s, 2H), 5.20 (s, 4H), 
6.67 (d, 4H, J 8.6 Hz), 7.02 (d, 4H, J 8.6 Hz), 7.19 – 7.39 (m, 20H), 7.98 (s, 1H), 8.10 (s, 1H), 
8.88 (s, 2H). 13C-NMR (150.9 MHz, HSQC, HMBC, [D4]methanol): δ (ppm) 25.7 (2 carb.), 30.1 
(2 carb.), 30.2 (2 carb.), 37.8 (2 carb.), 37.9 (2 carb.), 41.7 (2 carb.), 43.7 (2 carb.), 49.6 (2 
carb.), 54.4 (2 carb.), 58.7 (2 carb.), 94.6, 105.3, 116.3 (4 carb.), 128.1 (4 carb.), 128.2 (4 
carb.), 129.5 (4 carb.), 129.6 (4 carb.), 129.8 (4 carb.), 129.9 (4 carb.), 130.3 (2 carb.), 133.2 
(2 carb.), 136.9 (2 carb.), 140.8 (2 carb.), 140.9 (2 carb.), 155.6 (4 carb.), 157.8 (2 carb.), 
168.0 (2 carb.), 173.4 (2 carb.), 174.88 (2 carb.). RP-HPLC (220 nm): 99% (tR = 13.4 min, k = 
3.7). LRMS (ESI): m/z (%) 693.34 (15) [M+2H]2+, 462.56 (100) [M+3H]3+. HRMS (ESI): m/z 
[M+H]+ calcd. for C74H85N18O10
+: 1385.6691, found: 1385.6695. C74H84N18O10 · C4H2F6O4 
(1385.60 + 228.04). 
(2S)-2-(2,2-Diphenylacetamido)-5-{[({[3-(2-{7-[({3-[({N-[(4S)-4-(2,2-diphenylacetamido)-4-
{[(4-hydroxyphenyl)methyl]carbamoyl}butyl]carbamimidoyl}carbamoyl)amino]propyl}-
carbamoyl)methyl]-1H,7H-imidazo[4,5-f]benzimidazol-1-yl}acetamido)propyl]carbamoyl}-
amino)methanimidoyl]amino}-N-[(4-hydroxyphenyl)methyl]pentanamide ((S,S)-5.1). 
Compound (S,S)-5.1 was synthesized from 5.18 and (S)-5.13 (50 mg, 62 µmol) by analogy 
with the procedure for the preparation of (R,R)-5.1. The desired compound was obtained as 
  
 
152  Chapter 5 
 
a white lyophilisate (9.2 mg, 23%). The spectroscopic data were identical to those for (R,R)-
5.1. RP-HPLC (220 nm): >99% (tR = 14.0 min, k = 3.9). 
(2R)-5-Amino-N-{[4-(tert-butoxy)phenyl]methyl}-2-(2,2-diphenylacetamido)pentanamide 
((R)-5.7).
3
 Pd/C-catalyst (0.35 g) was added a suspension of (R)-5.6 (3.50 g, 5.63 mmol) in 
MeOH (30 mL). The mixture was stirred vigorously under hydrogen (reaction vessel was 
connected to a hydrogen balloon). The progress of the reaction could be observed, since the 
product dissolved in MeOH, whereas the starting material was poorly soluble. After 
completion of the hydrogenation (monitored by TLC (CH2Cl2/MeOH (10:1)), the solids were 
removed by filtration through celite, the volume was reduced on a rotary evaporator and 
the residue was dried in vacuum to yield (R)-5.7 (2.49 g, 91%) as a pale grey foam. 1H-NMR 
(300 MHz, [D6]DMSO): δ (ppm) 1.19 – 1.39 (m, 12H), 1.44 – 1.75 (m, 3H), 4.12 – 4.24 (m, 2H), 
4.29 (q, 1H, J 7.9 Hz, 6.0 Hz), 5.11 (s, 1H), 6.81 – 6.91 (m, 2H), 7.05 – 7.13 (m, 2H), 7.16 – 7.37 
(m, 10H), 8.39 – 8.55 (m, 2H). LRMS (ESI): m/z (%) 488.29 (100) [M+H]+. C30H37N3O3 (487.64). 
(2S)-5-Amino-N-{[4-(tert-butoxy)phenyl]methyl}-2-(2,2-diphenylacetamido)pentanamide 
((S)-5.7).
1
 Compound (S)-5.7was synthesized from (S)-5.6 (1.89 g, 3.04 mmol) by analogy 
with the procedure for the preparation of (R)-5.7. The desired compound was obtained as 
white foam (1.06 g, 72%). The spectroscopic data were identical to those for  (R)-5.7. 
tert-Butyl N-[(methylsulfanyl)methanimidoyl]carbamate (5.9).
16
 S-Methylisothiourea 
hydroiodide (2.3 g, 10.55 mmol) and TEA (1 equiv) were dissolved in chloroform (25 mL). A 
solution of Boc anhydride (2.3 g, 1 equiv) in chloroform (15 mL) was added over a period of 
30 min, and the mixture was stirred at room temperature overnight. After completion of the 
reaction, the mixture was washed with water (30 mL) and brine (20 mL). The solvent was 
removed under reduced pressure, and the residue was taken up in EtOAc/PE (1:2, 5 mL). The 
desired compound was purified by column chromatography (EtOAc/PE (1:5  1:1)). The Boc 
protected intermediate was obtained as a white solid (1.1 g, 55%). TLC (PE/EtOAc 1:1): Rf = 
0.52. TM 77 °C. 
1H-NMR (300 MHz, CDCl3): δ (ppm) 1.50 (s, 9H), 2.45 (s, 3H). LRMS (ESI): m/z 
(%) 191.08 (10) [M+H]+, 135.02 (100) [M-C4H8]
+. C7H14N2O2S (190.26). 
tert-Butyl N-(3-aminopropyl)carbamate (5.10).
17
 1,3-Diaminopropane (7.4 g, 100 mmol) was 
dissolved in chloroform (20 mL). After addition of a catalytic amount of TEA, a solution of 
Boc anhydride (2.18 g, 10 mmol) in chloroform (15 mL) was added dropwise over 30 min, 
and the mixture was stirred at room temperature for 40 h. The solvent was removed under 
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reduced pressure, and the residue was taken up in EtOAc (100 mL). The solution was washed 
with saturated aqueous NaHCO3 solution (50 mL), H2O/brine (2:1, 50 mL) and brine (30 mL). 
The organic layer was dried over MgSO4, and the solvent was removed under reduced 
pressure. Drying of the residue in vacuo afforded the desired Boc protected diamine as a 
yellowish oil (1.1 g, 63%). 1H-NMR (300 MHz, CDCl3): δ (ppm) 1.36 (s, 9H), 1.48 – 1.62 (m, 
2H), 2.70 (t, 2H, J 6.6 Hz), 3.05 – 3.18 (m, 2H). GCMS (CI (NH3)) : m/z (%) 175.1 (100) [M+H]+, 
118.0 (40) [M-C4H8]
+. C8H18N2O2 (174.24). 
N-tert-Butoxycarbonyl-N‘-[N-(3-tert-butoxycarbonylaminopropyl)aminocarbonyl]-S-
methylisothiourea (5.12).
18
 All used glass materials were dried in an oven at 120 °C, starting 
materials had been stored in a desiccator. Triphosgene (0.86 g, 2.9 mmol) was dissolved in 
anhydrous CH2Cl2 (15 mL) at room temperature. A solution of 5.10 in anhydrous CH2Cl2 (25 
mL) was added dropwise over 30 min. Subsequently, a solution of 5.9 in anhydrous CH2Cl2 
(15 mL) was added in one portion, and the mixture was stirred for 3 h. After completion, the 
mixture was concentrated to a volume of approximately 5 mL and subjected to column 
chromatography (CH2Cl2/EtOAc, 50:1  1:1). Fractions containing product and starting 
material were collected and subjected to column chromatography using the same gradient 
again. Evaporation of the solvent yielded the desired compound as a yellow, highly viscous 
oil (1.15 g, 55.6%). TLC (PE/EtOAc 1:1): Rf = 0.44. 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 
1.37 (s, 9H), 1.44 (s, 9H), 1.53 (dt, 2H, J  16.3, 8.1 Hz, 2H), 2.22-2.33 (m, 3H), 2.90 (dt, 2H, J 
13.6, 6.9 Hz), 3.03 (q, 2H, J  6.7 Hz), 6.76 (dt, 2H, J  11.6, 5.6), 7.75 (t, 1H, J  5.9 Hz). 13C-NMR 
(75.5 MHz, [D6]DMSO): δ (ppm) 13.5, 27.5, 28.1, 29.5, 37.0, 37.5, 77.3, 82.0, 150.1, 155.5, 
161.1, 164.7. LRMS (ESI): m/z (%) 391.20 (100) [M+H]+, 291.15 (10) [M-Boc]+. HRMS (ESI): 
m/z [M+H]+ calcd. for C16H31N4O5S
+: 391.2009, found: 391.2010. C16H30N4O5S (390.50). 
(R)-5-{3-[(3-aminopropyl)carbamoyl]guanidino}-2-(2,2-diphenylacetamido)-N-(4-
hydroxybenzyl)pentanamide ((R)-5.13). (R)-5.7 (0.24 g, 0.49 mmol) and 5.12 (0.21 g, 0.54 
mmol) were dissolved in anhydrous DMF (12 mL). DIPEA (1.2 equiv), and HgCl2 (0.2 g, 1.5 
equiv) was added which caused the formation of a white precipitate. The mixture was stirred 
at room temperature for 16 h. The solids were separated by centrifugation, and the 
supernatant was diluted with water (200 mL) and extracted with EtOAc (3 x 150 mL). The 
combined organic layers were dried over MgSO4, concentrated to a volume of about 5 mL on 
a rotary evaporator and subjected to column chromatography (CH2Cl2/EtOAc (2:1)). After 
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evaporation of the solvent, the protected intermediate was obtained as a white, glue-like 
solid that was dissolved in TFA/CH2Cl2/H2O (10:10:1, 10 mL) and stirred at room temperature 
for 2.5 h. After completion, the mixture was diluted with CH2Cl2 (100 mL), and the solvents 
were removed under reduced pressure. This procedure was repeated three times with 
CH2Cl2. The residue was taken up in water (150 mL) and subjected to lyophilization. The title 
compound was obtained as a white, hygroscopic lyophilisate (0.22 mg, 57%). 1H-NMR (75.5 
MHz, [D4]methanol): δ (ppm) 1.32 – 1.60 (m, 4H), 1.65 – 1.77 (m, 2H), 2.73 – 2.86 (m, 2H), 
3.10 – 3.15 (m, 4H), 4.06 – 4.23 (m, 2H), 4.27 – 4.38 (m, 1H), 5.13 (s, 1H), 6.61 – 7.04 (m, 4H), 
7.17 – 7.33 (m, 10H). 13C-NMR (300 MHz, [D4]methanol): δ (ppm) 25.7, 28.7, 30.3, 37.6, 38.3, 
41.7, 43.7, 54.3, 58.7, 116.3, 128.1, 128.2, 129.5, 129.6, 129.8, 129.9, 130.0, 130.3, 140.8, 
140.9, 155.7, 156.0, 157.8, 173.4, 174.9. LRMS (ESI): m/z (%) 574.31 (20) [M+H]+, 287.66 
(100) [M+2H]2+. HRMS (ESI): m/z [M+H]+ calcd. for C31H40N7O4
+: 574.3136, found: 574.3131. 
C31H39N7O4 · C4H2F6O4 (573.70 + 228.04). 
(S)-5-{3-[(3-aminopropyl)carbamoyl]guanidine}-2-(2,2-diphenylacetamido)-N-(4-
hydroxybenzyl)pentanamide ((S)-5.13). Compound (S)-5.13 was synthesized from (S)-5.7 
(0.3 g, 0.61 mmol) by analogy with the procedure for the preparation of (R)-5.13. The 
desired compound was obtained as a white lyophilisate (0.25 g, 51%). The spectroscopic 
data were identical to those for (R)-5.13. 
1,5-Dihydrobenzo[1,2-d:4,5-d']diimidazole (5.15).
19
 Benzene-1,2,4,5-tetraamine 
tetrahydrochloride (710 mg, 2.52 mmol) was dissolved in formic acid (35 mL) and stirred at 
100 °C for 30 h. The reaction mixture was allowed to cool down to ambient temperature, 
and the volume was concentrated to about 1 mL on a rotary evaporator. Addition of 
aqueous NaHCO3 solution caused the precipitation of the product, which was collected by 
filtration, washed with cold water and dried in vacuo. The title compound was obtained as a 
pale brown solid (0.44 g, 110%). TM > 300°C. 
1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 7.68 (s, 
2H), 8.20 (s, 2H), 12.23 (s, 2H). LRMS (ESI): m/z (%) 159.07 (100) [M+H]+, 80.04 (20) 
[M+2H]2+. C8H6N4 (158.16). 
2,2'-(Benzo[1,2-d:4,5-d']diimidazole-1,7-diyl)diacetic acid (5.18). 5.15 (85 mg, 0.54 mmol) 
was dissolved in anhydrous DMF (4 mL). NaH (60% suspension, 52 mg, 2.4 equiv) was added, 
and the mixture was stirred at 80 °C for 20 min. After cooling down to 60 °C, tert-butyl 
bromoacetate (214.5 mg, 2.04 equiv) was added dropwise over 10 min, and stirring was 
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continued for 2 h. Water (80 mL) was added, and the mixture was extracted with EtOAc (3 × 
50 mL). The combined organic layers were washed with water (50 mL) and water/brine (1:3, 
25 mL), and the volatiles were removed under reduced pressure. The residue was taken up 
in CH2Cl2/MeOH (10:1) and subjected to column chromatography (eluent: CH2Cl2/MeOH 
(20:1). Two fractions were isolated containing the desired product (5.17) and the 
corresponding 1,5-disubstituted isomer (5.16). Removal of the solvent from the second 
fraction under reduced pressure and drying in vacuo gave the desired 1,7-disubstituted tert-
butyl protected intermediate as a pale yellow solid that was dissolved in TFA/CH2Cl2/H2O 
(10:10:1, 4.2 mL) and stirred at room temperature for 4 h. After completion of deprotection, 
the mixture was diluted with CH2Cl2 (30 mL), and the solvents were removed under reduced 
pressure. This procedure was repeated three times with CH2Cl2. The residue was suspended 
in MeOH (10 mL) and sonicated for 5 min. Diethyl ether (10 mL) was added ,and the mixture 
was stored in a freezer overnight. The solids were collected by filtration, washed with ice-
cold diethyl ether and dried in vacuo to give the desired diacid 5.18 as a pale yellow solid (33 
mg, 22%). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 5.15 (s, 4H), 7.82 (s, 1H), 7.90 (s, 1H), 8,32 
(s, 2H), 13.26 (s, 2H). 13C-NMR (75.5 MHz, [D6]DMSO): δ (ppm) 45.6 (2 carb.), 90.3, 107.4, 
132.2 (2 carb.), 139.4 (2 carb.), 145.3 (2 carb.), 169.7 (2 carb.). HRMS (ESI): m/z [M+H]+ calcd. 
for C12H11N4O4
+: 275.0775, found: 275.0777. C12H10N4O4 (274.24). 
Glycine methyl ester hydrochloride.20 To a suspension of glycine (1.96 g, 26.1 mmol) in 
MeOH (10 mL) was added SOCl2 (3 equiv) dropwise under ice cooling. Subsequently, the 
mixture was stirred under reflux for 2 h. The volatiles were evaporated in vacuo to give 
glycine methyl ester hydrochloride as a white solid (3.15 g, 96.6%). TM = 176 °C. 
1H-NMR (300 
MHz, [D4]methanol): δ (ppm) 3.83 (s, 3H), 3.85 (s, 2H). C3H8ClNO2 (125.55). 
2,2'-[(Biphenyl-4,4'-dicarbonyl)bis(azanediyl)]diacetic acid (5.19). Biphenyl-4,4'-dicarboxylic 
acid (29 mg, 0.12 mmol) was suspended in anhydrous DMF (1 mL). The dicarboxylic acid 
dissolved upon addition of CDI (42.8 mg, 2.2 equiv) and DIPEA (42 µL, 2 equiv). The mixture 
was stirred at room temperature for 10 min. After addition of glycine methyl ester 
hydrochloride (60 mg, 4 equiv) and DIPEA (64 µL, 3 equiv), the temperature was raised to 70 
°C and stirring was continued for 3 h. After completion of the reaction (monitored by TLC 
(CH2Cl2/MeOH 10:1)), the mixture was quenched with water (15 mL) and extracted with 
EtOAc (3 x 10 mL). The combined organic layers were washed with water (10 mL) and 
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water/brine (2:8, 10 mL). The volatiles were removed under reduced pressure, and the 
residue was dried in vacuo overnight. The methyl-protected intermediate was suspended in 
a mixture of MeOH (2 mL) and 10% aqueous NaOH solution (0.4 mL) and stirred under ice 
cooling for 3 h. During the reaction, the suspended starting material dissolved slowly. After 
completion of the reaction (monitored by TLC (CH2Cl2/MeOH (5:1)), the mixture was filtered 
through celite. When the pH of the filtrate was adjusted to a value of 3 with 1 N HCl solution 
a white solid precipitated. After storage in a refrigerator for 2 d, the solids were collected by 
filtration, suspended in 0.1% aqueous TFA solution (10 mL) and subjected to lyophilization. 
Compound 5.19 was obtained as a white lyophilisate (16 mg, 37%). 1H-NMR (300 MHz, 
[D6]DMSO): δ (ppm) 3.95 (d, 4H J  5.9 Hz), 7.88 (d, 4H, J  8.5 Hz), 8.00 (d, 4H, J  8.5 Hz), 8.95 
(t, 2H, J  5.9 Hz), 12.62 (s, 2H). 13C-NMR (75.5 MHz, [D6]DMSO): δ (ppm) 41.1 (2 carb.), 126.7 
(2 carb.), 127.9 (2 carb.), 133.0 (2 carb.), 141.7 (2 carb.), 165.9 (2 carb.), 171.2 (2 carb.). 
LRMS (ESI): m/z (%) 713.21 (5) [2M+H]+, 357.11 (100) [M+H]+. HRMS (ESI): m/z [M+H]+ calcd. 
for C18H17N2O7
+: 3571081, found: 357.1083. C18H16N2O6 (356.33). 
N-tert-Butoxycarbonyl-glycine (5.20).
21
 Glycine (80 mg, 1.06 mmol) and DIPEA (275 µL, 1.5 
equiv) were dissolved in H2O/dioxane (1:1, 10 mL). A solution of Boc anhydride (232 mg, 1 
equiv) in dioxane (1 mL) was added, and the mixture was stirred at room temperature for 6 
h. The volatiles were removed on a rotary evaporator, and the residue was taken up in H2O 
(20 mL). The aqueous phase was washed with ether (20 mL), acidified with 1 N HCl solution 
to a pH value of 2 and extracted with EtOAc (2 × 20 mL). The volatiles were removed under 
reduced pressure, and the title compound was obtained as white solid (140 mg, 75%). 1H-
NMR (300 MHz, MeOD): δ (ppm) 1.44 (s, 9H), 3.75 (s, 2H). LRMS (ESI): m/z (%) 349.15 (55) 
[2M-H]-, 174.07 (100) [M-H]-. C7H13NO4 (175.18). 
N-tert-Butoxycarbonyl-glycylglycylglycine (5.21).
22 Triglycine (100 mg, 0.53 mmol) and 
DIPEA (138 µL, 1.5 equiv) were dissolved in H2O/dioxane (1:1, 5 mL). A solution of Boc 
anhydride (116 mg, 1 equiv) in dioxane (1 mL) was added, and the mixture was stirred at 
room temperature for 6 h. The volatiles were removed on a rotary evaporator, and the 
residue was taken up in H2O (20 mL). The aqueous phase was washed with ether (20 mL), 
acidified with 1 N HCl solution to a pH value of 2 and extracted with EtOAc (2 × 20 mL). The 
volatiles were removed under reduced pressure, and the title compound was obtained as 
white glue-like solid (63 mg,  41%). 1H-NMR (400 MHz, [D6]DMSO): δ (ppm) 1.38 (s, 9H), 3.58 
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(d, 2H, J 6.0 Hz), 3.71 – 3.78 (m, 4H), 6.99 (t, 1H, J 5.8 Hz), 8.05 (t, 1H, J 5.7 Hz), 8.13 (t, 1H, J 
5.8 Hz). 13C-NMR (400 MHz, [D6]DMSO): δ (ppm) 28.6 (3 carb.), 41.0, 42.2, 43.8, 78.6, 156.3, 
169.6, 170.1, 171.5. LRMS (ESI): m/z (%) 579.26 (40) [2M+H]+, 290.13 (30) [M+H]+, 234.07 
(100) [M-C8H8]
+, 190.08 (50) [M-Boc]+. C11H19N3O6 (289.29). 
(2R)-5-{[({[3-(2-Aminoacetamido)propyl]carbamoyl}amino)methanimidoyl]amino}-2-(2,2-
diphenylacetamido)-N-[(4-hydroxyphenyl)methyl]pentanamide di(hydrotrifluoroacetate) 
((R)-5.22). Compound 5.20 (32.8 mg, 0.188 mmol) and DIPEA (1 equiv) were dissolved in 
anhydrous DMF (1 mL). CDI (33 mg, 1.1 equiv) was added, and the mixture was stirred at 
room temperature under argon atmosphere for 15 min. A solution of (R)-5.13 (100 mg, 
0.125 mmol) and DIPEA (1 equiv) in anhydrous DMF (0.5 mL) was added, and stirring was 
continued at 80 °C for 2 h. The protected intermediate was purified by preparative HPLC 
(column: Nucleodur-100 C18 250 × 21 mm; gradient: 0–18 min: MeCN/0.1% aq TFA 24:76–
52:48, tR = 16.2 min). After removal of the solvents on a rotary evaporator followed by 
lyophilisation, the intermediate was taken up in CH2Cl2/TFA/H2O (10:10:1, 5 mL) and stirred 
at room temperature for 3 h. After completion of deprotection, the mixture was diluted with 
CH2Cl2 (30 mL), and the solvents were removed under reduced pressure. This procedure was 
repeated three times with CH2Cl2. The residue was taken up in water (50 mL). Lyophilisation 
afforded (R)-5.22 as a white fluffy solid (45 mg, 42%). 1H-NMR (600 MHz, COSY, 
[D4]methanol): δ (ppm) 1.50 – 1.63 (m, 2H), 1.67 – 1.78 (m, 3H), 1.81 – 1.88 (m, 1H), 3.18 – 
3.34 (m, overlap with solvent, 6H), 3.66 (s, 2H), 4.25 (q, 2H, J 14.6, 5.8), 4.43 (q, 1H, J 6.1, 
2.6), 5.07 (s, 1H), 6.71 (d, 2H, J 8.6 Hz), 7.06 (d, 2H, J 8.6 Hz), 7.22 – 7.32 (m, 10H). 13C-NMR 
(150.9 MHz, HSQC, HMBC, [D4]methanol): δ (ppm) 25.7, 30.3 (2 carb.), 37.9, 38.2, 41.4, 41.7, 
43.7, 54.2, 58.7, 116.3 (2 carb.), 128.1 (2 carb.), 128.2 (2 carb.), 129.5 (2 carb.), 129.6 (2 
carb.), 129.8 (2 carb.), 129.9 (2 carb.), 130.0 (2 carb.), 130.3, 140.8, 140.9, 155.7 (2 carb.), 
157.9, 167.3, 173.3, 174.9. LRMS (ESI): m/z (%) 631.34 [M+H]+ (25), 316.17 [M+2H]2+ (100). 
HRMS (ESI): m/z [M+H]+ calcd. for C33H43N8O5
+: 631.3351, found: 631.3354. C33H42N8O5 · 
C4H2F6O4 (630.75 + 228.04). 
(2S)-5-{[({[3-(2-Aminoacetamido)propyl]carbamoyl}amino)methanimidoyl]amino}-2-(2,2-
diphenylacetamido)-N-[(4-hydroxyphenyl)methyl]pentanamide di(hydrotrifluoroacetate) 
((S)-5.22). Compound (S)-5.22 was synthesized from 5.20 and (S)-5.13 (100 mg, 0.125 mmol) 
by analogy with the procedure for the preparation of (R)-5.22. The desired compound was 
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obtained as a white lyophilisate (51 mg, 48%). The spectroscopic data were identical to 
those for (R)-5.22. 
(2R)-5-[({[(3-{2-[2-(2-Aminoacetamido)acetamido]acetamido}propyl)carbamoyl]amino}-
methanimidoyl)amino]-2-(2,2-diphenylacetamido)-N-[(4-hydroxyphenyl)methyl]pentan-
amide ((R)-5.23). Compound 5.21 (31.1 mg, 0.1 mmol), TBTU (35.3 mg, 1.1 equiv) and DIPEA 
(10 µL, 1 equiv) were dissolved in anhydrous DMF (0.6 mL) and the mixture was stirred in a 
microwave vial under argon atmosphere at room temperature for 15 min. After addition of a 
solution of (R)-5.13 (80 mg, 1 equiv) and DIPEA (10 µL, 1 equiv) in anhydrous DMF (0.4 mL), 
the mixture was subjected to microwave irradiation (70 °C, 2 h). The Boc-protected 
intermediate was purified by preparative HPLC (column: Nucleodur-100 C18 250 × 21 mm; 
gradient: 0–18 min: MeCN/0.1% aq TFA 24:76–52:48, tR = 14.2 min). After removal of the 
solvents on a rotary evaporator and by lyophilisation, the intermediate was taken up in 
CH2Cl2/TFA/H2O (10:10:1, 5 mL) and stirred at room temperature for 3 h. After completion, 
the mixture was diluted with CH2Cl2 (30 mL), and the solvents were removed under reduced 
pressure. This procedure was repeated three times with CH2Cl2. The residue was taken up in 
water (50 mL). Lyophilisation afforded (R)-5.23 as a white fluffy solid (35 mg, 25.3%). 1H-
NMR (300 MHz, [D6]DMSO): δ (ppm) 1.35 – 1.48 (m, 2H), 1.50 – 1.71 (m, 4H), 3.03 – 3.13 (m, 
4H), 3.14 – 3.22 (m, 2H), 3.60 (q, 2H J  5.8, 5.5 Hz), 3.68 (d, 2H, J 5.8 Hz), 3.84 (d, 2H, J 5.5 
Hz), 4.05 – 4.21 (m, 2H), 4.32 (q, 1H, J 7.7 Hz), 5.11 (s, 1H), 6.66 (d, 2H, J 8.5 Hz), 7.00 (d, 2H, 
J 8.5 Hz), 7.17 – 7.32 (m, 10H), 7.49 (t, 1H, J 5.3 Hz), 7.90 (t, 1H, J 5.5 Hz), 7.94 – 8.06 (m, 3H), 
8.27 (t, 1H, J 5.8 Hz), 8.35 – 8.43 (m, 2H), 8.50 (d, 1H, J 8.2 Hz), 8.61 (t, 1H, J 5.7 Hz), 8.89 (s, 
1H), 9.30 (s, 1H), 9.98 (s, 1H). LRMS (ESI): m/z (%) 745.37 (10) [M+H]+, 373.19 (100) 
[M+2H]2+. HRMS (ESI): m/z [M+H]+ calcd. for C37H49N10O7
+: 745.3780, found: 745,3778. 
C37H48N10O7 · C4H2F6O4 (744.85 + 228.04). 
N
2
-(2,2-Diphenylacetyl)-N
ω
-[(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-yl)-
sulfonyl]arginine ((R/S)-5.24). Diphenylacetic acid (90.4 mg, 0.43 mmol), TBTU (137 mg, 1 
equiv) and DIPEA (111 µL, 1.5 equiv) were dissolved in CH2Cl2/DMF (5:3, 8 mL), and the 
mixture was stirred at room temperature for 15 min. (R/S)-4.14 (200 mg, 0.9 equiv) and 
DIPEA (74 µL, 1 equiv) were added, and stirring was continued for 14 h. EtOAc (40 mL) was 
added, and the mixture was washed with water (2 × 40 mL). The volume of the organic 
phase was reduced and the benzyl-protected intermediate was purified by column 
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chromatography (eluent: EtOAc/PE (2:1)). The intermediate was dissolved in methanol (20 
mL) followed by the addition of Pd/C (30 mg). The mixture was stirred vigorously under 
hydrogen (reaction vessel was connected to a hydrogen balloon). After completion of the 
reaction, the solids were removed by filtration through celite, and the solvent was removed 
under reduced pressure. (R/S)-5.24 was obtained as white, hardened foam (138 mg, 58%). 
1H-NMR (400 MHz, [D4]methanol): δ (ppm) 1.42 (d, 6H, J 1.3 Hz), 1.44 – 1.53 (m, 2H), 1.58 – 
1.73 (m, 1H), 1.77 – 1.91 (m, 1H), 2.06 (s, 3H), 2.50 (s, 3H), 2.56 (s, 3H), 2.96 (s, 2H), 3.10 (t, 
2H, J 6.5 Hz), 4.33 – 4.43 (m, 1H), 5.06 (s, 1H), 7.14 – 7.34 (m, 10H). 13C-NMR (400 MHz, 
[D4]methanol): δ (ppm) 11.2, 17.0, 18.3, 25.6, 27.3 (2 carb.), 28.4, 40.1, 42.6, 52.1, 57.3, 
86.3, 117.2, 124.8, 126.6, 126.8, 128.0 (2 carb.), 128.1 (2 carb.), 128.5 (2 carb.), 128.6 (2 
carb.), 132.2, 132.7, 138.1, 139.5, 139.6, 156.5, 158.6, 173.4, 173.6.HRMS (ESI): m/z [M+H]+ 
calcd. for C33H41N4O6S
+: 621.2741, found: 621.2749. C33H40N4O6S (620.76). 
Benzyl [4-(aminomethyl)benzyl]carbamate (5.25).
23 Benzene-1,4-dimethanamine (2 g, 1.47 
mmol) and DIPEA (500 µL, 0.2 equiv) were dissolved in CH2Cl2 (10 mL). A solution of benzyl 
chloroformate (833 mg, 0.33 equiv) in CH2Cl2 (10 mL) was added dropwise. The mixture was 
stirred at room temperature for 14 h. The solvent was removed on a rotary evaporator, and 
the residue was taken up in EtOAc (50 mL) and washed with 1 M aqueous NaOH solution (2 × 
50 mL). The volume of the organic phase was reduced and the desired compound was 
purified by column chromatography (eluent: MeOH/CH2Cl2 (1:2)). 5.25 was obtained as a 
yellow viscous oil (760 mg, 57%). 1H-NMR (300 MHz, [D6]DMSO): δ (ppm) 2.22 (br s, 2H), 
3.68 (s, 2H), 4.17 (d, 2H, J 6.2 Hz), 5.03 (s, 2H), 7.12 (d, 2H, J 8.1 Hz), 7.26 (d, 2H, J 8.2 Hz), 
7.29-7.42 (m, 5H), 7.81 (t, 1H, J 6.2 Hz). HRMS (ESI): m/z [M+H]+ calcd. for C16H19N2O2
+: 
271.1441, found: 271.1443. C16H18N2O2 (270.33). 
Benzyl {4-[(2-amino-5-{3-[(2,2,4,6,7-pentamethyl-2,3-dihydrobenzofuran-5-
yl)sulfonyl]guanidino}pentanamido)methyl]benzyl}carbamate ((R/S)-5.26). Fmoc-D/L-
Arg(Pbf)-OH (1.46 g, 2.25 mmol), 5.25 (620 mg, 1.02 equiv) and HOBt (541 mg, 1.8 equiv) 
were dissolved in DMF (30 mL). A solution of N,N′-diisopropylcarbodiimide (290 mg, 1.02 
equiv) in DMF (2 mL) was added slowly under ice cooling, and the resulting mixture was 
stirred at room temperature for 14 h. Water (350 mL) was added, and the mixture was 
extracted with EtOAc (2 × 300 mL). The combined organic phases were dried over MgSO4, 
and the volume was reduced on a rotary evaporator. The protected intermediate was 
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purified by column chromatography (eluent: EtOAc/PE (1:1)), and the volatiles were 
removed on a rotary evaporator. The residue was dissolved in CH2Cl2/DEA (8:1, 90 mL) and 
stirred for 16 h. The volatiles were removed under reduced pressure, and the desired 
compound was purified by column chromatography (eluent: EtOAc/PE (1:1)  CH2Cl2/7N 
NH3 in MeOH (20:1)) affording the title compound as a pale yellow solid (960 mg, 63%). 
1H-
NMR (300 MHz, [D6]DMSO): δ (ppm) 1.30-1.72 (m, 10 H), 2.00 (s, 3H), 2.43 (s, 3H), 2.49 (s, 
3H, overlap with solvent), 2.95 (s, 2H), 2.99-3.10 (m, 2H), 3.17 (s, 2H), 3.41 (t, 1H, J 5.5 Hz), 
4.17 (d, 2H, J 6.1 Hz), 4.22-4.31 (m, 2H), 5.03 (s, 2H), 6.50 (br s, 1H), 6.98 (br s, 1H), 7.14-7.24 
(m, 4H), 7.27-7.40 (m, 5H), 7.93 (t, 1H, J 6.2 Hz), 8.63 (t, 1H, J 5.7 Hz). 13C-NMR (75.5 MHz, 
[D6]DMSO): δ (ppm) 12.2, 17.5, 18.9, 25.1, 28.2 ( carb.), 30.6, 41.7, 42.3, 43.4, 48.5, 53.3, 
65.2, 86.2, 116.2, 124.2, 126.9 (2 carb.), 127.2 (2 carb.), 127.6 (2 carb.), 127.7, 128.2 (2 
carb.), 131.1, 137.0, 137.2, 137.5, 138.3, 156.0, 156.2, 157.3, 172.0. HRMS (ESI): m/z [M+H]+ 
calcd. for C35H47N6O6S
+: 679.3276, found: 679.3272. C35H46N6O6S (678.85). 
N-[4-(Aminomethyl)benzyl]-2-(2,2-diphenylacetamido)-5-({3-[(2,2,4,6,7-pentamethyl-2,3-
dihydrobenzofuran-5-yl)sulfonyl]guanidino}pentanamide ((R/S)-5.27). (R/S)-5.26 (960 mg, 
1.42 mmol) and DIPEA (250 µL, 1 equiv) were dissolved in DME/THF (3:1, 20 mL). A solution 
of 5.5 (570 mg, 1.3 equiv) in DME (10 mL) was added, and the mixture was stirred at room 
temperature for 14 h. The reaction mixture was concentrated under reduced pressure, and 
the Cbz-protected intermediate was purified by column chromatography (eluent: 
CH2Cl2/MeOH (30:1)). The intermediate compound was dissolved in MeOH (15 mL) and Pd/C 
(90 mg) was added. The mixture was stirred vigorously under hydrogen (reaction vessel was 
connected to a hydrogen balloon). After completion of the reaction (monitored by TLC: 
CH2Cl2/7N NH3 in MeOH (10:0.8)), the solids were removed by filtration through celite, and 
the solvent was removed on a rotary evaporator. Purification by column chromatography 
(eluent: CH2Cl2/MeOH (20:1)  CH2Cl2/7N NH3 in MeOH (3:1)) gave the title compound as a 
white hardened foam (400 mg, 38%). TLC (CH2Cl2/7N NH3 in MeOH 12:1) Rf = 0.29. 
1H-NMR 
(400 MHz, [D4]methanol): δ (ppm) 1.32 – 1.50 (m, 8H), 1.58 – 1.70 (m, 1H), 1.71 – 1.84 (m, 
1H), 2.05 (s, 3H), 2.50 (s, 3H), 2.56 (s, 3H), 2.94 (s, 2H), 3.00 – 3.16 (m, 2H), 3.97 (s, 2H), 4.25 
– 4.46 (m, 3H), 5.09 (s, 1H), 7.10 – 7.42 (m, 14H). 13C-NMR (400 MHz, [D4]methanol): δ (ppm) 
11.2, 17.1, 18.3, 25.7, 27.4 (2 carb.), 28.9, 39.8, 42.2, 42.6, 43.3, 53.4, 57.2, 86.3, 117.1, 
124.7, 126.6, 126.8, 127.6 (2 carb.), 128.1 (2 carb.), 128.2 (2 carb.), 128.4 (2 carb.), 128.5 (2 
carb.), 128.6 (2 carb.), 129.3, 132.1, 133.0, 134.2, 138.0, 139.0, 139.6, 156.7, 158.5, 172.7, 
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173.3. HRMS (ESI): m/z [M+H]+ calcd. for C41H51N6O5S
+: 739.3636, found: 739.3644. 
C41H50N6O5S (738.95). 
N
4
,N
4'
-Bis[(R)-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-9-imino-3,11-dioxo-
2,8,10,12-tetraazapentadecan-15-yl]-biphenyl-4,4'-dicarboxamide ((R,R)-5.28). Biphenyl-
ϰ,ϰ͛-dicarboxylic acid (7.7 mg, 0.032 mmol) was suspended in anhydrous DMF (0.6 mL). TBTU 
(22.6 mg, 2.2 equiv) and DIPEA (11 µL, 2 equiv) were added and the mixture was stirred for 
15 min which led to the dissolution of the suspended starting material. A solution of (R)-5.13 
(64.1 mg, 2.5 equiv) and DIPEA (28 µL, 5 equiv) in anhydrous DMF (0.4 mL) was added, and 
the mixture was subjected to microwave irradiation (70 °C, 30 min). The desired compound 
was purified by preparative HPLC (column: Nucleodur-100 C18 250 × 21 mm; gradient: 0–25 
min: MeCN/0.1% aq TFA 15:85–79:21, tR = 16.3 min). Lyophilisation of the eluate afforded 
(R,R)-5.28 as a white fluffy solid (20.7 mg, 41%). 1H-NMR (600 MHz, COSY, [D4]methanol): δ 
(ppm) 1.48 – 1.63 (m, 4H), 1.65 – 1.73 (m, 2H), 1.79 – 1.89 (m, 6H), 3.15 – 3.26 (m, 4H), 3.29 
– 3.34 (m, 4H), 3.47 (t, 4H, J 6.6 Hz), 4.23 (q, 4H, J 14.6 Hz, 8.6 Hz), 4.42 (t, 2H, J 6.9 Hz), 5.07 
(s, 2H), 6.7 (d, 4H, J 8.6), 7.05 (d, 4H, J 8.6 Hz), 7.18 – 7.32 (m, 20H), 7.72 – 7.95 (m, 8H). 13C-
NMR (150.9 MHz, HSQC, HMBC, [D4]methanol): δ (ppm) 25.7 (2 carb.), 30.3 (2 carb.), 30.4 (2 
carb.), 38.2 (2 carb.) 38.3 (2 carb.), 41.7 (2 carb.), 43.7 (2 carb.), 54.3 (2 carb.), 58.7 (2 carb.), 
116.3 (4 carb.), 128.1 (4 carb.), 128.2 (4 carb.), 129.0 (4 carb.), 129.5 (4 carb.), 129.6 (4 
carb.), 129.8 (4 carb.), 129.9 (4 carb.),  130.0 (4 carb.), 130.3 (2 carb.), 135.0 (2 carb.), 140.8 
(2 carb.), 140.9 (2 carb.), 144.3 (2 carb.), 155.6 (2 carb.), 155.7 (2 carb.), 157.8 (2 carb.) 169.9 
(2 carb.), 173.3 (2 carb.), 174.9 (2 carb.). RP-HPLC (220 nm): 98% (tR = 15.8 min, k = 4.5). 
LRMS (ESI): m/z (%) 1353.63 (1) [M+H]+, 677.33 (100) [M+2H]2+. HRMS (ESI): m/z [M+H]+ 
calcd. for C76H85N14O10
+: 1353.6568, found: 1353.6559. C76H84N14O10 · C4H2F6O4 (1353.60 + 
228.04). 
N
4
,N
4'
-Bis[(R)-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-9-imino-3,11,17-trioxo-
2,8,10,12,16-pentaazaoctadecan-18-yl]-biphenyl-4,4'-dicarboxamide ((R,R)-5.29). 
Compound 5.19 (10 mg, 0.028 mmol) was dissolved in anhydrous DMF (0.6 mL), TBTU (19.8 
mg, 2.2 equiv) and DIPEA (10 µL, 2 equiv) were added, and the mixture was stirred for 15 
min. A solution of (R)-5.13 (56.1 mg, 2.5 equiv) and DIPEA (25 µL, 5 equiv) in anhydrous DMF 
(0.4 mL) was added, and the mixture was subjected to microwave irradiation (70 °C, 30 min). 
The desired compound was purified by preparative HPLC (column: Nucleodur-100 C18 250 × 
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21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 15:85–79:21, tR = 13.2 min). Lyophilisation 
of the eluate afforded (R,R)-5.29 as a white fluffy solid (15.8 mg, 33%). 1H-NMR (600 MHz, 
COSY, [D6]DMSO,): δ (ppm) 1.35 – 1.48 (m, 4H), 1.49 – 1.55 (m, 2H), 1.56 – 1.62 (m, 4H), 1.63 
– 1.70 (m, 2H), 3.08 – 3.14 (m, 8H), 3.15 – 3.21 (m, 4H), 3.86 (d, 4H, J 5.6 Hz), 4.08 – 4.19 (m, 
4H), 4.32 (q, 2H, J 8.0 Hz, 6.3 Hz), 5.11 (s, 2H), 6.66 (d, 4H, J 8.6 Hz), 6.99 (d, 4H, J 8.6 Hz), 
7.17 – 7.24 (m, 4H), 7.24 – 7.30 (m, 16H), 7.49 (t, 2H, J 5.3 Hz), 7.85 (d, 4H, J 8.4 Hz, 4H), 7.97 
– 8.02 (m, 6H), 8.35 (t, 2H, J 5.8 Hz), 8.38 (s, 2H), 8.47 (d, 2H, J 8.1 Hz), 8.83 (t, 2H, J 5.7 Hz), 
8.90 (s, 2H), 9.29 (s, 2H), 10.02 (s, 2H). 13C-NMR (150.9 MHz, HSQC, HMBC, [D6]DMSO): δ 
(ppm) 24.6 (2 carb.), 29.2 (2 carb.), 29.4 (2 carb.), 36.0 (2 carb.), 36.9 (2 carb.), 40.3 (2 carb.), 
41.6 (2 carb.), 42.7 (4 carb.), 52.2 (2 carb.), 55.9 (2 carb.), 115.0 (4 carb.), 126.5 (4 carb.), 
126.6 (4 carb.), 128.1 (4 carb.), 128.1 (4 carb.), 128.2 (4 carb.), 128.4 (4 carb.), 128.5 (4 
carb.), 128.5 (4 carb.), 129.1 (2 carb.), 133.3 (2 carb.), 140.2 (2 carb.), 140.4 (2 carb.), 141.7 
(2 carb.), 153.5 (2 carb.), 153.7 (2 carb.), 156.2 (2 carb.), 166.0 (2 carb.), 169.1 (2 carb.), 
170.9 (2 carb.), 171.0 (2 carb.). RP-HPLC (220 nm): 98% (tR = 14.7 min, k = 4.1). LRMS (ESI): 
m/z (%) 734.35 (100) [M+2H]2+. HRMS (ESI): m/z [M+2H]2+ calcd. for C80H92N16O12
2+: 
734.3534, found: 734.3537. C80H90N16O12 · C4H2F6O4 (1476.7 + 228.04). 
N
4
,N
4'
-Bis[(R)-4-(2,2-diphenylacetamido)-1-(4-hydroxyphenyl)-9-imino-3,11,17,20,23-
pentaoxo-2,8,10,12,16,19,22-heptaazatetracosan-24-yl]-biphenyl-4,4'-dicarboxamide 
((R,R)-5.30). Biphenyl-ϰ,ϰ͛-dicarboxylic acid (5.5 mg, 22.6 µmol) was suspended in anhydrous 
DMF (0.6 mL). TBTU (16.0 mg, 2.2 equiv), DIPEA (8 µL, 2 equiv) was added, and the mixture 
was stirred for 15 min, leading to the dissolution of the suspended starting material. A 
solution of (R)-5.23 (55 mg, 2.5 equiv) and DIPEA (20 µL, 5 equiv) in anhydrous DMF (0.4 mL) 
was added, and the mixture was subjected to microwave irradiation (70 °C, 30 min). The 
desired compound was purified by preparative HPLC (column: Nucleodur-100 C18 250 × 21 
mm; gradient: 0–20 min: MeCN/0.1% aq TFA 14:86–62:38, tR = 15.1 min). Lyophilisation of 
the eluate afforded (R,R)-5.30 as a white fluffy solid (10 mg, 32%). 1H-NMR (600 MHz, COSY, 
[D6]DMSO): δ (ppm) 1.35 – 1.46 (m, 2H), 1.49 – 1.58 (m, 6H), 1.62 – 1.69 (m, 2H), 3.04 – 3.11 
(m, 8H), 3.14 – 3.21 (m, 4H), 3.68 (d, 4H, J 5.7 Hz), 3.76 (d, 4H, J 5.6 Hz), 3.95 (d, 4H, J 5.6 Hz), 
4.08 – 4.19 (m, 4H), 4.32 (q, 2H, J 7.7 Hz, 6.5 Hz), 5.11 (s, 2H), 6.66 (d, 4H, J 8.4 Hz), 6.99 (d, 
4H, J 8.4 Hz), 7.18 – 7.23 (m, 4H), 7.25 – 7.29 (m, 16H), 7.42 – 7.46 (m, 2H), 7.78 (t, 2H, J 5.6 
Hz), 7.85 (d, 4H, J 8.4 Hz), 7.99 (d, 4H, J 8.4), 8.16 (t, 2H, J 5.8 Hz), 8.30 (t, 2H, J 5.6 Hz, 2H), 
8.33 – 8.40 (m, 4H), 8.47 (t, 2H, J 8.1 Hz), 8.87 (s, 2H), 8.90 (t, 2H, J 5.6 Hz), 9.28 (s, 2H), 9.89 
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(s, 2H). RP-HPLC (220 nm): 98% (tR = 14.1 min, k = 3.9). LRMS (ESI): m/z (%) 848.40 (100) 
[M+2H]2. HRMS (ESI): m/z [M+H]2+ calcd. for C88H104N20O16
2+: 848.3964, found: 848.3967. 
C88H102N20O16 · C4H2F6O4 (1695.91 + 228.04). 
(2R)-2-(2,2-Diphenylacetamido)-5-{[({[3-(2-{2-[7-({[({3-[({N-[(4R)-4-(2,2-
diphenylacetamido)-4-{[(4-hydroxyphenyl)methyl]carbamoyl}butyl]carbamimidoyl}-
carbamoyl)amino]propyl}carbamoyl)methyl]carbamoyl}methyl)-1H,7H-imidazo[4,5-
f]benzimidazol-1-yl]acetamido}acetamido)propyl]carbamoyl}amino)methanimidoyl]-
amino}-N-[(4-hydroxyphenyl)methyl]pentanamide ((R,R)-5.31). Compound 5.18 (6 mg, 21.9 
µmol) was suspended in anhydrous DMF (0.6 mL). TBTU (15.5 mg, 2.2 equiv), DIPEA (8 µL, 2 
equiv) was added, and the mixture was stirred for 15 min leading to the dissolution of the 
suspended starting material. A solution of (R)-5.22 (47 mg, 2.5 equiv) and DIPEA (20 µL, 5 
equiv) in anhydrous DMF (0.4 mL) was added, and the mixture was subjected to microwave 
irradiation (70 °C, 30 min). The desired compound was purified by preparative HPLC 
(column: Nucleodur-100 C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 14:86–
62:38, tR = 14.6 min). Lyophilisation of the eluate afforded (R,R)-5.31 as a white fluffy solid 
(11 mg, 29%). 1H-NMR (600 MHz, COSY, [D4]methanol): δ (ppm) 1.46 – 1.61 (m, 4H), 1.63 – 
1.73 (m, 6H), 1.78 – 1.86 (m, 2H), 3.11 – 3.20 (m, 8H), 3.22 – 3.27 (m, 4H), 3.93 (s, 4H), 4.22 
(q, 4H, J 14.7 Hz, 9.3 Hz), 4.42 (q, 2H, J 6.1 Hz, 2.1 Hz), 5.06 (s, 2H), 5.29 (s, 4H), 6.66 (d, 4H, J 
8.2 Hz), 7.02 (d, 4H, J 8.2 Hz), 7.17 – 7.30 (m, 20H), 8.06 (s, 1H), 8.16 (s, 1H), 8.88 (s, 2H). RP-
HPLC (220 nm): 97% (tR = 13.0 min, k = 3.5). LRMS (ESI): m/z (%) 750.36 (20) [M+2H]
2+, 
500.58 (100) [M+3H]3+. HRMS (ESI): m/z [M+H]2+ calcd. for C78H92N20O12
2+: 750.3596, found: 
750.3601. C78H90N20O12 · C4H2F6O4 (1499.71 + 228.04). 
(2S)-2-(2,2-Diphenylacetamido)-5-{[({[3-(2-{2-[7-({[({3-[({N-[(4S)-4-(2,2-
diphenylacetamido)-4-{[(4-hydroxyphenyl)methyl]carbamoyl}butyl]-
carbamimidoyl}carbamoyl)amino]propyl}carbamoyl)methyl]carbamoyl}methyl)-1H,7H-
imidazo[4,5-f]benzimidazol-1-yl]acetamido}acetamido)propyl]carbamoyl}amino)-
methanimidoyl]amino}-N-[(4-hydroxyphenyl)methyl]pentanamide ((S,S)-5.31). Compound 
(S,S)-5.31 was synthesized from 5.18 (6.4 mg, 23.4 µmol) and (S)-5.22 (50 mg, 58.3 µmol) by 
analogy with the procedure for the preparation of (R,R)-5.31. The desired compound was 
obtained as a white lyophilisate (12.3 mg, 31%). The spectroscopic data were identical to 
those for (R,R)-5.31. RP-HPLC (220 nm): 99% (tR = 13.1 min, k = 3.6). 
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(R)-17-(2,2-Diphenylacetamido)-N
1
-[3-(2-{7-[(R)-4-(2,2-diphenylacetamido)-1-(4-
hydroxyphenyl)-9-imino-3,11,17,20,23,26-hexaoxo-2,8,10,12,16,18,21,24-
octaazaheptacosan-27-yl]benzo[1,2-d:4,5-d']diimidazol-1(7H)-yl}acetamido)-2-oxopropyl]-
N
18
-(4-hydroxybenzyl)-12-imino-4,10-dioxo-3,5,9,11,13-pentaazaoctadecanediamide 
((R,R)-5.32). Compound 5.18 (3.39 mg, 12.4 µmol) was suspended in anhydrous DMF (0.6 
mL). TBTU (8.8 mg, 2.2 equiv), DIPEA (5 µL, 2 equiv) was added, and the mixture was stirred 
for 15 min leading to the dissolution of the suspended starting material. A solution of (R)-
5.23 (30 mg, 2.5 equiv) and DIPEA (12 µL, 5 equiv) in anhydrous DMF (0.4 mL) was added, 
and the mixture was subjected to microwave irradiation (70 °C, 30 min). The desired 
compound was purified by preparative HPLC (column: Nucleodur-100 C18 250 × 21 mm; 
gradient: 0–20 min: MeCN/0.1% aq TFA 14:86–62:38, tR = 14.6 min). Lyophilisation of the 
eluate afforded (R,R)-5.32 as a white fluffy solid (10 mg, 41%). 1H-NMR (600 MHz, COSY, 
[D6]DMSO): δ (ppm) 1.34 – 1.48 (m, 4H), 1.49 – 1.59 (m, 6H), 1.62 – 1.70 (m, 2H), 3.07 (m, 
8H), 3.18 (q, 4H, J 6.1 Hz, 5.9 Hz), 3.64 (d, 4H, J 5.6 Hz), 3.78 (d, 4H, J 5.5 Hz), 3.84 (d, 4H, J 
5.4 Hz), 4.08 – 4.19 (m, 4H), 4.32 (q, 2H, J 7.9 Hz, 6.3 Hz), 5.11 (s, 2H), 5.20 (s, 4H), 6.66 (d, 
4H, J 8.5 Hz), 6.99 (d, 4H, J 8.5 Hz), 7.18 – 7.24 (m, 4H), 7.25 – 7.30 (m, 16H), 7.47 (t, 2H, J 5.1 
Hz), 7.83 (t, 2H, J 5.6 Hz), 8.12 – 8.15 (m, 3H), 8.31 (t, 2H, J 5.7 Hz), 8.33 – 8.43 (m, 5H), 8.47 
(d, 2H, J 8.1 Hz), 8.73 (t, 2H, J 5.1 Hz), 8.89 (s, 2H), 9.29 (s, 2H), 10.05 (s, 2H). RP-HPLC (220 
nm): 98% (tR = 12.6 min, k = 3.4). LRMS (ESI): m/z (%) 864.40 (10) [M+2H]
2+, 576.60 (100) 
[M+3H]3+. HRMS (ESI): m/z [M+H]2+ calcd. for C86H104N24O16
2+: 864.4026, found: 864.9037. 
C86H102N24O16 · C4H2F6O4 (1727.91 + 228.04). 
N
1
-((6S,9S,12S,15S)-1-Amino-6-{[(S)-1-amino-3-(4-hydroxyphenyl)-1-oxopropan-2-
yl]carbamoyl}-12-(3-guanidinopropyl)-16-(4-hydroxyphenyl)-1-imino-9-isobutyl-8,11,14-
trioxo-2,7,10,13-tetraazahexadecan-15-yl)-N
8
-[(S)-4-(2,2-diphenylacetamido)-1-(4-
hydroxyphenyl)-9-imino-3,11-dioxo-2,8,10,12-tetraazapentadecan-15-yl]octanediamide 
tri(hydrotrifluoroacetate) (all-S-5.33). Compound 2.13 (30 mg, 19.5 µmol), HOBt (2.76 mg, 
1.05 equiv), HBTU (7.8 mg, 1.05 equiv) and DIPEA (8.4 µl, 2.5 equiv) were dissolved in 
anhydrous DMF (500 µL) and incubated for 10 min at rt. A solution of (S)-5.13 (23.4 mg, 1.5 
equiv) and DIPEA (5 µL, 1.5 equiv) in DMF (300 µL) was added, and the mixture was stirred at 
70 °C under microwave irradiation for 30 min. After addition of water (8 mL), a white solid 
precipitated. The solids were collected by filtration, dried in vacuo and stirred for 2.5 h in 
TFA/H2O (95:5, 2 mL). The mixture was poured into ice-cold diethyl ether (15 mL) to afford a 
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white precipitate. After centrifugation, the supernatant was discarded, and the residue was 
dissolved in H2O (8 mL). The desired compound was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–25 min: MeCN/0.1% aq TFA 24:76–62:38, tR = 17.8 
min). Lyophilisation of the eluate afforded all-S-5.33 as a white fluffy solid (20 mg, 49%). 1H-
NMR (400 MHz, [D6]DMSO): δ (ppm) 0.77 – 0.94 (m, 6H), 1.03 – 1.22 (m, 4H), 1.27 – 1.78 (m, 
21H), 1.94 – 2.11 (m, 4H), 2.78 – 2.92 (m, 2H), 2.97 – 3.15 (m, 8H), 3.16 – 3.25 (m, 2H), 4.05 – 
4.48 (m, 8H), 5.13 (s, 1H), 6.57 – 6.73 (m, 6H), 6.92 – 7.16 (m, 10H), 7.18 – 7.25 (m, 3H), 7.26 
– 7.33 (m, 9H), 7.36 (s, 2H), 7.51 (t, J 5.0 Hz, 1H), 7.54 – 7.64 (m, 2H), 7.75 (d, J 7.8 Hz, 1H), 
7.82 (t, J 5.5 Hz, 1H), 7.89 (d, J 8.0 Hz, 1H), 7.94 (d, J 8.0 Hz, 1H), 8.03 (d, J 7.6 Hz, 1H), 8.16 
(d, J 7.9 Hz, 1H), 8.36 (t, J 5.9 Hz, 1H), 8.41 (br s, 2H), 8.49 (d, J 8.0 Hz, 1H), 8.94 (br s, 1H), 
9.21 (br s, 3H), 10.17 (s, 1H). RP-HPLC (220 nm): 95% (tR = 28.58 min, k = 9.0). HRMS (ESI): 
m/z [M+H]+ calcd. for C75H108N19O13
3+: 494.2786, found: 494.2795. C75H105N19O13 · C6H3F9O6 
(1480.79 + 342.06). 
N,N'-[1,4-Phenylenebis(methylene)]bis[2-(2,2-diphenylacetamido)-5-
guanidinopentanamide] di(hydrotrifluoroacetate) ((R/S)-5.34). (R/S)-5.24 (16.1 mg, 25.9 
µmol), HOBt (4 mg, 1 equiv), TBTU (8.3 mg, 1 equiv) and DIPEA (7 µl, 1.5 equiv) were 
dissolved in anhydrous DMF (1 mL) and incubated for 15 min at room temperature. A 
solution of (R/S)-5.27 (18.2 mg, 0.95 equiv) and DIPEA (7 µL, 1.5 equiv) in DMF (500 µL) was 
added, and the mixture was stirred at 70 °C under microwave irradiation for 30 min. Water 
(20 mL) was added, and the mixture was extracted with EtOAc (2 × 15 mL). The organic 
phases were combined, and the solvent was removed under reduced pressure. The residue 
was dissolved in TFA/H2O (95:5, 3 mL) and stirred at room temperature for 3 h. The mixture 
was poured into ice-cold diethyl ether (15 mL) affording a white precipitate. After 
centrifugation, the supernatant was discarded, and the precipitate was purified by 
preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–18 min: MeCN/0.1% aq 
TFA 24:76–62:38, tR = 12.3 min). Lyophilisation of the eluate afforded (R/S)-5.34 as a white 
fluffy solid (14.2 mg, 54%). 1H-NMR (600 MHz, COSY, [D6]DMSO): δ (ppm) 1.30-1.48 (m, 4H), 
1.48-1.59 (m, 2H), 1.62-1.74 (m, 2H), 3.00-3.10 (m, 4H), 4.16-4.29 (m, 4H), 4.30-4.37 (m, 2H), 
5.12 (s, 2H), ca. 6.95 (br s, 4H), 7.11 (s, 4H), 7.17-7.23 (m, 4H), 7.24-7.37 (m, 16H), 7.61 (t, 
2H, J 5.7 Hz), 8.47 (t,  2H, J 6.0 Hz), 8.50 (d, 2H, J 8.0 Hz). 13C-NMR (150.9 MHz, HSQC, HMBC, 
[D6]DMSO): δ (ppm) 25.1 (2 carb.), 29.4 (2 carb.), 40.3 (2 carb.), 41.8 (2 carb.), 52.4 (2 carb.), 
55.9 (2 carb.), 126.5 (2 carb.), 126.6 (2 carb.), 127.0 (4 carb.), 128.1 (4 carb.), 128.2 (4 carb.), 
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128.4 (4 carb.), 128.5 (4 carb.), 137.6 (2 carb.), 140.3 (2 carb.), 140.5 (2 carb.), 156.7 (2 
carb.), 171.0 (2 carb.), 171.2 (2 carb.). RP-HPLC (220 nm): 99% (tR = 14.2 min, k = 3.9). HRMS 
(ESI): m/z [M+2H]2+ calcd. for C48H58N10O4
2+: 419.2316, found: 419.2324. C48H56N10O4 · 
C4H2F6O4 (837.04 + 228.04). 
N,N'-{[({[2,2'-(benzo[1,2-d:4,5-d']diimidazole-1,7-
diyl)bis(acetyl)]bis(azanediyl)}bis(methylene))bis(4,1-phenylene)]bis(methylene)}bis(2-
(2,2-diphenylacetamido)-5-guanidinopentanamide) di(hydrotrifluoroacetate) ((R/S)-5.35). 
Compound 5.18 (3.8 mg, 13.9 µmol) was suspended in anhydrous DMF (0.6 mL), TBTU (9.4 
mg, 2.1 equiv), HOBt (4.5 mg, 2.1 equiv) and DIPEA (6 µL, 2.5 equiv) were added, and the 
mixture was stirred for 10 min resulting in the dissolution of the suspended starting 
material. A solution of (R/S)-5.27 (25.7 mg, 2.5 equiv) and DIPEA (6 µL, 2.5 equiv) in 
anhydrous DMF (0.5 mL) was added, and the mixture was subjected to microwave 
irradiation (70 °C, 30 min). Water (20 mL) was added, and the mixture was extracted with 
EtOAc (2 × 20 mL). The volatiles were removed under reduced pressure, the residue was 
dissolved in TFA/H2O (95:5, 3 mL), and the solution was stirred at room temperature for 3 h. 
Water (100 mL) was added followed by lyophilisation. The desired compound was purified 
by preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–18 min: MeCN/0.1% 
aq TFA 14:86–62:38, tR = 14.6 min). Lyophilisation of the eluate afforded (R/S)-5.35 as a 
white fluffy solid (9.4 mg, 47%). 1H-NMR (400 MHz, [D4]methanol): δ (ppm) 1.40 – 1.61 (m, 
4H), 1.62 – 1.74 (m, 2H), 1.75 – 1.90 (m, 2H), 3.00 – 3.20 (m, 4H), 4.30 (s, 4H), 4.34 – 4.45 (m, 
6H), 5.07 (s, 2H), 5.18 (s, 4H), 7.05 – 7.35 (m, 28H), 7.81 (br s, 1H), 8.12 (br s, 1H), 8.93 (br s, 
2H). RP-HPLC (220 nm): >99% (tR = 12.2 min, k = 3.3). HRMS (ESI): m/z [M+2H]
2+ calcd. for 
C68H76N16O6: 606.3061, found: 606.3069. C68H74N16O6 · C4H2F6O4 (1211.44 + 228.04). 
5.5.3  Pharmacology 
Buffers and media used in binding assays. Cf. chapter 2.4.5 
Radioligand binding assays. Cf. chapter 2.4.5 
Aequorin assay. The assay was performed on CHO-hY4-Gqi5-mtAEQ cells as previously 
described5 using a GENios Pro plate reader (Tecan, Salzburg, Austria). Areas under the curve 
were calculated using SigmaPlot 12.5 software (Systat Software Inc., Chicago, IL). 
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Dynamic mass redistribution (DMR) assay. One day prior to the experiment, CHO-hY4R-Gqi5-
mtAEQ cells were trypsinized and centrifuged (400 g, 5 min). The cells were re-suspended in 
HAM͛s FϭϮ ŶutƌieŶt ŵiǆtuƌe suppleŵeŶted ǁith ϭϬ% FC“ at a density of 500,000 cells/ mL, 
and 40 µL of the cell suspension were seeded in uncoated 384-well EnSpire microplates. The 
cells were allowed to attach overnight at 37 °C, 5% CO2 in a water-saturated atmosphere. 
The cells were washed four times with serum-free L-15 medium supplemented with 1% BSA 
and 0.1 mg/mL bacitracin and allowed to equilibrate in a volume of 30 µL of the same 
medium per well in the multimode reader at 37 °C for about 60 min. After recording baseline 
date, 10 µL of the test substances dissolved in L-15 medium (4-fold concentrated) were 
added with a multichannel electronic finnpipette (Thermo Fisher Scientific, Waltham, MA, 
USA) and the cellular response was recorded continuously for 40 min. Data processing was 
performed as previously described.24 
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6.1  Introduction 
The thiourea CYM 9484 (6.4, Figure 1) is a high affinity (IC50 = 19 nM) Y2R antagonist.
1 
Structure activity relationships from other series of Y2R ligands suggest that the introduction 
of a basic moiety into 6.4 might further increase the Y2R affinity. Moreover, the water 
solubility of 6.4 is rather low. The introduction of a basic moiety as well as the replacement 
of the lipophilic benhydrylpiperidine portion with a more polar substructure, e.g. the 
͞ǁesteƌŶ paƌt͟ of the Y2R antagonist JNJ 310200282 (Figure 1) should increase the solubility 
and improve the applicability of 6.4 as a pharmacological tool, e.g. as a stabilizing ligand for 
co-crystallization with the Y2R. 
 
Figure 1: Y2R antagonists CYM 9484 and JNJ 31020028. 
 
6.2  Results and Discussion 
6.2.1  Chemistry 
The thiourea CYM 9484 (6.4) (Scheme 1) was prepared in a one-pot reaction by analogy with 
procedures from literature.1 Methylation of the thiourea with iodomethane gave the 
isothiourea 6.5, which was expected to be a suitable guanidinylating reagent. However, in 
contrast to S-methylisothioureas derived from primary amines, 6.5 was not reactive in a 
mercury(II) chloride mediated guanidinylation reaction. Presumably, the disubstitution at 
the nitrogen atom in the piperidine ring of 6.5 prevents the elimination of methanethiol and 
thus the formation of an activated carbodiimide intermediate. 
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Scheme 1: Synthesis of the thiourea CYM9484 (6.4) and the isothiourea analog (6.5)a 
 
aReagents and conditions: (a) Di(2-pyridyl) thionocarbonate, CH2Cl2, rt, 6h. (b) CH2Cl2, rt, 15 min. (c) 
iodomethane, DMF, rt, 21 h. 
 
To circumvent this problem, the thiourea 6.7 (Scheme 2) was prepared by treating the 
intermediate isothiocyanate 6.2 with an aqueous ammonia solution. Compound 6.7 was S-
methylated and subsequently treated with α,α-diphenyl-4-piperidinemethanol to give the 
desired guanidine 6.6. The application of mercury(II) chloride was not necessary. 
Scheme 2: Synthesis of the guanidine analog (6.6) of 6.4a 
aReagents and conditions: (a) ammonia solution (32%), CH2Cl2, rt, 40 min. (b) iodomethane, MeOH, 
rt, 36 h. (c) α,α-diphenyl-4-piperidinemethanol, t-BuOH/DMF, reflux, 2 h. 
 
The thiourea 6.12 (Scheme 3) is a hybrid compound comprising structural moieties of 6.4 
and JNJ 31020028 (Figure 1).3 Apart from the slightly higher Y2R affinity, the water solubility 
of JNJ ϯϭϬϮϬϬϮϴ is suďstaŶtiallǇ ďetteƌ. “iŵilaƌlǇ, the iŶtƌoduĐtioŶ of the ͞easteƌŶ paƌt͟ of 
JNJ 31020028 into 6.4 was considered a promising approach to improve both, Y2R affinity 
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and water solubility. Phenylacetyl chloride was brominated under Wohl-Ziegler conditions to 
form the intermediate 6.9 that was treated with diethylamine without prior purification 
resulting in the amide 6.10. Alkylation of mono-Boc-protected piperazine with compound 
6.10 under microwave irradiation and subsequent Boc deprotection gave compound 6.11. 
Finally, the thiourea 6.12 was prepared from 6.11 and 4-Amino-N,N-
dimethylbenzenesulfonamide by analogy with the synthesis of 6.4. 
 
Scheme 3: Synthesis of the thiourea 6.12.a 
 
aReagents and conditions: (a) NBS, AIBN, chloroform, reflux, 5 h. (b) diethylamine, DIPEA, chloroform, 
rt, 3 h. (c) 1-Boc-piperazine, MeCN, microwave conditions, 110 °C, 30 min. (d) 6.11, DIPEA, CH2Cl2, rt, 
1 h. 
 
6.2.2  Competition Binding Studies at NPY Receptor Subtypes 
The target compounds 6.4, 6.5, 6.6 and 6.12 were investigated for Y2R affinity and subtype 
selectivity in radioligand binding assays (Y1R, Y2R, Y4R and Y5R) and a fluorescent ligand 
binding assay (Y2R) (for results see Table 1). The Ki value of 6.4 at the Y2R determined by 
displacement of the fluorescent ligand Cy5-pNPY was in good agreement with published 
data (Ki = 23.9 nM (determined with Cy5-pNPY), IC50 = 19 nM
1). Methylation of the thiourea 
did not affect Y2R affinity, that is, 6.5 (Ki = 18.5 nM) had the same affinity as 6.4. Suprisingly, 
the guanidine analog of CYM 9484, compound 6.6, showed a considerably decreased Y2R 
affinity (Ki > 10000 nM). This result does not support the hypothesis that the introduction of 
a basic moiety into CYM 9484 might improve the interaction with the Y2R. The hybrid 
compound 6.12 (Ki = 407 nM) still binds to the Y2R in the nanomolar range, but has a 
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considerably lower affinity than 6.4. The binding constants determined in the radioligand 
binding assay and the fluorescent ligand binding assay were essentially in the same range 
(6.4: Ki = 69.7 nM (radioligand binding), Ki = 23.9 nM (fluorescent ligand binding)). 
The Ki values of 6.4 and 6.12 at Y1R, Y4R and Y5R were not determined due to low affinity. 
The same holds for compound 6.6 with exception of the Y5R (Ki = 5330 nM). The isothiourea 
6.5 was inactive at Y1R and Y5R, but a weak binder at the Y4R (Ki = 5200 nM). Since we could 
previously show that the affinity of Y4R ligands is affected by the concentration of sodium 
ions in the binding buffer, Y4R affinity of 6.5 was additionally investigated in the sodium 
containing L-15 medium. However, the affinity of 6.5 in the L-15 medium was lower (IC50 > 
30000 nM) than in the sodium-free buffer. Therefore, 6.5 was not considered a promising 
lead compound for further structural optimizations regarding Y4R affinity. 
 
Table 1. NPY receptor binding data. 
 Y1R Y2R Y4R Y5R 
Compd. Ki [nM]
a 
Ki [nM]
b 
Ki [nM]
c
 Ki [nM]
d 
Ki [nM]
e 
6.4 >10000 69.7 ± 20.1 23.9 ± 2.6 >10000 >10000 
6.5 >10000 87.5 ± 6.1 18.5 ± 5.1 5200 ± 90f >10000 
6.6 >10000 >10000 >10000 >10000 5330 ± 390 
6.12 >10000 935 ± 322 407 ± 129 >10000 >10000 
aRadioligand competition binding assay with [3H]UR-MK1364 (Kd = 6.2 nM, c = 4 nM) using MCF-7-hY1 
cells in buffer II.5 bRadioligand competition binding assay with [3H]propionyl-pNPY6 (Kd = 1.4 nM, c = 1 
nM) using CHO-hY2-Gqi5-mtAEQ cells
7 in buffer I. cFlow cytometric binding assay with Cy5-pNPY (Kd = 
5.2 nM, c = 5 nM) using CHO-hY2-Gqi5-mtAEQ cells in buffer I.
7 cRadioligand competition binding assay 
with [3H]2.108 (Kd = 0.67 nM, c = 0.6 nM) using CHO-hY4R-Gqi5-mtAEQ cells
9 in buffer I. eRadioligand 
competition binding assay with [3H]propionyl-pNPY (Kd = 4.83 nM, c = 4 nM) using HEC-1b hY5R cells
10 
in buffer II. fY4R binding with [
3H]2.108 (Kd = 9.8 nM, c = 10 nM) at CHO-hY4R-Gqi5-mtAEQ cells in 
Leiďoǀitz͛ Lϭϱ-medium: IC50 > 30000 nM. 
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Figure 2: Competition binding performed with the fluorescent ligand Cy5-pNPY at CHO-hY2R-Gqi5-
mtAEQ cells. Displacement of Cy5-pNPY (Kd = 5.2 nM, c = 5 nM). Data represent mean values ± SEM 
of at least 2 independent experiments, each performed in triplicate. 
 
 
Figure 3: Competition binding performed with the radioligand [3H]pNPY at CHO-hY2R-Gqi5-mtAEQ 
cells. Displacement of [3H]pNPY (Kd = 1.4 nM, c = 1 nM). Data represent mean values ± SEM of at least 
3 independent experiments, each performed in triplicate. 
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6.3  Conclusions 
Whereas guanidinylation of the isothiourea 6.5 was not successful, the synthesis of the 
guanidine analog of the thiourea 6.4, compound 6.6, was accomplished via the 
guanidinylation of α,α-diphenyl-4-piperidinemethanol with the isothiourea 6.8. However, 
the working hypothesis was not confirmed: the replacement of the thiourea moiety in CYM 
9484 with a basic guanidine substructure did not result in increased Y2R affinity.  
 
6.4  Experimental Section 
6.4.1  General Experimental Conditions 
Chemicals and solvents were purchased from commercial suppliers and used without further 
purification unless otherwise indicated. MeCN for HPLC (gradient grade) and ammonia 
solutioŶ ;ϯϮ%Ϳ ǁeƌe puƌĐhased foƌŵ MeƌĐk ;Daƌŵstadt, GeƌŵaŶǇͿ aŶd Ϯ,Ϯ′-Azobis(2-
methylpropionitrile) was from Acros Organics/Fisher Scientific (Nidderau, Germany). 
Trifluoroacetic acid, dichloromethane, diethyl ether, dimethylformamide, iodomethane 
(99%), Di-2-pyridyl thionocarbonate (98%), N-bromosuccinimide (99%), α,α-diphenyl-4-
piperidinemethanol and phenylacetyl chloride (98%) were obtained from Sigma Aldrich 
(Deisenhofen, Germany), N,N-diisopropylethylamine (DIPEA) (99%) was from ABCR 
(Karlsruhe, Germany). 4-Amino-N,N-dimethylbenzenesulfonamide (97%) was from Alfa Aesar 
(Karlsruhe, Germany) and tert-butanol was from Carl Roth (Karlsruhe, Germany). Bovine 
serum albumin and bacitracin were purchased from Serva (Heidelberg, Germany), human 
pancreatic polypeptide and porcine neuropeptide Y were from Synpeptide (Shanghai, China). 
1-Boc-piperidine was synthesized by Dr. Paul Baumeister. The synthesis of [3H]2.108 and 
[3H]propionyl-pNPY6 was previously described. Millipore water was used throughout for the 
preparation of buffers and HPLC eluents. Polypropylene reaction vessels (1.5 or 2 mL) with 
screw cap (Süd-Laborbedarf, Gauting, Germany) were used for the storage of stock 
solutions. TL chromatography was performed on Merck silica gel 60 F254 TLC aluminum 
plates, silica gel 60 (40-63 µm, Merck) was used for column chromatography. Visualization 
was accomplished by UV light ( = 254 nm or 366 nm). NMR-spectra were recorded on a 
Bruker Avance 300 (7.05 T, 1H: 300.1 MHz, 13C: 75.5 MHz), a Bruker Avance III HD 400 (1H: 
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400 MHz, 13C: 101 MHz) or a Bruker Avance 600 instrument with cryogenic probe (14.1 T, 1H: 
600.3 MHz, 13C: 150.9 MHz) (Bruker, Karlsruhe, Germany). Mass spectra were recorded on a 
Finnigan MAT95 (EI-MS 70eV) or a Finnigan MAT SSQ 710 A (CI-MS (NH3)). For HRMS an 
Agilent Q-TOF 6540 UHD (Agilent, Waldbronn, Germany) equipped with an ESI source was 
used. Preparative HPLC was performed on a system from Knauer (Berlin, Germany) 
consisting of two K-1800 pumps, a K-2001 detector and a RP-column (Kinetex-XB C18, 5 µm, 
250 mm × 21 mm, Phenomenex, Aschaffenburg, Germany) at a flow-rate of 16 mL/min using 
mixtures of acetonitrile and 0.1% aqueous TFA solution as mobile phase. A detection 
wavelength of 220 nm was used throughout. The collected fractions were lyophilised using 
an alpha 2-4 LD apparatus (Martin Christ, Osterode am Harz, Germany) equipped with a RZ 6 
rotary vane vacuum pump (vacuubrand, Wertheim, Germany). Analytical HPLC analysis was 
performed on a system from Merck-Hitachi (Hitachi, Düsseldorf, Germany) composed of a L-
6200-A pump, a AS-2000A autosampler, a L-4000A UV detector, a D-6000 interface and a RP-
column Kinetex-XB C18, 5 µm, 250 mm × 4.6 mm (Phenomenex, Aschaffenburg, Germany) at 
a flow rate of 0.8 mL/min. Mixtures of acetonitrile (A) and 0.1% aqueous TFA solution (B) 
were used as mobile phase. The following gradient was applied: A/B: 0-25 min: 20:80 - 95:5, 
25-35 min: 95:5 - 95:5. Detection was performed at 220 nm, the oven temperature was 30 
°C. 
6.4.2  Chemistry: Experimental Protocols and Analytical Data 
N-[4-(N,N-Dimethylsulfamoyl)phenyl]-4-(hydroxydiphenylmethyl)piperidine-1-
carbothioamide (6.4).
1 Compound 6.1 (50 mg, 0.25 mmol) was dissolved in CH2Cl2 (4 mL), 
di(2-pyridyl) thionocarbonate (58 mg, 1 equiv) was added, and the mixture was stirred for 6 
h to give the isocyanate 6.2. After addition of α,α-diphenyl-4-piperidinemethanol (94 mg, 1.4 
equiv) stirring was continued for 15 min. The mixture was diluted with CH2Cl2 (15 mL) and 
washed with water (2 × 15 mL). The solvent was removed on a rotary evaporator and the 
residue was taken up in EtOAc/Hexane (6:1, 3.5 mL). Purification via column 
chromatography (eluent: Hexane/EtOAc (2:1)) afforded the desired compound as a grey 
solid (110 mg, 87%). TLC (PE/EtOAc 1:1): Rf = 0.56. 
1H-NMR (300 MHz, [D6]DMSO): 1.28-1.62 
(m, 4H), 2.58 (s, 6H), 2.94 (t, 1H, J 11.5 Hz), 3.11 (t, 2H, J 11.7 Hz), 4.72 (d, 2H, J 12.3 Hz), 5.44 
(s, 1H), 7.15 (t, 2H, J 7.2 Hz), 7.29 (t, 4H, J 7.6 Hz), 7.50-7.60 (m, 6H), 7.60-7.67 (m, 2H), 9.52 
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(s, 1H).HRMS (m/z): [M+H]+ calcd. for C27H32N3O3S2
+, 510.1874; found, 510.1884. RP-HPLC 
(220 nm): 99% (tR = 22.09 min, k = 6.7). C27H31N3O3S2 (509.68). 
Methyl N-[4-(N,N-dimethylsulfamoyl)phenyl]-4-(hydroxydiphenylmethyl)piperidine-1-
carbimidothioate (6.5). 6.4 (50 mg, 0.098 mmol) was dissolved in DMF (1 mL), and a solution 
of iodomethane (13.9 mg, 1 equiv) in DMF (300 µL) was slowly added at room temperature. 
The resulting mixture was stirred at room temperature for 21 h. The mixture was taken up in 
H2O (20 mL), DIPEA (20 µL) was added, and the mixture was extracted with EtOAc (3 × 20 
mL). The organic layers were combined, and the volume was reduced to approximately 4 mL. 
Purification via column chromatography (eluent: Hexane/EtOAc (1:1)) afforded the title 
compound as a white solid (40 mg, 78%). TLC (PE/EtOAc 2:1): Rf = 0.34. 
1H-NMR (600 MHz, 
[D6]DMSO): δ 1.33 (d, 2H, J 12.5 Hz), 1.43-1.54 (m, 2H), 2.02 (s, 3H), 2.54 (s, 6H), 2.80-2.88 
(m, 1H), 2.91-2.99 (m, 2H), 4.24 (d, 2H, J 12.9 Hz), 5.36 (s, 1H), 6.92-6.97 (m, 2H), 7.13 (t, 2H, 
J 7.4 Hz), 7.27 (t, 4H, J 7.6 Hz), 7.52-7.57 (m, 6H). 13C-NMR (150.9 MHz, [D6]DMSO): δ 15.6, 
26.1 (2 carb.), 37.7 (2 carb.), 43.4, 47.9 (2 carb.), 78.5, 121.6 (2 carb.), 125.7 (4 carb.), 125.9 
(2 carb.), 126.0, 127.8 (4 carb.), 128.6 (2 carb.), 147.0 (2 carb.), 154.4, 156.5. HRMS (m/z): 
[M+H]+ calcd. for C27H34N3O3S2
+, 524.2036; found, 524.2039. RP-HPLC (220 nm): >99% (tR = 
16.91 min, k = 4.9). C28H33N3O3S2 (523.71). 
N'-[4-(N,N-Dimethylsulfamoyl)phenyl]-4-(hydroxydiphenylmethyl)piperidine-1-
carboximidamide hydrotrifluoroacetate (6.6). Compound 6.8 (30 mg, 0.075 mmol) was 
dissolved in t-BuOH/DMF (1:1, 6 mL), α,α-diphenyl-4-piperidinemethanol (24 mg, 1.2 equiv) 
was added, and the mixture was stirred under reflux for 2 h. The desired compound was 
purified by preparative HPLC (column: Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: 
MeCN/0.1% aq TFA 14:86–62:38, tR = 16.8 min). Lyophilisation of the eluate afforded 6.6 as a 
white fluffy solid (17.7 mg, 39%). 1H-NMR (600 MHz, [D6]DMSO): δ 1.39 (d, 2H, J 12.5 Hz), 
1.49-1.53 (m, 2H), 2.60 (s, 6H), 2.89-2.96 (m, 1H), 3.16 (t, 2H, J 12.5 Hz), 3.92 (d, 2H, J 13.2 
Hz), 5.51 (br s, 1H), 7.15 (t, 2H, J 7.3 Hz), 7.28 (t, 4H, J 8.1 Hz), 7.36 (d, 2H, J 8.8 Hz), 7.53 (d, 
4H, J 7.4 Hz), 7.34 (d, 2H, J 8.8 Hz), 8.27 (s, 2H), 9.93 (s, 1H). 13C-NMR (150.9 MHz, 
[D6]DMSO): δ 25.9 (2 carb.), 37.6 (2 carb.), 42.1, 46.9 (2 carb.), 78.5, 121.6 (2 carb.), 125.7 (4 
carb.), 126.1 (2 carb.), 127.9 (2 carb.), 129.2 (2 carb.), 129.9, 142.3, 146.8 (2 carb.), 153.5. 
HRMS (m/z): [M+H]+ calcd. for C27H33N4O3S
+, 493.2268; found, 493.2283. RP-HPLC (220 nm): 
>99% (tR = 15.83 min, k = 4.5). C27H32N4O3S · C2H1F3O2 (492.64 + 114.02). 
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N,N-Dimethyl-4-thioureidobenzenesulfonamide (6.7). Compound 6.1 (100 mg, 0.5 mmol) 
was dissolved in CH2Cl2 (8 mL), di(2-pyridyl) thionocarbonate (116 mg, 1 equiv) was added, 
and the mixture was stirred for 10 h to form the isocyanate 6.2. Ammonia solution (32%) 
was added and vigorous stirring was continued for 40 min. After addition of EtOAc (30 mL), 
the mixture was washed with water (2 × 20 mL), the volume of the organic phase was 
reduced on a rotary evaporator, and the desired compound was purified by column 
chromatography (eluent: EtOAc/MeOH (20:1)). Compound 6.7 was obtained as a yellow 
solid (120 mg, 93%). TLC (EtOAc): Rf = 0.67. 
1H-NMR (400 MHz, [D6]DMSO): δ 2.60 (s, 6H), 
7.50 (br s, 1H), 7.66 (d, 2H, J 8.8 Hz), 7.81 (d, 2H, J 8.8 Hz), 8.02 (br s, 1H), 10.1 (s, 1H). 13C-
NMR (100.6 MHz, [D6]DMSO): δ 38.1 (2 carb.), 121.9 (2 carb.), 128.8 (2 carb.), 129.2, 144.2 
181.7. HRMS (m/z): [M+H]+ calcd. for C9H14N3O2S2
+, 260.0522; found, 260.0517. C9H13N3O2S2 
(259.35). 
Methyl [4-(N,N-dimethylsulfamoyl)phenyl]carbamimidothioate hydroiodide (6.8). 
Compound 6.7 (110 mg, 0.42 mmol) was dissolved in MeOH (8 mL). A solution of 
iodomethane (60.3 mg, 1 equiv) in MeOH (2 mL) was slowly added, and the mixture was 
stirred at room temperature for 36 h. After completion of the reaction (monitored by TLC 
(CH2Cl2/MeOH (10:0.8))), the volume of the mixture was reduced to approximately 2 mL, and 
ice-cold diethyl ether (10 mL) was added. After storage in a freezer for 14 h, the precipitated 
compound 6.8 was isolated by filtration as a white solid (150 mg, 93%). 1H-NMR (400 MHz, 
[D4]methanol): δ 2.74 (s, 6H), 2.78 (s, 3H), 7.65 (d, 2H, J 8.8 Hz), 7.94 (s, 2H, J 8.8 Hz). 13C-
NMR (100.6 MHz, [D4]methanol): δ 13.2, 36.9 (2 carb.), 125.9 (2 carb.), 129.6 (2 carb.), 135.5, 
138.9, 171.5. HRMS (m/z): [M+H]+ calcd. for C10H16N3O2S2
+, 274.0678; found, 274.0676. 
C10H15N3O2S2 · HI (273.37 + 127.91). 
2-Bromo-N,N-diethyl-2-phenylacetamide (6.10).
11
 Phenylacetyl chloride (200 mg, 1.3 
mmol), NBS (232 mg, 1 equiv) and AIBN (15 mg, 0.06 equiv) were suspended in chloroform 
(3 mL), and the mixture was stirred under reflux conditions. After 5 h, PE (10 mL) was added, 
and the solids were filtered off. The volume of the filtrate was reduced on a rotary 
evaporator, and the residue was taken up in chloroform (2 mL), followed by the addition of 
DIPEA (221 µL, 1 equiv) and diethylamine (136 µL, 1 equiv). After stirring at room 
temperature for additional 3 h, the mixture was washed with water (2 × 10 mL). Purification 
by column chromatography (eluent: Hexane/EtOAc (1:1)) afforded the title compound as a 
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white glue-like solid (202 mg, 58%). TLC (PE/EtOAc 2:1): Rf = 0.68.  
1H-NMR (300 MHz, CDCl3): 
δ 1.09-1.19 (m, 6H), 3.27-3.48 (m, 4H), 5.67 (s, 1H), 7.30-7.60 (m, 5H). GCMS (CI): m/z = 
192.1 [M-Br+2H]+ (100), 270.1 [M+H]+ (85), 272.0 [M+H]+ (85). C12H16BrNO (270.17). 
N,N-Diethyl-2-phenyl-2-(piperazin-1-yl)acetamide di(hydrotrifluoroacetate) (6.11).
12
 
Compound 6.10 (100 mg, 0.37 mmol), 1-Boc-piperazine (90 mg, 1.3 equiv) and DIPEA (84 µL, 
1.3 equiv) were dissolved in MeCN (4 mL). The mixture was stirred under microwave 
conditions (110 °C, 30 min). Purification by column chromatography (eluent: EtOAc/Hexane 
(1:1)) afforded the Boc-protected intermediate that was dissolved in CH2Cl2/TFA/H2O 
(10:10:1, 10 mL). The mixture was stirred at room temperature for 3 h. Removal of the 
volatiles under reduced pressure afforded compound 6.11 as a hygroscopic white solid (134 
mg, 72%). 1H-NMR (300 MHz, [D6]DMSO): δ 0.83 (t, 3H, J 7.00 Hz), 1.00 (t, 3H, J 7.00 Hz), 2.96 
(br s, 4H), 3.10-3.37 (m, 8H, overlap with H2O), 5.14 (s, 1H), 7.35-7.56 (m, 5H), 8.89 (br s, 1H), 
9.17 (br s, 1H). LRMS (ESI): m/z = 275.9 [M+H]+ (100). C16H25N3O · C4H2F6O4 (275.39 + 
228.04). 
2-(4-{[4-(N,N-dimethylsulfamoyl)phenyl]carbamothioyl}piperazin-1-yl)-N,N-diethyl-2-
phenylacetamide di(hydrotrifluoroacetate) (6.12). Compound 6.1 (25 mg, 0.125 mmol) was 
dissolved in CH2Cl2 (3 mL) and di(2-pyridyl) thionocarbonate (29 mg, 1 equiv) was added. The 
mixture was stirred for 6 h to form the isocyanate 6.2. Compound 6.11 (63 mg, 1 equiv) and 
DIPEA (56 µL, 2.5 equiv) were added and stirring was continued for 1 h. The mixture was 
diluted with CH2Cl2 (15 mL) and washed with water (2 × 15 mL). The solvent was removed on 
a rotary evaporator and the desired compound was purified by preparative HPLC (column: 
Kinetex-XB C18 250 × 21 mm; gradient: 0–20 min: MeCN/0.1% aq TFA 14:86–62:38, tR = 14 
min). Lyophilisation of the eluate afforded 6.12 as a white fluffy solid (34.6 mg, 43%). 1H-
NMR (600 MHz, [D6]DMSO): δ 0.85 (t, 3H, J 7.0 Hz), 1.01 (t, 3H, J 7.1 Hz), 2.59 (s, 6H), 3.16-
3.25 (m, 3H), 3.26-3.34 (m, 2H), 3.35-3.43 (m, 2H), 3.58 (br s, 3H), 4.68 (br s, 1H), 4.89 (br s, 
1H), 5.60 (s, 1H), 7.50-7.59 (m, 5H), 7.61 (d, 2H, J 8.8 Hz), 7.67 (d, 2H, J 8.8 Hz), 9.98 (s, 1H), 
10.65 (br s, 1H). 13C-NMR (150.9 MHz, [D6]DMSO): δ 12.4, 13.7, 37.6 (2 carb.), 40.0 (2 carb.), 
40.3 (2 carb.), 41.3 (2 carb.), 68.1, 123,3 (2 carb.), 127.9 (2 carb.), 129.1, 129.7 (4 carb.), 
130.6, 145.1, 164.8, 181.3. HRMS (m/z): [M+H]+ calcd. for C25H36N5O3S2
+, 518.2254; found, 
518.2264. RP-HPLC (220 nm): 99% (tR = 13.79 min, k = 3.8). C25H35N5O3S2 · C4H2F6O4 (517.71 + 
228.04). 
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6.4.3  Pharmacology  
Buffers and media used in binding assays. Cf. chapter 2.4.5 
Radioligand binding assays. Cf. chapter 2.4.5 
Fluorescent ligand binding assays. The flow cytometric binding assay with Cy5-pNPY (Kd = 
5.2 nM, c = 5 nM) at CHO-hY2-Gqi5-mtAEQ cells was performed with a FACSCalibur
TM flow 
cytometer (Becton D ickinson, Heidelberg, Germany), equipped with an argon laser (488 nm) 
and a red diode laser (635 nm) as previously described.13 
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Chapter 7 
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The neuropeptide Y family comprises three 36-amino acid peptides, namely neuropeptide Y 
(NPY), peptide YY (PYY) and pancreatic polypeptide (PP). In humans, the three peptides 
activate four functionally expressed G-protein coupled receptors (Y1R, Y2R, Y4R and Y5R) and 
contribute to the regulation of numerous (patho)physiological processes such as feeding 
behavior, pain sensitivity or the formation of mental disorders. Among the NPY receptors, 
the Y4R is unique, because it preferentially binds PP over NPY or PYY. Recently, Y4R agonists 
were proposed as anti-obesity agents. However, due to the lack of appropriate 
pharmacological tools, the physiological role of the Y4R is still far from being understood. 
Therefore, this work aimed at the development of selective high affinity Y4R ligands, agonists 
and antagonists, and labeled Y4R ligands. 
Bivalent, NG-carbamoylated argininamides such as UR-MK188 represent the only class of Y4R 
antagonists with affinities in the nanomolar range known so far. UR-MK188 (Ki = 130 nM, Kb 
= 20 nM) was used as a lead structure for the development of truncated, centrally 
constrained dimeric ligands. Aromatic substructures in the core of the linker were tolerated. 
Bivalent ligands with a central bent 1,7-disubstituted imidazo[4,5-f]benzimidazol moiety had 
slightlǇ higheƌ affiŶities thaŶ those ǁith a ϰ,ϰ͛-disubstituted biphenyl moiety. A truncation of 
the linker length from 39 to 21 atoms did not compromise the Y4R affinity of the investigated 
ligands. An exchange of the linker attachment position from the guanidine group to the 
carboxylic acid of the argininamides improved the synthetic availability, but resulted in Y4R 
bivalent ligands with slightly reduced affinities. 
The diastereomeric mixture of D/L-2,7-diaminooctanedioyl-bis(YRLRY-NH2) (BVD-74D) was 
described as a high affinity Y4R agonist. The pure diastereomers (2R,7R)-BVD-74D and 
(2S,7S)-BVD-74D and a series of homo- and heterodimeric analogs in which octanedioic acid 
was used as an achiral linker were prepared. To investigate the role of the amino acid 
residues, selected amino acids were replaced by Ala. (2R,7R)-BVD-74D was superior to 
(2S,7S)-BVD-74D in binding and functional cellular assays, and the presence of at least one 
unaltered tetrapeptide sequence Arg-Leu-Arg-Tyr-NH2 was indispensable with regard to Y4R 
affinity. [3H]Propionylation of one amino group in the linker of (2R,7R)-BVD-74D resulted in 
the high affinity Y4R radioligand [
3H]UR-KK193 (Kd (Y4R) = 0.67 nM), a useful new tool for the 
Y4R. Binding experiments with [
3H]UR-KK193 revealed that the affinity of peptide Y4R 
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agonists may be considerably higher in the absence of sodium ions, conditions widely used 
for the investigation of NPY receptor ligands. 
Recently, analogs of the C-teƌŵiŶus of PP ĐoŶtaiŶiŶg aƌtifiĐial ĐǇĐliĐ β-amino acids such as 
[cpen34]pNPY(32-36), were described as partial Y4R agonists. With respect to the 
development of Y4R antagonists, aza-amino acids and D-amino acids where introduced into 
peptide agonist precursors. The incorporation of aza-amino acids, either azaArg or azaLeu, 
into the above-ŵeŶtioŶed ͚diŵeƌiĐ͛ peptides ĐhaŶged the ƋualitǇ of aĐtioŶ fƌoŵ agoŶisŵ to 
antagonism in functional assays with complementary readouts. The amino acid sequence of 
the Y4R agonist Ac-YRLRY-NH2 was optimized with respect to Y4R affinity by the replacement 
of Arg2 with an NG-carbamoylated arginine building block and the extension of the N-
terminus by an additional arginine. A D-amino acid scan was performed with this 
hexapeptide. Hexapeptides, in which either one of the three C-terminal L-amino acids had 
been replaced with the respective D-amino acid, were Y4R antagonists. Due to their 
extremely facile synthetic availability, linear peptides containing D-amino acids are 
promising building blocks for further structural modifications and might pave the way for the 
development of peptide Y4R antagonists with increased affinity and antagonistic activity. 
In summary, the high-affinity ligands and radiolabeled molecular tools described in this 
thesis should contribute to gain deeper insight into the physiological role and the signaling 
mechanisms of the neuropeptide Y Y4 receptor. 
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